Structure, Recognition, and Processing of Cisplatinâ^'D

Chemical Reviews

99, 2467-2498

DOI: 10.1021/cr980421n

Citation Report

#	Article	IF	Citations
1	Current Status of Platinum-Based Antitumor Drugs. Chemical Reviews, 1999, 99, 2451-2466.	23.0	1,744
2	Non-Platinum Chemotherapeutic Metallopharmaceuticals. Chemical Reviews, 1999, 99, 2511-2534.	23.0	874
3	Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?. Chemical Reviews, 1999, 99, 2499-2510.	23.0	755
4	Nucleic Acid Recognition by Metal Complexes of Bleomycin. Chemical Reviews, 1999, 99, 2797-2816.	23.0	253
5	Replacement of an NH3 by an Iminoether in Transplatin Makes an Antitumor Drug from an Inactive Compound. Molecular Pharmacology, 2000, 58, 1525-1535.	1.0	57
6	Covalent Interaction of Ru(terpy)(tmephen)Cl⁺ with DNA: A Potential Rutheniumâ€Based Anticancer Drug. Journal of the Chinese Chemical Society, 2000, 47, 213-220.	0.8	18
7	Sequence-Dependent Bending of DNA Induced by Cisplatin: NMR Structures of an Aâ‹…T-Rich 14-mer Duplex. Chemistry - A European Journal, 2000, 6, 3636-3644.	1.7	13
8	Synthesis and Structural Characterisation of a New Form of Bis(acyclovir)(ethylenediamine)platinum(II) â˜ Correlation between the Puckering of the Carrier Ligand and the Canting of the Nucleobases. European Journal of Inorganic Chemistry, 2000, 2000, 1601-1607.	1.0	27
9	Novel spacer linked bile acidâ€“cisplatin compounds as a model for specific drug delivery, synthesis and characterization. Inorganica Chimica Acta, 2000, 304, 241-249.	1.2	31
10	Pt(II) complexes with different N-donor aromatic ligands for specific inhibition of telomerase. Inorganica Chimica Acta, 2000, 305, 61-68.	1.2	36
11	Kinetics of binding properties of 5â€²-GMP with cisplatin under simulated physiological conditions by capillary electrophoresis. Biomedical Applications, 2000, 745, 211-219.	1.7	34
12	Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene, 2000, 19, 3138-3145.	2.6	107
13	DNA polymerase versus DNA binding to the anticancer drug, cis-platin. Inorganica Chimica Acta, 2000, 300-302, 937-943.	1.2	4
14	Is reduction required for antitumour activity of platinum(IV) compounds? Characterisation of a platinum(IV)â€“nucleotide adduct [enPt(OCOCH3)3(5â€²-GMP)] by NMR spectroscopy and ESI-MS. Inorganica Chimica Acta, 2000, 300-302, 783-789.	1.2	43
15	Modification of natural, double-helical DNA by antitumor cis- and trans-[Cl2(Me2SO4)4Ru] in cell-free media. Biochemical Pharmacology, 2000, 60, 1761-1771.	2.0	16
16	New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy. Journal of Biological Inorganic Chemistry, 2000, 5, 655-665.	1.1	106
17	Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 107 Td (oxime)di Inorganic Chemistry, 2000, 5, 675-681.	1.1	20
18	High-throughput synthesis and screening of platinum drug candidates. Journal of Biological Inorganic Chemistry, 2000, 5, 774-783.	1.1	47

#	Article	IF	Citations
19	Circular dichroism spectra of the individual rotamers of [Pt(N,N-dmen)(GpG)]+ (N,N-dmen=N,N-dimethylethylenediamine) indicate that the base-base oscillator coupling is not the main source of ellipticity in cis-PtG2L2 head-to-head complexes. Journal of Biological Inorganic Chemistry, 2000, 5, 45-50.	1.1	5
20	Time-dependent interactions of platinum(II) complexes with 5â€²-GMP under simulated physiological conditions studied by capillary electrophoresis. Journal of Biological Inorganic Chemistry, 2000, 5, 498-504.	1.1	28
21	Binding of Antitumor Ruthenium(III) Complexes to Plasma Proteins. Metal-Based Drugs, 2000, 7, 335-342.	3.8	55
22	Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent. Nucleic Acids Research, 2000, 28, 4237-4243.	6.5	50
23	Reaction of DNA oligonucleotides with [Pt(dien)GSMe]2+ (GSMe =S-methylated glutathione) and cis-[Pt(NH3)2(GSMe)2]2+: evidence of oligonucleotide platination via sulfur-coordinated platinum intermediates. Journal of Biological Inorganic Chemistry, 2000, 5, 463-468.	1.1	43
24	Trans alkenylpyridine and alkenylamine complexes of platinum. Canadian Journal of Chemistry, 2000, 78, 568-576.	0.6	29
25	Tuning the Rotational Behavior of Lopsided Heterocyclic Nitrogen Ligands (L) in Octahedral cis-[Ru(bpy)2(L)2](PF6)2 Complexes. A Variable-Temperature 1H NMR Study. Inorganic Chemistry, 2000, 39, 4073-4080.	1.9	27
26	28â€ƒInorganic pharmaceuticals. Annual Reports on the Progress of Chemistry Section A, 2000, 96, 645-662.	0.8	15
27	Competitive binding of the anticancer drug titanocene dichloride to N,Nâ€Šâ€²-ethylenebis(o-hydroxyphenylglycine) and adenosine triphosphate: a model for TiIV uptake and release by transferrin. Dalton Transactions RSC, 2000, , 7-9.	2.3	50
28	Stopped-Flow Fluorescence Studies of HMG-Domain Protein Binding to Cisplatin-Modified DNAâ€. Biochemistry, 2000, 39, 8426-8438.	1.2	25
29	HMG-Domain Protein Recognition of Cisplatin 1,2-Intrastrand d(GpG) Cross-Links in Purine-Rich Sequence Contextsâ€. Biochemistry, 2000, 39, 11771-11776.	1.2	49
30	cis- andtrans-Diamminedichloroplatinum(II) Interstrand Cross-Linking of a Defined Sequence Nucleosomal Core Particleâ€‚â€¡. Biochemistry, 2000, 39, 16046-16055.	1.2	14
31	Intercalating Residues Determine the Mode of HMG1 Domains A and B Binding to Cisplatin-Modified DNA. Biochemistry, 2000, 39, 14426-14435.	1.2	81
32	Cisplatin Adducts Inhibit 1,N6-Ethenoadenine Repair by Interacting with the Human 3-Methyladenine DNA Glycosylase. Biochemistry, 2000, 39, 8032-8038.	1.2	30
33	cis-Pt(NH3)2(GpG) Properties Interpreted through Comparison with Retro-Model GpG Adducts Having Carrier Ligands Designed to Slow Dynamic Motion and Control Cross-Link Handedness. Journal of the American Chemical Society, 2000, 122, 8021-8030.	6.6	31
34	Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5768-5772.	3.3	193
35	Enhanced Binding of the TATA-Binding Protein to TATA Boxes Containing Flanking Cisplatin 1,2-Cross-Linksâ€. Biochemistry, 2000, 39, 8259-8265.	1.2	46
36	TiIV Uptake and Release by Human Serum Transferrin and Recognition of TiIV-Transferrin by Cancer Cells:â€‰ Understanding the Mechanism of Action of the Anticancer Drug Titanocene Dichloride. Biochemistry, 2000, 39, 10023-10033.	1.2	226

#	Article	IF	Citations
37	New Antitumor-Active Azole-Bridged Dinuclear Platinum(II) Complexes:Â Synthesis, Characterization, Crystal Structures, and Cytotoxic Studies. Inorganic Chemistry, 2000, 39, 4230-4236.	1.9	162
38	Platinum binding to DNA: structural controls and consequences. Dalton Transactions RSC, 2001, , 2711-2718.	2.3	128
39	The Literature of Heterocyclic Chemistry, Part VII: 1997â€“1999. Advances in Heterocyclic Chemistry, 2001, 79, 199-318.	0.9	18
40	Cisplatin: From DNA damage to cancer chemotherapy. Progress in Molecular Biology and Translational Science, 2001, 67, 93-130.	1.9	524
41	Adsorption/Desorption Characteristics of cis-Platin on Mercapto-Silylated Silica Surfaces. Langmuir, 2001, 17, 5958-5963.	1.6	23
42	2.4 Ã... Crystal Structure of an Oxaliplatin 1,2-d(GpG) Intrastrand Cross-Link in a DNA Dodecamer Duplex. Inorganic Chemistry, 2001, 40, 5596-5602.	1.9	212
43	Cisplatinâ˜Protein Adducts Are Efficiently Removed by Glutathione but Not by 5â€˜-Guanosine Monophosphate. Journal of the American Chemical Society, 2001, 123, 3171-3172.	6.6	69
44	Inductively coupled plasma mass spectrometry to identify protein drug targets from whole cell systemsElectronic supplementary information (ESI) available: full details of laser ablation ICP-MS and QTOF operating conditions, further experimental details for peptide separation and peptide sequencing maps for OmpA. See http://www.rsc.org/suppdata/cc/b1/b108418f/. Chemical Communications, 2001, , 2708-2709.	2.2	53
45	Relationship of Solution and Protein-Bound Structures of DNA Duplexes with the Major Intrastrand Cross-Link Lesions Formed on Cisplatin Binding to DNA. Journal of the American Chemical Society, 2001, 123, 2764-2770.	6.6	119
46	Synthesis, characterisation and ion transport studies on polypyrrole/deoxyribonucleic acid conducting polymer membranes. Synthetic Metals, 2001, 123, 279-286.	2.1	34
47	Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. International Journal of Biological Macromolecules, 2001, 28, 191-198.	3.6	66
48	Mononuclear Platinum(II) Complex with 2-Phenylpyridine Ligands Showing High Cytotoxicity against Mouse Sarcoma 180 Cells Acquiring High Cisplatin Resistance. Journal of Medicinal Chemistry, 2001, 44, 4661-4667.	2.9	104
49	Design, Synthesis, and Biological Activity of a Novel Non-Cisplatin-type Platinumâ˜Acridine Pharmacophore. Journal of Medicinal Chemistry, 2001, 44, 4492-4496.	2.9	122
50	Structure and dynamics of a platinum(II) aminophosphine complex and its nucleobase adducts. Dalton Transactions RSC, 2001, , 362-372.	2.3	22
51	Lobaplatin: a new antitumour platinum drug. Expert Opinion on Investigational Drugs, 2001, 10, 119-128.	1.9	138
52	Transcription inhibition by Rh(phi)2(phen)3+. Chemical Communications, 2001, , 279-280.	2.2	24
53	Isomer formation in the binding of [PtCl2(cis-cyclohexane-1,3-diamine)] to oligonucleotides and the X-ray crystal structure of [PtCl2(cis-cyclohexane-1,3-diamine)]Â·dimethylformamideâ€. Dalton Transactions RSC, 2001, , 2769-2774.	2.3	6
54	Direct Evidence for Preassociation Preceding Covalent Binding in the Reaction ofcis-[Pt(NH3)2(H2O)2]2+with Surface Immobilized Oligonucleotides. Journal of the American Chemical Society, 2001, 123, 5576-5577.	6.6	36

#	Article	IF	Citations
55	Imprinting Structural Information from a GpG Ligand into the Configuration of a Chiral Diamine Ligand through Second-Sphere Communication in Platinum(II) Complexes. Inorganic Chemistry, 2001, 40, 445-454.	1.9	23
56	Laser-Induced Photo-Cross-Linking of Cisplatin-Modified DNA to HMG-Domain Proteinsâ€. Biochemistry, 2001, 40, 7533-7541.	1.2	17
57	A Rare Example of Three Abundant Conformers in One Retro Model of the Cisplatinâ^'DNA d(GpG) Intrastrand Cross Link. Unambiguous Evidence That Guanine O6 to Carrier Amine Ligand Hydrogen Bonding Is Not Important. Possible Effect of the Lippard Base Pair Step Adjacent to the Lesion on Carrier Ligand Hydrogen Bonding in DNA Adducts. Journal of the American Chemical Society, 2001, 123, 9345-9355.	6.6	54
58	Hydrolysis Theory for Cisplatin and Its Analogues Based on Density Functional Studies. Journal of the American Chemical Society, 2001, 123, 9378-9387.	6.6	293
59	Kinetic Analysis of the Stepwise Formation of a Long-Range DNA Interstrand Cross-link by a Dinuclear Platinum Antitumor Complex:Â Evidence for Aquated Intermediates and Formation of Both Kinetically and Thermodynamically Controlled Conformers. Journal of the American Chemical Society, 2001, 123, 1316-1326.	6.6	106
60	Estrogen-Derived Steroidal Metal Complexes:â€‰ Agents for Cellular Delivery of Metal Centers to Estrogen Receptor-Positive Cells. Inorganic Chemistry, 2001, 40, 3964-3973.	1.9	82
61	Dinuclear Alkyldiamine Platinum Antitumor Compounds:Â A Structureâ^'Activity Relationship Study. Journal of Medicinal Chemistry, 2001, 44, 245-249.	2.9	46
62	Quantum Chemical Studies on Molecular and Electronic Structure of Platinum and Tin Adducts with Guanine. International Journal of Molecular Sciences, 2001, 2, 148-155.	1.8	7
63	Cellular Uptake, DNA Binding and Apoptosis Induction of Cytotoxic Trans-[PtCl2(N,N-dimethylamine)(Isopropylamine)] in A2780cisR Ovarian Tumor Cells. Metal-Based Drugs, 2001, 8, 29-37.	3.8	15
65	Chemical Reagents for Investigating the Major Groove of DNA. Current Protocols in Nucleic Acid Chemistry, 2001, 5, Unit 6.6.	0.5	0
66	Capillary electrophoretic study of carboplatin and analogues with nucleoside monophosphates, di- and trinucleotides. Journal of Inorganic Biochemistry, 2001, 83, 181-186.	1.5	22
67	Synthesis and antitumour activity of platinum(II) and platinum(IV) complexes containing ethylenediamine-derived ligands having alcohol, carboxylic acid and acetate substituents. Journal of Inorganic Biochemistry, 2001, 83, 91-100.	1.5	32
68	Study of the interaction of cis-dichloro-(1,2 diethyl-3-aminopyrrolidine)Pt(II) complex with poly(I), poly(C) and poly(I)Â·poly(C). Journal of Inorganic Biochemistry, 2001, 85, 279-290.	1.5	13
69	Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5â€²-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. Journal of Inorganic Biochemistry, 2001, 86, 691-698.	1.5	77
70	Investigations into the interaction between tumor-inhibiting ruthenium(III) complexes and nucleotides by capillary electrophoresis. Biomedical Applications, 2001, 759, 81-89.	1.7	31
71	Synthesis and glycosidase inhibition of new enantiopure 2,3-diamino conduritols. Tetrahedron, 2001, 57, 3439-3444.	1.0	20
72	Unprecedented sugar-dependent in vivo antitumor activity of carbohydrate-pendant cis-diamminedichloroplatinum(II) complexes. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3045-3047.	1.0	54
73	The performance of different density functional methods in the calculation of molecular structures and vibrational spectra of platinum(II) antitumor drugs: cisplatin and carboplatin. Journal of Computational Chemistry, 2001, 22, 901-912.	1.5	107

#	Article	IF	Citations
74	The Intramolecular Ligand-Exchange Reaction of (SP-4-2)-Dichlorobis(2-hydroxyethylamine)platinum(II) and (OC-6-22)-Tetrachlorobis(2-hydroxyethylamine)platinum(IV), a1H and15N,1H-HMQC NMR Study. European Journal of Inorganic Chemistry, 2001, 2001, 1145-1149.	1.0	15
76	Towards a Better Understanding of the Cisplatin Mode of Action. Chemistry - A European Journal, 2001, 7, 808-815.	1.7	55
77	Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones. Angewandte Chemie - International Edition, 2001, 40, 40-73.	7.2	1,760
78	Study of the interaction of a cis-dichloroaminopyrrolidine Pt(II) complex and the polynucleotide poly(I)â€“poly(C) acid by means of -NMR and multivariate curve resolution. Analytica Chimica Acta, 2001, 446, 437-448.	2.6	12
79	Current status of trans-platinum compounds in cancer therapy. Coordination Chemistry Reviews, 2001, 216-217, 383-410.	9.5	192
80	Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. British Journal of Cancer, 2001, 85, 1219-1225.	2.9	100
81	Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media. Journal of Biological Inorganic Chemistry, 2001, 6, 435-445.	1.1	76
82	Interaction of cisplatin with methionine- and histidine-containing peptides: competition between backbone binding, macrochelation and peptide cleavage. Journal of Biological Inorganic Chemistry, 2001, 6, 556-566.	1.1	78
83	Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride. Journal of Biological Inorganic Chemistry, 2001, 6, 698-707.	1.1	77
84	The DNA-bound orientation of Cu(II)Â·Xaa-Gly-His metallopeptides. Journal of Inorganic Biochemistry, 2001, 83, 17-23.	1.5	35
85	Sterically hindered cisplatin derivatives with multiple carboxylate auxiliary arms: synthesis and reactions with guanosine-5â€²-monophosphate and plasmid DNA. Journal of Inorganic Biochemistry, 2001, 85, 229-235.	1.5	20
86	Thermal and Thermodynamic Properties of Duplex DNA Containing Site-specific Interstrand Cross-link of Antitumor Cisplatin or Its Clinically Ineffective Trans Isomer. Journal of Biological Chemistry, 2001, 276, 9655-9661.	1.6	56
87	Effect of Glutathione Depletion on Antitumor Drug Toxicity (Apoptosis and Necrosis) in U-937 Human Promonocytic Cells. Journal of Biological Chemistry, 2001, 276, 47107-47115.	1.6	135
89	Interaction of FACT, SSRP1, and the High Mobility Group (HMG) Domain of SSRP1 with DNA Damaged by the Anticancer Drug Cisplatin. Journal of Biological Chemistry, 2001, 276, 25736-25741.	1.6	85
90	Interaction with p53 Enhances Binding of Cisplatin-modified DNA by High Mobility Group 1 Protein. Journal of Biological Chemistry, 2001, 276, 7534-7540.	1.6	84
92	Effects of Spectator Ligands on the Specific Recognition of Intrastrand Platinum-DNA Cross-links by High Mobility Group Box and TATA-binding Proteins. Journal of Biological Chemistry, 2001, 276, 38774-38780.	1.6	75
93	Different Recognition of DNA Modified by Antitumor Cisplatin and Its Clinically Ineffective trans Isomer by Tumor Suppressor Protein p53. Journal of Biological Chemistry, 2001, 276, 16064-16069.	1.6	30
94	Conformation, Recognition by High Mobility Group Domain Proteins, and Nucleotide Excision Repair of DNA Intrastrand Cross-links of Novel Antitumor Trinuclear Platinum Complex BBR3464. Journal of Biological Chemistry, 2001, 276, 22191-22199.	1.6	74

#	Article	IF	Citations
95	Thermodynamic properties of duplex DNA containing a site-specific d(GpG) intrastrand crosslink formed by an antitumor dinuclear platinum complex. Nucleic Acids Research, 2001, 29, 2034-2040.	6.5	31
96	Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?. Molecular Pharmacology, 2001, 59, 657-663.	1.0	501
97	Kinetic Studies of the TATA-binding Protein Interaction with Cisplatin-modified DNA. Journal of Biological Chemistry, 2001, 276, 43589-43596.	1.6	27
98	Synthesis and reactivity of palladium and platinum diimine complexes containing boronate esters. Canadian Journal of Chemistry, 2002, 80, 1217-1222.	0.6	14
99	DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464. Journal of Biological Chemistry, 2002, 277, 48076-48086.	1.6	140
100	DNA and RNA Recognition and Modification by Gly-Gly-His-Derived Metallopeptides. , 0, , 88-125.		0
101	2.4-Ã... Crystal Structure of the Asymmetric Platinum Complex {Pt(ammine)(cyclohexylamine)}2+ Bound to a Dodecamer DNA Duplex. Journal of Biological Chemistry, 2002, 277, 49743-49749.	1.6	66
102	MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA. Journal of Biological Chemistry, 2002, 277, 1255-1260.	1.6	99
103	DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent. Nucleic Acids Research, 2002, 30, 2894-2898.	6.5	54
104	Rearrangement of a 1,3-trans-Pt(NH3)2[(GXG)-N7G,N7G] intrastrand cross-link into interstrand cross-links within RNA duplexes. Nucleic Acids Research, 2002, 30, 5222-5228.	6.5	6
105	Biomolecular Targets for Platinum Antitumor Drugs. Mini-Reviews in Medicinal Chemistry, 2002, 2, 103-111.	1.1	79
106	Metals in Medicine. , 0, , 265-335.		1
107	DNA Interactions of Novel Platinum Anticancer Drugs. , 0, , 178-223.		1
108	Assembly of Gold Nanoparticles on DNA Strands. Materials Research Society Symposia Proceedings, 2002, 735, 941.	0.1	0
109	Assembly of Gold Nanoparticles on DNA Strands. Materials Research Society Symposia Proceedings, 2002, 761, 1.	0.1	1
110	Recent Progress of Functional Glycoconjugated Metal Complexes. Bulletin of the Chemical Society of Japan, 2002, 75, 2097-2113.	2.0	33
111	l-Methionine Inhibits Reaction of DNA with Anticancercis-Diamminedichloroplatinum(II)â€. Biochemistry, 2002, 41, 10994-10999.	1.2	31
112	Formation of Adenineâ˜N3/Guanineâ˜N7 Cross-Link in the Reaction of trans-Oriented Platinum Substrates with Dinucleotides. Journal of the American Chemical Society, 2002, 124, 12854-12862.	6.6	45

#	Article	IF	Citations
113	The HMG1 Ta(i)le. Journal of Biomolecular Structure and Dynamics, 2002, 19, 1053-1062.	2.0	28
114	On the Competition of the Purine Bases, Functionalities of Peptide Side Chains, and Protecting Agents for the Coordination Sites of Dicationic Cisplatin Derivativesâ€. Journal of the American Chemical Society, 2002, 124, 5834-5842.	6.6	90
115	Total Analysis and Purification of Cellular Proteins Binding to Cisplatin-Damaged DNA Using Submicron Beads. Bioconjugate Chemistry, 2002, 13, 163-166.	1.8	31
116	Modification of Second-Sphere Communication, Leading to an Unusually High Abundance of the Head-to-Head Conformer of Cisplatin Cross-Link Retro Models. Inorganic Chemistry, 2002, 41, 546-557.	1.9	31
117	Theoretical Study on the Stability ofN-Glycosyl Bonds:Â Why Does N7-Platination Not Promote Depurination?. Journal of the American Chemical Society, 2002, 124, 4495-4503.	6.6	91
118	Factors Influencing Conformer Equilibria in Retro Models of Cisplatinâ^'DNA Adducts As Revealed by Moderately Dynamic (N,Nâ€˜-Dimethyl-2,3-diaminobutane)PtG2Retro Models (G = a Guanine Derivative). Inorganic Chemistry, 2002, 41, 4923-4935.	1.9	23
119	Cross-Linking of a DNA Conjugate Tethering acis-Bifunctional Platinated Complex to a Target DNA Duplex. Journal of the American Chemical Society, 2002, 124, 9658-9659.	6.6	15
120	A Rationally Designed Genotoxin that Selectively Destroys Estrogen Receptor-Positive Breast Cancer Cells. Journal of the American Chemical Society, 2002, 124, 1862-1863.	6.6	45
121	Novel Apoptosis-Inducingtrans-Platinum Piperidine Derivatives:Â Synthesis and Biological Characterization. Journal of Medicinal Chemistry, 2002, 45, 5196-5204.	2.9	64
122	Organometallic Ruthenium(II) Diamine Anticancer Complexes:Â Arene-Nucleobase Stacking and Stereospecific Hydrogen-Bonding in Guanine Adducts. Journal of the American Chemical Society, 2002, 124, 3064-3082.	6.6	430
123	New aspects of metal-nucleobase chemistry. Advances in Inorganic Chemistry, 2002, 53, 87-158.	0.4	49
124	Reactivity Studies of Anticancer Active Dirhodium Complexes with 2-Aminothiophenol. Inorganic Chemistry, 2002, 41, 433-436.	1.9	35
125	A Novel Isomerization on Interaction of Antitumor-Active Azole-Bridged Dinuclear Platinum(II) Complexes with 9-Ethylguanine. Platinum(II) Atom Migration from N2 to N3 on 1,2,3-Triazole. Journal of the American Chemical Society, 2002, 124, 4738-4746.	6.6	161
126	Kinetics and mechanism of the reactions of [Pt(terpy)H2O]2+ with thiols in acidic aqueous solution. Synthesis and crystal structure of [Pt(terpy)(tu)](ClO4)2 (tu = thiourea). Dalton Transactions RSC, 2002, , 2825.	2.3	50
127	Anti-tumour platinum acylthiourea complexes and their interactions with DNA. Dalton Transactions RSC, 2002, , 3656-3663.	2.3	28
128	Substitution reactions of [Pt(dien)Cl]+, [Pt(dien)(GSMe)]2+, cis-[PtCl2(NH3)2] and cis-[Pt(NH3)2(GSMe)2]2+ (GSMe =S-methylglutathione) with some sulfur-bonding chemoprotective agents. Dalton Transactions RSC, 2002, , 1281.	2.3	36
129	Syntheses, characterisation and photophysical studies of novel biological labelling reagents derived from luminescent iridium(III) terpyridine complexes. New Journal of Chemistry, 2002, 26, 81-88.	1.4	84
130	Kinetics and mechanism of the reaction of chelated Pd(ii) complexes with thiols in acidic aqueous solution. Synthesis and crystal structure of [Pd(bpma)Cl]ClÂ·H2O (bpma = bis(2-pyridylmethyl)amine). Dalton Transactions RSC, 2002, , 951.	2.3	70

#	Article	IF	Citations
131	Kinetic study of the reaction between an antitumor 15N labeled trans-platinum iminoether complex and GMP by [1H, 15N] HMQC NMR. Dalton Transactions RSC, 2002, , 3489.	2.3	21
132	Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA. Biochemical and Biophysical Research Communications, 2002, 295, 945-951.	1.0	58
133	DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair. Progress in Molecular Biology and Translational Science, 2002, 71, 1-68.	1.9	212
134	Molecular aspects of resistance to antitumor platinum drugs. Drug Resistance Updates, 2002, 5, 147-161.	6.5	149
136	Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates. Biochemical Pharmacology, 2002, 64, 191-200.	2.0	78
137	Stereospecificity and Enantioselectivity in the Binding of the Platinum(II) Complex [PtCl2(tmdz)] (tmdz=5,5,7-Trimethyl-1,4-diazacycloheptane) to Dinucleotides and Oligonucleotides. Chemistry - A European Journal, 2002, 8, 5486-5493.	1.7	4
138	Oxa-aza Crown Ethers as Ligands for Mixed-Ligand Cisplatin Derivatives and Dinuclear Platinum Anticancer Drugs. European Journal of Inorganic Chemistry, 2002, 2002, 2375-2379.	1.0	10
139	Apoptosis Induction and DNA Interstrand Cross-Link Formation by Cytotoxictrans-[PtCl2(NH(CH3)2)(NHCH(CH3)2)]: Cross-Linking between d(G) and Complementary d(C) within Oligonucleotide Duplexes. ChemBioChem, 2002, 3, 61-67.	1.3	29
140	Application of capillary electrophoresis-mass spectrometry for the investigation of the binding behavior of oxaliplatin to 5â€™-GMP in the presence of the sulfur-containing amino acid L-methionine. Electrophoresis, 2002, 23, 74.	1.3	32
141	Density functional theory and surface enhanced Raman spectroscopy characterization of novel platinum drugs. Biopolymers, 2002, 67, 294-297.	1.2	19
142	Oligonucleotide analysis with MALDIâ€“ion-mobilityâ€“TOFMS. Analytical and Bioanalytical Chemistry, 2002, 373, 612-617.	1.9	70
143	DNA binding of mixed-metal supramolecular Ru, Pt complexes. Inorganic Chemistry Communication, 2002, 5, 1078-1081.	1.8	22
144	Photoactivation of dichloro(ethylenediamine)platinum(II). Journal of Photochemistry and Photobiology A: Chemistry, 2002, 150, 37-40.	2.0	8
145	Rhodium and its compounds as potential agents in cancer treatment. Critical Reviews in Oncology/Hematology, 2002, 42, 297-308.	2.0	134
146	Studies of the binding of a series of platinum(IV) complexes to plasma proteins. Journal of Inorganic Biochemistry, 2002, 88, 260-267.	1.5	58
147	Interactions of cisplatin and transplatin with proteins. Journal of Inorganic Biochemistry, 2002, 91, 306-311.	1.5	118
148	Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. Journal of Inorganic Biochemistry, 2002, 89, 197-202.	1.5	128
149	Testis-specific HMG-domain protein alters the responses of cells to cisplatin. Journal of Inorganic Biochemistry, 2002, 91, 451-462.	1.5	79

#	Article	IF	Citations
150	Conformation of adenosine-5â€²-triphosphate in the presence of Mg2+ at different pH. Polyhedron, 2002, 21, 435-438.	1.0	14
151	DNA and its associated processes as targets for cancer therapy. Nature Reviews Cancer, 2002, 2, 188-200.	12.8	1,223
152	In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. British Journal of Cancer, 2002, 86, 1652-1657.	2.9	531
153	Ruthenium metallopharmaceuticals. Coordination Chemistry Reviews, 2002, 232, 69-93.	9.5	368
154	Recognition of Major DNA Adducts of Enantiomeric Cisplatin Analogs by HMG Box Proteins and Nucleotide Excision Repair of These Adducts. Chemistry and Biology, 2002, 9, 629-638.	6.2	58
155	Synthesis and spectroscopic properties of anhydrotetracyclineplatinum(II)dichloride. Inorganic Chemistry Communication, 2002, 5, 411-413.	1.8	12
156	Manganese(II) complex of 6,7-dicycanodipyridoquinoxaline with antitumor activities: synthesis, crystal structure and binding with DNA. Journal of Inorganic Biochemistry, 2002, 92, 149-155.	1.5	37
157	Reaction of (SP-4-2)-dichlorobis(2-hydroxyethylamine)platinum(II) with 5â€²-GMP under simulated physiological conditions, a CZE-ESI-MS study. Inorganica Chimica Acta, 2002, 339, 9-13.	1.2	21
158	Determination of platinated purines in oligoribonucleotides by limited digestion with ribonucleases T1 and U2. Analytical Biochemistry, 2002, 310, 42-49.	1.1	6
159	Biophysical analysis of natural, double-helical DNA modified by a dinuclear platinum(II) organometallic compound in a cell-free medium. Journal of Biological Inorganic Chemistry, 2002, 7, 725-734.	1.1	15
160	HPLC determination of binding of cisplatin to DNA in the presence of biological thiols: implications of dominant platinum-thiol binding to its anticancer action. Pharmaceutical Research, 2002, 19, 124-131.	1.7	63
161	DNA modification by cis-diaminoplatinum(ii) complexes with aminonitroxide ligands. Russian Chemical Bulletin, 2002, 51, 1058-1064.	0.4	3
162	Title is missing!. Molecular Biology, 2002, 36, 594-600.	0.4	6
163	Unusual Coordination of the Rare Neutral Imine Tautomer of 9-Methyladenine Chelating in theN6,N7-Mode to Ruthenium(II) Complexes. European Journal of Inorganic Chemistry, 2002, 2002, 369-376.	1.0	27
164	Title is missing!. Angewandte Chemie, 2003, 115, 2236-2238.	1.6	16
165	Tamoxifen Derivatives for Delivery of the Antitumoral (DACH)Pt Group: Selective Synthesis by McMurry Coupling, and Biochemical Behaviour. ChemBioChem, 2003, 4, 754-761.	1.3	54
166	Unprecedented Head-to-Head Conformers of d(GpG) Bound to the Antitumor Active Compound Tetrakis (Î¼-carboxylato)dirhodium(II,II). Journal of the American Chemical Society, 2003, 125, 10703-10713.	6.6	70
167	Stabilization of Duplex DNA Structure and Suppression of Transcription in Vitro by Bis(quinone) Tj ETQq1 1 0.784314 rgBT /Overlock	1.9	61

#	Article	IF	Citations
168	Biochemical Modulation of Cisplatin Mechanisms of Action:â€‰ Enhancement of Antitumor Activity and Circumvention of Drug Resistance. Chemical Reviews, 2003, 103, 645-662.	23.0	796
169	Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn orientation of adenine bases outside the binding sites. Journal of Biological Inorganic Chemistry, 2003, 8, 19-28.	1.1	59
170	Kinetics and mechanism for platination of thione-containing nucleotides and oligonucleotides: evaluation of the salt dependence. Journal of Biological Inorganic Chemistry, 2003, 8, 38-44.	1.1	4
171	Formation of platinated GG cross-links on DNA by photoactivation of a platinum(IV) azide complex. Journal of Biological Inorganic Chemistry, 2003, 8, 741-745.	1.1	48
172	Tumour-inhibiting platinum complexesâ€”state of the art and future perspectives. , 2003, 146, 1-53.		355
173	Recognition of DNA modified by antitumor cisplatin by â€œlatentâ€•and â€œactiveâ€•protein p53. Biochemical Pharmacology, 2003, 65, 1305-1316.	2.0	22
174	Novel Adducts of the Anticancer Drug Oxaliplatin with Glutathione and Redox Reactions with Glutathione Disulfide. European Journal of Inorganic Chemistry, 2003, 2003, 1206-1214.	1.0	51
175	Capillary electrophoresis in anti-cancer metallodrug research: Advances and future challenges. Electrophoresis, 2003, 24, 2023-2037.	1.3	55
176	Platinum-based anticancer agents: Innovative design strategies and biological perspectives. Medicinal Research Reviews, 2003, 23, 633-655.	5.0	305
177	Structure and function of ?metalloantibiotics?. Medicinal Research Reviews, 2003, 23, 697-762.	5.0	195
178	Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Medical and Pediatric Oncology, 2003, 41, 186-189.	1.0	46
179	Chemie und Biologie der DNA-Reparatur. Angewandte Chemie, 2003, 115, 3052-3082.	1.6	36
180	A Bifunctional Platinum(II) Complex Capable of Intercalation and Hydrogen-Bonding Interactions with DNA: Binding Studies and Cytotoxicity. Chemistry - A European Journal, 2003, 9, 6133-6144.	1.7	124
181	GA and AG Sequences of DNA React with Cisplatin at Comparable Rates. Chemistry - A European Journal, 2003, 9, 4739-4745.	1.7	21
182	X-ray Structure and Circular Dichroism of Pure Rotamers of Bis[guanosine-5â€²-monophosphate(â^'1)](N,N,Nâ€²,Nâ€²-tetramethylcyclohexyl-1,2-diamine)platinum(II) Complexes That HaveR,R andS,S Configurations at the Asymmetric Diamine. Chemistry - A European Journal, 2003, 9, 6122-6132.	1.7	32
183	A Versatile Approach Towards Regioselective Platinated DNA Sequences. Chemistry - A European Journal, 2003, 9, 1823-1827.	1.7	6
184	Platinum(II)-Based Coordination Compounds as Nucleic Acid Labeling Reagents: Synthesis, Reactivity, and Applications in Hybridization Assays. ChemBioChem, 2003, 4, 573-583.	1.3	32
185	Chemistry and Biology of DNA Repair. Angewandte Chemie - International Edition, 2003, 42, 2946-2974.	7.2	343

#	Article	IF	Citations
186	Facile Formation of N-Confused Porphyrin Dimers by Platinum(II) Coordination to the Outer-Nitrogen Atoms. Angewandte Chemie - International Edition, 2003, 42, 2186-2188.	7.2	58
187	Direct evidence for co-binding of cisplatin and cadmium to a native zinc- and cadmium-containing metallothionein. Applied Organometallic Chemistry, 2003, 17, 675-681.	1.7	21
188	Cisplatin adducts of d(CCTCTG*G*TCTCC)Â·d(GGAGACCAGAGG) in aqueous solution by vibrational circular dichroism spectroscopy. Biopolymers, 2003, 72, 490-499.	1.2	9
189	Interaction of anticancer drug cisplatin with guanine: Density functional theory and surface-enhanced Raman spectroscopy study. Biopolymers, 2003, 72, 472-489.	1.2	29
190	Synthesis of 17Î²-estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3927-3931.	1.0	75
191	Cisplatin analogues with 2,2â€²-dipyridylamine ligands and their reactions with DNA model nucleobases. Inorganica Chimica Acta, 2003, 350, 355-365.	1.2	67
192	The synthesis, structural characterization, and in vitro anti-cancer activity of chloro(p-cymene) complexes of ruthenium(II) containing a disulfoxide ligand. Inorganica Chimica Acta, 2003, 352, 238-246.	1.2	64
193	Studies on the interaction of altromycin B and its platinum(II) and palladium(II) metal complexes with calf thymus DNA and nucleotides. Journal of Inorganic Biochemistry, 2003, 95, 177-193.	1.5	37
194	Kinetic study of azole-bridged dinuclear platinum(II) complexes reacting with a hairpin-stabilized double-stranded oligonucleotide. Journal of Inorganic Biochemistry, 2003, 96, 357-366.	1.5	39
195	Platinum complexes of diaminocarboxylic acids and their ethyl ester derivatives: the effect of the chelate ring size on antitumor activity and interactions with GMP and DNA. Journal of Inorganic Biochemistry, 2003, 96, 493-502.	1.5	45
196	Quantum chemical studies on newly synthesized tin anticancer compounds. Computational and Theoretical Chemistry, 2003, 630, 291-295.	1.5	12
197	Influence of sodium dodecyl sulfate on the kinetics of complex formation between [PdCl(dien)]+ and sulfur containing ligands l-cysteine and glutathione. Polyhedron, 2003, 22, 279-285.	1.0	18
198	Cisplatin forms a 1:2 complex with ATP in aqueous solutions between pH 2 and 9. Polyhedron, 2003, 22, 611-616.	1.0	3
199	Novel reactivity of unconjugated diimines with [PtCl2(coe)]2 (coe=cis-cyclooctene). Inorganic Chemistry Communication, 2003, 6, 1086-1090.	1.8	2
200	New metal complexes as potential therapeutics. Current Opinion in Chemical Biology, 2003, 7, 481-489.	2.8	863
201	The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutathione-depleted human promonocytic cells. Cell Death and Differentiation, 2003, 10, 889-898.	5.0	105
202	Synthesis, characterization and in vitro cytotoxic, mutagenic and antimicrobial activity of platinum(II) complexes with substituted benzimidazole ligands. Journal of Inorganic Biochemistry, 2003, 94, 255-262.	1.5	54
203	Platinum(II) catalysis and radical intervention in reductions of platinum(IV) antitumor drugs by ascorbic acid. Journal of Inorganic Biochemistry, 2003, 95, 231-239.	1.5	49

#	Article	IF	Citations
204	Synthesis, cytotoxic activity on MCF-7 cell line and mutagenic activity of platinum(II) complexes with 2-substituted benzimidazole ligands. European Journal of Medicinal Chemistry, 2003, 38, 473-480.	2.6	74
206	Synthesis and evaluation of peptidomimetics that bind DNA. Bioorganic and Medicinal Chemistry, 2003, 11, 2355-2365.	1.4	3
207	Synthesis, Characterization, and DNA Binding Properties of a Series of Ru, Pt Mixed-Metal Complexes. Inorganic Chemistry, 2003, 42, 4394-4400.	1.9	83
208	Toward Novel DNA Binding Metal Complexes:Â Structure and Basic Kinetic Data of [M(9MeG)2(CH3OH)(CO)3]+(M =99Tc, Re). Inorganic Chemistry, 2003, 42, 2818-2820.	1.9	62
209	Cisplatin-DNA Adducts by Vibrational Circular Dichroism Spectroscopy:Â Structure and Isomerization of d(CCTG*G*TCC)Â·d(GGACCAGG) Intrastrand Cross-Linked by Cisplatin. Journal of Physical Chemistry B, 2003, 107, 6479-6485.	1.2	13
210	NMR and Theoretical Investigations on the Structures and Dynamics of Octahedral Bis(chelate)dichloro VIII Compounds Isolated by an Unusual Reduction of Non-Oxo VIV Species. Inorganic Chemistry, 2003, 42, 4640-4649.	1.9	10
211	Nucleotide Excision Repair from Site-Specifically Platinum-Modified Nucleosomesâ€. Biochemistry, 2003, 42, 6747-6753.	1.2	98
212	cis-{Pt(NH3)2(L)}2+/+(L = Cl, H2O, NH3) Binding to Purines and CO:Â Does Ï€-Back-Donation Play a Role?. Inorganic Chemistry, 2003, 42, 8615-8617.	1.9	16
213	Nature of Full-Length HMGB1 Binding to Cisplatin-Modified DNAâ€. Biochemistry, 2003, 42, 2664-2671.	1.2	97
214	Isolation of the Novel Dirhodium(II/II) Thiolate Compound Rh2(Î·1-C6H5S)2(Î¼-C6H5S)2(bpy)2. Inorganic Chemistry, 2003, 42, 661-663.	1.9	18
215	Theoretical Study of Cisplatin Binding to Purine Bases:Â Why Does Cisplatin Prefer Guanine over Adenine?. Journal of the American Chemical Society, 2003, 125, 14082-14092.	6.6	256
216	How Strong Can the Bend Be on a DNA Helix from Cisplatin? DFT and MP2 Quantum Chemical Calculations of Cisplatin-Bridged DNA Purine Bases. Inorganic Chemistry, 2003, 42, 7162-7172.	1.9	71
217	Novel Binding Interactions of the DNA Fragment d(pGpG) Cross-Linked by the Antitumor Active Compound Tetrakis(Î¼-carboxylato)dirhodium(II,II). Journal of the American Chemical Society, 2003, 125, 10714-10724.	6.6	71
218	Inhibition of Transcription in Vitro by Anticancer Active Dirhodium(II) Complexes. Inorganic Chemistry, 2003, 42, 1267-1271.	1.9	70
219	DNA Interactions of Monofunctional Organometallic Ruthenium(II) Antitumor Complexes in Cell-free Media. Biochemistry, 2003, 42, 11544-11554.	1.2	309
220	DNA Binding Mode of the Cis and Trans Geometries of New Antitumor Nonclassical Platinum Complexes Containing Piperidine, Piperazine, or 4-Picoline Ligand in Cell-Free Media. Relations to Their Activity in Cancer Cell Linesâ€. Biochemistry, 2003, 42, 6321-6332.	1.2	109
221	Reaction of Polynuclear Platinum Antitumor Compounds with Reduced Glutathione Studied by Multinuclear (1H,1Hâ^'15N Gradient Heteronuclear Single-Quantum Coherence, and195Pt) NMR Spectroscopy. Inorganic Chemistry, 2003, 42, 5498-5506.	1.9	86
222	DNA and RNA as Ligands. , 2003, , 787-813.		13

#	Article	IF	Citations
224	DNA Binding by Antitumortrans-[PtCl2(NH3)(thiazole)]. Protein Recognition and Nucleotide Excision Repair of Monofunctional Adductsâ€. Biochemistry, 2003, 42, 792-800.	1.2	83
225	Extending solid-phase methods in inorganic synthesis: the first dinuclear platinum complex synthesised via the solid phaseElectronic supplementary information (ESI) available: Definitions for abbreviations used, and synthesis of 1a, 1b, 4 and 7. See http://www.rsc.org/suppdata/cc/b2/b212388f/. Chemical Communications, 2003, , 634-635.	2.2	29
226	Unprecedented Monofunctional Metalation of Adenine Nucleobase in Guanine- and Thymine-Containing Dinucleotide Sequences by a Cytotoxic Platinumâ^'Acridine Hybrid Agent. Journal of the American Chemical Society, 2003, 125, 9629-9637.	6.6	50
227	2-Thiophen-2-ylbenzothiazole, -benzoxazole, and -benzimidazole platinum complexes. Canadian Journal of Chemistry, 2003, 81, 861-865.	0.6	7
228	Similar rates for platination of hairpin loops and single-stranded DNA. Dalton Transactions, 2003, , 2867-2871.	1.6	3
229	Unwinding of DNA polymerases by the antitumor drug, cis-diamminedichloroplatinum(ii). Chemical Communications, 2003, , 1128-1129.	2.2	13
230	DNA binding of the anti-cancer platinum complex trans-[{Pt(NH3)2Cl}2Î¼-dpzm]2+. Dalton Transactions, 2003, , 3486-3492.	1.6	25
231	Synthesis and characterization of new transition metal complexes containing DNA intercalators of the acridine family. New Journal of Chemistry, 2003, 27, 1497.	1.4	13
232	Structural evidence for monodentate binding of guanine to the dirhodium(ii,ii) core in a manner akin to that of cisplatin. Dalton Transactions, 2003, , 4426-4430.	1.6	18
233	Reaction of (C-(6-aminomethyl-pyridin-2-yl)methylamine)chloroplatinum(ii) with nucleosides and its biological activity. Dalton Transactions, 2003, , 184-188.	1.6	12
234	Ground-State Stability and Rotational Activation Parameters for Individual Rotamers of (R,S,S,R)-(N,Nâ€˜-Dimethyl-2,3-diaminobutane)PtG2 Complexes (G = 9-EtG, 3â€˜-GMP, and 5â€˜-GMP). Inorganic Chemistry, 2003, 42, 997-1005.	1.9	16
235	Unusual intercalation of acridin-9-ylthiourea into the 5'-GA/TC DNA base step from the minor groove: implications for the covalent DNA adduct profile of a novel platinum-intercalator conjugate. Nucleic Acids Research, 2003, 31, 4138-4146.	6.5	43
236	Multiple States of Stalled T7 RNA Polymerase at DNA Lesions Generated by Platinum Anticancer Agents. Journal of Biological Chemistry, 2003, 278, 52084-52092.	1.6	32
237	New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3611-3616.	3.3	584
238	Synthesis and in vitro reactivity of cis-dichloro-(pyridin-2-ylcarboxaldimine)platinum(II) complexes with DNA. Canadian Journal of Chemistry, 2003, 81, 269-274.	0.6	26
239	DNA-protein cross-linking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans geometry in platinum antitumor complexes. Nucleic Acids Research, 2003, 31, 6450-6460.	6.5	94
240	HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB Journal, 2003, 17, 1295-1297.	0.2	181
241	Cisplatin Sensitivity in Hmgb1â^'/â^' and Hmgb1+/+ Mouse Cells. Journal of Biological Chemistry, 2003, 278, 1769-1773.	1.6	36

#	Article	IF	Citations
242	Nuclease-Deficient FEN-1 Blocks Rad51/BRCA1-Mediated Repair and Causes Trinucleotide Repeat Instability. Molecular and Cellular Biology, 2003, 23, 6063-6074.	1.1	73
243	Activation of Trans Geometry in Bifunctional Mononuclear Platinum Complexes by a Piperidine Ligand. Journal of Biological Chemistry, 2003, 278, 47516-47525.	1.6	60
244	Binding Discrimination of MutS to a Set of Lesions and Compound Lesions (Base Damage and Mismatch) Reveals Its Potential Role as a Cisplatin-damaged DNA Sensing Protein. Journal of Biological Chemistry, 2003, 278, 21267-21275.	1.6	50
245	The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer. Current Medicinal Chemistry, 2004, 11, 2505-2517.	1.2	252
246	Platinum-Intercalator Conjugates: From DNA-Targeted Cisplatin Derivatives to Adenine Binding Complexes as Potential Modulators of Gene Regulation. Current Topics in Medicinal Chemistry, 2004, 4, 1537-1549.	1.0	99
247	Microelectrochemical Techniques for Probing Kinetics at Liquid/Liquid Interfaces. Progress in Reaction Kinetics and Mechanism, 2004, 29, 43-166.	1.1	13
248	Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Nucleic Acids Research, 2004, 32, 5546-5552.	6.5	21
249	SMC1 coordinates DNA double-strand break repair pathways. Nucleic Acids Research, 2004, 32, 3921-3929.	6.5	67
250	Cisplatin-induced Post-translational Modification of Histones H3 and H4. Journal of Biological Chemistry, 2004, 279, 20622-20625.	1.6	50
251	DNA Damage-Processing Pathways Involved in the Eukaryotic Cellular Response to Anticancer DNA Cross-Linking Drugs. Molecular Pharmacology, 2004, 65, 1496-1506.	1.0	59
252	Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. Journal of Internal Medicine, 2004, 255, 332-343.	2.7	316
253	Oxaliplatin. Nature Reviews Drug Discovery, 2004, 3, 11-12.	21.5	228
254	Biological evaluation of novel Pt(II) and Pd(II) complexes with pyrazole-containing ligands. European Journal of Pharmacology, 2004, 502, 59-65.	1.7	70
255	Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. Biochemical Pharmacology, 2004, 67, 17-30.	2.0	49
256	DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand. Biochemical Pharmacology, 2004, 67, 1097-1109.	2.0	39
257	Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chemico-Biological Interactions, 2004, 148, 37-48.	1.7	40
258	Structure of cis-[Pt(NH3)(2-picoline)]2+ and DNA adduct and its bonding characteristics. Science in China Series B: Chemistry, 2004, 47, 67.	0.8	1
259	The Effect of Ca2+Ions on DNA Compaction in the Complex with HMGB1 Nonhistone Chromosomal Protein. Molecular Biology, 2004, 38, 590-600.	0.4	7

#	Article	IF	Citations
260	Dinuclear platinum complexes with N,Nâ€²-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part I. Synthesis, cytotoxicity, and cellular studies in A2780 human ovarian carcinoma cells. Journal of Biological Inorganic Chemistry, 2004, 9, 403-413.	1.1	52
261	Structureâ€“activity relationships in platinumâ€“acridinylthiourea conjugates: effect of the thiourea nonleaving group on drug stability, nucleobase affinity, and in vitro cytotoxicity. Journal of Biological Inorganic Chemistry, 2004, 9, 453-461.	1.1	42
262	Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties. Journal of Biological Inorganic Chemistry, 2004, 9, 768-780.	1.1	36
263	Preconcentration and Separation Procedures for the Spectrochemical Determination of Platinum and Palladium. Mikrochimica Acta, 2004, 147, 189-210.	2.5	119
264	Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir. Journal of Inorganic Biochemistry, 2004, 98, 1385-1390.	1.5	30
265	Triplex mediated delivery of a platinum complex to a specific DNA target site. Journal of Inorganic Biochemistry, 2004, 98, 1570-1577.	1.5	14
266	Improved potency of cisplatin by hydrophobic ion pairing. Cancer Chemotherapy and Pharmacology, 2004, 54, 441-448.	1.1	30
267	First bent form for the hydroxo-bridged cis-diammineplatinum(II) dimer [Pt2(NH3)4(Î¼-OH)2](ClO4)2. Acta Crystallographica Section B: Structural Science, 2004, 60, 255-262.	1.8	14
268	[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) Complexes, Compounds for the Endocrine Therapy of Breast Cancer - Mode of Action I: Antitumor Activity Due to the Reduction of the Endogenous Estrogen Level. Archiv Der Pharmazie, 2004, 337, 335-348.	2.1	11
269	Novel Cytotoxic Copper(II) Complexes of 8-Aminoquinoline Derivatives: Crystal Structure and Different Reactivity towards Glutathione. European Journal of Inorganic Chemistry, 2004, 2004, 4028-4035.	1.0	33
270	A Kinetic Study on the Reactions of Azolato-Bridged Dinuclear Platinum(II) Complexes with Guanosine 5?-Monophosphate. European Journal of Inorganic Chemistry, 2004, 2004, 4828-4835.	1.0	19
271	Synthesis and reactivity of sulfonamides containing boronate esters. Heteroatom Chemistry, 2004, 15, 369-375.	0.4	5
272	Flavonoid compounds: a review of anticancer properties and interactions withcis-diamminedichloroplatinum(II). Drug Development Research, 2004, 63, 200-211.	1.4	64
273	ZNF143 activates gene expression in response to DNA damage and binds to cisplatin-modified DNA. International Journal of Cancer, 2004, 111, 900-909.	2.3	35
274	Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. International Journal of Cancer, 2004, 112, 974-985.	2.3	138
275	Hydrogen bonding, solvation, and hydrolysis of cisplatin: A theoretical study. Journal of Computational Chemistry, 2004, 25, 1060-1067.	1.5	73
276	Contribution of electrospray mass spectrometry for the characterization, design, and development of nitrido technetium and rhenium heterocomplexes as potential radiopharmaceuticals. Mass Spectrometry Reviews, 2004, 23, 309-332.	2.8	18
277	Analysis of Platinum Adducts with DNA Nucleotides and Nucleosides by Capillary Electrophoresis Coupled to ESI-MS: Indications of Guanosine 5â€²-Monophosphate O6-N7 Chelation. ChemBioChem, 2004, 5, 1543-1549.	1.3	52

#	Article	IF	Citations
278	Comparative study between the interaction of dephosphorylated amifostine (WR-1065) and amoxicilline with pBR322 in absence and presence of cisplatin by AFM. International Journal of Pharmaceutics, 2004, 270, 75-82.	2.6	5
279	Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancersâ€"molecular modeling studies. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5919-5924.	1.0	51
280	Binding of palladium(II) complexes to guanine, guanosine or guanosine 5â€²-monophosphate in aqueous solution: potentiometric and NMR studies. Inorganica Chimica Acta, 2004, 357, 411-420.	1.2	33
281	Synthesis, crystal structure and photo-induced DNA cleavage activity of ternary copper(II)-thiosemicarbazone complexes having heterocyclic bases. Inorganica Chimica Acta, 2004, 357, 2315-2323.	1.2	79
282	Kinetics and mechanism of the complex formation of [Pd(NNN)Cl]+ with pyridines in methanol: synthesis and crystal structure of [Pd(terpy)(py)](ClO4)2. Inorganica Chimica Acta, 2004, 357, 2650-2656.	1.2	45
283	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-Î²2N,O)platinum(II) â€" a representative of novel pH sensitive anticancer platinum complexes. Inorganica Chimica Acta, 2004, 357, 3237-3244.	1.2	46
284	Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Journal of Organometallic Chemistry, 2004, 689, 2242-2249.	0.8	91
285	The binding properties of photosensitizer methylene blue to herring sperm DNA: a spectroscopic study. Journal of Photochemistry and Photobiology B: Biology, 2004, 74, 119-125.	1.7	127
286	Electrochemical and spectroscopic analysis of the interaction of molybdenocene dichloride with nitrogen bases. Journal of Electroanalytical Chemistry, 2004, 565, 77-83.	1.9	12
287	DNA binding and cleavage properties of certain tetrammine ruthenium(II) complexes of modified 1,10-phenanthrolines â€" effect of hydrogen-bonding on DNA-binding affinity. Journal of Inorganic Biochemistry, 2004, 98, 219-230.	1.5	458
288	Coordination modes vs. antitumor activity: synthesis and antitumor activity of novel platinum(II) complexes of N -substituted amino dicarboxylic acids. Journal of Inorganic Biochemistry, 2004, 98, 98-104.	1.5	39
289	Protonated nucleobase ligands: synthesis, structure and characterization of 9-methyladeninium hexachloroplatinate and pentachloro(9-methyladeninium)platinum(IV). Journal of Inorganic Biochemistry, 2004, 98, 439-446.	1.5	12
290	Pd(II) and Pt(II) complexes with aromatic diamines: study of their interaction with DNA. Journal of Inorganic Biochemistry, 2004, 98, 510-521.	1.5	30
291	Studies on activities, cell up take and DNA binding of four multinuclear complexes of the form: [{trans-PtCl(NH3)2}2Î¼-{trans-Pd(NH3)2-(H2N(CH2)nNH2)2}]Cl4 where n=4â€"7. Journal of Inorganic Biochemistry, 2004, 98, 1722-1733.	1.5	27
292	Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride. Journal of Inorganic Biochemistry, 2004, 98, 1987-1994.	1.5	54
293	Synthesis, characterization, and cytotoxic activity of copper(II) and platinum(II) complexes of 2-benzoylpyrrole and X-ray structure of bis[2-benzoylpyrrolato(N,O)]copper(II). Journal of Inorganic Biochemistry, 2004, 98, 2071-2079.	1.5	9
294	Pyridyl benzimidazole, benzoxazole, and benzothiazole platinum complexes. Polyhedron, 2004, 23, 155-160.	1.0	57
295	Synthesis, characterization, and cytotoxicities of palladium(II) and platinum(II) complexes containing fluorinated pyridinecarboxaldimines. Polyhedron, 2004, 23, 2169-2176.	1.0	39

#	Article	IF	Citations
296	Novel platinum complexes having chirality and free tertiary amine groups for multiple interactions with DNA. Inorganic Chemistry Communication, 2004, 7, 1178-1180.	1.8	3
297	Synthesis, Characterization, and Cytotoxicity of a Series of Estrogen-Tethered Platinum(IV) Complexes. Chemistry and Biology, 2004, 11, 557-564.	6.2	246
298	Amperometric DNA biosensor for the determination of auto-antibodies using DNA interaction with Pt(II) complex. Analytica Chimica Acta, 2004, 502, 23-30.	2.6	26
299	Synthesis, characterisation, activities, cell uptake and DNA binding of [{trans-PtCl(NH3)2} {Î¼-(H2N(CH2)6NH2)} {trans-PdCl(NH3)2](NO3)Cl. European Journal of Medicinal Chemistry, 2004, 39, 947-958.	2.6	22
300	Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 233-242.	1.1	130
301	A nucleic acid base derivative tethered to a ruthenium carbene complex: hydrogen bonded dimers in both the solid state and solution?. Chemical Communications, 2004, , 1364-1365.	2.2	17
302	Substitution reactions of [Pt(terpy)X]2+with some biologically relevant ligands. Synthesis and crystal structure of [Pt(terpy)(cyst-S)](ClO4)2Â·0.5H2O and [Pt(terpy)(guo-N7)](ClO4)2Â·0.5guoÂ·1.5H2O. Dalton Transactions, 2004, , 279-286.	1.6	77
303	The influence of a sugar-phosphate backbone on the cisplatin-bridged BpB? models of DNA purine bases. Quantum chemical calculations of Pt(ii) bonding characteristics. Physical Chemistry Chemical Physics, 2004, 6, 3585.	1.3	46
304	Switching extended 1,3-diequatorial and bent 1,3-diaxial states of a disubstituted hinge sugar by ligand exchange reactions on Pt(ii)Electronic supplementary information (ESI) available: experimental procedures and full characterization of the reported compounds. See http://www.rsc.org/suppdata/cc/b3/b311811h/. Chemical Communications, 2004, , 94.	2.2	12
305	Platinum pyridinecarboxaldimine complexes containing boronate esters. Canadian Journal of Chemistry, 2004, 82, 1692-1699.	0.6	8
306	Factors Governing the Kinetic Competition of Nitrogen and Sulfur Ligands in Cisplatin Binding to Biological Targetsâ€. Journal of the American Chemical Society, 2004, 126, 5999-6004.	6.6	85
307	Tuning the DNA Reactivity ofcis-Platinum:Â Conjugation to a Mismatch-Specific Metallointercalator. Journal of the American Chemical Society, 2004, 126, 14728-14729.	6.6	45
308	Identification of Nuclear Proteins that Interact with Platinum-Modified DNA by Photoaffinity Labeling. Journal of the American Chemical Society, 2004, 126, 6536-6537.	6.6	57
309	Binding of DNA Purine Sites to Dirhodium Compounds Probed by Mass Spectrometry. Inorganic Chemistry, 2004, 43, 6177-6187.	1.9	39
310	Interaction of Oxaliplatin, Cisplatin, and Carboplatin with Hemoglobin and the Resulting Release of a Heme Group. Chemical Research in Toxicology, 2004, 17, 1391-1397.	1.7	98
311	Effect of Equatorial Ligands of Dirhodium(II,II) Complexes on the Efficiency and Mechanism of Transcription Inhibitionin Vitro. Inorganic Chemistry, 2004, 43, 1175-1183.	1.9	51
312	Cisplatin Binding to DNA Oligomers from Hybrid Car-Parrinello/Molecular Dynamics Simulations. Journal of Physical Chemistry B, 2004, 108, 2699-2707.	1.2	109
313	Trifunctional Dinuclear Platinum Complexes as DNAâ^'Protein Cross-Linking Agents. Biochemistry, 2004, 43, 7776-7786.	1.2	35

#	Article	IF	Citations
314	Synthesis, Photophysical Properties, and Biomolecular Labeling Studies of Luminescent Platinum(II)-Terpyridyl Alkynyl Complexes. Organometallics, 2004, 23, 3459-3465.	1.1	148
315	Multivariate Curve Resolution Applied to the Analysis and Resolution of Two-Dimensional [1H,15N] NMR Reaction Spectra. Analytical Chemistry, 2004, 76, 7094-7101.	3.2	55
316	Primer on Medical Genomics: Part XII: Pharmacogenomicsâ€"General Principles With Cancer as a Model. Mayo Clinic Proceedings, 2004, 79, 376-384.	1.4	29
317	Effect of Amine Ligand Bulk on the Interaction of Methionine with Platinum(II) Diamine Complexes. Inorganic Chemistry, 2004, 43, 1190-1196.	1.9	32
318	Bis(dipyridophenazine)copper(ii) complex as major groove directing synthetic hydrolase. Dalton Transactions, 2004, , 1896.	1.6	87
319	Head-to-Head (HH) and Head-to-Tail (HT) Conformers ofcis-Bis Guanine Ligands Bound to the [Re(CO)3]+Core. Inorganic Chemistry, 2004, 43, 2087-2096.	1.9	40
320	Photoinitiated DNA Binding bycis-[Ru(bpy)2(NH3)2]2+. Inorganic Chemistry, 2004, 43, 7260-7262.	1.9	128
321	Equilibrium, kinetic and HPLC study of the reactions between platinum(ii) complexes and DNA constituents in the presence and absence of glutathione. Dalton Transactions, 2004, , 3869-3877.	1.6	43
322	Metallomics as integrated biometal science. Journal of Analytical Atomic Spectrometry, 2004, 19, 5.	1.6	332
323	Induction of apoptosis and necrosis in lymphocytes by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2004, 558, 169-179.	0.9	35
324	Activation of tubulin assembly into microtubules upon a series of repeated femtosecond laser impulses. Journal of Chemical Physics, 2004, 121, 11345.	1.2	9
325	First Bivalent Palladium and Platinum Cyanoximates:Â Synthesis, Characterization, and Biological Activityâ€. Inorganic Chemistry, 2004, 43, 3894-3909.	1.9	55
326	Covalent modification of DNA by cis-Rh(phen)2Cl2+ upon irradiation in the Red Region. Toxicology in Vitro, 2004, 18, 45-53.	1.1	5
327	Platinums: Extending Their Therapeutic Spectrum. Journal of Chemotherapy, 2004, 16, 77-82.	0.7	55
328	Molecular Structure and Bonding in Platinum-Picoline Anticancer Complex: Density Functional Study. Collection of Czechoslovak Chemical Communications, 2004, 69, 63-72.	1.0	14
329	Effect of copper-sulphur bond on the DNA photo-cleavage activity of 2-(methylthio)ethylpyridine-2-carbaldimine copper(II) complexes. Journal of Chemical Sciences, 2005, 117, 123-132.	0.7	10
330	The Facettes of [99TcCl3 (CO) 3]2- Chemistry and Its Application to Life Science. Journal of Nuclear and Radiochemical Sciences, 2005, 6, 173-176.	0.7	9
331	Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming units. Anti-Cancer Drugs, 2005, 16, 1071-1073.	0.7	45

#	Article	IF	Citations
332	In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. Anti-Cancer Drugs, 2005, 16, 1091-1098.	0.7	105
333	Selective and Monofunctional Guanosine 5â€²-Monophosphate Binding by Chloro[3-(2,3-diaminopropionylamino)propionic acid](dimethyl sulfoxide)platinum(II) Complex. Bulletin of the Chemical Society of Japan, 2005, 78, 1629-1634.	2.0	3
334	44Ru Perspectives of Ruthenium Complexes in Cancer Therapy. , 2005, , 359-378.		7
335	Continuous Exposure to Low-Dose Cisplatin and Apoptosis. Biological and Pharmaceutical Bulletin, 2005, 28, 1954-1957.	0.6	16
336	Identification of bifunctional GA and AG intrastrand crosslinks formed between cisplatin and DNA. Journal of Inorganic Biochemistry, 2005, 99, 552-559.	1.5	25
337	Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3Â·H2O. Journal of Inorganic Biochemistry, 2005, 99, 795-804.	1.5	42
338	Effects of Tris and Hepes buffers on the interaction of palladiumâ€“diaminopropane complexes with DNA. Journal of Inorganic Biochemistry, 2005, 99, 1360-1368.	1.5	43
339	Synthesis, structure, and reactivity of monofunctional platinum(II) and palladium(II) complexes containing the sterically hindered ligand 6-(methylpyridin-2-yl)acetate. Journal of Inorganic Biochemistry, 2005, 99, 2013-2023.	1.5	16
340	Interaction of N-acetylmethionine with a non-C2-symmetrical platinum diamine complex. Journal of Inorganic Biochemistry, 2005, 99, 2119-2126.	1.5	8
341	Mixed complexes of Pt(II) and Pd(II) with ethylsarcosinedithiocarbamate and 2-/3-picoline as antitumor agents. Journal of Inorganic Biochemistry, 2005, 99, 2139-2150.	1.5	47
342	Studies of interaction of dichloro[Î·2-dimethyl-(2-methylidene-cyclohexylmethyl)-amino]platinum(II) with DNA: Effects on secondary and tertiary structures of DNA â€“ Cytotoxic assays on human cancer cell lines Capan 1 and A431. Journal of Inorganic Biochemistry, 2005, 99, 2387-2394.	1.5	12
343	A trimethoxyphenyl substituted ansa-titanocene: A possible anti-cancer drug. Polyhedron, 2005, 24, 1250-1255.	1.0	40
344	Structural perturbation of a C4 zinc-finger module by cis-diamminedichloroplatinum(II): insights into the inhibition of transcription processes by the antitumor drug. Inorganica Chimica Acta, 2005, 358, 2844-2854.	1.2	31
345	Synthesis, characterization, and cytotoxicities of platinum(II) complexes bearing pyridinecarboxaldimines containing bulky aromatic groups. Inorganica Chimica Acta, 2005, 358, 63-69.	1.2	30
346	Syntheses and activity of some platinum(IV) complexes with N-methyl derivate of glycine and halogeno ligands against HeLa, K562 cell lines and human PBMC. Inorganica Chimica Acta, 2005, 358, 2239-2245.	1.2	22
347	Synthesis, crystal structure and photo-induced DNA cleavage activity of ternary copper(II) complexes of NSO-donor Schiff bases and NN-donor heterocyclic ligands. Inorganica Chimica Acta, 2005, 358, 2437-2444.	1.2	70
348	Synthesis of 17Î²-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells. Bioorganic Chemistry, 2005, 33, 1-15.	2.0	48
349	Synthesis and pharmacological activities of some mononuclear Ru(II) complexes. Bioorganic and Medicinal Chemistry, 2005, 13, 5766-5773.	1.4	41

#	Article	IF	Citations
350	A non-crosslinking platinumâ€“acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 443-446.	1.0	25
351	Conformation of DNA Modified by Monofunctional Ru(II) Arene Complexes: Recognition by DNA Binding Proteins and Repair. Relationship to Cytotoxicity. Chemistry and Biology, 2005, 12, 121-129.	6.2	124
352	Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Critical Reviews in Oncology/Hematology, 2005, 53, 3-11.	2.0	306
353	Synthesis, in vitro cytotoxic and antiviral activity of cis-[Pt(R(â€“) and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 627 Td (S(+)-2-Î±-h 40, 135-141.	2.6	52
354	Synthesis, characterization, activities, cell uptake and DNA binding of trinuclear complex: [{trans-PtCl(NH3)}2Î¼-{trans-Pt(NH3)(2-hydroxypyridine)-(H2N(CH2)6NH2)2]Cl4. European Journal of Medicinal Chemistry, 2005, 40, 772-781.	2.6	55
355	Covalent Binding and Interstrand Cross-Linking of Duplex DNA by Dirhodium(II,II) Carboxylate Compoundsâ€. Biochemistry, 2005, 44, 996-1003.	1.2	61
356	Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery, 2005, 4, 307-320.	21.5	3,194
357	Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia cells via glutathione-independent reduction in intracellular drug accumulation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2005, 1743, 269-279.	1.9	28
358	The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes. Biochemical Pharmacology, 2005, 70, 1137-1146.	2.0	46
359	DNAâ€Based Assembly of Metal Nanoparticles. European Journal of Inorganic Chemistry, 2005, 2005, 3641-3655.	1.0	116
360	Analysis of anticancer platinum(II)-complexes by microemulsion electrokinetic chromatography: Separation of diastereomers and estimation of octanol-water partition coefficients. Electrophoresis, 2005, 26, 878-884.	1.3	54
361	RNA-Selective Modification by a Platinum(II) Complex Conjugated to Amino- and Guanidinoglycosides. Angewandte Chemie - International Edition, 2005, 44, 927-932.	7.2	37
362	Heteroaryl substitutedansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Applied Organometallic Chemistry, 2005, 19, 293-300.	1.7	68
364	DNA Interstrand Crosslinks: Natural and Drug-Induced DNA Adducts that Induce Unique Cellular Responses. ChemBioChem, 2005, 6, 27-32.	1.3	162
365	Synthesis, Characterization and Biological Activity of trans-Platinum(II) and trans-Platinum(IV) Complexes with 4-Hydroxymethylpyridine. ChemBioChem, 2005, 6, 2068-2077.	1.3	19
366	Loss of Ammine from Platinum(II) Complexes: Implications for Cisplatin Inactivation, Storage, and Resistance. Chemistry - A European Journal, 2005, 11, 2849-2855.	1.7	89
367	Influence of dT20 and [d(AT)10]2 on Cisplatin Hydrolysis Studied by Two-Dimensional [1H,15N] HMQC NMR Spectroscopy. Chemistry - A European Journal, 2005, 11, 3863-3871.	1.7	37
368	Rotamer Stability incis-[Pt(diA)G2] Complexes (diA=Diamine Derivative and G=Guanine Derivative) Mediated by Carrier-Ligand Amine Stereochemistry as Revealed by Circular Dichroism Spectroscopy. Chemistry - A European Journal, 2005, 11, 5302-5310.	1.7	27

#	Article	IF	Citations
369	G-G Base-Pairing in Nucleobase Adducts of the Anticancer Drugcis-[PtCl2(NH3)(2-picoline)] and ItstransIsomer. Chemistry - A European Journal, 2005, 11, 4396-4404.	1.7	17
370	Roles of Volume-sensitive Clâ˜ Channel in Cisplatin-induced Apoptosis in Human Epidermoid Cancer Cells. Journal of Membrane Biology, 2005, 205, 139-145.	1.0	54
371	Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin. Cancer Chemotherapy and Pharmacology, 2005, 56, 337-343.	1.1	24
372	Linear free energy relationship for 4-substituted (o-phenylenediamine)platinum(II) dichloride derivatives using quantum mechanical descriptors. Journal of Inorganic Biochemistry, 2005, 99, 575-583.	1.5	25
373	Study of the reactions between platinum(II) complexes and l-methionine in the presence and absence of 5â€²-GMP. Journal of Inorganic Biochemistry, 2005, 99, 1472-1479.	1.5	67
374	Novel benzyl substituted titanocene anti-cancer drugs. Journal of Organometallic Chemistry, 2005, 690, 4537-4544.	0.8	118
375	Synthesis, structure and biological activity of a new and efficient Cd(II)â€“uracil derivative complex system for cleavage of DNA. Journal of Biological Inorganic Chemistry, 2005, 10, 924-934.	1.1	36
376	Dinuclear platinum anticancer complexes with fluorescent N,Nâ€²-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles. Journal of Biological Inorganic Chemistry, 2005, 10, 305-315.	1.1	41
377	Synthesis, characterization and DNA-binding properties of mixed porphyrin?polypyridyl ruthenium(II) complexes. Transition Metal Chemistry, 2005, 30, 82-88.	0.7	20
378	Synthesis and Characterization of [(1,4-diamine)dichloro]platinum(II) Compounds Preliminary Studies on their Biological Activity. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2005, 631, 2054-2061.	0.6	6
379	Influence of acidity on the reaction between [PdCl(dien)]+ andL-cysteine or glutathione in the presence of sodium dodecyl sulfate micelles. Journal of Physical Organic Chemistry, 2005, 18, 441-447.	0.9	12
381	Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy. Current Medicinal Chemistry, 2005, 12, 1283-1294.	1.2	101
382	Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of Antitumor trans-[PtCl2(NH3)(thiazole)]. Nucleic Acids Research, 2005, 33, 5819-5828.	6.5	45
383	Rhodium Compounds. , 2005, , 465-589.		39
384	Mechanistic Studies of Pt and Ru Compounds with Antitumor Properties. ACS Symposium Series, 2005, , 80-109.	0.5	5
385	The Chemoprotective Agent N-Acetylcysteine Blocks Cisplatin-Induced Apoptosis through Caspase Signaling Pathway. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 424-431.	1.3	172
386	A Novel, Evolutionarily Conserved Protein Phosphatase Complex Involved in Cisplatin Sensitivity. Molecular and Cellular Proteomics, 2005, 4, 1725-1740.	2.5	173
387	Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12311-12316.	3.3	61

#	Article	IF	Citations
388	Kinetic and Mechanistic Study on the Reactions of [Pd(dien)H2O]2+ and [Pt(dien)H2O]2+ with L-Cysteine and S-Methyl-L-cysteine. Australian Journal of Chemistry, 2005, 58, 544.	0.5	11
389	Biological coordination chemistry, a confluence of chemistry and biochemistry. Comptes Rendus Chimie, 2005, 8, 199-210.	0.2	2
390	Decreased cell survival and DNA repair capacity after UVC irradiation in association with down-regulation of GRP78/BiP in human RSa cells. Experimental Cell Research, 2005, 305, 244-252.	1.2	53
391	Reactions of Potent Antitumor Complex trans-[RuIIICl4(indazole)2]- with a DNA-Relevant Nucleobase and Thioethers:â€‰ Insight into Biological Action. Inorganic Chemistry, 2005, 44, 122-132.	1.9	59
392	THEORETICAL STUDY ON THE FACTORS THAT AFFECT THE STRUCTURE AND STABILITY OF THE ADDUCT OF A NEW PLATINUM ANTICANCER DRUG WITH A DUPLEX DNA. International Journal of Modern Physics B, 2005, 19, 2939-2949.	1.0	11
393	Metal-assisted red light-induced DNA cleavage by ternary l-methionine copper(ii) complexes of planar heterocyclic bases. Dalton Transactions, 2005, , 896.	1.6	123
394	Enhancement of Aqueous Solubility and Stability Employing a Trans Acetate Axis in Trans Planar Amine Platinum Compounds while Maintaining the Biological Profile. Journal of Medicinal Chemistry, 2005, 48, 5651-5654.	2.9	52
395	DNA Minor Groove Adducts Formed by a Platinumâ^'Acridine Conjugate Inhibit Association of TATA-Binding Protein with Its Cognate Sequenceâ€. Biochemistry, 2005, 44, 11262-11268.	1.2	22
396	Steric Protection of a Photosensitizer in a N,N-Bis[2-(2-pyridyl)ethyl]-2-phenylethylamine-copper(II) Bowl that Enhances Red Light-Induced DNA Cleavage Activity. Inorganic Chemistry, 2005, 44, 8876-8883.	1.9	64
397	In Vitro Anticancer Activities and Optical Imaging of Novel Intercalative Non-Cisplatin Conjugates. Journal of Medicinal Chemistry, 2005, 48, 7192-7197.	2.9	27
398	Intrinsically Fluorescent Cytotoxic Cisplatin Analogues as DNA Marker Molecules. Bioconjugate Chemistry, 2005, 16, 275-282.	1.8	15
399	Hydrolysis Process of the Second Generation Platinum-Based Anticancer Drug cis-Amminedichlorocyclohexylamineplatinum(II). Journal of Physical Chemistry B, 2005, 109, 12195-12205.	1.2	63
400	[N-Ethyl- and [N,Nâ€˜-Diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II):â€‰ Structure and Cytotoxic/Estrogenic Activity in Breast Cancer Cells. Journal of Medicinal Chemistry, 2005, 48, 7132-7144.	2.9	12
401	The Inhibitory Effect of HMGB-1 Protein on the Repair of Cisplatin-Damaged DNA Is Accomplished through the Acidic Domainâ€. Biochemistry, 2005, 44, 5893-5898.	1.2	35
402	Marked Dependence on Carrier-Ligand Bulk but Not on Carrier-Ligand Chirality of the Duplex versus Single-Strand Forms of a DNA Oligonucleotide with a Series of Gâ^'Pt(II)â^'G Intrastrand Cross-Links Modeling Cisplatinâ^'DNA Adducts. Journal of the American Chemical Society, 2005, 127, 15833-15842.	6.6	34
403	DNA adducts of the enantiomers of the Pt(II) complexes of the ahaz ligand (ahaz=3-aminohexahydroazepine) and recognition of these adducts by HMG domain proteins. Biochemical and Biophysical Research Communications, 2005, 332, 1034-1041.	1.0	10
404	Modifications of DNA by platinum complexes. Drug Resistance Updates, 2005, 8, 131-146.	6.5	338
405	Chiral Differentiation of DNA Adducts Formed by Enantiomeric Analogues of Antitumor Cisplatin Is Sequence-Dependent. Biophysical Journal, 2005, 88, 4159-4169.	0.2	27

#	Article	IF	Citations
406	Solution Structural Study of a DNA Duplex Containing the Guanine-N7 Adduct Formed by a Cytotoxic Platinumâ^'Acridine Hybrid Agent,. Biochemistry, 2005, 44, 6059-6070.	1.2	79
407	Interactions of Metalâ^'Metal-Bonded Antitumor Active Complexes with DNA Fragments and DNA. Accounts of Chemical Research, 2005, 38, 146-156.	7.6	429
408	Red-light photosensitized cleavage of DNA by (l-lysine)(phenanthroline base)copper(ii) complexes. Dalton Transactions, 2005, , 2798.	1.6	79
409	New Palladium(II) and Platinum(II) Complexes with the Model Nucleobase 1-Methylcytosine:Â Antitumor Activity and Interactions with DNA. Inorganic Chemistry, 2005, 44, 7365-7376.	1.9	107
410	A Third Mode of DNA Binding:Â Phosphate Clamps by a Polynuclear Platinum Complex. Journal of the American Chemical Society, 2006, 128, 16092-16103.	6.6	166
411	Modeling anticancer drugâ€“DNA interactions via mixed QM/MM molecular dynamics simulations. Organic and Biomolecular Chemistry, 2006, 4, 2507-2517.	1.5	85
412	A tris(2,2â€²-bipyridine)ruthenium(ii) derivative tethered to a cis-PtCl2(amine)2moiety: syntheses, spectroscopic properties, and visible-light-induced scission of DNA. Dalton Transactions, 2006, , 3300-3305.	1.6	35
413	Kinetics and mechanism of the reactions of Pd(ii) complexes with azoles and diazines. Crystal structure of [Pd(bpma)(H2O)](ClO4)2Â·2H2O. Dalton Transactions, 2006, , 2984-2990.	1.6	39
414	Phenol quaternary ammonium derivatives: charge and linker effect on their DNA photo-inducible cross-linking abilities. Organic and Biomolecular Chemistry, 2006, 4, 3358.	1.5	18
415	Synthesis, Biological Activity, and DNA-Damage Profile of Platinum-Threading Intercalator Conjugates Designed To Target Adenine. Journal of Medicinal Chemistry, 2006, 49, 3204-3214.	2.9	41
417	NMR Structures of Damaged DNA. Chemical Reviews, 2006, 106, 607-686.	23.0	150
418	Molecular Mechanisms of Mammalian Global Genome Nucleotide Excision Repair. Chemical Reviews, 2006, 106, 253-276.	23.0	551
419	EXAFS and IR Structural Study of Platinum-Based Anticancer Drugs' Degradation by Diethyl Dithiocarbamate. Inorganic Chemistry, 2006, 45, 3393-3398.	1.9	27
420	Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds. Organometallics, 2006, 25, 756-765.	1.1	154
421	Interactions between N- and C-Terminal Domains of the Saccharomyces cerevisiae High-Mobility Group Protein HMO1 Are Required for DNA Bending. Biochemistry, 2006, 45, 3635-3645.	1.2	30
422	Palladium(II) and Platinum(II) Organometallic Complexes with the Model Nucleobase Anions of Thymine, Uracil, and Cytosine:Â Antitumor Activity and Interactions with DNA of the Platinum Compoundsâ—‹. Inorganic Chemistry, 2006, 45, 6347-6360.	1.9	82
423	Binding of Novel Azole-Bridged Dinuclear Platinum(II) Anticancer Drugs to DNA:Â Insights from Hybrid QM/MM Molecular Dynamics Simulationsâ€. Journal of Physical Chemistry B, 2006, 110, 3604-3613.	1.2	63
424	Targeting DNA Mismatches with Rhodium Intercalators Functionalized with a Cell-Penetrating Peptideâ€. Biochemistry, 2006, 45, 12295-12302.	1.2	98

#	Article	IF	Citations
425	Monte Carlo Simulation of Cisplatin Molecule in Aqueous Solution. Journal of Physical Chemistry B, 2006, 110, 12047-12054.	1.2	55
426	Mechanism of the Membrane Interaction of Polynuclear Platinum Anticancer Agents. Implications for Cellular Uptakeâ€. Biochemistry, 2006, 45, 4248-4256.	1.2	50
427	Sensitization of Cancer Cells to DNA Damaging Agents by Imidazolines. Journal of the American Chemical Society, 2006, 128, 9137-9143.	6.6	38
428	Synthesis, Characterization, and Cytotoxic Properties of Platinum(II)â€Amine Complexes. Xâ€ray Crystal Structure Determination of [Pt(C₆H₁₂N₄)Cl₂]ÂÂ·Â3H₂O. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2006, 36, 719-722.	0.6	1
429	New water-soluble platinum(ii) phenanthroline complexes tested as cisplatin analogues: first-time comparison of cytotoxic activity between analogous four- and five-coordinate species. Dalton Transactions, 2006, , 5077.	1.6	42
430	Mono- and Polynuclear [Alkylamine]platinum(II) Complexes of [1,2-Bis(4-fluorophenyl)ethylenediamine]platinum(II):Â Synthesis and Investigations on Cytotoxicity, Cellular Distribution, and DNA and Protein Binding. Journal of Medicinal Chemistry, 2006, 49, 1182-1190.	2.9	46
431	Kinetics of Carboplatinâ^'DNA Binding in Genomic DNA and Bladder Cancer Cells As Determined by Accelerator Mass Spectrometry. Chemical Research in Toxicology, 2006, 19, 622-626.	1.7	89
432	Interactions of Platinum Complexes Containing Cationic, Bicyclic, Nonplanar Piperidinopiperidine Ligands with Biological Nucleophiles. Journal of Medicinal Chemistry, 2006, 49, 4674-4683.	2.9	19
433	A Multifunctional Tetrametallic Ruâ^'Pt Supramolecular Complex Exhibiting Both DNA Binding and Photocleavage. Inorganic Chemistry, 2006, 45, 10413-10415.	1.9	54
434	Recognition of cisplatin-damaged DNA by p53 protein: Critical role of the p53 C-terminal domain. Biochemical and Biophysical Research Communications, 2006, 339, 477-484.	1.0	19
435	DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resistance Updates, 2006, 9, 111-122.	6.5	347
436	Dirhodium(II,II) Complexes:Â Molecular Characteristics that Affect in Vitro Activity. Journal of Medicinal Chemistry, 2006, 49, 6841-6847.	2.9	110
437	DNA damage-induced cell death by apoptosis. Trends in Molecular Medicine, 2006, 12, 440-450.	3.5	1,272
438	Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. Anti-Cancer Drugs, 2006, 17, 333-336.	0.7	69
439	Platinum Complexes as Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 1-22.	0.8	415
440	Recent Developments in the Field of Anticancer Platinum Complexes. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 285-295.	0.8	201
441	Studies of the Interaction of Platinum Drugs with DNA Using Oligonucleotide Microarrays. Macromolecular Symposia, 2006, 235, 115-120.	0.4	2
444	Kinetics and structural aspects of the cisplatin interactions with guanine: A quantum mechanical description. International Journal of Quantum Chemistry, 2006, 106, 2129-2144.	1.0	35

#	Article	IF	Citations
445	DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner. FEBS Journal, 2006, 273, 4693-4706.	2.2	9
446	Synthesis andÂantitumor activity ofÂcis-dichloroplatinum(II) complexes ofÂ1-(2-aminophenyl)-1,2,3,4-tetrahydroisoquinolines. European Journal of Medicinal Chemistry, 2006, 41, 940-949.	2.6	18
447	Synthesis, characterisation, activities, cell uptake andÂDNA binding ofÂaÂtrinuclear complex: [{trans-PtCl(NH3)}2Î¼-{trans-Pd(NH3)(2-hydroxypyridine)-(H2N(CH2)6NH2)2]Cl4. European Journal of Medicinal Chemistry, 2006, 41, 896-903.	2.6	35
448	Biological studies of photoinducible phenol quaternary ammonium derivatives. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1660-1664.	1.0	11
449	Synchronous fluorescence, UVâ€“visible spectrophotometric, and voltammetric studies of the competitive interaction of bis(1,10-phenanthroline)copper(II) complex and neutral red with DNA. Analytical Biochemistry, 2006, 352, 231-242.	1.1	145
450	Photo-reduction of polyazaaromatic Ru(II) complexes by biomolecules and possible applications. Coordination Chemistry Reviews, 2006, 250, 1627-1641.	9.5	179
451	Non-covalent interactions in adducts of platinum drugs with nucleobases in nucleotides and DNA as revealed by using chiral substrates. Coordination Chemistry Reviews, 2006, 250, 1315-1331.	9.5	63
452	Light-Activated Destruction of Cancer Cell Nuclei by Platinum Diazide Complexes. Chemistry and Biology, 2006, 13, 61-67.	6.2	92
453	trans-Platinum Reporting for Duty. Chemistry and Biology, 2006, 13, 465-467.	6.2	0
454	Studies of interaction of trichloro{Î·2-cis-N,N-dimethyl-1-[6-(Nâ€²,Nâ€²-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin. Bioorganic and Medicinal Chemistry, 2006, 14, 1565-1572.	1.4	12
455	On the reactivity of platinum(IV) complexes: Synthesis and spectroscopic studies of platinum(IV) complexes with hypoxanthine. Journal of Molecular Structure, 2006, 782, 204-208.	1.8	7
456	Synthesis, characterization, and aqueous chemistry of cytotoxic Au(III) polypyridyl complexes. Inorganica Chimica Acta, 2006, 359, 44-52.	1.2	31
457	Diheteroarylmethyl substituted titanocenes: A novel class of possible anti-cancer drugs. Inorganica Chimica Acta, 2006, 359, 3969-3975.	1.2	30
458	Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy. Progress in Nuclear Magnetic Resonance Spectroscopy, 2006, 49, 65-98.	3.9	159
459	Synthesis and reaction kinetics of Pd(1,5-cyclooctadiene)Cl2 with N,Nâ€²-methylene-bis(2-aminopyridyl): An efficient catalyst for Suzuki-cross-coupling reactions. Polyhedron, 2006, 25, 815-820.	1.0	23
460	Perspectives in bioinorganic chemistry of some metal based therapeutic agents. Polyhedron, 2006, 25, 1633-1645.	1.0	138
461	Homopiperazine Pt(II) adducts with DNA bases and nucleosides: Crystal structure of [PtII(homopiperazine)(9-ethylguanine)2](NO3)2. Polyhedron, 2006, 25, 2065-2071.	1.0	50
462	Diarylmethyl substituted titanocenes: Promising anti-cancer drugs. Polyhedron, 2006, 25, 2101-2108.	1.0	32

#	Article	IF	Citations
463	Molybdenum S-bonded mono-thiocarboxylate complexes CpMo(CO)3SCOR: Structure of CpMo(CO)3SCOPh. Polyhedron, 2006, 25, 3413-3416.	1.0	9
464	Toward building a database of bifunctional probes for the MS3D investigation of nucleic acids structures. Journal of the American Society for Mass Spectrometry, 2006, 17, 1570-1581.	1.2	35
465	Guanine binding of a cytotoxic platinumâ€“acridin-9-ylthiourea conjugate monitored by 1-D 1H and 2-D [1H,15N] NMR spectroscopy: Hydrolysis is not the rate-determining step. Journal of Inorganic Biochemistry, 2006, 100, 972-979.	1.5	5
466	Comparative studies on the mechanism of cytotoxic action of novel platinum II complexes with pyrazole ligands. Journal of Inorganic Biochemistry, 2006, 100, 1579-1585.	1.5	30
467	DNA-binding and molecular mechanics modelling studies of the bulky chiral platinum(II) complex [PtCl2(mepyrr)] (mepyrr=N-methyl-2-aminomethylpyrrolidine). Journal of Inorganic Biochemistry, 2006, 100, 1965-1973.	1.5	10
468	Synthesis of amino- and diaminoconduritols and their applications. Tetrahedron, 2006, 62, 2733-2768.	1.0	50
469	Enantioselective synthesis of chiral 1,2-diamines by the catalytic ring opening of azabenzonorbornadienes: application in the preparation of new chiral ligands. Tetrahedron: Asymmetry, 2006, 17, 416-427.	1.8	33
470	Synthesis, Structure, and Anticancer Activity of Gallium(III) Complexes with Asymmetric Tridentate Ligands:Â Growth Inhibition and Apoptosis Induction of Cisplatin-Resistant Neuroblastoma Cells. Inorganic Chemistry, 2006, 45, 6263-6268.	1.9	65
471	Direct Reversal of DNA Alkylation Damage. Chemical Reviews, 2006, 106, 215-232.	23.0	193
472	The Discovery and Development of Cisplatin. Journal of Chemical Education, 2006, 83, 728.	1.1	403
473	Biological Consequences of Trinuclear Platinum Complexes: Comparison of [{trans-PtCl(NH3)2}2Î¼-(trans-Pt(NH3)2(H2N(CH2)6-NH2)2)]4+ (BBR 3464) with Its Noncovalent Congeners. Molecular Pharmacology, 2006, 69, 666-672.	1.0	56
474	cis-[Rh2(Î¼-O2CCH3)2(CH3CN)6]2+as a Photoactivated Cisplatin Analog. Journal of the American Chemical Society, 2006, 128, 738-739.	6.6	80
475	Platinum(II) cationic complexes with derivatives of 2-acyl-1,3-cyclopentanedions. Russian Journal of General Chemistry, 2006, 76, 669-676.	0.3	3
476	Structural and mechanistic aspects of platinum anticancer agents. Transition Metal Chemistry, 2006, 31, 1003-1016.	0.7	55
477	Preferential Energy- and Potential-Dependent Accumulation of Cisplatinâ€“Gutathione Complexes in Human Cancer Cell Lines (GLC4 and K562): A Likely Role of Mitochondria. Journal of Bioenergetics and Biomembranes, 2006, 38, 11-21.	1.0	18
478	Fixing the conformations of diamineplatinum(II)-GpG chelates: NMR and CD signatures of individual rotamers. Journal of Biological Inorganic Chemistry, 2006, 11, 139-152.	1.1	10
479	The trans labilization of cis-[PtCl2(13CH3NH2)2] by glutathione can be monitored at physiological pH by [1H,13C] HSQC NMR. Journal of Biological Inorganic Chemistry, 2006, 11, 179-188.	1.1	20
480	Synthesis, characterization, X-ray structure and DNA photocleavage by cis-dichloro bis(diimine) Co(III) complexes. Journal of Inorganic Biochemistry, 2006, 100, 331-343.	1.5	116

#	Article	IF	Citations
481	Heteroaryl substituted titanocenes as potential anti-cancer drugs. Journal of Inorganic Biochemistry, 2006, 100, 1479-1486.	1.5	40
482	Synthesis and anticancer activity of cyclopalladated complexes containing 4-hydroxy-acridine. Journal of Inorganic Biochemistry, 2006, 100, 1575-1578.	1.5	42
483	Variation of DNA photocleavage efficiency for [(TL)2Ru(dpp)]Cl2 complexes where TL=2,2â€²-bipyridine, 1,10-phenanthroline, or 4,7-diphenyl-1,10-phenanthroline. Journal of Inorganic Biochemistry, 2006, 100, 1983-1987.	1.5	12
484	Photocleavage of DNA by copper(II) complexes. Journal of Chemical Sciences, 2006, 118, 443-453.	0.7	28
485	Cytotoxic efficacy of an anthraquinone linked platinum anticancer drug. Biochemical Pharmacology, 2006, 71, 1136-1145.	2.0	47
486	Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochemical Pharmacology, 2006, 72, 693-700.	2.0	35
487	A Photoactivatedtrans-Diammine Platinum Complex as Cytotoxic as Cisplatin. Chemistry - A European Journal, 2006, 12, 3155-3161.	1.7	151
488	Ruthenation of Duplex and Single-Stranded d(CGGCCG) by Organometallic Anticancer Complexes. Chemistry - A European Journal, 2006, 12, 6151-6165.	1.7	72
489	DNA-Binding Studies of Mixed-Ligand (Ethylenediamine)ruthenium(II) Complexes. Chemistry and Biodiversity, 2006, 3, 1219-1229.	1.0	33
490	Structural Investigation of Cisplatinâ€“Protein Interactions: Selective Platination of His19 in a Cuprozinc Superoxide Dismutase. Angewandte Chemie - International Edition, 2006, 45, 1267-1269.	7.2	107
491	2D NMR Spectroscopic Evidence for Unprecedented Interactions ofcis-[Rh2(dap)(Î¼-O2CCH3)2(Î·1-O2CCH3)(CH3OH)](O2CCH3) with a DNA Oligonucleotide: Combination of Intercalative and Coordinative Binding. Angewandte Chemie - International Edition, 2006, 45, 6148-6151.	7.2	32
492	Platinum-Group Chelate Complexes with 9-Hydroxyphenalenone Derivatives: Synthesis, Structures, Spectroscopic Properties and Cytotoxic Activities. European Journal of Inorganic Chemistry, 2006, 2006, 558-565.	1.0	17
493	Oxidative Addition of Cl2, HClO to Square-Planar PtII Complexes: Synthesis and Structural Characterization of Platinum(II) and Platinum(IV) Bis(amidate) Complexes. European Journal of Inorganic Chemistry, 2006, 2006, 1168-1173.	1.0	8
494	Bis(2-amino alcohol-Î²N)dicarboxylatoplatinum(II) Complexes â€“ Elegant Synthesis via Ring-Opening of Bis(2-amino alcoholato-Î²2N,O)platinum(II) Species with Dicarboxylic Acids. European Journal of Inorganic Chemistry, 2006, 2006, 2476-2483.	1.0	14
495	Synthesis and Characterization of [(1R,2R)-trans-Diaminocyclohexane]platinum(II) Coordinated to Sulfur and Selenium Amino Acids. European Journal of Inorganic Chemistry, 2006, 2006, 3746-3752.	1.0	29
496	Glycol Methyl Ether and Glycol Amine Substituted Titanocenes as Antitumor Agents. European Journal of Inorganic Chemistry, 2006, 2006, 4621-4628.	1.0	23
497	How can the Cross-Link Adducts Formed by NovelTrans Platinum Drug be Influenced by Hydrogen Bond. Chinese Journal of Chemistry, 2006, 24, 1514-1522.	2.6	1
498	Role of bridging diamine linkers on the rate of ligand substitution in a series of dinuclear PtIIcomplexes. International Journal of Chemical Kinetics, 2006, 38, 202-210.	1.0	17

#	Article	IF	Citations
501	Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis, 2006, 27, 682-692.	1.3	190
502	Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opinion on Investigational Drugs, 2006, 15, 669-690.	1.9	19
504	RNA Polymerase II Blockage by Cisplatin-damaged DNA. Journal of Biological Chemistry, 2006, 281, 1361-1370.	1.6	60
505	Nitric Oxide Regulates Cell Sensitivity to Cisplatin-Induced Apoptosis through S-Nitrosylation and Inhibition of Bcl-2 Ubiquitination. Cancer Research, 2006, 66, 6353-6360.	0.4	116
506	Reversion of Structure-Activity Relationships of Antitumor Platinum Complexes by Acetoxime but Not Hydroxylamine Ligands. Molecular Pharmacology, 2007, 71, 357-365.	1.0	53
507	Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo. British Journal of Cancer, 2007, 97, 1234-1241.	2.9	50
508	The Relation Between Stereochemistry and Biological Activity of Platinum(II) Complexes Chelated with Chiral Diamine Ligands: An Intricate Problem. Current Pharmaceutical Design, 2007, 13, 2781-2794.	0.9	31
509	Chromatin as a Target for the DNA-Binding Anticancer Drugs. Sub-Cellular Biochemistry, 2007, 41, 145-192.	1.0	8
510	Mechanism of the formation of DNAâ€“protein cross-links by antitumor cisplatin. Nucleic Acids Research, 2007, 35, 1812-1821.	6.5	131
511	Evaluation of Action Mechanisms of Toxic Chemicals Using JFCR39, a Panel of Human Cancer Cell Lines. Molecular Pharmacology, 2007, 72, 1171-1180.	1.0	37
512	General Classification of Organometallic Reactions. , 2007, , 93-117.		2
513	Bioorganometallic Chemistry. , 2007, , 883-920.		6
515	Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice. Anti-Cancer Drugs, 2007, 18, 311-315.	0.7	50
516	Acridine and Acridone Derivatives, Anticancer Properties and Synthetic Methods: Where Are We Now?. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 139-169.	0.9	198
517	1,2-GG intrastrand cross-link of antitumor dinuclear bifunctional platinum compound with spermidine linker inhibits DNA polymerization more effectively than the cross-link of conventional cisplatin. Archives of Biochemistry and Biophysics, 2007, 459, 264-272.	1.4	16
518	Inhibition of endonuclease cleavage and DNA replication of E. coli plasmid by the antitumor rhodium(II) complex. Archives of Biochemistry and Biophysics, 2007, 464, 28-35.	1.4	14
519	Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells. Biochemical and Biophysical Research Communications, 2007, 358, 92-98.	1.0	17
520	Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Letters, 2007, 251, 1-16.	3.2	189

#	Article	IF	Citations
521	Raman spectroscopy of DNA modified by intrastrand cross-links of antitumor cisplatin. Journal of Structural Biology, 2007, 159, 1-8.	1.3	30
522	The changing face of p53 in head and neck cancer. International Journal of Oral and Maxillofacial Surgery, 2007, 36, 1123-1138.	0.7	38
523	Differential effects of tannic acid on cisplatin induced nephrotoxicity in rats. FEBS Letters, 2007, 581, 2027-2035.	1.3	57
524	Bisphosphonate complexation and calcium doping in silica xerogels as a combined strategy for local and controlled release of active platinum antitumor compounds. Dalton Transactions, 2007, , 3131.	1.6	48
525	Bifunctional Binding of Cisplatin to DNA:Â Why Does Cisplatin Form 1,2-Intrastrand Cross-Links with AG But Not with GA?. Journal of the American Chemical Society, 2007, 129, 5023-5030.	6.6	88
526	Metallo-intercalators and metallo-insertors. Chemical Communications, 2007, , 4565.	2.2	746
528	Azole-Bridged Diplatinum Anticancer Compounds. Modulating DNA Flexibility to Escape Repair Mechanism and Avoid Cross Resistance. Journal of Physical Chemistry B, 2007, 111, 11873-11876.	1.2	29
529	Direct Cellular Responses to Platinum-Induced DNA Damage. Chemical Reviews, 2007, 107, 1387-1407.	23.0	1,277
530	Characterization of Oxaliplatinâ˜DNA Adduct Formation in DNA and Differentiation of Cancer Cell Drug Sensitivity at Microdose Concentrations. Chemical Research in Toxicology, 2007, 20, 1745-1751.	1.7	62
531	Anticancer and Antimicrobial Metallopharmaceutical Agents Based on Palladium, Gold, and Silver N-Heterocyclic Carbene Complexes. Journal of the American Chemical Society, 2007, 129, 15042-15053.	6.6	576
532	Binding of Antitumor Ruthenium Complexes to DNA and Proteins:â€‰ A Theoretical Approach. Journal of Physical Chemistry B, 2007, 111, 9955-9964.	1.2	34
533	Transition metal vinylidene complexes as supramolecular building blocks: nucleobase-mediated self-assembly of crystals with hexagonal symmetry. Dalton Transactions, 2007, , 4427.	1.6	17
534	Maternalâ€“fetal transport kinetics of carboplatin in the perfused human placental lobule:In vitrostudy. Journal of Maternal-Fetal and Neonatal Medicine, 2007, 20, 695-701.	0.7	9
535	Cisplatin Damage Overrides the Predefined Rotational Setting of Positioned Nucleosomes. Journal of the American Chemical Society, 2007, 129, 6278-6286.	6.6	28
536	Kinetics and mechanism of the substitution behaviour of Pd(ii) piperazine complexes with different biologically relevant nucleophiles. Dalton Transactions, 2007, , 4169.	1.6	20
537	Platination of superoxide dismutase with cisplatin: tracking the ammonia ligands using Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS). Chemical Communications, 2007, , 1719.	2.2	21
538	Binding Interaction of [Re(H₂O)₃(CO)₃]⁺ with the DNA Fragment d(CpGpG). Inorganic Chemistry, 2007, 46, 10458-10460.	1.9	28
539	Bifunctional Amine-Tethered Ruthenium(II) Arene Complexes Form Monofunctional Adducts on DNA. Inorganic Chemistry, 2007, 46, 8950-8962.	1.9	88

#	Article	IF	Citations
540	Effect of Axial Coordination on the Electronic Structure and Biological Activity of Dirhodium(II,II) Complexes. Inorganic Chemistry, 2007, 46, 7494-7502.	1.9	57
541	Tetrakis- and Tris(1-Methyluracil) Complexes of PtII:â€‰ Formation and Properties of a Carbon-Bonded Nucleobase Species as Well as of Heternonuclear Derivatives. Inorganic Chemistry, 2007, 46, 11356-11365.	1.9	17
542	DNA Three-Way Junction with a Dinuclear Iron(II) Supramolecular Helicate at the Center:Â A NMR Structural Study. Inorganic Chemistry, 2007, 46, 6245-6251.	1.9	74
543	Total Syntheses, Fragmentation Studies, and Antitumor/Antiproliferative Activities of FR901464 and Its Low Picomolar Analogue. Journal of the American Chemical Society, 2007, 129, 2648-2659.	6.6	150
544	Understanding the Effect of Carbonate Ion on Cisplatin Binding to DNA. Journal of the American Chemical Society, 2007, 129, 6370-6371.	6.6	57
545	fac-[Re(CO)3(H2O)3]+Nucleoside Monophosphate Adducts Investigated in Aqueous Solution by Multinuclear NMR Spectroscopy. Inorganic Chemistry, 2007, 46, 4926-4936.	1.9	7
546	Conformation of DNA GG Intrastrand Cross-Link of Antitumor Oxaliplatin and Its Enantiomeric Analog. Biophysical Journal, 2007, 93, 3950-3962.	0.2	64
547	Effect of the Diamine Nonleaving Group in Platinumâ^'Acridinylthiourea Conjugates on DNA Damage and Cytotoxicity. Journal of Medicinal Chemistry, 2007, 50, 2259-2263.	2.9	44
548	Detection of Picomole Amounts of Biological Substrates by para-Hydrogen-Enhanced NMR Methods in Conjunction with a Suitable Receptor Complex. Journal of the American Chemical Society, 2007, 129, 11012-11013.	6.6	38
549	Mixed-Ligand Copper(II)-phenolate Complexes:â€‰ Effect of Coligand on Enhanced DNA and Protein Binding, DNA Cleavage, and Anticancer Activity. Inorganic Chemistry, 2007, 46, 8208-8221.	1.9	543
550	Ferrocene Linked to PtL₂ Fragments (L₂ = Cl₂, Fumaronitrile,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf and Charge Distributions. Organometallics, 2007, 26, 5406-5414.	1.1	28
551	DNA Binding and Cytotoxicity of Ruthenium(II) and Rhenium(I) Complexes of 2-Amino-4-phenylamino-6-(2-pyridyl)-1,3,5-triazine. Inorganic Chemistry, 2007, 46, 740-749.	1.9	138
552	Synthesis, Structural Characterization, and Cytotoxic Activity of Novel Paramagnetic Platinum Hematoporphyrin IX Complexes: Potent Antitumor Agents. Metal-Based Drugs, 2007, 2007, 1-13.	3.8	11
553	Histone H1 Interacts Preferentially with DNA Fragments Containing a Cisplatin- Induced 1,2-Intrastrand Cross-Link. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2007, 62, 905-908.	0.6	2
554	Chirality as a tool in nucleic acid recognition: Principles and relevance in biotechnology and in medicinal chemistry. Chirality, 2007, 19, 269-294.	1.3	127
555	Interaction between Platinum Complexes and a Methionine Motif Found in Copper Transport Proteins. Angewandte Chemie - International Edition, 2007, 46, 9062-9064.	7.2	91
556	The synthesis and cytotoxic evaluation of a series of benzodioxole substituted titanocenes. Applied Organometallic Chemistry, 2007, 21, 57-65.	1.7	27
557	Medicinal Studies of Dimeric Phenols with Multiple Quaternary-Ammonium Pendant Arms. Chemistry and Biodiversity, 2007, 4, 947-954.	1.0	0

#	Article	IF	Citations
559	Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. International Journal of Cancer, 2007, 120, 175-180.	2.3	187
560	Cisplatin cytotoxicity in organ of corti-derived immortalized cells. Journal of Cellular Biochemistry, 2007, 101, 1185-1197.	1.2	32
561	Synthesis of Cycloruthenated Compounds as Potential Anticancer Agents. European Journal of Inorganic Chemistry, 2007, 2007, 3055-3066.	1.0	72
562	Synthesis, Structure, Protolytic Properties, Alkylating and Cytotoxic Activity of Novel Platinum(II) and Palladium(II) Complexes with Pyrazole-Derived Ligands. European Journal of Inorganic Chemistry, 2007, 2007, 3728-3735.	1.0	32
563	Quantitative proteome analysis of cisplatinâ€induced apoptotic Jurkat T cells by stable isotope labeling with amino acids in cell culture, SDSâ€PAGE, and LCâ€MALDIâ€TOF/TOF MS. Electrophoresis, 2007, 28, 4359-4368.	1.3	24
564	Steroid Conjugates of Dichloro(6-aminomethylnicotinate)platinum(II): Effects on DNA, Sex Hormone Binding Globulin, the Estrogen Receptor, and Various Breast Cancer Cell Lines. ChemMedChem, 2007, 2, 333-342.	1.6	30
565	Antiapoptotic mechanism of cannabinoid receptor 2 agonist on cisplatin-induced apoptosis in the HEI-OC1 auditory cell line. Journal of Neuroscience Research, 2007, 85, 896-905.	1.3	39
566	Studies of interactions between platinum(II) complexes and some biologically relevant molecules. Bioorganic and Medicinal Chemistry, 2007, 15, 4203-4211.	1.4	39
567	Synthesis and biological activities of quinazoline derivatives with ortho-phenol-quaternary ammonium salt groups. Bioorganic and Medicinal Chemistry, 2007, 15, 6920-6926.	1.4	11
568	In vitro cytotoxicity study on platinum (II) complexes with epoxysuccinates as leaving groups. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3831-3834.	1.0	17
569	New approaches for medicinal applications of bioinorganic chemistry. Current Opinion in Chemical Biology, 2007, 11, 115-120.	2.8	100
570	Hybrid molecules between distamycin A and active moieties of antitumor agents. Bioorganic and Medicinal Chemistry, 2007, 15, 17-35.	1.4	56
571	A new platinum complex of triazine demonstrates G1 arrest with novel biological profile in human breast cancer cell line, MDA-MB-468. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2139-2145.	1.0	12
572	Synthesis characterization and X-ray crystal structures of cis-1,4-diaminocyclohexane-platinum(II) nucleobase adducts. Polyhedron, 2007, 26, 637-644.	1.0	10
573	X-ray structure and multinuclear NMR studies of platinum(II) complexes with 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one. Polyhedron, 2007, 26, 803-810.	1.0	22
574	Synthesis and characterization of ionic Ru(III) complexes containing dimethylsulfoxide and dinitrogen heterocyclic ligands. Polyhedron, 2007, 26, 3661-3668.	1.0	24
575	DNA binding and oxidative cleavage activity of ternary (l-proline)copper(II) complexes of heterocyclic bases. Polyhedron, 2007, 26, 5331-5338.	1.0	75
576	Group 4 metallocenes in bioorganometallic chemistry. Journal of Organometallic Chemistry, 2007, 692, 1187-1197.	0.8	24

#	Article	IF	Citations
577	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and heteroaryl-substituted titanocene anti-cancer drugs. Journal of Organometallic Chemistry, 2007, 692, 2153-2159.	0.8	45
578	Synthesis, crystal structure, magnetic property and oxidative DNA cleavage activity of an octanuclear copper(II) complex showing waterâ€“perchlorate helical network. Journal of Inorganic Biochemistry, 2007, 101, 95-103.	1.5	87
579	Synthesis, crystal structures and cytotoxicities of some transition metal complexes with N-[2-{(pyridin-2-ylmethylidene)amino}ethyl]acetamide. Journal of Inorganic Biochemistry, 2007, 101, 321-328.	1.5	26
580	GG sequence of DNA and the human telomeric sequence react with cis-diammine-diaquaplatinum at comparable rates. Journal of Inorganic Biochemistry, 2007, 101, 514-524.	1.5	24
581	Selective guanosine binding and cytotoxicity of a benzimidazole derived dinickel complex. Journal of Inorganic Biochemistry, 2007, 101, 1894-1902.	1.5	18
582	Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC/MS-based protein quantification method. Proteomics - Clinical Applications, 2007, 1, 246-263.	0.8	29
583	Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells. Oncogene, 2007, 26, 5822-5827.	2.6	33
584	Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-Î±. BJU International, 2007, 101, 071008070648017-???.	1.3	15
585	Chemotherapyâ€induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. Journal of Thrombosis and Haemostasis, 2007, 5, 2445-2452.	1.9	99
586	Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([{trans-PtCl(NH3)2}2Î¼-(trans-Pt(NH3)2(H2N(CH2)6-NH2)2)]4+) influenced by copper homeostasis. Biochemical Pharmacology, 2007, 73, 1270-1279.	2.0	37
587	DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)]. Biochemical Pharmacology, 2007, 73, 1887-1900.	2.0	12
588	Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead. European Journal of Pharmacology, 2007, 554, 113-122.	1.7	71
589	Investigating biological systems using first principles Carâ€“Parrinello molecular dynamics simulations. Current Opinion in Structural Biology, 2007, 17, 149-156.	2.6	90
590	A portrait of cisplatin-induced transcriptional changes in mouse embryonic stem cells reveals a dominant p53-like response. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 617, 58-70.	0.4	16
591	A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry. Analytical and Bioanalytical Chemistry, 2007, 387, 2815-2822.	1.9	50
592	Mixed ligand complexes with 2-piperidine-carboxylic acid as primary ligand and ethylene diamine, 2,2â€²-bipyridyl, 1,10-phenanthroline and 2(2â€²-pyridyl)quinoxaline as secondary ligands: preparation, characterization and biological activity. Transition Metal Chemistry, 2007, 32, 769-775.	0.7	51
593	cis-Pt Mediated Assembly of Gold Nanoparticles on DNA. Journal of Cluster Science, 2007, 18, 193-204.	1.7	13
594	Thermodynamic and Kinetic Studies on Reactions of Pt(II) Complexes with Pyrazole, Pyridazine, and 1,2,4-Triazole. Monatshefte FÃ¼r Chemie, 2007, 138, 1-11.	0.9	18

#	Article	IF	Citations
595	The impact of different chelating leaving groups on the substitution kinetics of mononuclear PtII(1,2-trans-R,R-diaminocyclohexane)(Xâ€“Y) complexes. Journal of Biological Inorganic Chemistry, 2007, 12, 461-475.	1.1	55
596	Kinetics and mechanism of the substitution reactions of [PtCl(bpma)]+, [PtCl(gly-met-S,N,N)] and their aqua analogues with l-methionine, glutathione and 5â€²-GMP. Journal of Biological Inorganic Chemistry, 2007, 12, 1141-1150.	1.1	36
597	Pt-bridges in various single-strand and double-helix DNA sequences. DFT and MP2 study of the cisplatin coordination with guanine, adenine, and cytosine. Journal of Molecular Modeling, 2007, 13, 367-379.	0.8	20
598	Synthesis, crystal structure, DNA binding and photo-induced DNA cleavage activity of (S-methyl-l-cysteine)copper(II) complexes of heterocyclic bases. Journal of Inorganic Biochemistry, 2007, 101, 233-244.	1.5	145
599	Antiproliferative activity of Pt(II) and Pd(II) phosphine complexes with thymine and thymidine. Journal of Inorganic Biochemistry, 2007, 101, 254-260.	1.5	33
600	Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O,O-chelating ligands. Journal of Inorganic Biochemistry, 2007, 101, 1903-1912.	1.5	44
601	Synthesis, structural characteristics, DNA binding properties and cytotoxicity studies of a series of Ru(III) complexes. Journal of Inorganic Biochemistry, 2008, 102, 1644-1653.	1.5	196
602	Synthesis, crystal structures and DNA-binding properties of two new mononuclear copper(II) complexes. Transition Metal Chemistry, 2008, 33, 781-789.	0.7	8
603	Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 599-608.	1.4	8
604	A study of oxaliplatinâ€“nucleobase interactions using ion trap electrospray mass spectrometry. Analytical and Bioanalytical Chemistry, 2008, 391, 2339-2348.	1.9	16
605	Energy basis of recognition of base pair for platinum-based antitumour drug ZD0473 and cisplatin. Science in China Series B: Chemistry, 2008, 51, 359-366.	0.8	2
606	Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry. Journal of Biological Inorganic Chemistry, 2008, 13, 421-434.	1.1	59
607	DNA cleavage and binding selectivity of a heterodinuclear Ptâ€“Cu(3-Clip-Phen) complex. Journal of Biological Inorganic Chemistry, 2008, 13, 575-586.	1.1	31
608	Comparison of the electronic properties, and thermodynamic and kinetic parameters of the aquation of selected platinum(II) derivatives with their anticancer IC50 indexes. Journal of Molecular Modeling, 2008, 14, 705-716.	0.8	21
609	Solvent effect on the reactivity of CISâ€platinum (II) complexes: A density functional approach. International Journal of Quantum Chemistry, 2008, 108, 1400-1409.	1.0	36
610	Investigation of interaction between human hemoglobin A₀ and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection. Journal of Separation Science, 2008, 31, 1803-1809.	1.3	14
611	Unique Properties of DNA Interstrand Crossâ€Links of Antitumor Oxaliplatin and the Effect of Chirality of the Carrier Ligand. Chemistry - A European Journal, 2008, 14, 1330-1341.	1.7	76
612	Platinated Copper(3â€Clipâ€Phen) Complexes as Effective DNAâ€Cleaving and Cytotoxic Agents. Chemistry - A European Journal, 2008, 14, 3418-3426.	1.7	42

#	Article	IF	Citations
613	Parameterization of azoleâ€bridged dinuclear platinum anticancer drugs via a QM/MM force matching procedure. Journal of Computational Chemistry, 2008, 29, 38-49.	1.5	34
614	The trans effect in squareâ€planar platinum(II) complexesâ€"A density functional study. Journal of Computational Chemistry, 2008, 29, 2370-2381.	1.5	69
615	A novel approach for analysis of oligonucleotideâ€"cisplatin interactions by continuous elution gel electrophoresis coupled to isotope dilution inductively coupled plasma mass spectrometry and matrixâ€assisted laser desorption/ionization mass spectrometry. Electrophoresis, 2008, 29, 1451-1459.	1.3	26
616	Terpene Conjugates of Diaminedichloridoplatinum(II) Complexes: Antiproliferative Effects in HL-60 Leukemia, 518A2 Melanoma, and HT-29 Colon Cancer Cells. Chemistry and Biodiversity, 2008, 5, 1645-1659.	1.0	16
617	Experimental Evidence That a DNA Polymerase Can Incorporate N7â€Platinated Guanines To Give Platinated DNA. Angewandte Chemie - International Edition, 2008, 47, 507-510.	7.2	31
620	Synthesis, structure, DNA binding and oxidative cleavage activity of ternary (l-leucine/isoleucine) copper(II) complexes of heterocyclic bases. Polyhedron, 2008, 27, 1343-1352.	1.0	97
621	LEF-1 recognition of platinated GG sequences within double-stranded DNA. Influence of flanking bases. Journal of Inorganic Biochemistry, 2008, 102, 242-250.	1.5	14
622	Synthesis, structure, DNA binding and DNA cleavage activity of oxovanadium(IV) N-salicylidene-S-methyldithiocarbazate complexes of phenanthroline bases. Journal of Inorganic Biochemistry, 2008, 102, 1463-1472.	1.5	113
623	Synthesis, crystal structure, antibacterial assay and DNA binding activity of new binuclear Cu(II) complexes with bridging oxamidate. Journal of Inorganic Biochemistry, 2008, 102, 1691-1699.	1.5	62
624	Studies on the interaction of copper complexes of (â^')-epicatechin gallate and (â^')-epigallocatechin gallate with calf thymus DNA. Journal of Inorganic Biochemistry, 2008, 102, 1711-1718.	1.5	93
625	Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(Î·6-p-cymene)Cl2(pta)]. Journal of Inorganic Biochemistry, 2008, 102, 1743-1748.	1.5	108
626	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and aryl-substituted titanocene anti-cancer agents. European Journal of Medicinal Chemistry, 2008, 43, 122-128.	2.6	30
627	Insight into the reactive form of the anticancer agent iproplatin. European Journal of Medicinal Chemistry, 2008, 43, 1081-1084.	2.6	12
628	Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorganic and Medicinal Chemistry, 2008, 16, 10121-10128.	1.4	42
629	Synthesis of 17Î²-estradiol-platinum(II) hybrid molecules showing cytotoxic activity on breast cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2282-2287.	1.0	55
630	Electron-transfer activated metal-based anticancer drugs. Inorganica Chimica Acta, 2008, 361, 1569-1583.	1.2	177
631	Structure and characterization of platinum(II) and platinum(IV) complexes with protonated nucleobase ligands. Inorganica Chimica Acta, 2008, 361, 2070-2080.	1.2	15
632	Chromatin â€" a New, Old Drug Target?. Chemical Biology and Drug Design, 2008, 72, 165-170.	1.5	12

#	Article	IF	Citations
633	DNA binding studies of PdCl2(LL)(LL = chelating diamine ligand: N,N-dimethyltrimethylenediamine) complex. Biochemistry (Moscow), 2008, 73, 929-936.	0.7	27
634	Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death and Differentiation, 2008, 15, 530-544.	5.0	83
635	Renal protection by 3H-1,2-dithiole-3-thione against cisplatin through the Nrf2-antioxidant pathway. Biochemical Pharmacology, 2008, 76, 597-607.	2.0	32
636	Anticancer cisplatin interactions with bilayers of total lipid extract from pig brain: A 13C, 31P and 15N solid-state NMR study. European Journal of Pharmaceutical Sciences, 2008, 34, 140-148.	1.9	20
637	pH-Responsive Nanoparticles for Cancer Drug Delivery. Methods in Molecular Biology, 2008, 437, 183-216.	0.4	61
638	Biophysical Studies on the Stability of DNA Intrastrand Cross-Links of Transplatin. Biophysical Journal, 2008, 95, 4361-4371.	0.2	37
639	Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney International, 2008, 73, 994-1007.	2.6	1,476
640	Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response. Pharmacology, 2008, 81, 275-300.	0.9	150
641	The Hydrolysis Mechanism of the Anticancer Ruthenium Drugs NAMI-A and ICR Investigated by DFTâˆ’PCM Calculations. Journal of Physical Chemistry B, 2008, 112, 4401-4409.	1.2	60
642	Applications in Bioinorganic Chemistry. , 0, , 333-402.		0
643	Bioactive fragments synergically involved in the design of new generation Pt(ii) and Pd(ii)-based anticancer compounds. Dalton Transactions, 2008, , 5897.	1.6	21
644	Targeted Single-Wall Carbon Nanotube-Mediated Pt(IV) Prodrug Delivery Using Folate as a Homing Device. Journal of the American Chemical Society, 2008, 130, 11467-11476.	6.6	646
645	DNA Interaction with Novel Antitumor Estradiolâ€“Platinum(II) Hybrid Molecule: A Comparative Study with Cisplatin Drug. DNA and Cell Biology, 2008, 27, 101-107.	0.9	65
646	The Degradation Pathways in Chloride Medium of the Third Generation Anticancer Drug Oxaliplatin. Journal of Physical Chemistry B, 2008, 112, 10765-10768.	1.2	40
647	Mixed ligand ruthenium(ii) complexes of bis(pyrid-2-yl)-/bis(benzimidazol-2-yl)-dithioether and diimines: Study of non-covalent DNA binding and cytotoxicity. Dalton Transactions, 2008, , 148-163.	1.6	117
648	Conjugated Platinum(IV)âˆ’Peptide Complexes for Targeting Angiogenic Tumor Vasculature. Bioconjugate Chemistry, 2008, 19, 39-49.	1.8	211
649	Synthesis, characterization and electrochemistry of 4â€²-functionalized 2,2â€²:6â€²,2â€³-terpyridine ruthenium(ii) complexes and their biological activity. Dalton Transactions, 2008, , 2136.	1.6	66
650	Bioinorganic Electrochemistry. , 2008, , .		17

#	Article	IF	Citations
651	Effects of cisplatin and other Pt(II) complexes on spontaneous motility of isolated human oviduct. Toxicology in Vitro, 2008, 22, 1878-1882.	1.1	6
652	Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGAâ€“PEG nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17356-17361.	3.3	904
653	Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance. Cancer Letters, 2008, 260, 96-108.	3.2	145
654	Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. Experimental Neurology, 2008, 210, 368-374.	2.0	28
655	Structural and Energetic Study of Cisplatin and Derivatives: Comparison of the Performance of Density Funtional Theory Implementations. Journal of Chemical Theory and Computation, 2008, 4, 740-750.	2.3	18
656	Bisursodeoxycholate(ethylenediamine)platinum(ii): a new autofluorescent compound. Cytotoxic activity and cell cycle analysis in ovarian and hematological cell lines. Dalton Transactions, 2008, , 6159.	1.6	10
657	Non-covalent DNA binding and cytotoxicity of certain mixed-ligand ruthenium(ii) complexes of 2,2â€²-dipyridylamine and diimines. Dalton Transactions, 2008, , 2157.	1.6	142
658	Synthesis and characterization of platinum(II) complexes with 2-imidazolidinethione. X-ray crystal structure of tetra(2-imidazolidinethione- S)platinum(II) iodide dimethylsulfoxide solvate monohydrate. Journal of Coordination Chemistry, 2008, 61, 2457-2469.	0.8	13
659	Nucleobase-containing transition metal complexes as building blocks for biological markers and supramolecular structures. Dalton Transactions, 2008, , 4067.	1.6	24
660	Hydrophilic interaction liquid chromatography (HILIC) coupled to inductively coupled plasma mass spectrometry (ICPMS) utilizing a mobile phase with a low-volatile organic modifier for the determination of cisplatin, and its monohydrolyzed metabolite. Journal of Analytical Atomic Spectrometry, 2008, 23, 948.	1.6	29
661	Transport kinetics of cisplatin in the perfused human placental lobulein vitro. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 726-731.	0.7	11
662	Melting of Crosslinked DNA: VI. Comparison of Influence of Interstrand Crosslinks and Other Chemical Modifications Formed by Antitumor Compounds on DNA Stability. Journal of Biomolecular Structure and Dynamics, 2008, 26, 175-185.	2.0	10
663	A 1,2-d(GpG) Cisplatin Intrastrand Cross-Link Influences the Rotational and Translational Setting of DNA in Nucleosomes. Journal of the American Chemical Society, 2008, 130, 2851-2861.	6.6	53
664	Ru(iii)-based compounds with sulfur donor ligands: synthesis, characterization, electrochemical behaviour and anticancer activity. Dalton Transactions, 2008, , 6699.	1.6	23
665	A new role for cisplatin: probing ribosomal RNA structure. Chemical Communications, 2008, , 107-109.	2.2	33
666	NMR and X-ray Structural Characterization of a Cisplatin Analogue Able To Slow Down the Ptâ^'N7 Rotation of a Coordinated Guanine Base by a Billion-Fold Times: 2,2â€²-Bipiperidine(dimethylmalonato)platinum(II) Complex. Inorganic Chemistry, 2008, 47, 4909-4917.	1.9	8
667	Synthesis, Characterization, and in Vitro Evaluation of a Potentially Selective Anticancer, Mixed-Metal [Ruthenium(III)â^'Platinum(II)] Trinuclear Complex. Inorganic Chemistry, 2008, 47, 274-280.	1.9	42
668	Neglected Bidentate sp²N-Donor Carrier Ligands with Triazine Nitrogen Lone Pairs: Platinum Complexes Retromodeling Cisplatin Guanine Nucleobase Adducts. Inorganic Chemistry, 2008, 47, 9303-9313.	1.9	20

#	Article	IF	Citations
669	Preparation of a DNA Aptamerâ^'Pt Complex and Its Use in the Colorimetric Sensing of Thrombin and Anti-Thrombin Antibodies. Analytical Chemistry, 2008, 80, 6580-6586.	3.2	75
670	N2-Functionalized Blue Luminescent Guanosines by 2,2â€²-Dipyridylamino and 2-(2â€²-Pyridyl)benzimidazolyl Chelate Groups and Their Interactions with Zn(II) Ions. Inorganic Chemistry, 2008, 47, 8315-8323.	1.9	14
671	2D NMR Study of the DNA Duplex d(CTCTC*A*ACTTCC)Â·d(GGAAGTTGAGAG) Cross-Linked by the Antitumor-Active Dirhodium(II,II) Unit at the Cytosineâ^'Adenine Step. Biochemistry, 2008, 47, 2265-2276.	1.2	33
672	Structure, Cytotoxicity, and DNA-Cleavage Properties of the Complex [Cu^{II}(pbt)Br₂]. Inorganic Chemistry, 2008, 47, 3719-3727.	1.9	118
673	[¹H, ¹⁵N] Heteronuclear Single Quantum Coherence NMR Study of the Mechanism of Aquation of Platinum(IV) Ammine Complexes. Inorganic Chemistry, 2008, 47, 7673-7680.	1.9	41
674	Binding to DNA Purine Base and Structureâ^'Activity Relationship of a Series of Structurally Related Ru(II) Antitumor Complexes: A Theoretical Study. Journal of Physical Chemistry B, 2008, 112, 9966-9974.	1.2	20
675	DNA Structural Distortions Induced by Rutheniumâ^'Arene Anticancer Compounds. Journal of the American Chemical Society, 2008, 130, 10921-10928.	6.6	94
676	2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): A Novel Platinum Compound that Overcomes Cisplatin Resistance and Induces Apoptosis by Mechanisms Different from that of Cisplatin. Journal of Medicinal Chemistry, 2008, 51, 5413-5422.	2.9	25
678	Theoretical study of the potential energy surface for the interaction of cisplatin and their aquated species with water. Journal of Chemical Physics, 2008, 128, 165103.	1.2	30
679	SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism. Molecular Cancer Research, 2008, 6, 1499-1506.	1.5	101
680	Cytoplasmic initiation of cisplatin cytotoxicity. American Journal of Physiology - Renal Physiology, 2008, 295, F44-F52.	1.3	70
681	Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 300-307.	1.3	130
682	Transfer RNA Bindings to Antitumor Estradiol-Platinum(II) Hybrid and Cisplatin. DNA and Cell Biology, 2008, 27, 337-343.	0.9	27
683	Compensation of DNA Stabilization and Destabilization Effects Caused by Cisplatin is Partially Disturbed in Alkaline Medium. Journal of Biomolecular Structure and Dynamics, 2008, 25, 407-417.	2.0	10
685	Metal-Containing Drugs. , 0, , 303-356.		2
686	Medicinal Applications of Metal Complexes Binding to Biological Macromolecules. Macromolecular Symposia, 2008, 270, 193-201.	0.4	31
687	Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism. Metal-Based Drugs, 2008, 2008, 1-15.	3.8	13
689	The Anti-tumour Agent, Cisplatin, and its Clinically Ineffective Isomer, Transplatin, Produce Unique Gene Expression Profiles in Human Cells. Cancer Informatics, 2008, 6, CIN.S802.	0.9	13

#	Article	IF	Citations
691	Quantitative Proteomics Analysis Integrated with Microarray Data Reveals That Extracellular Matrix Proteins, Catenins, and P53 Binding Protein 1 Are Important for Chemotherapy Response in Ovarian Cancers. OMICS A Journal of Integrative Biology, 2009, 13, 345-354.	1.0	76
692	A platform for in situ real-time measurement of protein induced conformational changes of DNA. , 2009, , .		1
693	Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. Anti-Cancer Drugs, 2009, 20, 115-122.	0.7	22
694	Functional Interactions of Cu-ATPase ATP7B with Cisplatin and the Role of ATP7B in the Resistance of Cells to the Drug. Journal of Biological Chemistry, 2009, 284, 7793-7802.	1.6	56
695	Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirusâ€"Related Head and Neck Cancer. JAMA Otolaryngology, 2009, 135, 1137.	1.5	220
697	DNA Repair Proteins and Telomerase Reverse Transcriptase in the Cochlear Lateral Wall of Cisplatin-Treated Rats. Journal of Chemotherapy, 2009, 21, 74-79.	0.7	15
698	Fluorescent Cisplatin Analogues and Cytotoxic Activity. Current Medicinal Chemistry, 2009, 16, 4314-4327.	1.2	16
699	Nanocapsules of platinum anticancer drugs: development towards therapeutic use. Future Medicinal Chemistry, 2009, 1, 1467-1480.	1.1	16
700	The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship. Current Medicinal Chemistry, 2009, 16, 2235-2260.	1.2	120
701	The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View. Current Medicinal Chemistry, 2009, 16, 4544-4580.	1.2	71
702	Metallothioneins and Platinum(II) Anti-Tumor Compounds. Current Medicinal Chemistry, 2009, 16, 522-537.	1.2	71
703	Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer. Clinical Cancer Research, 2009, 15, 3423-3432.	3.2	373
704	Palladium(II) complexes with R2edda derived ligands, Part I: Reaction of diisopropyl (S,S)-2,2'-(1,2-ethanediyldiimino)- dipropanoate with K2[PdCl4]. Journal of the Serbian Chemical Society, 2009, 74, 389-400.	0.4	11
705	Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes. Nucleic Acids Research, 2009, 37, 5432-5442.	6.5	14
706	Inhibition of p38-MAPK Potentiates Cisplatin-Induced Apoptosis via GSH Depletion and Increases Intracellular Drug Accumulation in Growth-Arrested Kidney Tubular Epithelial Cells. Toxicological Sciences, 2009, 111, 413-423.	1.4	23
707	Differences in conformational dynamics of [Pt3(HPTAB)]6+-DNA adducts with various cross-linking modes. Nucleic Acids Research, 2009, 37, 5930-5942.	6.5	14
708	TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Molecular Cancer Therapeutics, 2009, 8, 893-903.	1.9	50
709	Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 670, 32-41.	0.4	28

#	Article	IF	Citations
710	DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media. Biochemical Pharmacology, 2009, 77, 364-374.	2.0	76
711	Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Experimental and Toxicologic Pathology, 2009, 61, 223-242.	2.1	416
712	Synthesis, characterization, and DNAâ€binding of chiral complexes Î”â€•and Î›â€[Ru(bpy)₂(pyip)]²⁺. Chirality, 2009, 21, 276-283.	1.3	20
713	Toxicity of Copper(I)â€“NHC Complexes Against Human Tumor Cells: Induction of Cell Cycle Arrest, Apoptosis, and DNA Cleavage. Chemistry - A European Journal, 2009, 15, 314-318.	1.7	86
714	DNA Crossâ€Linking Patterns Induced by an Antitumorâ€Active Trinuclear Platinum Complex and Comparison with Its Dinuclear Analogue. Chemistry - A European Journal, 2009, 15, 5245-5253.	1.7	43
715	Energetics, Conformation, and Recognition of DNA Duplexes Modified by Methylated Analogues of [PtCl(dien)]⁺. Chemistry - A European Journal, 2009, 15, 6211-6221.	1.7	20
716	Photoaffinity Isolation and Identification of Proteins in Cancer Cell Extracts that Bind to Platinumâ€Modified DNA. ChemBioChem, 2009, 10, 141-157.	1.3	60
717	Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology, 2009, 50, 565-574.	3.6	68
718	Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a threeâ€dimensional carcinoma culture model. International Journal of Cancer, 2009, 125, 2450-2455.	2.3	33
719	Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design. European Journal of Inorganic Chemistry, 2009, 2009, 1303-1312.	1.0	316
721	Reversible Cellâ€Specific Drug Delivery with Aptamerâ€Functionalized Liposomes. Angewandte Chemie - International Edition, 2009, 48, 6494-6498.	7.2	343
722	Selective recognition of thymidine homopolymer (poly T) oligonucleotide with cobalt(II)â€“4â€[(5â€chloroâ€2â€pyridyl)azo]â€1,3â€diaminobenzene complex. Luminescence, 2009, 24, 150-154.	1.5	2
723	Identifying protein interactions with metal-modified DNA using microarray technology. Journal of Biological Inorganic Chemistry, 2009, 14, 193-199.	1.1	10
724	Ruthenium polypyridyl complexes and their modes of interaction with DNA: Is there a correlation between these interactions and the antitumor activity of the compounds?. Journal of Biological Inorganic Chemistry, 2009, 14, 439-448.	1.1	78
725	DNA adducts of antitumor cisplatin preclude telomeric sequences from forming GÂquadruplexes. Journal of Biological Inorganic Chemistry, 2009, 14, 959-968.	1.1	22
726	Structural consequences of a 3â€²Ââ†'Â3â€² DNA interstrand cross-link by a trinuclear platinum complex: unique formation of two such cross-links in a 10-mer duplex. Journal of Biological Inorganic Chemistry, 2009, 14, 969-977.	1.1	14
727	Reaction of human metallothionein-3 with cisplatin and transplatin. Journal of Biological Inorganic Chemistry, 2009, 14, 1129-1138.	1.1	36
728	A detailed theoretical study of the interaction of thiourea with cis-diaqua(ethylenediamine) platinum(II). Computational and Theoretical Chemistry, 2009, 913, 97-106.	1.5	12

#	Article	IF	Citations
729	Optimization of cisplatin for the treatment of hormone dependent tumoral diseases. Coordination Chemistry Reviews, 2009, 253, 2742-2759.	9.5	91
730	DFT-based QSAR and QSPR models of several cis-platinum complexes: solvent effect. Journal of Computer-Aided Molecular Design, 2009, 23, 343-354.	1.3	39
731	Post-translational and transcriptional regulation of glycolipid glycosyltransferase genes in apoptotic breast carcinoma cells: VII. Studied by DNA-microarray after treatment with l-PPMP. Glycoconjugate Journal, 2009, 26, 647-661.	1.4	8
732	Equilibrium and 1H NMR Kinetic Study of the Reactions of Dichlorido [S-Methyl-L-Cysteine(N,S)]Platinum(II) Complex with Some Relevant Biomolecules. Journal of Solution Chemistry, 2009, 38, 57-71.	0.6	5
733	Review on supermolecules as chemical drugs. Science in China Series B: Chemistry, 2009, 52, 415-458.	0.8	77
734	Metallomics: An integrated biometal science. Science in China Series B: Chemistry, 2009, 52, 2055-2070.	0.8	18
735	DNA bindings of a novel anticancer drug, trans-[PtCl2(isopropylamine)(3-picoline)], and kinetic competition of purine bases with protein residues in the bifunctional substitutions: a theoretical DFT study. Theoretical Chemistry Accounts, 2009, 123, 455-468.	0.5	10
736	Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B. Cancer Chemotherapy and Pharmacology, 2009, 63, 643-650.	1.1	27
737	Stimulatory heterotrimeric GTPâ€binding protein augments cisplatinâ€induced apoptosis by upregulating Bak expression in human lung cancer cells. Cancer Science, 2009, 100, 1069-1074.	1.7	10
738	Platination of telomeric sequences and nuclease hypersensitive elements of human câ€myc and PDGFâ€A promoters and their ability to form Gâ€quadruplexes. FEBS Journal, 2009, 276, 401-409.	2.2	20
739	Binuclear monofunctional platinum(II) complexes formed by hexaazamacrocyclic bisdien ligands: Crystal structure, DNA binding and cytotoxicity studies. Inorganica Chimica Acta, 2009, 362, 967-974.	1.2	10
740	Cytotoxicity studies of [PtCl2(H2bim)] (H2bim=2,2â€²-biimidazole): Study of its interaction with a small protein PCI (potato carboxypeptidase inhibitor). Inorganica Chimica Acta, 2009, 362, 946-952.	1.2	4
741	Molecular structure and antitumor activity of platinum(II) complexes containing purine analogs. Inorganica Chimica Acta, 2009, 362, 669-681.	1.2	59
742	Synthesis and characterization of the novel Pt(II) complexes of the types cis- and trans-Pt(Ypy)(pyrazine)Cl2, K2[Cl3Pt(Î¼-pyrazine)PtCl3] and trans, trans-(Ypy)Cl2Pt(Î¼-pyrazine)Pt(Ypy)Cl2 (Ypy=pyridine derivative). Inorganica Chimica Acta, 2009, 362, 458-470.	1.2	8
743	Synthesis and NMR characterization of the novel mixed-ligand Pt(II) complexes cis- and trans-Pt(Ypy)(pyrimidine)Cl2 and trans,trans-Cl2(Ypy)Pt(Î¼-pyrimidine)Pt(Ypy)Cl2 (Ypy=pyridine derivative). Inorganica Chimica Acta, 2009, 362, 1455-1466.	1.2	16
744	Synthesis, crystal structures, DNA binding and cleavage activity of l-glutamine copper(II) complexes of heterocyclic bases. Inorganica Chimica Acta, 2009, 362, 1591-1599.	1.2	74
745	New ternary copper(II) complexes of l-alanine and heterocyclic bases: DNA binding and oxidative DNA cleavage activity. Inorganica Chimica Acta, 2009, 362, 4692-4698.	1.2	34
746	A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor. Journal of Inorganic Biochemistry, 2009, 103, 256-261.	1.5	49

#	Article	IF	Citations
747	Synthesis, crystal structure, cytotoxic activities and DNA-binding properties of new binuclear copper(II) complexes bridged by N,Nâ€²-bis(N-hydroxyethylaminoethyl)oxamide. Journal of Inorganic Biochemistry, 2009, 103, 833-844.	1.5	89
748	Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: Synthesis, characterizations, DFT calculations, cytotoxic assays and binding to a DNA model base. Journal of Inorganic Biochemistry, 2009, 103, 1278-1287.	1.5	21
749	The influence of cisplatin on the gas-phase dissociation of oligonucleotides studied by electrospray ionization tandem mass spectrometry. Journal of the American Society for Mass Spectrometry, 2009, 20, 792-804.	1.2	26
750	Direct determination of the primary binding site of cisplatin on cytochrome c by mass spectrometry. Journal of the American Society for Mass Spectrometry, 2009, 20, 1141-1147.	1.2	46
751	Synthesis, crystal structure and in vitro antitumor activity of carboxylate bridged dinuclear organotin(IV) complexes. Journal of Organometallic Chemistry, 2009, 694, 3768-3774.	0.8	43
752	Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method. Journal of Pharmaceutical and Biomedical Analysis, 2009, 50, 570-575.	1.4	34
753	Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. Coordination Chemistry Reviews, 2009, 253, 2070-2081.	9.5	251
754	Biological activity of metal ions complexes of chromones, coumarins and flavones. Coordination Chemistry Reviews, 2009, 253, 2588-2598.	9.5	251
755	Cisplatin and its analogues induce a significant change in the higher-order structure of long duplex DNA. Chemical Physics Letters, 2009, 473, 155-159.	1.2	12
756	The synthesis of N-phenoxyethyl-1-substituted-1,2,3,4-tetrahydroisoquinolines and their Î±1-adrenoceptor blocking activity. European Journal of Medicinal Chemistry, 2009, 44, 1271-1277.	2.6	1
757	Palladium(II) complexes with R2edda-derived ligands. Part II. Synthesis, characterization and in vitro antitumoral studies of R2eddip esters and palladium(II) complexes. European Journal of Medicinal Chemistry, 2009, 44, 3452-3458.	2.6	24
758	Metals in anticancer therapy: Copper(II) complexes as inhibitors of the 20S proteasome. European Journal of Medicinal Chemistry, 2009, 44, 4353-4361.	2.6	98
759	Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) Warheads. Journal of the American Chemical Society, 2009, 131, 14652-14653.	6.6	481
760	The Trans Effect: A Guided-Inquiry Experiment for Upper-Division Inorganic Chemistry. Journal of Chemical Education, 2009, 86, 1416.	1.1	9
761	In Vitro Transcription Inhibition by Ruthenium(II) Polypyridyl Complexes with Electropositive Ancillary Ligands. Inorganic Chemistry, 2009, 48, 5599-5601.	1.9	50
762	Anticancer activity of heteroleptic diimine complexes of dirhodium: A study of intercalating properties, hydrophobicity and in cellulo activity. Dalton Transactions, 2009, , 10806.	1.6	48
763	Photoaffinity Labeling Reveals Nuclear Proteins That Uniquely Recognize Cisplatinâ€”DNA Interstrand Cross-Links. Biochemistry, 2009, 48, 4916-4925.	1.2	73
764	Origins of the Distortions in the Base Pair Step Adjacent to Platinum Anticancer Drugâ€”DNA Adducts. Fundamental NMR Solution Studies Utilizing Right-Handed Cross-Link Models Having 5â€²- and 3â€²-Flanking Residues. Journal of the American Chemical Society, 2009, 131, 12314-12324.	6.6	24

#	Article	IF	Citations
765	Preparation of Mammalian Expression Vectors Incorporating Site-Specifically Platinated-DNA Lesions. Bioconjugate Chemistry, 2009, 20, 1058-1063.	1.8	12
766	Study of DNA Interactions with Steroidal and Nonsteroidal Estrogenâ€“Platinum (II)â€“Based Anticancer Drugs. DNA and Cell Biology, 2009, 28, 31-39.	0.9	21
767	Cytotoxicity of the traditional chinese medicine (TCM) plumbagin in its copper chemistry. Dalton Transactions, 2009, , 10824.	1.6	61
768	An Iron Complex of Dipyridophenazine as a Potent Photocytotoxic Agent in Visible Light. Inorganic Chemistry, 2009, 48, 2652-2663.	1.9	123
769	The Second-Generation Anticancer Drug Nedaplatin: A Theoretical Investigation on the Hydrolysis Mechanism. Journal of Physical Chemistry B, 2009, 113, 14473-14479.	1.2	98
770	Native HMGB1 protein inhibits repair of cisplatin-damaged nucleosomes in vitro. International Journal of Biochemistry and Cell Biology, 2009, 41, 1556-1562.	1.2	34
771	Unusual DNA binding modes for metal anticancer complexes. Biochimie, 2009, 91, 1198-1211.	1.3	192
772	In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide - Biology and Chemistry, 2009, 20, 182-194.	1.2	49
773	Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Hearing Research, 2009, 251, 70-82.	0.9	91
774	Structural and Mechanistic Studies of Anticancer Platinum Drugs: Uptake, Activation, and the Cellular Response to DNA Binding. , 2009, , 135-147.		4
775	Porous Hollow Fe₃O₄ Nanoparticles for Targeted Delivery and Controlled Release of Cisplatin. Journal of the American Chemical Society, 2009, 131, 10637-10644.	6.6	429
776	From cisplatin to photoreactive Ru complexes: targeting DNA for biomedical applications. New Journal of Chemistry, 2009, 33, 235-245.	1.4	91
777	Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting. Dalton Transactions, 2009, , 10651.	1.6	205
778	Synthesis, Cytotoxicity, and DNA Interactions of New Cisplatin Analogues Containing Substituted Benzimidazole Ligands. Journal of Medicinal Chemistry, 2009, 52, 1345-1357.	2.9	93
779	Photocytotoxic 3d-Metal Scorpionates with a 1,8-Naphthalimide Chromophore Showing Photoinduced DNA and Protein Cleavage Activity. Inorganic Chemistry, 2009, 48, 9501-9509.	1.9	55
780	Structural basis for the sequence-dependent effects of platinumâ€“DNA adducts. Nucleic Acids Research, 2009, 37, 2434-2448.	6.5	27
781	Divalent later transition metal complexes of the traditional chinese medicine (TCM) liriodenine: coordination chemistry, cytotoxicity and DNA binding studies. Dalton Transactions, 2009, , 10813.	1.6	52
782	Dumbbell-like Auâ^'Fe₃O₄ Nanoparticles for Target-Specific Platin Delivery. Journal of the American Chemical Society, 2009, 131, 4216-4217.	6.6	378

#	Article	IF	Citations
783	Neutral and Acidic Hydrolysis Reactions of the Third Generation Anticancer Drug Oxaliplatin. Journal of Physical Chemistry B, 2009, 113, 831-838.	1.2	77
784	Copperâ˜'1,10-Phenanthroline Complexes Binding to DNA: Structural Predictions from Molecular Simulations. Journal of Physical Chemistry B, 2009, 113, 10881-10890.	1.2	78
785	Mixed-Ligand Copper(II) Maltolate Complexes: Synthesis, Characterization, DNA Binding and Cleavage, and Cytotoxicity. Inorganic Chemistry, 2009, 48, 9120-9132.	1.9	157
786	Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) liriodenine with metal ions, and DNA binding studies. Dalton Transactions, 2009, , 262-272.	1.6	57
787	DNA binding and oxidative DNA cleavage activity of (Î¼-oxo)diiron(iii) complexes in visible light. Dalton Transactions, 2009, , 1024-1033.	1.6	36
789	Peptide Targeting of Platinum Anti-Cancer Drugs. Bioconjugate Chemistry, 2009, 20, 1869-1878.	1.8	71
791	Metal-NHC complexes: a survey of anti-cancer properties. Dalton Transactions, 2009, , 6894.	1.6	332
792	Photoinduced DNA and Protein Cleavage Activity of Ferrocene-Conjugated Ternary Copper(II) Complexes. Organometallics, 2009, 28, 1495-1505.	1.1	72
793	Identification by NMR Spectroscopy of the Two Stereoisomers of the Platinum Complex [PtCl2(S-ahaz)] (S-ahaz = 3(S)-Aminohexahydroazepine) Bound to a DNA 14-mer Oligonucleotide. NMR Evidence of Structural Alteration of a Platinated AÂ·T-rich 14-mer DNA Duplex. Inorganic Chemistry, 2009, 48, 3047-3056.	1.9	9
794	Decomposition pathways for the photoactivated anticancer complex cis,trans,cis-[Pt(N3)2(OH)2(NH3)2]: insights from DFT calculations. Physical Chemistry Chemical Physics, 2009, 11, 10311.	1.3	51
795	On the many roles of NH3 ligands in mono- and multinuclear complexes of platinum. Dalton Transactions, 2009, , 10774.	1.6	39
796	Molecular combo of photodynamic therapeutic agent silicon(iv) phthalocyanine and anticancer drug cisplatin. Chemical Communications, 2009, , 908.	2.2	89
797	DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation. Dalton Transactions, 2009, , 10846.	1.6	44
798	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. Journal of Analytical Atomic Spectrometry, 2009, 24, 51-61.	1.6	100
799	Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 22199-22204.	3.3	337
800	A Comparative Study on the Interaction of Cis- and Trans-Platin with DNA and RNA. DNA and Cell Biology, 2009, 28, 469-477.	0.9	42
801	Live Cell Cytotoxicity Studies: Documentation of the Interactions of Antitumor Active Dirhodium Compounds with Nuclear DNA. Journal of the American Chemical Society, 2009, 131, 11353-11360.	6.6	92
802	Does the metal influence non-covalent binding of complexes to DNA?. Dalton Transactions, 2009, , 504-513.	1.6	27

#	Article	IF	Citations
803	Novel and emerging approaches for the delivery of metallo-drugs. Dalton Transactions, 2009, , 10702.	1.6	79
804	Copper(II) Complexes of <scp>l</scp>-Arginine as Netropsin Mimics Showing DNA Cleavage Activity in Red Light. Inorganic Chemistry, 2009, 48, 2932-2943.	1.9	137
805	Platinum(II) Complexes with Dipyridophenazine Ligands as Human Telomerase Inhibitors and Luminescent Probes for G-Quadruplex DNA. Journal of the American Chemical Society, 2009, 131, 1835-1846.	6.6	268
806	Synthesis of Apoptosis-Inducing Iminophosphorane Organogold(III) Complexes and Study of Their Interactions with Biomolecular Targets. Inorganic Chemistry, 2009, 48, 1577-1587.	1.9	79
807	Cisplatin enhances the anticancer effect of Î²-lapachone by upregulating NQO1. Anti-Cancer Drugs, 2009, 20, 901-909.	0.7	34
808	Degradation of platinum based anticancer drugs by methionine: An EXAFS study. Journal of Physics: Conference Series, 2009, 190, 012206.	0.3	5
809	The soluble metal-binding domain of the copper transporter ATP7B binds and detoxifies cisplatin. Biochemical Journal, 2009, 419, 51-59.	1.7	60
811	Telomeres and Telomerase: Potential Targets for Platinum Complexes. , 0, , 209-234.		7
812	Platinum Drugs, Nucleotides and DNA: The Role of Interligand Interactions. , 0, , 133-173.		2
813	Novel Metals and Metal Complexes as Platforms for Cancer Therapy. Current Pharmaceutical Design, 2010, 16, 1813-1825.	0.9	427
814	Cytoskeletal changes during cellular response of the A549 lung cancer cells to continuous cisplatin treatment. Cell Biology International, 2010, 34, 197-211.	1.4	2
815	A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. Journal of Pharmacy and Pharmacology, 2010, 56, 1067-1081.	1.2	28
816	Design, synthesis, characterisation and chemical reactivity of mixed-ligand platinum(ii) oxadiazoline complexes with potential cytotoxic properties. Dalton Transactions, 2010, 39, 7747.	1.6	18
817	Unusual Interstrand Pt(S,Sâ€diaminocyclohexane)â€GG Crosslink Formed by Rearrangement of a Classical Intrastrand Crosslink Within a DNA Duplex. Chemistry - an Asian Journal, 2010, 5, 244-247.	1.7	5
818	Chapter 9. Nuclear-based Metallomics in Metal-based Drugs. , 2010, , 265-298.		0
819	Novel platinum(ii) complexes of 3-(aminomethyl)naphthoquinone Mannich bases: synthesis, crystal structure and cytotoxic activities. Dalton Transactions, 2010, 39, 10203.	1.6	32
820	Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemotherapy and Pharmacology, 2010, 66, 265-267.	1.1	8
821	Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy. Cellular and Molecular Life Sciences, 2010, 67, 3683-3697.	2.4	58

#	Article	IF	Citations
822	Palladium(II) complexes with R2edda derived ligands. Part IV. O,Oâ€²-dialkyl esters of (S,S)-ethylenediamine-N,Nâ€²-di-2-(4-methyl)-pentanoic acid dihydrochloride and their palladium(II) complexes: Synthesis, characterization and in vitro antitumoral activity against chronic lymphocytic leukemia (CLL) cells. European Journal of Medicinal Chemistry, 2010, 45, 3601-3606.	2.6	31
823	DNA modified with metal complexes: Applications in the construction of higher order metalâ€“DNA nanostructures. Coordination Chemistry Reviews, 2010, 254, 2403-2415.	9.5	95
824	Hydrolysis and binding mechanism of AMD473 (cis-[PtCl2(NH3)(2-picoline)]) with guanine: A quantum mechanical study. Computational and Theoretical Chemistry, 2010, 955, 53-60.	1.5	16
825	Cisplatin interaction with phosphatidylserine bilayer studied by solid-state NMR spectroscopy. Journal of Biological Inorganic Chemistry, 2010, 15, 213-223.	1.1	20
826	Biological assays and noncovalent interactions of pyridine-2-carbaldehyde thiosemicarbazonecopper(II) drugs with [poly(dAâ€“dT)]2, [poly(dGâ€“dC)]2, and calf thymus DNA. Journal of Biological Inorganic Chemistry, 2010, 15, 515-532.	1.1	39
827	Platination of telomeric DNA by cisplatin disrupts recognition by TRF2 and TRF1. Journal of Biological Inorganic Chemistry, 2010, 15, 641-654.	1.1	11
828	Characteristic effect of an anticancer dinuclear platinum(II) complex on the higher-order structure of DNA. Journal of Biological Inorganic Chemistry, 2010, 15, 701-707.	1.1	20
829	Biological activity of enantiomeric complexes [PtCl2L2] (L2ÂisÂaromatic bisphosphanes and aromatic) Tj ETQq1 1 0.784314 rgBT /Ov	1.1	25
830	Thermal degradation of platinum(IV) precursors to antitumor drugs. Journal of Thermal Analysis and Calorimetry, 2010, 102, 499-503.	2.0	9
831	Binding of ansa- and non-ansa-titanocene anticancer drugs to DNA: a DFT study. Structural Chemistry, 2010, 21, 735-744.	1.0	6
832	Platinum(II) complexes with thiourea derivatives containing oxygen, sulfur or selenium in a heterocyclic ring: computational studies and cytotoxic properties. Transition Metal Chemistry, 2010, 35, 639-647.	0.7	11
833	Upregulations of P2X3 and ASIC3 involve in hyperalgesia induced by cisplatin administration in rats. Pain, 2010, 149, 393-405.	2.0	64
834	ROS-mediated autophagy was involved in cancer cell death induced by novel copper(II) complex. Experimental and Toxicologic Pathology, 2010, 62, 577-582.	2.1	64
835	Cisplatin resistance: Preclinical findings and clinical implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 172-182.	3.3	220
836	Conformation and recognition of DNA modified by a new antitumor dinuclear PtII complex resistant to decomposition by sulfur nucleophiles. Biochemical Pharmacology, 2010, 79, 112-121.	2.0	33
837	Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring PtII chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand. Biochemical Pharmacology, 2010, 79, 552-564.	2.0	48
838	Mechanistic insights into antitumor effects of new dinuclear cis PtII complexes containing aromatic linkers. Biochemical Pharmacology, 2010, 80, 344-351.	2.0	21
839	The Î±-mangostin prevention on cisplatin-induced apoptotic death in LLC-PK1 cells is associated to an inhibition of ROS production and p53 induction. Chemico-Biological Interactions, 2010, 188, 144-150.	1.7	48

#	Article	IF	Citations
840	Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator. Cancer Cell, 2010, 17, 574-583.	7.7	238
841	Complexes of glutathione with heavy metal ions as a new biochemical marker of aquatic environment pollution. Environmental Toxicology and Chemistry, 2010, 29, 497-500.	2.2	21
842	Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrixâ€metalloproteinase expression. Cytoskeleton, 2010, 67, 535-544.	1.0	32
843	Waterâ€soluble Organometallic Analogues of Oxaliplatin with Cytotoxic and Anticlonogenic Activity. ChemMedChem, 2010, 5, 46-51.	1.6	30
844	Photoactivated Biological Activity of Transitionâ€Metal Complexes. European Journal of Inorganic Chemistry, 2010, 2010, 1451-1467.	1.0	310
847	Translesion Synthesis of 1,3â€GTG Cisplatin DNA Lesions. ChemBioChem, 2010, 11, 1521-1524.	1.3	12
849	Redoxâ€Induced Binding of [(tacn)Re^{II}Br(CO)₂]⁺ to Guanine, Oligonucleotides, and Peptides. Chemistry - A European Journal, 2010, 16, 2710-2713.	1.7	4
850	Energetics, Conformation, and Recognition of DNA Duplexes Modified by Monodentate Ru^{II} Complexes Containing Terphenyl Arenes. Chemistry - A European Journal, 2010, 16, 5744-5754.	1.7	24
851	Advances in Platinum Chemotherapeutics. Chemistry - A European Journal, 2010, 16, 7064-7077.	1.7	238
852	Photolysis and Thermolysis of Platinum(IV) 2,2â€²â€Bipyridine Complexes Lead to Identical Platinum(II)â€“DNA Adducts. Chemistry - A European Journal, 2010, 16, 11420-11431.	1.7	11
853	Platinumâ€“DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes. Chemistry and Biodiversity, 2010, 7, 543-566.	1.0	176
854	Platinum and Palladiumâ€triazole Complexes as Highly Potential Antitumor Agents. Archiv Der Pharmazie, 2010, 343, 222-227.	2.1	18
856	Crystal Structure of a Cisplatinâ€“(1,3â€GTG) Crossâ€Link within DNA Polymerase Î·. Angewandte Chemie - International Edition, 2010, 49, 3077-3080.	7.2	37
857	Shape changes induced by N-terminal platination of ubiquitin by cisplatin. Journal of the American Society for Mass Spectrometry, 2010, 21, 1097-1106.	1.2	50
858	In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. Journal of Inorganic Biochemistry, 2010, 104, 79-86.	1.5	161
859	A mass spectrometric comparison of the interactions of cisplatin and transplatin with myoglobin. Journal of Inorganic Biochemistry, 2010, 104, 186-192.	1.5	19
860	Effect of ancillary ligands on the topoisomerases II and transcription inhibition activity of polypyridyl ruthenium(II) complexes. Journal of Inorganic Biochemistry, 2010, 104, 576-582.	1.5	33
861	Synthesis and characterization of the ligand based on benzoxazole and its transition metal complexes: DNA-binding and antitumor activity. Journal of Inorganic Biochemistry, 2010, 104, 583-591.	1.5	47

#	Article	IF	Citations
862	Carboplatin interaction with calf-thymus DNA: A FTIR spectroscopic approach. Journal of Molecular Structure, 2010, 969, 126-129.	1.8	103
863	Synthesis and NMR characterization of the novel mixed-ligands Pt(II) complexes Pt(amine)(pyrimidine)X2 and trans,trans-X2(amine)Pt(Î¼-pyrimidine)Pt(amine)X2 (X=I and Cl). Inorganica Chimica Acta, 2010, 363, 1679-1693.	1.2	5
864	Synthesis and multinuclear magnetic resonance spectroscopy of the novel ionic Pt(II) mixed-ligands complexes cis- and trans-[Pt(amine)2(pyrimidine)2](NO3)2. Inorganica Chimica Acta, 2010, 363, 1619-1626.	1.2	1
865	Exploring water-soluble Pt(II) complexes of diethylenetriamine derivatives functionalized at the central nitrogen. Synthesis, characterization, and reaction with 5â€²-GMP. Inorganica Chimica Acta, 2010, 363, 1796-1804.	1.2	15
866	The interactions of cisplatin and DNA studied by atomic force microscopy. Micron, 2010, 41, 833-839.	1.1	37
867	Towards biomarker-dependent individualized chemotherapy: Exploring cell-specific differences in oxaliplatinâ€“DNA adduct distribution using accelerator mass spectrometry. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2448-2451.	1.0	17
868	Consequences of Cisplatin Binding on Nucleosome Structure and Dynamics. Chemistry and Biology, 2010, 17, 1334-1343.	6.2	40
869	A detailed theoretical DFT study of the hydrolysis mechanism of orally active anticancer drug ZD0473. Chemical Physics Letters, 2010, 487, 108-115.	1.2	30
870	Synthesis and antitumor activity of cis-dichloridoplatinum(II) complexes of 1,1â€²-biisoquinolines. European Journal of Medicinal Chemistry, 2010, 45, 55-62.	2.6	17
871	The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. European Journal of Medicinal Chemistry, 2010, 45, 134-141.	2.6	22
872	Chiral preference of l-tryptophan derived metal-based antitumor agent of late 3d-metal ions (Co(II),) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 DNA, 5â€²-GMP and 5â€²-TMP. European Journal of Medicinal Chemistry, 2010, 45, 3549-3557.	2.6	87
873	[Cyclopentadienyl]metalcarbonyl complexes of acetylsalicylic acid as neo-anticancer agents. European Journal of Medicinal Chemistry, 2010, 45, 5157-5163.	2.6	27
874	Quantitative proteome analysis of detergentâ€resistant membranes identifies the differential regulation of protein kinase C isoforms in apoptotic T cells. Proteomics, 2010, 10, 2758-2768.	1.3	19
875	The Role of Surface Functionality on Acute Cytotoxicity, ROS Generation and DNA Damage by Cationic Gold Nanoparticles. Small, 2010, 6, 2246-2249.	5.2	232
876	Structural insight into dynamic bypass of the major cisplatin-DNA adduct by Y-family polymerase Dpo4. EMBO Journal, 2010, 29, 2059-2069.	3.5	36
877	Cellular Responses to Cisplatin-Induced DNA Damage. Journal of Nucleic Acids, 2010, 2010, 1-16.	0.8	361
878	Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs. Nucleic Acids Research, 2010, 38, 7089-7099.	6.5	68
879	Cisplatin and Oxaliplatin Inhibit Gap Junctional Communication by Direct Action and by Reduction of Connexin Expression, Thereby Counteracting Cytotoxic Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 903-911.	1.3	42

#	Article	IF	Citations
880	The XPA-binding domain of ERCC1 Is Required for Nucleotide Excision Repair but Not Other DNA Repair Pathways. Journal of Biological Chemistry, 2010, 285, 3705-3712.	1.6	97
881	Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review. Metal-Based Drugs, 2010, 2010, 1-11.	3.8	153
882	BNP7787-Mediated Modulation of Paclitaxel- and Cisplatin-Induced Aberrant Microtubule Protein Polymerization In vitro. Molecular Cancer Therapeutics, 2010, 9, 2558-2567.	1.9	9
883	Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. Carcinogenesis, 2010, 31, 59-70.	1.3	241
884	Anticancer activities of the ruthenium carboxylato, amido and pyridine complexes. International Journal of Oncology, 2010, 36, 1591-8.	1.4	3
885	Synthesis, structure, and DNA-binding studies of a new tetracopper(II) complex bridged by dissymmetrical N-benzoato-Nâ€²-(2-aminoethyl)oxamide. Journal of Coordination Chemistry, 2010, 63, 1582-1596.	0.8	14
886	Molecular dynamics study of solvation differences between cis- and transplatin molecules in water. Journal of Chemical Physics, 2010, 132, 174507.	1.2	15
887	UV-Vis, HPLC, and ¹H-NMR studies of the substitution reactions of some Pt(IV) complexes with 5â€²-GMP and <scp>L</scp>-histidine. Journal of Coordination Chemistry, 2010, 63, 2419-2430.	0.8	11
888	Cis-dichlorodiammineplatinum Upregulates Angiotensin II Type 1 Receptors through Reactive Oxygen Species Generation and Enhances VEGF Production in Bladder Cancer. Molecular Cancer Therapeutics, 2010, 9, 2982-2992.	1.9	25
889	X-ray structure and mechanism of RNA polymerase II stalled at an antineoplastic monofunctional platinum-DNA adduct. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9584-9589.	3.3	116
890	Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17939-17944.	3.3	545
891	Platform for in situ real-time measurement of protein-induced conformational changes of DNA. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1397-1401.	3.3	29
892	Fourier Transform Infrared (FTIR) spectroscopy to monitor the cellular impact of newly synthesized platinum derivatives. International Journal of Oncology, 2010, 37, 679-86.	1.4	6
893	Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 324-337.	0.9	31
894	Fascinating frontiers of N/O-functionalized N-heterocyclic carbene chemistry: from chemical catalysis to biomedical applications. Dalton Transactions, 2010, 39, 7183.	1.6	171
895	Gold nanorods for platinum based prodrug delivery. Chemical Communications, 2010, 46, 8424.	2.2	94
896	Transcription Inhibition by Platinumâ^'DNA Cross-Links in Live Mammalian Cells. Journal of the American Chemical Society, 2010, 132, 7429-7435.	6.6	80
897	Determination of the Level of DNA Modification with Cisplatin by Catalytic Hydrogen Evolution at Mercury-Based Electrodes. Analytical Chemistry, 2010, 82, 2969-2976.	3.2	24

#	Article	IF	Citations
898	A Single Watsonâ"Crick GÂ·C Base Pair in Water: Aqueous Hydrogen Bonds in Hydrophobic Cavities. Journal of the American Chemical Society, 2010, 132, 7194-7201.	6.6	92
899	Multifunctional Nanocarriers for Cell Imaging, Drug Delivery, and Near-IR Photothermal Therapy. Langmuir, 2010, 26, 5428-5434.	1.6	174
900	Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. Journal of Translational Medicine, 2010, 8, 78.	1.8	74
901	Synthesis, Characterization, and Photophysical Properties of Three Platinum(II) Complexes Bearing Fluorescent Analogues of the Di-2-pyridylmethane Ligand. Inorganic Chemistry, 2010, 49, 5303-5315.	1.9	24
902	X-Ray Structural Characterization of the Bis-Guanine Derivative of a Cisplatin Analogue Having Just One Proton on Each Coordinated Nitrogen and a Head-to-Head Conformation: [Pt{(Â±)-N,Nâ€²-Dimethyl-2,3-diaminobutane}(9-ethyl-guanine)₂]dinitrate. Inorganic Chemistry, 2010, 49, 7853-7860.	1.9	6
903	Synthesis, structure, and DNA-binding of a new binuclear copper(II) complex: [Cu2(heap)(H2O)2](pic)2 Â·2H2O. Journal of Coordination Chemistry, 2010, 63, 2985-2998.	0.8	9
904	Enzymatic Processing of Platinated RNAs. Journal of the American Chemical Society, 2010, 132, 1946-1952.	6.6	35
905	Different Features of the DNA Binding Mode of Antitumor cis-Amminedichlorido(cyclohexylamine)platinum(II) (JM118) and Cisplatin in Vitro. Chemical Research in Toxicology, 2010, 23, 1833-1842.	1.7	21
906	Extending Ï€-Conjugation of Triarylborons with a 2,2-Bpy Core: Impact of Donorâ"Acceptor Geometry on Luminescence, Anion Sensing, and Metal Ion Binding. Inorganic Chemistry, 2010, 49, 4394-4404.	1.9	64
907	Photogeneration and Reactivity of Naphthoquinone Methides as Purine Selective DNA Alkylating Agents. Journal of the American Chemical Society, 2010, 132, 14625-14637.	6.6	91
908	Spectroscopy, Electrochemistry, and Structure of 3d-Transition Metal Complexes of Thiosemicarbazones with Quinoline Core: Evaluation of Antimicrobial Property. Spectroscopy Letters, 2010, 43, 235-246.	0.5	19
909	Confirming the 3D Solution Structure of a Short Double-Stranded DNA Sequence Using NMR Spectroscopy. Journal of Chemical Education, 2010, 87, 732-734.	1.1	4
910	Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12435-12440.	3.3	121
911	Effects and applications of ultrashort-lived prehydrated electrons in radiation biology and radiotherapy of cancer. Mutation Research - Reviews in Mutation Research, 2010, 704, 190-199.	2.4	34
912	Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549. Biochemical and Biophysical Research Communications, 2010, 399, 91-97.	1.0	10
913	Nrf2/HO-1 signaling pathway may be the prime target for chemoprevention of cisplatin-induced nephrotoxicity by lycopene. Food and Chemical Toxicology, 2010, 48, 2670-2674.	1.8	93
914	Synthesis of 17Î±-substituted ethynylestradiols: Potential ligands for drug vectors. Steroids, 2010, 75, 489-498.	0.8	7
915	Polymer/Dendrimer Supported Organoplatinum Drugs. ACS Symposium Series, 2010, , 161-179.	0.5	0

#	Article	IF	Citations
916	Ligand Exchange Processes on the Solvated Zinc Cation II. [Zn(H2O)4L]2+Â·2H2O with L = NH3, NH2(CH3), NH(CH3)2, and N(CH3)3. Australian Journal of Chemistry, 2010, 63, 236.	0.5	13
917	The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Transactions, 2010, 39, 8113.	1.6	1,398
918	DNA interstrand crosslink repair in mammalian cells: step by step. Critical Reviews in Biochemistry and Molecular Biology, 2010, 45, 23-49.	2.3	150
919	Mechanistic Aspects of Nucleophilic Substitution at Half-Sandwich Metal Complexes. Organometallics, 2010, 29, 6209-6218.	1.1	8
920	Recognition of Platinumâ^'DNA Damage by Poly(ADP-ribose) Polymerase-1. Biochemistry, 2010, 49, 6177-6183.	1.2	56
921	Drug-DNA Interaction Protocols. Methods in Molecular Biology, 2010, , .	0.4	13
922	Cytotoxic copper(ii) salicylaldehyde semicarbazone complexes: Mode of action and proteomic analysis. Metallomics, 2010, 2, 694.	1.0	29
923	DNA Binding to an Anticancer Organo-Ruthenium Complex. Journal of Physical Chemistry B, 2010, 114, 14041-14047.	1.2	38
924	Probing Platinumâ^'Adenine-N3 Adduct Formation with DNA Minor-Groove Binding Agents. Chemical Research in Toxicology, 2010, 23, 1148-1150.	1.7	10
925	Oxovanadium(iv) complexes of phenanthroline bases: the dipyridophenazine complex as a near-IR photocytotoxic agent. Dalton Transactions, 2010, 39, 2147.	1.6	50
926	Synthesis, DNA binding, photo-induced DNA cleavage and cytotoxicity studies of europium(iii) complexes. Dalton Transactions, 2010, 39, 10637.	1.6	39
927	Cyclometalated gold(iii) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons. Chemical Communications, 2010, 46, 3893.	2.2	163
928	Mononuclear Fe(ii)-N4Py complexes in oxidative DNA cleavage: structure, activity and mechanism. Dalton Transactions, 2010, 39, 8012.	1.6	26
929	Conjugation of testosterone modifies the interaction of mono-functional cationic platinum(ii) complexes with DNA, causing significant alterations to the DNA helix. Dalton Transactions, 2010, 39, 11365.	1.6	37
930	Tuning the reactivity of chelated dinuclear Pt(ii) complexes through a flexible diamine linker. A detailed kinetic and mechanistic study. Dalton Transactions, 2010, 39, 3595.	1.6	43
931	Metallomics: An integrated science for metals in biology and medicine. Annual Reports on the Progress of Chemistry Section A, 2010, 106, 20.	0.8	34
932	Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein1. Metallomics, 2010, 2, 74-83.	1.0	64
933	Synthesis, characterization, cytotoxicity, and DNA binding of some new platinum(II) and platinum(IV) complexes with benzimidazole ligands. Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25, 502-508.	2.5	12

#	Article	IF	Citations
934	Specific Blockage of Caspase-1 Activation by Purple Bamboo-Salt Prevents Apoptosis of Auditory Cell Line, HEI-OC1. Journal of Medicinal Food, 2011, 14, 53-61.	0.8	7
935	Synthesis, characterization, plasmid cleavage and cytotoxicity of cancer cells by a copper(ii) complex of anthracenyl-terpyridine. Dalton Transactions, 2011, 40, 10865.	1.6	52
936	Cyclometalated platinum(ii) complexes as topoisomerase IIÎ± poisons. Chemical Communications, 2011, 47, 719-721.	2.2	50
937	Modulation of drug activation profiles through carboxylate ligand modification in cytotoxic trans-platinum planar amine compounds. Dalton Transactions, 2011, 40, 10983.	1.6	16
938	Cytotoxic activity, cell imaging and photocleavage of DNA induced by a Pt(ii) cyclophane bearing 1,2 diamino ethane as a terminal ligand. MedChemComm, 2011, 2, 1208.	3.5	24
939	Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1850-1855.	3.3	467
940	Highly Efficient DNA Compaction Mediated by an In Vivo Antitumor-Active Tetrazolato-Bridged Dinuclear Platinum(II) Complex. Inorganic Chemistry, 2011, 50, 11729-11735.	1.9	31
941	Effect of Electronic Structure on the Photoinduced Ligand Exchange of Ru(II) Polypyridine Complexes. Inorganic Chemistry, 2011, 50, 4384-4391.	1.9	77
942	Tetra-2,3-pyrazinoporphyrazines with Externally Appended Pyridine Rings. 10. A Water-Soluble Bimetallic (Zn^{II}/Pt^{II}) Porphyrazine Hexacation as Potential Plurimodal Agent for Cancer Therapy: Exploring the Behavior as Ligand of Telomeric DNA G-Quadruplex Structures. Inorganic Chemistry, 2011, 50, 7403-7411.	1.9	23
943	Water-Soluble Cp Ruthenium Complex Containing 1,3,5-Triaza-7-phosphaadamantane and 8-Thiotheophylline Derivatives: Synthesis, Characterization, and Antiproliferative Activity. Inorganic Chemistry, 2011, 50, 873-882.	1.9	30
944	Effect of Thioethers on DNA Platination bytrans-Platinum Complexes. Inorganic Chemistry, 2011, 50, 8168-8176.	1.9	17
945	Redox State-Dependent Interaction of HMGB1 and Cisplatin-Modified DNA. Biochemistry, 2011, 50, 2567-2574.	1.2	59
946	FAB, ESI and MALDI Mass Spectrometric methods in the study of metallo-drugs and their biomolecular interactions. Metallomics, 2011, 3, 550.	1.0	16
947	Probing the Interaction of Cisplatin with the Human Copper Chaperone Atox1 by Solution and In-Cell NMR Spectroscopy. Journal of the American Chemical Society, 2011, 133, 18361-18369.	6.6	114
948	Structureâ€“activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity. Dalton Transactions, 2011, 40, 10553.	1.6	76
949	Reduction of Cisplatin-Induced Nephrotoxicity in Vivo by Selenomethionine: The Effect on Cisplatinâ€“DNA Adducts. Chemical Research in Toxicology, 2011, 24, 896-904.	1.7	27
950	Synthesis, Electronic Structure, DNA and Protein Binding, DNA Cleavage, and Anticancer Activity of Fluorophore-Labeled Copper(II) Complexes. Inorganic Chemistry, 2011, 50, 545-558.	1.9	249
951	Multinuclear solid-state NMR of square-planar platinum complexesÂâ€” Cisplatin and related systems. Canadian Journal of Chemistry, 2011, 89, 919-937.	0.6	65

#	Article	IF	Citations
952	Speciation of oxaliplatin adducts with DNA nucleotides. Metallomics, 2011, 3, 991.	1.0	31
953	Ternary Dinuclear Copper(II) Complexes of a Hydroxybenzamide Ligand with Diimine Coligands: the 5,6-dmp Ligand Enhances DNA Binding and Cleavage and Induces Apoptosis. Inorganic Chemistry, 2011, 50, 6458-6471.	1.9	184
954	Laser desorption and ionization time-of-flightversus matrix-assisted laser desorption and ionization time-of-flight mass spectrometry of Pt(ii) and Ru(iii) metal complexes. Analytical Methods, 2011, 3, 400-407.	1.3	16
955	Synthesis, characterization, DNA interaction and cleavage, and in vitro cytotoxicity of copper(ii) mixed-ligand complexes with 2-phenyl-3-hydroxy-4(1H)-quinolinone. Dalton Transactions, 2011, 40, 9404.	1.6	59
956	Reactivity of Aquadiethylenetriamineplatinum(II) Ion with Disulfide Moiety Cystine: A Kinetic and Mechanistic Approach. Phosphorus, Sulfur and Silicon and the Related Elements, 2011, 186, 1702-1713.	0.8	0
957	High cytotoxicity of dihalo-substituted 8-quinolinolato-lanthanides. Dalton Transactions, 2011, 40, 1684.	1.6	46
958	Unique DNA Binding Mode of Antitumor Trinuclear Tridentate Platinum(II) Compound. Molecular Pharmaceutics, 2011, 8, 2368-2378.	2.3	25
959	Synthesis and characterization of some potential antitumor palladium(II) complexes of 2-aminomethylbenzimidazole and amino acids. Journal of Coordination Chemistry, 2011, 64, 2035-2055.	0.8	46
960	Which One among the Pt-Containing Anticancer Drugs More Easily Forms Monoadducts with G and A DNA Bases? A Comparative Study among Oxaliplatin, Nedaplatin, and Carboplatin. Inorganic Chemistry, 2011, 50, 6965-6971.	1.9	54
961	Palladium(II) and Platinum(II) Bind Strongly to an Engineered Blue Copper Protein. Inorganic Chemistry, 2011, 50, 11294-11296.	1.9	21
962	Interaction of rac-[M(diimine)3]2+ (M = Co, Ni) complexes with CT DNA: role of 5,6-dmp ligand on DNA binding and cleavage and cytotoxicity. Dalton Transactions, 2011, 40, 3245.	1.6	86
963	Turn-On DNA Damage Sensors for the Direct Detection of 8-Oxoguanine and Photoproducts in Native DNA. Journal of the American Chemical Society, 2011, 133, 12518-12527.	6.6	27
964	Rhenium(iv) compounds inducing apoptosis in cancer cells. Chemical Communications, 2011, 47, 5283.	2.2	35
965	Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7BThis paper is one of a selection of papers published in a Special Issue entitled CSBMCB 53rd Annual Meeting â€" Membrane Proteins in Health and Disease, and has undergone the Journalâ€™s usual peer review process.. Biochemistry and Cell Biology, 2011, 89, 138-147.	0.9	42
966	Synthesis, structure, and DNA-binding studies of a dicopper(II) complex with N-phenolato-Nâ€²-[2-(dimethylamino) ethyl]oxamide as ligand. Journal of Coordination Chemistry, 2011, 64, 1360-1374.	0.8	31
967	Electrogenerated Chemiluminescence of Platinum(II) Alkynyl Terpyridine Complex with Peroxydisulfate as Coreactant. Inorganic Chemistry, 2011, 50, 2125-2132.	1.9	49
968	Modeling the Cytotoxicity of Cisplatin. Industrial & Engineering Chemistry Research, 2011, 50, 12872-12880.	1.8	7
972	Inhibition of human DNA topoisomerase IB by a Cyclometalated Gold III compound: Analysis on the different steps of the enzyme catalytic cycle. Archives of Biochemistry and Biophysics, 2011, 516, 108-112.	1.4	27

#	Article	IF	Citations
973	Design, synthesis and biological evaluation of estradiol-PEG-linked platinum(II) hybrid molecules: Comparative molecular modeling study of three distinct families of hybrids. Steroids, 2011, 76, 94-103.	0.8	33
974	Lead genetic studies in Dictyostelium discoideum and translational studies in human cells demonstrate that sphingolipids are key regulators of sensitivity to cisplatin and other anticancer drugs. Seminars in Cell and Developmental Biology, 2011, 22, 97-104.	2.3	19
975	Unique platinumâ€"DNA interactions may lead to more effective platinum-based antitumor drugs. Metallomics, 2011, 3, 650.	1.0	58
977	Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism. Current Drug Metabolism, 2011, 12, 287-299.	0.7	12
980	Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX. Cancer Science, 2011, 102, 578-582.	1.7	28
981	Impaired nucleotide excision repair pathway as a possible factor in pathogenesis of head and neck cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 716, 51-58.	0.4	11
982	Core cross-linked block ionomer micelles as pH-responsive carriers for cis-diamminedichloroplatinum(II). Journal of Controlled Release, 2011, 153, 64-72.	4.8	90
983	Determination of Ptâ€"DNA adducts and the sub-cellular distribution of Pt in human cancer cell lines and the leukocytes of cancer patients, following mono- or combination treatments, by inductively-coupled plasma mass spectrometry. International Journal of Mass Spectrometry, 2011, 307, 70-78.	0.7	22
984	A comparative study on interactions of cisplatin and ruthenium arene anticancer complexes with metallothionein using MALDI-TOF-MS. International Journal of Mass Spectrometry, 2011, 307, 79-84.	0.7	17
985	Synthesis and structure of new bicopper(II) complexes bridged by N-(2-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 387 Td (amino activities and DNA-binding properties. European Journal of Medicinal Chemistry, 2011, 46, 3851-3857.	2.6	39
986	Effects of intercalative ligands on the DNA binding, DNA topoisomerase II and DNA transcription inhibition of polypyridyl ruthenium(II) complexes. Inorganica Chimica Acta, 2011, 378, 140-147.	1.2	20
987	Pt-rotaxanes as cytotoxic agents. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6880-6883.	1.0	9
988	Mixed ligand cobalt(ii) picolinate complexes: synthesis, characterization, DNA binding and photocleavage. Dalton Transactions, 2011, 40, 639-650.	1.6	53
989	Mono- and 1,1â€²-Disubstituted Organoruthenium Cyclopentadiene Complexes: Synthesis, Structural Characterization, and Antitumoral Evaluation. Organometallics, 2011, 30, 1395-1403.	1.1	17
990	Nucleosideâ€"Lipid-Based Nanoparticles for Cisplatin Delivery. ACS Nano, 2011, 5, 8649-8655.	7.3	64
991	Use of an automated capillary DNA sequencer to investigate the interaction of cisplatin with telomeric DNA sequences. Biomedical Chromatography, 2012, 26, 350-354.	0.8	29
992	Effects of Noncovalent Platinum Drugâ€"Protein Interactions on Drug Efficacy: Use of Fluorescent Conjugates as Probes for Drug Metabolism. Molecular Pharmaceutics, 2011, 8, 940-948.	2.3	55
993	Conformational properties of nuclear protein HMGB1 and specificity of its interaction with DNA. Cell and Tissue Biology, 2011, 5, 114-119.	0.2	6

#	Article	IF	Citations
994	Novel benzyl-substituted N-heterocyclic carbeneâ€“silver acetate complexes: synthesis, cytotoxicity and antibacterial studies. Metallomics, 2011, 3, 74-88.	1.0	137
995	Mass Spectrometry Evidence for Cisplatin As a Protein Cross-Linking Reagent. Analytical Chemistry, 2011, 83, 5369-5376.	3.2	53
996	Cytotoxicity in human cancer cells and mitochondrial dysfunction induced by a series of new copper(I) complexes containing tris(2-cyanoethyl)phosphines. Investigational New Drugs, 2011, 29, 1213-1223.	1.2	32
997	Proteomic Analyses of Sirt1-Mediated Cisplatin Resistance in OSCC Cell Line. Protein Journal, 2011, 30, 499-508.	0.7	32
998	Kinetics and Mechanism of the Ligand Substitution Reaction ofÂtheÂDi-Î¼-hydroxobis(bipyridyl)dipalladium(II) Ion withÂsome Bio-relevant Ligands. Journal of Solution Chemistry, 2011, 40, 532-544.	0.6	4
999	Cytotoxic effects of two organotin compounds and their mode of inflicting cell death on four mammalian cancer cells. Cell Biology and Toxicology, 2011, 27, 159-168.	2.4	53
1000	Palladium(II) complexes with R2edda-derived ligands. Part V. Reaction of O,Oâ€²-diethyl-(S,S)-ethylenediamine-N,Nâ€²-di-2-(3-methyl)butanoate with K2[PdCl4]. Transition Metal Chemistry, 2011, 36, 331-336.	0.7	9
1001	Vitamin B12 as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies. Journal of Biological Inorganic Chemistry, 2011, 16, 33-44.	1.1	46
1002	Mass-spectrometric characterization of cisplatin binding sites on native and denatured ubiquitin. Journal of Biological Inorganic Chemistry, 2011, 16, 633-639.	1.1	19
1003	Platinum(II) chloride indenyl complexes: electrochemical and biological evaluation. Journal of Biological Inorganic Chemistry, 2011, 16, 695-713.	1.1	14
1004	The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence. Journal of Biological Inorganic Chemistry, 2011, 16, 735-743.	1.1	18
1005	Non-empirical quantum chemical studies on electron transfer reactions in trans- and cis-diamminedichloroplatinum(II) complexes. Journal of Molecular Modeling, 2011, 17, 2411-2421.	0.8	10
1006	Equilibrium studies on complex formation reactions of dichlorido[(R,R)-trans-1,2-diaminocyclohexane]platinum(II) complex with ligands of biological significance. Monatshefte FÃ¼r Chemie, 2011, 142, 985-992.	0.9	3
1007	Comparative study of the hydrolysis of a third- and a first-generation platinum anticancer complexes. Theoretical Chemistry Accounts, 2011, 128, 627-638.	0.5	36
1008	Activation of carboplatin by chloride ions: a theoretical investigation. Theoretical Chemistry Accounts, 2011, 129, 757-769.	0.5	20
1009	Palladium(II) and platinum(II) complexes containing benzimidazole ligands: Molecular structures, vibrational frequencies and cytotoxicity. Journal of Molecular Structure, 2011, 991, 108-126.	1.8	71
1010	Synthesis, structure, cytotoxic activities and DNA-binding properties of tetracopper(II) complexes with dissymmetrical N,Nâ€²-bis(substituted)oxamides as ligands. Inorganica Chimica Acta, 2011, 367, 64-72.	1.2	19
1011	Novel Pd(II) and Pt(II) complexes of N,N-donor benzimidazole ligand: Synthesis, spectral, electrochemical, DFT studies and evaluation of biological activity. Inorganica Chimica Acta, 2011, 373, 249-258.	1.2	84

#	Article	IF	Citations
1012	Density functional theory calculations on the molecular structures and vibration spectra of platinum(II) antitumor drugs. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2011, 78, 1234-1239.	2.0	17
1013	Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clinical and Translational Oncology, 2011, 13, 889-898.	1.2	13
1014	Synthesis, Cytotoxicity and Antibacterial Studies of Novel Symmetrically and Nonâ€Symmetrically pâ€Nitrobenzylâ€Substituted Nâ€Heterocyclic Carbeneâ€“Silver(I) Acetate Complexes. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2011, 637, 386-396.	0.6	61
1015	Synthesis of Amphiphilic Polythiophene for Cell Imaging and Monitoring the Cellular Distribution of a Cisplatin Anticancer Drug. Small, 2011, 7, 1464-1470.	5.2	38
1016	Cisplatinâ€Loaded Porous Si Microparticles Capped by Electroless Deposition of Platinum. Small, 2011, 7, 2061-2069.	5.2	38
1017	A DFT study of a novel oxime anticancer trans platinum complex: Monofunctional and bifunctional binding to purine bases. International Journal of Quantum Chemistry, 2011, 111, 1907-1920.	1.0	11
1018	Influence of the bridging azine ligand on the rate of ligand substitution in a series of dinuclear platinum(II) complexes. International Journal of Chemical Kinetics, 2011, 43, 161-174.	1.0	18
1019	Kinetics of the substitution reactions of some Pt(II) complexes with 5â€²-GMP and <scp>L</scp> -histidine. International Journal of Chemical Kinetics, 2011, 43, 99-106.	1.0	13
1020	Organometallic cisâ€Dichlorido Ruthenium(II) Ammine Complexes. European Journal of Inorganic Chemistry, 2011, 2011, 3257-3264.	1.0	20
1021	A Tetrazolatoâ€Bridged Dinuclear Platinum(II) Complex Exhibits Markedly High inâ€…vivo Antitumor Activity against Pancreatic Cancer. ChemMedChem, 2011, 6, 987-990.	1.6	53
1022	Novel Benzylâ€•or 4â€Cyanobenzylâ€Substituted Nâ€Heterocyclic (Bromo)(carbene)silver(I) and (Carbene)(chloro)gold(I) Complexes: Synthesis and Preliminary Cytotoxicity Studies. Helvetica Chimica Acta, 2011, 94, 1551-1562.	1.0	40
1023	Copper(II) complexes of hydroxyflavone derivatives as potential bioactive molecule to combat antioxidants: synthesis, characterization and pharmacological activities. Applied Organometallic Chemistry, 2011, 25, 704-717.	1.7	11
1024	Synthesis, Characterisation and Biological Evaluation of Copper and Silver Complexes based on Acetylsalicylic Acid. Archiv Der Pharmazie, 2011, 344, 684-688.	2.1	17
1025	Metalâ€Ionâ€Dependent Folding of a Uranylâ€Specific DNAzyme: Insight into Function from Fluorescence Resonance Energy Transfer Studies. Chemistry - A European Journal, 2011, 17, 13732-13742.	1.7	32
1026	Tridentate Nâ€Donor Palladium(II) Complexes as Efficient Coordinating Quadruplex DNA Binders. Chemistry - A European Journal, 2011, 17, 13274-13283.	1.7	63
1027	Role of Endonucleases XPF and XPG in Nucleotide Excision Repair of Platinated DNA and Cisplatin/Oxaliplatin Cytotoxicity. ChemBioChem, 2011, 12, 1115-1123.	1.3	46
1028	Recent advances of discrete coordination complexes and coordination polymers in drug delivery. Coordination Chemistry Reviews, 2011, 255, 1623-1641.	9.5	271
1029	Polyfluorinated bipyridine cisplatins manipulate cytotoxicity through the induction of S-G2/M arrest and partial intercalation mechanism. Bioorganic and Medicinal Chemistry, 2011, 19, 4887-4894.	1.4	18

#	Article	IF	Citations
1030	Synthesis and cytotoxicity of cis-dichloroplatinum (II) complexes of (1S,3S)-1,2,3,4-tetrahydroisoquinolines. European Journal of Medicinal Chemistry, 2011, 46, 356-363.	2.6	10
1031	Ruthenium(II) arene complexes with oligocationic triarylphosphine ligands: Synthesis, DNA interactions and in vitro properties. Journal of Organometallic Chemistry, 2011, 696, 1108-1116.	0.8	16
1032	Synthesis, spectroscopic and electrochemical studies of N,N-bis[(E)-2-thienylmethylidene]-1,8-naphthalenediamine and its Cu(II) complex: DNA cleavage and generation of superoxide anion. Journal of Photochemistry and Photobiology B: Biology, 2011, 104, 449-456.	1.7	54
1033	The synthesis and characterization of a series of cobalt(II) Î²-ketoaminato complexes and their cytotoxic activity towards human tumor cell lines. Journal of Inorganic Biochemistry, 2011, 105, 858-866.	1.5	15
1034	DNA binding, oxidative DNA cleavage, cytotoxicity, and apoptosis-inducing activity of copper(II) complexes with 1,4-tpbd (N,N,Nâ€²,Nâ€²-tetrakis(2-yridylmethyl)benzene-1,4-diamine) ligand. Journal of Inorganic Biochemistry, 2011, 105, 894-901.	1.5	83
1035	Synthesis, spectroscopic studies and crystal structure of the Schiff base ligand L derived from condensation of 2-thiophenecarboxaldehyde and 3,3â€²-diaminobenzidine and its complexes with Co(II), Ni(II), Cu(II), Cd(II) and Hg(II): Comparative DNA binding studies of L and its Co(II), Ni(II) and Cu(II) complexes. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2011, 79, 1866-1875.	2.0	49
1036	Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 222-232.	0.9	32
1037	A six-coordinate picrate cadmium(II) complex with a new V-shaped ligand 1,3-bis(1-ethylbenzimidazol-2-yl)-2-thiapropane: synthesis, crystal structure, and DNA-binding properties. Journal of Coordination Chemistry, 2011, 64, 2676-2687.	0.8	21
1038	Transition Metal Based Anticancer Drugs. Current Topics in Medicinal Chemistry, 2011, 11, 521-542.	1.0	132
1039	Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease. Cellular and Molecular Immunology, 2011, 8, 289-295.	4.8	8
1040	Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity. Current Topics in Medicinal Chemistry, 2011, 11, 2602-2612.	1.0	75
1041	Cytotoxicity, Apoptosis, Cellular Uptake, Cell Cycle Arrest, Photocleavage, and Antioxidant Activity of 1, 10-Phenanthroline Ruthenium(II) Complexes. DNA and Cell Biology, 2011, 30, 839-848.	0.9	19
1042	The phosphate clamp: a small and independent motif for nucleic acid backbone recognition. Nucleic Acids Research, 2011, 39, 325-336.	6.5	61
1043	DNA Interaction Studies of a New Platinum(II) Complex Containing Different Aromatic Dinitrogen Ligands. Bioinorganic Chemistry and Applications, 2011, 2011, 1-8.	1.8	28
1044	Thermodynamics of the reactions of [Pd(Et4en)(H2O)2]2+ with ligands of biological significance: deactivation of based-drug by the sulfur-containing biomolecules. Journal of Sulfur Chemistry, 2011, 32, 563-573.	1.0	1
1045	Identification of Binding Mode of a Platinum (II) Complex, (DIP), and Calf Thymus DNA. Bioinorganic Chemistry and Applications, 2011, 2011, 1-7.	1.8	27
1046	Effect of Cisplatin on the Flexibility of Linear DNA. Chinese Physics Letters, 2011, 28, 068702.	1.3	7
1047	Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology, 2011, 22, 265101.	1.3	27

#	Article	IF	Citations
1049	Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer. Oncology Reports, 2011, 26, 703-10.	1.2	12
1050	Walking of antitumor bifunctional trinuclear Pt II complex on double-helical DNA. Nucleic Acids Research, 2011, 39, 720-728.	6.5	21
1051	Synthesis, Characterization, and DNA-Binding of the Manganese(II) Complex Based on Tridentate 1,3-Bis(benzimidazol-2-yl)-2-Oxopropane Ligand. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2011, 41, 577-582.	0.6	1
1052	Synthesis, structure, DNA-binding, and cytotoxic activities of N-(5-chloro-2-hydroxyphenyl)-Nâ€²-[3-(2-hydroxyethylamino)propyl]oxamide and its dicopper(II) complex. Journal of Coordination Chemistry, 2011, 64, 4209-4224.	0.8	16
1053	Late Activation of Stress-activated Protein Kinases/c-Jun N-terminal Kinases Triggered by Cisplatin-induced DNA Damage in Repair-defective Cells. Journal of Biological Chemistry, 2011, 286, 12991-13001.	1.6	17
1054	Kinetics and Mechanism of Interaction of Thiosemicarbazide with Di-Î¼-hydroxobis(1,10-phenanthroline) Dipalladium(II) Perchlorate in Aqueous Solution. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2011, 41, 15-21.	0.6	0
1055	Synthesis, characterization, and DNA-binding of a four-coordinate cobalt(II) complex with 1,3-bis(1-ethylbenzimidazol-2-yl)-2-oxopropane. Journal of Coordination Chemistry, 2011, 64, 3041-3050.	0.8	9
1056	Synthesis and Cancer Cell Cytotoxicity of Gold(III) Tetraarylporphyrins with a C5-Carboxylate Substituent. Journal of Chemical Research, 2011, 35, 698-702.	0.6	7
1057	Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. Nucleic Acids Research, 2012, 40, 8953-8964.	6.5	142
1058	Gold(III) Tetraarylporphyrin Phosphonate Derivatives as Potential Anticancer Agents. Journal of Chemical Research, 2012, 36, 501-505.	0.6	4
1059	Molecules of Natural Origin, Semi-synthesis and Synthesis with Anti-Inflammatory and Anticancer Utilities. Current Pharmaceutical Design, 2012, 18, 3979-4046.	0.9	42
1060	DEVELOPMENT OF PLATINUM(IV) COMPLEXES AS ANTICANCER PRODRUGS: THE STORY SO FAR. Cosmos, 2012, 08, 121-134.	0.4	6
1061	DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment. Current Cancer Drug Targets, 2012, 12, 356-371.	0.8	34
1062	Elastic response and length change of single DNA molecules induced by a combination of cisplatin and transplatin. Physical Review E, 2012, 85, 021918.	0.8	17
1063	Synthesis, structure, cytotoxic activities, and DNA-binding of 1-D copper(II) and zinc(II) coordination polymers. Journal of Coordination Chemistry, 2012, 65, 1858-1871.	0.8	18
1064	Daintain/AIF-1 Reinforces the Resistance of Breast Cancer Cells to Cisplatin. Bioscience, Biotechnology and Biochemistry, 2012, 76, 2338-2341.	0.6	7
1065	On the Discovery, Biological Effects, and Use of Cisplatin and Metallocenes in Anticancer Chemotherapy. Bioinorganic Chemistry and Applications, 2012, 2012, 1-14.	1.8	115
1066	DNA-Platinum Thin Films for Use in Chemoradiation Therapy Studies. Bioinorganic Chemistry and Applications, 2012, 2012, 1-9.	1.8	14

#	Article	IF	Citations
1067	Evaluation of Effect of Ligand on Cellular Internalization: A Comparative Study of Nanoparticles and Multifunctional Nanoparticles on MDA-MB-231 Cells. Current Nanoscience, 2012, 8, 432-440.	0.7	0
1068	Gene Therapy for Cisplatin-Induced Ototoxicity. Otology and Neurotology, 2012, 33, 302-310.	0.7	15
1069	What Does the Future Hold for Photo-Oxidizing RuII Complexes with Polyazaaromatic Ligands in Medicinal Chemistry?. Current Topics in Medicinal Chemistry, 2012, 12, 185-196.	1.0	20
1070	Next-Generation Anticancer Metallodrugs. Current Topics in Medicinal Chemistry, 2012, 12, 219-235.	1.0	188
1071	Downregulation of midkine induces cisplatin resistance in human oral squamous cell carcinoma. Oncology Reports, 2012, 27, 1674-80.	1.2	5
1072	Biological Evaluation of Mechlorethamine-Pt(II) Complex, Part II: Antimicrobial Screening and Lox Study of the Complex and its Ligand. Medicinal Chemistry, 2012, 8, 947-952.	0.7	4
1073	Hetero-multinuclear Ruthenium(III)/Platinum(II) Complexes That Potentially Exhibit Both Antimetastatic and Antineoplastic Properties. Inorganic Chemistry, 2012, 51, 12917-12924.	1.9	50
1074	Copper(II) and Palladium(II) Complexes with Cytotoxic and Antibacterial Activity. Australian Journal of Chemistry, 2012, 65, 860.	0.5	15
1075	Binding Interaction of HMGB4 with Cisplatin-Modified DNA. Biochemistry, 2012, 51, 6728-6737.	1.2	31
1076	Activities of a novel Schiff Base copper(II) complex on growth inhibition and apoptosis induction toward MCF-7 human breast cancer cells via mitochondrial pathway. Journal of Inorganic Biochemistry, 2012, 117, 1-9.	1.5	66
1077	Valuable Insight into the Anticancer Activity of the Platinum-Histone Deacetylase Inhibitor Conjugate, 2012, 9, 1990-1999.	2.3	41
1078	A circular dichroism study uncovers a two-step interaction of antitumor azolato-bridged dinuclear platinum(ii) complexes with calf thymus DNA. Metallomics, 2012, 4, 641.	1.0	17
1079	Syntheses, characterizations and biophysical studies of Cu(II) diphenylphosphate complexes: Effect of co-ligands on their biological properties. Polyhedron, 2012, 48, 157-166.	1.0	6
1080	Monofunctional Platinumâ€"DNA Adducts Are Strong Inhibitors of Transcription and Substrates for Nucleotide Excision Repair in Live Mammalian Cells. Cancer Research, 2012, 72, 790-800.	0.4	65
1081	Cellular interactions of platinum drugs. Inorganica Chimica Acta, 2012, 393, 75-83.	1.2	60
1082	In Vitro Anticancer Activity of cis-Diammineplatinum(II) Complexes with Î²-Diketonate Leaving Group Ligands. Journal of Medicinal Chemistry, 2012, 55, 5326-5336.	2.9	110
1083	A Single Nuclease-Resistant Linkage in DNA as a Versatile Tool for the Characterization of DNA Lesions: Application to the Guanine Oxidative Lesion â€œG+34â€•Generated by Metalloporphyrin/KHSO5 Reagent. Chemical Research in Toxicology, 2012, 25, 2505-2512.	1.7	10
1084	Interactions with herring sperm DNA and biological studies of sparfloxacin drugâ€based copper(II) compounds. Applied Organometallic Chemistry, 2012, 26, 641-649.	1.7	6

#	Article	IF	Citations
1085	Thermodynamic and Mechanistic Insights into Translesion DNA Synthesis Catalyzed by Yâ€Family DNA Polymerase Across a Bulky Doubleâ€Base Lesion of an Antitumor Platinum Drug. Chemistry - A European Journal, 2012, 18, 15439-15448.	1.7	29
1086	The anti-inflammatory effects of platinum nanoparticles on the lipopolysaccharide-induced inflammatory response in RAW 264.7 macrophages. Inflammation Research, 2012, 61, 1177-1185.	1.6	85
1087	Synthesis and Structure of 1D Copper(II) Polymers with Dissymmetrical N,Nâ€²-Bis(substituted)oxamide Ligands: Cytotoxicity and DNA-Binding Property. Journal of Inorganic and Organometallic Polymers and Materials, 2012, 22, 1128-1138.	1.9	7
1088	Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. International Journal of Pharmaceutics, 2012, 438, 98-106.	2.6	80
1089	Walnut consumption protects rats against cisplatin-induced neurotoxicity. NeuroToxicology, 2012, 33, 1314-1321.	1.4	74
1090	Effects of amine ligand bulk and hydrogen bonding on the rate of reaction of platinum(II) diamine complexes with key nucleotide and amino acid residues. Inorganica Chimica Acta, 2012, 391, 135-140.	1.2	7
1091	Novel hydrophilic cis-bis(cyclopentylamine)platinum(II) complexes: Synthesis, characterization, antitumor activity and interaction with DNA. Inorganica Chimica Acta, 2012, 391, 158-161.	1.2	6
1092	Long-term Smoking Mediated Down-regulation of Smad3 Induces Resistance to Carboplatin in Non-Small Cell Lung Cancer. Neoplasia, 2012, 14, 644-IN23.	2.3	19
1093	RNA-Pt Adducts Following Cisplatin Treatment of Saccharomyces cerevisiae. ACS Chemical Biology, 2012, 7, 218-225.	1.6	80
1094	Co-delivery of all-trans-retinoic-acid and cisplatin(iv) prodrug based on polymerâ€“drug conjugates for enhanced efficacy and safety. Journal of Materials Chemistry, 2012, 22, 25453.	6.7	15
1095	Spectral characteristics, DNA-binding and cytotoxicity of two functional Ru(ii) mixed-ligand complexes. Dalton Transactions, 2012, 41, 4575.	1.6	45
1096	A dual-targeting hybrid platinum(iv) prodrug for enhancing efficacy. Chemical Communications, 2012, 48, 10730.	2.2	70
1097	Activation of carboplatin by carbonate: a theoretical investigation. Dalton Transactions, 2012, 41, 12960.	1.6	27
1098	Interactions of DNA with a New Platinum(IV) Azide Dipyridine Complex Activated by UVA and Visible Light: Relationship to Toxicity in Tumor Cells. Chemical Research in Toxicology, 2012, 25, 1099-1111.	1.7	72
1099	Mitaplatin Increases Sensitivity of Tumor Cells to Cisplatin by Inducing Mitochondrial Dysfunction. Molecular Pharmaceutics, 2012, 9, 634-644.	2.3	83
1100	In situ analysis of cisplatin binding to DNA: the effects of physiological ionic conditions. Physical Chemistry Chemical Physics, 2012, 14, 3128.	1.3	6
1101	Studying the interactions of a platinum(ii) 9-aminoacridine complex with proteins and oligonucleotides by ESI-TOF MS. Dalton Transactions, 2012, 41, 300-306.	1.6	10
1102	Metal to ligand charge transfer induced DNA photobinding in a Ru(ii)â€“Pt(ii) supramolecule using red light in the therapeutic window: a new mechanism for DNA modification. Chemical Communications, 2012, 48, 67-69.	2.2	92

#	Article	IF	Citations
1103	Nâ€“H and Nâ€“C Bond Activation of Pyrimidinic Nucleobases and Nucleosides Promoted by an Osmium Polyhydride. Inorganic Chemistry, 2012, 51, 5975-5984.	1.9	34
1104	Reactions of an Osmium-Hexahydride Complex with Cytosine, Deoxycytidine, and Cytidine: The Importance of the Minor Tautomers. Inorganic Chemistry, 2012, 51, 9522-9528.	1.9	30
1105	Photoinduced Ligand Exchange and Covalent DNA Binding by Two New Dirhodium Bis-Amidato Complexes. Inorganic Chemistry, 2012, 51, 11882-11890.	1.9	22
1106	Coinage Metal Complexes Against Breast Cancer. Current Medicinal Chemistry, 2012, 19, 3949-3956.	1.2	57
1107	Tuning the Activity of Platinum(IV) Anticancer Complexes through Asymmetric Acylation. Journal of Medicinal Chemistry, 2012, 55, 7571-7582.	2.9	92
1108	Stimuli-responsive Pd₂L₄metallosupramolecular cages: towards targeted cisplatin drug delivery. Chemical Science, 2012, 3, 778-784.	3.7	392
1109	Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Archives of Toxicology, 2012, 86, 1233-1250.	1.9	298
1110	Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11987-11992.	3.3	280
1111	Synthesis, characterization and antitumor activity of new ferrocene incorporated N,Nâ€²-disubstituted thioureas. Dalton Transactions, 2012, 41, 14643.	1.6	54
1112	Induction of DNA fragmentation, chromosome aberrations and micronuclei by cisplatin in rat bone-marrow cells: Protective effect of recombinant human erythropoietin. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 747, 202-206.	0.9	20
1113	Synthesis and structures of binuclear copper(II) complexes bridged by N-(5-chloro-2-hydroxyphenyl)-Nâ€²-[3-(dimethylamino)propyl]oxalamide ligand: DNA-binding properties and cytotoxic activities. Journal of Organometallic Chemistry, 2012, 700, 48-57.	0.8	7
1114	Chiral nano heterobimetallic DNA receptors: InÂvitro binding studies, cleavage activity and DNA condensation studies (TEM and AFM imaging). Journal of Organometallic Chemistry, 2012, 713, 123-133.	0.8	9
1115	Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear PtII complex. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1502-1511.	1.1	16
1116	DNA compaction by mononuclear platinum cancer drug cisplatin and the trisplatinum anticancer agent BBR3464: Differences and similarities. Biochimie, 2012, 94, 494-502.	1.3	9
1117	Gap junctions propagate opposite effects in normal and tumor testicular cells in response to cisplatin. Cancer Letters, 2012, 317, 165-171.	3.2	53
1118	Differences in hydration between cis- and trans-platin: Quantum insights by ab initio fragment molecular orbital-based molecular dynamics (FMO-MD). Computational and Theoretical Chemistry, 2012, 986, 30-34.	1.1	21
1119	A detailed quantum chemical study of the interactions of [Pt(dien)Cl]+ with a series of S-donor ligands: A computational approach. Computational and Theoretical Chemistry, 2012, 991, 116-123.	1.1	14
1120	Palladium(II) complex taken as a model of an antitumour agent: Synthesis and equilibrium investigation involving biologically relevant ligands. Comptes Rendus Chimie, 2012, 15, 356-364.	0.2	5

#	Article	IF	Citations
1121	How to modify 7-azaindole to form cytotoxic Pt(II) complexes: Highly in vitro anticancer effective cisplatin derivatives involving halogeno-substituted 7-azaindole. Journal of Inorganic Biochemistry, 2012, 115, 57-63.	1.5	46
1122	Systematic differences in electrochemical reduction of the structurally characterized anti-cancer platinum(IV) complexes [Pt{((p-HC6F4)NCH2)2}-(pyridine)2Cl2], [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)2], and [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)Cl]. Journal of Inorganic Biochemistry, 2012, 115, 226-239.	1.5	32
1123	Role of structure and dynamics of DNA with cisplatin and oxaliplatin adducts in various sequence contexts on binding of HMGB1a. Molecular Simulation, 2012, 38, 793-808.	0.9	5
1124	Sequence-Specific Recognition of Cancer Drug-DNA Adducts by HMGB1a Repair Protein. Biophysical Journal, 2012, 102, 2331-2338.	0.2	11
1125	Groupâ€10 Metal Complexes of Biological Molecules and Related Ligands: Structural and Functional Properties. Chemistry and Biodiversity, 2012, 9, 1635-1658.	1.0	14
1126	The Selective Synthesis of Metallanucleosides and Metallanucleotides: A New Tool for the Functionalization of Nucleic Acids. Chemistry - A European Journal, 2012, 18, 12603-12608.	1.7	25
1127	Studies of the Electronic Properties of Nâ€Heterocyclic Carbene Ligands in the Context of Homogeneous Catalysis and Bioorganometallic Chemistry. European Journal of Inorganic Chemistry, 2012, 2012, 3955-3969.	1.0	69
1128	Generation of a selectively cytotoxic fusion protein against p53 mutated cancers. BMC Cancer, 2012, 12, 338.	1.1	8
1129	Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. BMC Cancer, 2012, 12, 370.	1.1	28
1130	Protective effect of cactus cladode extract against cisplatin induced oxidative stress, genotoxicity and apoptosis in balb/c mice: combination with phytochemical composition. BMC Complementary and Alternative Medicine, 2012, 12, 111.	3.7	24
1131	Synthesis, characterization, DNA binding and cleavage, BSA interaction and anticancer activity of dinuclear zinc complexes. Dalton Transactions, 2012, 41, 12220.	1.6	86
1132	Combined Theoretical and Computational Study of Interstrand DNA Guanineâ€“Guanine Cross-Linking bytrans-[Pt(pyridine)2] Derived from the Photoactivated Prodrugtrans,trans,trans-[Pt(N3)2(OH)2(pyridine)2]. Inorganic Chemistry, 2012, 51, 6830-6841.	1.9	42
1133	Conjugate of Pt(IV)â€“Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy. Molecular Pharmaceutics, 2012, 9, 2793-2800.	2.3	108
1134	Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. Journal of Controlled Release, 2012, 163, 304-314.	4.8	110
1135	Antiproliferative potential of astaxanthin-rich alga Haematococcus pluvialis Flotow on human hepatic cancer (HepG2) cell line. Biomedicine and Preventive Nutrition, 2012, 2, 149-153.	0.9	34
1136	Subcellular targets of cisplatin cytotoxicity: An integrated view. , 2012, 136, 35-55.		148
1137	Oxidative DNA cleavage, cytotoxicity and antimicrobial studies of l-ornithine copper (II) complexes. Polyhedron, 2012, 48, 43-50.	1.0	21
1138	Supramolecular and structural modification on conformational by mixed ligand. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2012, 99, 211-217.	2.0	13

#	Article	IF	Citations
1139	Structural and anticancer properties of hydrogen bonded diphenyl phosphate adducts of Pt(IV) complexes: The importance of pKa matching. Journal of Inorganic Biochemistry, 2012, 115, 220-225.	1.5	2
1140	Cytotoxic copper(II), cobalt(II), zinc(II), and nickel(II) coordination compounds of clotrimazole. Journal of Inorganic Biochemistry, 2012, 114, 82-93.	1.5	72
1141	What do we know about the reduction of Pt(IV) pro-drugs?. Journal of Inorganic Biochemistry, 2012, 117, 220-229.	1.5	307
1142	In vitro cytotoxicity, DNA cleavage and SOD-mimic activity of copper(II) mixed-ligand quinolinonato complexes. Journal of Inorganic Biochemistry, 2012, 116, 163-171.	1.5	59
1143	Temporal behavior of DNA thermal stability in the presence of platinum compounds. Role of monofunctional and bifunctional adducts. Journal of Inorganic Biochemistry, 2012, 117, 164-170.	1.5	4
1144	Synthesis and characterisation of metallopolyamide complexes. Inorganica Chimica Acta, 2012, 393, 187-197.	1.2	3
1145	d-Methionine protects against cisplatin-induced neurotoxicity in cortical networks. Neurotoxicology and Teratology, 2012, 34, 495-504.	1.2	38
1146	TCM Active Ingredient Oxoglaucine Metal Complexes: Crystal Structure, Cytotoxicity, and Interaction with DNA. Inorganic Chemistry, 2012, 51, 1998-2009.	1.9	74
1147	Application of a Fluorescent C-Linked Phenolic Purine Adduct for Selective N7-Metalation of DNA. Journal of Physical Chemistry B, 2012, 116, 6158-6165.	1.2	10
1148	Probing the Interaction of Cisplatin with Cytochromecby Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry. Analytical Chemistry, 2012, 84, 6206-6212.	3.2	31
1149	Cu(II) complexes of glyco-imino-aromatic conjugates in DNA binding, plasmid cleavage and cell cytotoxicity. Journal of Chemical Sciences, 2012, 124, 1217-1228.	0.7	15
1150	Mechanistic insights into toxic effects of a benzotriazolate-bridged dinuclear platinum(II) compound in tumor cells. Inorganica Chimica Acta, 2012, 393, 204-211.	1.2	12
1151	Synthesis, characterization, and antibacterial activities of two new copper(II) glycinate complexes incorporating 2-(4â€²-thiazolyl)benzimidazole/2-(2-pyridyl)benzimidazole. Journal of Coordination Chemistry, 2012, 65, 2182-2191.	0.8	12
1152	Theoretical Prediction of the Complexation Behaviors of Antitumor Platinum Drugs with Cucurbiturils. Journal of Physical Chemistry B, 2012, 116, 14029-14039.	1.2	42
1153	Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding. Journal of Biological Inorganic Chemistry, 2012, 17, 891-898.	1.1	31
1154	Interaction of liposome-encapsulated cisplatin with biomolecules. Journal of Biological Inorganic Chemistry, 2012, 17, 899-910.	1.1	9
1155	Binding of anticancer drug Ru(Î· 6 -C6H5(CH2)2OH)Cl2(DAPTA) to DNA purine bases and amino acid residues: a theoretical study. Structural Chemistry, 2012, 23, 1931-1940.	1.0	5
1156	Synthesis, crystal structure, cytotoxicities and DNA-binding properties of a tetracopper(II) complex with N-benzoato-Nâ€²-[2-(2-hydroxyethylamino)ethyl-amino]oxamide ligand. Transition Metal Chemistry, 2012, 37, 569-577.	0.7	8

#	Article	IF	Citations
1157	Platinum(iv) prodrugs entrapped within multiwalled carbon nanotubes: Selective release by chemical reduction and hydrophobicity reversal. Chemical Science, 2012, 3, 2083.	3.7	84
1158	Syntheses and structures of new dicopper(ii) complexes bridged by N-(2-hydroxyphenyl)-Nâ€²-(3-aminopropyl)oxamide: DNA-binding properties and cytotoxic activities. New Journal of Chemistry, 2012, 36, 2078.	1.4	23
1159	Cisplatin cytotoxicity: a theoretical study of induced mutations. Physical Chemistry Chemical Physics, 2012, 14, 12457.	1.3	37
1160	Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: antigenotoxic and antiapoptotic effect. Drug and Chemical Toxicology, 2012, 35, 89-95.	1.2	11
1161	A Series of Oxyimine-Based Macrocyclic Dinuclear Zinc(II) Complexes Enhances Phosphate Ester Hydrolysis, DNA Binding, DNA Hydrolysis, and Lactate Dehydrogenase Inhibition and Induces Apoptosis. Inorganic Chemistry, 2012, 51, 5580-5592.	1.9	142
1162	The paramagnetic and luminescent [Re6Se8I6]3â^' cluster. Its potential use as an antitumoral and biomarker agent. New Journal of Chemistry, 2012, 36, 927.	1.4	45
1163	Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs. Future Medicinal Chemistry, 2012, 4, 1113-1151.	1.1	18
1164	Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex. Metallomics, 2012, 4, 139.	1.0	19
1165	Interplay between Metal Ions and Nucleic Acids. Metal Ions in Life Sciences, 2012, , .	2.8	17
1166	Influence of terminal substitution on structural, DNA, Protein binding, anticancer and antibacterial activities of palladium(ii) complexes containing 3-methoxy salicylaldehyde-4(N) substituted thiosemicarbazones. Dalton Transactions, 2012, 41, 2486.	1.6	123
1167	Transcriptional Activation and Cell Cycle Block Are the Keys for 5-Fluorouracil Induced Up-Regulation of Human Thymidylate Synthase Expression. PLoS ONE, 2012, 7, e47318.	1.1	20
1168	New insight into DNA damage by cisplatin at the atomic scale. Nature Precedings, 2012, , .	0.1	1
1169	The Molecular Basis of Cisplatin Resistance in Bladder Cancer Cells. , 2012, , .		3
1170	Curtailing side effects in chemotherapy: a tale of PKCÎ´ in cisplatin treatment. Oncotarget, 2012, 3, 107-111.	0.8	53
1171	Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31, 1869-1883.	2.6	2,058
1172	Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. Future Medicinal Chemistry, 2012, 4, 1093-1111.	1.1	21
1173	Multiscale Modeling of Double-Helical DNA and RNA: A Unification through Lie Groups. Journal of Physical Chemistry B, 2012, 116, 8556-8572.	1.2	15
1174	Synthesis of a New 2,3â€Diaminoconduritol with Conduritol F Structure. European Journal of Organic Chemistry, 2012, 2012, 4988-4995.	1.2	10

#	Article	IF	Citations
1176	Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System. Angewandte Chemie - International Edition, 2012, 51, 6742-6747.	7.2	199
1177	The Thermodynamics of Translesion DNA Synthesis Past Major Adducts of Enantiomeric Analogues of Antitumor Cisplatin. Chemistry - an Asian Journal, 2012, 7, 1026-1031.	1.7	11
1178	Synthesis, DNA and Photocleavage Studies of Ru(II) Polypyridyl Complexes: [Ru(dppz)(pyz)₄](ClO₄)₂ and [Ru(dppz)(dmpyz)₄](ClO₄)₂ Complexes. Chinese Journal of Chemistry, 2012, 30, 1641-1646.	2.6	2
1179	A platinumâ€based covalent viability reagent for singleâ€cell mass cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 467-475.	1.1	177
1180	Precursors of Solvated Electrons in Radiobiological Physics and Chemistry. Chemical Reviews, 2012, 112, 5578-5602.	23.0	309
1181	Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs. Dalton Transactions, 2012, 41, 8226.	1.6	94
1182	Synthesis, spectroscopic, powder X-ray diffraction and DNA binding studies on copper(II) complexes of 4,4â€²-diaminodiphenyl sulfone. Journal of the Iranian Chemical Society, 2012, 9, 441-448.	1.2	4
1183	Synthesis, characterization, DNA binding and antimicrobial studies on bis(1-amidino-O-2-alkoxyethylurea) copper(II) chloride complexes (alkoxyÂ=Âmethoxy or ethoxy). Journal of the Iranian Chemical Society, 2012, 9, 455-465.	1.2	1
1184	Synthesis, Structure, Cytotoxic Activities and DNA-Binding Properties of a 1D Copper(II) Complex Bridged both by Oxamidate and Terephthalato Groups. Journal of Inorganic and Organometallic Polymers and Materials, 2012, 22, 756-765.	1.9	5
1185	Bioevaluation of 99mTc(CO)3â€“Guanine in vitro and in vivo. Journal of Radioanalytical and Nuclear Chemistry, 2012, 292, 739-743.	0.7	0
1186	Cytotoxic properties of platinum(IV) and dinuclear platinum(II) complexes and their ligand substitution reactions with guanosine-5â€²-monophosphate. Transition Metal Chemistry, 2012, 37, 481-488.	0.7	16
1187	PDCD6 additively cooperates with anti-cancer drugs through activation of NF-ÎºB pathways. Cellular Signalling, 2012, 24, 726-733.	1.7	34
1188	Syntheses and structures of bicopper(II) complexes bridged by N-(5-chloro-2-hydroxyphenyl)-Nâ€²-[3-(dimethylamino)propyl]oxamide: Cytotoxic activities, and reactivities towards DNA and protein. Inorganica Chimica Acta, 2012, 390, 190-198.	1.2	15
1189	Filamin-A as a marker and target for DNA damage based cancer therapy. DNA Repair, 2012, 11, 192-200.	1.3	36
1190	Novel palladium(II) and platinum(II) complexes with 1H-benzimidazol-2-ylmethyl-N-(4-bromo-phenyl)-amine: Structural studies and anticancer activity. European Journal of Medicinal Chemistry, 2012, 47, 399-411.	2.6	105
1191	Design, synthesis and characterization of zinc-3 hydroxy flavone, a novel zinc metallo complex for the treatment of experimental diabetes in rats. European Journal of Pharmacology, 2012, 680, 122-129.	1.7	47
1192	Therapy-induced carboplatinâ€“DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. Biochemical Pharmacology, 2012, 83, 69-77.	2.0	14
1193	Methods for direct alkene diamination, new & old. Tetrahedron, 2012, 68, 4067-4105.	1.0	136

#	Article	IF	Citations
1194	Cu(II), Ni(II), Zn(II) and Fe(III) complexes containing a N2O2 donor ligand: Synthesis, characterization, DNA cleavage studies and crystal structure of [Cu(HL)Cl]. Polyhedron, 2012, 31, 12-18.	1.0	13
1195	Synthesis, DNA binding, photo-induced DNA cleavage and cell cytotoxicity studies of a family of light rare earth complexes. Journal of Inorganic Biochemistry, 2012, 109, 90-96.	1.5	39
1196	Novel methylene modified cyclohexyl ethylenediamine-N,Nâ€²-diacetate ligands and their platinum(IV) complexes. Influence on biological activity. Journal of Inorganic Biochemistry, 2012, 109, 40-48.	1.5	29
1197	Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells. Journal of Inorganic Biochemistry, 2012, 110, 58-63.	1.5	95
1198	Antitumor platinum(II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance. Journal of Inorganic Biochemistry, 2012, 112, 68-76.	1.5	28
1199	ER signaling regulation drives the switch between autophagy and apoptosis in NRK-52E cells exposed to cisplatin. Experimental Cell Research, 2012, 318, 238-250.	1.2	46
1200	The interaction of [Pd(N,N-dimethylaminopropylamine)(H2O)]2+ with dicarboxylic acids and inosine: Thermodynamic model for carboplatin drug. Open Chemistry, 2012, 10, 1253-1261.	1.0	1
1201	Siteâ€Specific Control of N7â€“Metal Coordination in DNA by a Fluorescent Purine Derivative. Chemistry - A European Journal, 2012, 18, 245-254.	1.7	32
1202	Adding a combination of hydroxycitrate and lipoic acid (METABLOCâ„¢) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Investigational New Drugs, 2012, 30, 200-211.	1.2	49
1203	Synthesis, characterization, and in vitro antitumor properties of gold(III) compounds with the traditional Chinese medicine (TCM) active ingredient liriodenine. Journal of Biological Inorganic Chemistry, 2012, 17, 247-261.	1.1	32
1204	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. Journal of Biological Inorganic Chemistry, 2012, 17, 465-474.	1.1	51
1205	Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutrition and Metabolism, 2013, 10, 7.	1.3	119
1206	ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. Journal of Ovarian Research, 2013, 6, 25.	1.3	103
1207	Competitive Binding Sites of a Ruthenium Arene Anticancer Complex on Oligonucleotides Studied by Mass Spectrometry: Ladder-Sequencing versus Top-Down. Journal of the American Society for Mass Spectrometry, 2013, 24, 410-420.	1.2	32
1208	Kinetic Studies on Interaction of Platinum(II) Complexes with an â€˜Sâ€™ Containing Ligand in Aqueous Medium. Journal of Solution Chemistry, 2013, 42, 441-458.	0.6	7
1209	Glutathione modified <scp>CdTe</scp> quantum dots as a label for studying <scp>DNA</scp> interactions with platinum based cytostatics. Electrophoresis, 2013, 34, 801-808.	1.3	9
1210	Cellular Toxicity Induced by the Photorelease of a Caged Bioactive Molecule: Design of a Potential Dual-Action Ru(II) Complex. Journal of the American Chemical Society, 2013, 135, 11274-11282.	6.6	199
1211	Comparison of MS/MS Methods for Characterization of DNA/Cisplatin Adducts. Journal of the American Society for Mass Spectrometry, 2013, 24, 265-273.	1.2	17

#	Article	IF	Citations
1212	Nonclassic Metallointercalators with Dipyridophenazine: DNA Interaction Studies and Leishmanicidal Activity. Inorganic Chemistry, 2013, 52, 8881-8894.	1.9	18
1213	Nuclease and anti-proliferative activities of copper(ii) complexes of N3O tripodal ligands involving a sterically hindered phenolate. Dalton Transactions, 2013, 42, 8468.	1.6	26
1214	Picazoplatin, an Azide-Containing Platinum(II) Derivative for Target Analysis by Click Chemistry. Journal of the American Chemical Society, 2013, 135, 11680-11683.	6.6	54
1215	Chlorido-containing ruthenium(ii) and iridium(iii) complexes as antimicrobial agents. Dalton Transactions, 2013, 42, 4686.	1.6	63
1216	Effect of a Monofunctional Phenanthriplatin-DNA Adduct on RNA Polymerase II Transcriptional Fidelity and Translesion Synthesis. Journal of the American Chemical Society, 2013, 135, 13054-13061.	6.6	67
1217	Cisplatin downregulates BCL2L12, a novel apoptosis-related gene, in glioblastoma cells. In Vitro Cellular and Developmental Biology - Animal, 2013, 49, 465-472.	0.7	13
1218	Metal-Based Biologically Active Compounds: Synthesis, Characterization, DNA Interaction, Antibacterial, Cytotoxic and SOD Mimic Activities. Applied Biochemistry and Biotechnology, 2013, 169, 1329-1345.	1.4	21
1219	Anticancer Activity and DNA Binding of a Bifunctional Ru(II) Arene Aqua-Complex with the 2,4-Diamino-6-(2-pyridyl)-1,3,5-triazine Ligand. Inorganic Chemistry, 2013, 52, 9962-9974.	1.9	67
1220	A Core Cross-Linked Polymeric Micellar Platium(IV) Prodrug with Enhanced Anticancer Efficiency. Macromolecular Bioscience, 2013, 13, 954-965.	2.1	16
1221	Synthesis, characterization, and DNA-binding of two new Cd(II) complexes with 8-[(2-pyridylmethyl)amino]-quinoline. Journal of Coordination Chemistry, 2013, 66, 3280-3290.	0.8	17
1222	Syntheses and crystal structures of tetracopper(II) complexes bridged by asymmetric N,Nâ€²-bis(substituted)oxamides: Molecular docking, DNA-binding and in vitro anticancer activity. Journal of Inorganic Biochemistry, 2013, 128, 97-107.	1.5	13
1223	Breast Cancer Metastasis and Drug Resistance. , 2013, , .		12
1224	Metalâ€“DNA Coordination Complexes. , 2013, , 751-784.		5
1225	Hydration of Cisplatin Studied by an Effective Ab Initio Pair Potential Including Soluteâ€“Solvent Polarization. Journal of Chemical Theory and Computation, 2013, 9, 4562-4573.	2.3	27
1226	Synthesis and Crystal Structure of Binuclear Copper(II) Complex Bridged by Nâ€(2â€Hydroxyphenyl)â€Nâ€²â€[3â€(diethylamino)propyl]oxamide: In Vitro Anticancer Activity and Reactivity Toward DNA and Protein. Journal of Biochemical and Molecular Toxicology, 2013, 27, 412-424.	1.4	4
1227	Rutheniumâ€“Areneâ€“Î²â€Carboline Complexes as Potent Inhibitors of Cyclinâ€Dependent Kinaseâ€…1: Synthesis, Characterization and Anticancer Mechanism Studies. Chemistry - A European Journal, 2013, 19, 12152-12160.	1.7	63
1228	Studies on synthesis, structure, and DNA cleaving of homo-dinuclear Mn(II), Cu(II), Ni(II), and Zn(II) complexes with a heterocycle-based macroacyclic Schiff base. Monatshefte FÃ¼r Chemie, 2013, 144, 1107-1115.	0.9	8
1229	Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells. Journal of Biological Inorganic Chemistry, 2013, 18, 579-589.	1.1	24

#	Article	IF	Citations
1230	Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand. Journal of Inorganic Biochemistry, 2013, 126, 46-54.	1.5	6
1231	trans effect and trans influence: importance of metal mediated ligandâ€“ligand repulsion. Physical Chemistry Chemical Physics, 2013, 15, 17354.	1.3	57
1232	Bidentate Ligands on Osmium(VI) Nitrido Complexes Control Intracellular Targeting and Cell Death Pathways. Journal of the American Chemical Society, 2013, 135, 14060-14063.	6.6	88
1233	Vibrational Signatures of the Naked Aqua Complexes from Platinum(II) Anticancer Drugs. Journal of Physical Chemistry Letters, 2013, 4, 3631-3635.	2.1	39
1234	Micellar nanoparticle formation via electrostatic interactions for delivering multinuclear platinum(ii) drugs. Chemical Communications, 2013, 49, 4809.	2.2	40
1235	Nanocarriers for delivery of platinum anticancer drugs. Advanced Drug Delivery Reviews, 2013, 65, 1667-1685.	6.6	345
1236	Visualizing Inhibition of Nucleosome Mobility and Transcription by Cisplatinâ€“DNA Interstrand Crosslinks in Live Mammalian Cells. Cancer Research, 2013, 73, 4451-4460.	0.4	29
1237	Urinary neutrophil gelatinaseâ€associated lipocalin levels predict cisplatinâ€induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung Journal of Medical Sciences, 2013, 29, 304-311.	0.8	40
1238	Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles. Metallomics, 2013, 5, 461.	1.0	39
1239	Synthesis, characterization and cytotoxicity of a new palladium(II) complex with a coumarin-derived ligand. Crystal structure of 4-hydroxy-3-(1-(p-tolylimino)ethyl)-2H-chromen-2-one-palladium(II) complex. Journal of Molecular Structure, 2013, 1040, 216-220.	1.8	11
1240	Structure-Based DNA-Targeting Strategies with Small Molecule Ligands for Drug Discovery. Medicinal Research Reviews, 2013, 33, 1119-1173.	5.0	81
1241	Destabilization of the MutSÎ±â€™s protein-protein interface due to binding to the DNA adduct induced by anticancer agent carboplatin via molecular dynamics simulations. Journal of Molecular Modeling, 2013, 19, 4969-4989.	0.8	5
1242	Kinetics and mechanism of interaction of some bioactive ligands with cis-diaqua(cis-1,2-diaminocyclohexane)platinum(II) in aqueous medium. Journal of Chemical Sciences, 2013, 125, 1133-1143.	0.7	2
1243	Analysis of the cytotoxic effects of rutheniumâ€“ketoconazole and rutheniumâ€“clotrimazole complexes on cancer cells. Cell Biology and Toxicology, 2013, 29, 431-443.	2.4	38
1244	Analysis and Modeling of Chromosome Congression During Mitosis in the Chemotherapy Drug Cisplatin. Cellular and Molecular Bioengineering, 2013, 6, 406-417.	1.0	6
1245	Synthesis of [PtCl2(4,4â€²-dialkoxy-2,2â€²-bipyridine)] complexes and their in vitro anticancer properties. Metallomics, 2013, 5, 973.	1.0	5
1246	Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis, 2013, 5, 369-391.	0.6	52
1247	Metals and Metal Derivatives in Medicine. Mini-Reviews in Medicinal Chemistry, 2013, 13, 211-221.	1.1	4

#	Article	IF	Citations
1248	Selective label-free detection of G-quadruplex structure of human telomere by emission spectral changes in visible-and-NIR region under physiological condition through the FRET of a two-component PPE-SO₃^{â˜’}â€“Pt(<scp>II</scp>) complex ensemble with Ptâ‹¯Pt, electrostatic and Ïâ€“Ï€ interactions. Chemical Science, 2013, 4, 377-387.	3.7	50
1249	Rational design of [Co(acacen)L2]+ inhibitors of protein function. Dalton Transactions, 2013, 42, 4002.	1.6	13
1250	Cisplatin Enhances the Formation of DNA Single- and Double-Strand Breaks by Hydrated Electrons and Hydroxyl Radicals. Radiation Research, 2013, 179, 323-331.	0.7	64
1251	Effect of 1,10-phenanthroline on DNA binding, DNA cleavage, cytotoxic and lactate dehydrogenase inhibition properties of Robson type macrocyclic dicopper(II) complex. Journal of Coordination Chemistry, 2013, 66, 3989-4003.	0.8	26
1252	DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis. Cancer Letters, 2013, 332, 237-248.	3.2	720
1253	Axial Ligand Exchange of N-heterocyclic Cobalt(III) Schiff Base Complexes: Molecular Structure and NMR Solution Dynamics. Inorganic Chemistry, 2013, 52, 1069-1076.	1.9	36
1254	Interaction of Cisplatin with Adenine and Guanine: A Combined IRMPD, MS/MS, and Theoretical Study. Journal of the American Chemical Society, 2013, 135, 1445-1455.	6.6	64
1255	The DNA binding site specificity and antiproliferative property of ternary Pt(ii) and Zn(ii) complexes of phenanthroline and N,Nâ€²-ethylenediaminediacetic acid. Dalton Transactions, 2013, 42, 3337.	1.6	13
1256	Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chemical Society Reviews, 2013, 42, 755-773.	18.7	672
1257	Interactions of Metal Ions with DNA and Some Applications. Journal of Inorganic and Organometallic Polymers and Materials, 2013, 23, 4-23.	1.9	89
1258	Water-soluble platinum(II) complexes of reduced amino acid Schiff bases: synthesis, characterization, and antitumor activity. Research on Chemical Intermediates, 2013, 39, 733-746.	1.3	27
1259	PEGylated Multi-Walled Carbon Nanotubes for Encapsulation and Sustained Release of Oxaliplatin. Pharmaceutical Research, 2013, 30, 412-423.	1.7	76
1260	N-Acetyl-l-cysteine modulates the metabolism of cis-platin in human plasma in vitro. Metallomics, 2013, 5, 197.	1.0	19
1261	Synthesis, structure, DNA interaction and nuclease activity of rhodium(III)â€“arylazoimidazole complexes. Inorganica Chimica Acta, 2013, 394, 98-106.	1.2	8
1262	Synthesis, cytotoxic activity and DNA interaction of Pd(II) complexes bearing Nâ€²-methyl-3,5-dimethyl-1-thiocarbamoylpyrazole. Polyhedron, 2013, 65, 214-220.	1.0	12
1263	Modulation of EGFR and ROS induced cytochrome c release by combination of photodynamic therapy and carboplatin in human cultured head and neck cancer cells and tumor xenograft in nude mice. Journal of Photochemistry and Photobiology B: Biology, 2013, 128, 70-77.	1.7	27
1264	Monomeric cisplatin complexes with glutathione: Coordination modes and binding affinities. Inorganica Chimica Acta, 2013, 405, 258-264.	1.2	13
1265	Nuclease digestion and mass spectrometric characterization of oligodeoxyribonucleotides containing 1,2-GpG, 1,2-ApG, and 1,3-GpXpG cisplatin intrastrand cross-links. Clinica Chimica Acta, 2013, 420, 160-170.	0.5	4

#	Article	IF	Citations
1266	Transplatin enhances effect of cisplatin on both single DNA molecules and live tumor cells. Archives of Biochemistry and Biophysics, 2013, 536, 12-24.	1.4	12
1267	The interaction of cisplatin with a human telomeric DNA sequence containing seventeen tandem repeats. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1041-1045.	1.0	12
1268	Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular â€œlight switchâ€•complexes. European Journal of Medicinal Chemistry, 2013, 64, 410-421.	2.6	71
1269	Synthesis and cytotoxicity of dinuclear platinum(II) complexes of (1S,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 622 Td (3S)-1,2,	4.8	4
1270	Cisplatin-induced ototoxicity: Transporters playing a role in cisplatin toxicity. Hearing Research, 2013, 299, 37-45.	0.9	84
1271	Synthesis, characterization, and DNA binding of complexes [Pt(bpy)(pip)]2+ and [Pt(bpy)(hpip)]2+. Journal of Biological Inorganic Chemistry, 2013, 18, 461-471.	1.1	24
1272	In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. Metallomics, 2013, 5, 636.	1.0	33
1273	Mechanistic elucidation of linker and ancillary ligand substitution reactions in Pt(<scp>ii</scp>) dinuclear complexes. Dalton Transactions, 2013, 42, 2724-2734.	1.6	33
1274	Impact of metal on the DNA photo-induced cleavage activity of a family of Phterpy complexes. Journal of Inorganic Biochemistry, 2013, 122, 49-56.	1.5	18
1275	A platinum complex that binds non-covalently to DNA and induces cell death via a different mechanism than cisplatin. Metallomics, 2013, 5, 514.	1.0	77
1276	Elucidation of the Molecular Interaction between Cisplatin and Flavonol(s) and their Effect on DNA Binding. Journal of Medicinal Chemistry, 2013, 56, 1491-1498.	2.9	8
1277	Site-specific inter-strand cross-links of DNA duplexes. Chemical Science, 2013, 4, 1319.	3.7	14
1278	Recent Developments in Texaphyrin Chemistry and Drug Discovery. Inorganic Chemistry, 2013, 52, 12184-12192.	1.9	65
1279	Reduction of some Pt(iv) complexes with biologically important sulfur-donor ligands. Dalton Transactions, 2013, 42, 8890.	1.6	37
1280	Complex conversion of the redox pair CoIIIâ€“NO2 to CoIIâ€“NO3: Synthesis, crystal structure and DNA-binding of trans,trans,trans-[Co(py)2(H2O)2(NO3)2]. Polyhedron, 2013, 53, 179-186.	1.0	8
1281	Competition between glutathione and DNA oligonucleotides for ruthenium(<scp>ii</scp>) arene anticancer complexes. Dalton Transactions, 2013, 42, 3188-3195.	1.6	43
1282	Synthesis and structure of a new tetracopper(II) complex bridged both by oxamido and phenolato groups: Cytotoxic activity, and reactivity towards DNA and BSA. Journal of Molecular Structure, 2013, 1039, 28-36.	1.8	9
1283	Anticancer cyclometalated complexes of platinum group metals and gold. Coordination Chemistry Reviews, 2013, 257, 2784-2797.	9.5	289

#	Article	IF	Citations
1284	A novel insulin mimetic vanadiumâ€“flavonol complex: Synthesis, characterization and inÂvivo evaluation in STZ-induced rats. European Journal of Medicinal Chemistry, 2013, 63, 109-117.	2.6	66
1285	Exploration of the medical periodic table: towards new targets. Chemical Communications, 2013, 49, 5106.	2.2	633
1286	Human cancerous and healthy cell cytotoxicity studies of a chiral Î¼-dicarbeneâ€“digold(i) metallamacrocycle. Dalton Transactions, 2013, 42, 7440.	1.6	25
1287	Mechanism of the cis-[Pt(1R,2R-DACH)(H₂O)₂]²⁺ Intrastrand Binding to the Double-Stranded (pGpG)Â·(CpC) Dinucleotide in Aqueous Solution: A Computational DFT Study. Inorganic Chemistry, 2013, 52, 5801-5813.	1.9	14
1288	Understanding the preferential binding interaction of aqua-cisplatins with nucleobase guanine over adenine: a density functional reactivity theory based approach. RSC Advances, 2013, 3, 2822.	1.7	32
1289	Pt(II) complexes with (N,Nâ€²) or (C,N,E)â^' (E=N,S) ligands: Cytotoxic studies, effect on DNA tertiary structure and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2013, 21, 4210-4217.	1.4	22
1290	Syntheses and structures of new trimetallic complexes bridged by N-(5-chloro-2-hydroxyphenyl)-Nâ€²-[3-(dimethylamino)propyl]oxamide: Cytotoxic activities, and reactivities towards DNA and protein. Journal of Photochemistry and Photobiology B: Biology, 2013, 118, 22-32.	1.7	45
1291	Polymorphism in Cisplatin Anticancer Drug. Journal of Physical Chemistry B, 2013, 117, 6421-6429.	1.2	34
1292	Mesoporous silica nanoparticle-based cisplatin prodrug delivery and anticancer effect under reductive cellular environment. Journal of Materials Chemistry B, 2013, 1, 2829.	2.9	56
1293	trans-Thionate Derivatives of Pt(II) and Pd(II) with Water-Soluble Phosphane PTA and DAPTA Ligands: Antiproliferative Activity against Human Ovarian Cancer Cell Lines. Inorganic Chemistry, 2013, 52, 6635-6647.	1.9	53
1294	Interaction of mixed ligand copper(II) complexes with CT DNA and BSA: Effect of primary ligand hydrophobicity on DNA and protein binding and cleavage and anticancer activities. Polyhedron, 2013, 52, 924-938.	1.0	98
1295	Synthesis, characterization, structural analysis and DNA binding studies of nickel(II)â€“triphenylphosphine complex of ONS donor ligand â€“ Multisubstituted thiosemicarbazone as highly selective sensor for fluoride ion. Polyhedron, 2013, 59, 58-68.	1.0	34
1296	A cross-linked polymeric micellar delivery system for cisplatin(IV) complex. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 63-75.	2.0	29
1297	S-Propargylthiopyridine Phosphane Derivatives As Anticancer Agents: Characterization and Antitumor Activity. Organometallics, 2013, 32, 3710-3720.	1.1	53
1298	Platinum and Ruthenium Complexes for the Therapy of Breast Cancer Diseases. , 2013, , 275-290.		2
1299	BODIPY-modified Ru(ii) arene complexâ€"a new ligand dissociation mechanism and a novel strategy to red shift the photoactivation wavelength of anticancer metallodrugs. Dalton Transactions, 2013, 42, 2786-2791.	1.6	42
1300	Synthesis, spectral and thermal studies of some polymeric mixed ligand uracilâ€“hydrazide complexes with transition metal ions. Designed Monomers and Polymers, 2013, 16, 456-464.	0.7	8
1301	Second- and higher-order structural changes of DNA induced by antitumor-active tetrazolato-bridged dinuclear platinum(II) complexes with different types of 5-substituent. Journal of Inorganic Biochemistry, 2013, 127, 169-174.	1.5	24

#	Article	IF	Citations
1302	Synthesis and crystal structure of a new copper(II) complex with N,Nâ€²-(4,4â€²-bithiazole-2,2â€²-diyl)diacetimidamide as ligand: Molecular docking, DNA-binding and cytotoxicity activity studies. Journal of Molecular Structure, 2013, 1037, 15-22.	1.8	20
1303	Monofunctional and Higher-Valent Platinum Anticancer Agents. Inorganic Chemistry, 2013, 52, 12234-12249.	1.9	199
1304	Interaction between Platinum Complexes and the C-Terminal Motif of Human Copper Transporter 1. Inorganic Chemistry, 2013, 52, 6153-6159.	1.9	7
1305	Drug delivery systems based on nucleic acid nanostructures. Journal of Controlled Release, 2013, 172, 467-483.	4.8	78
1306	Hydrated Electrons React with High Specificity with Cisplatin Bound to Single-Stranded DNA. Journal of Physical Chemistry B, 2013, 117, 15994-15999.	1.2	11
1307	Isomerization of Platinum-Coordinated Iminoethers Induced by Spectator Ligands: Stabilization of theZanti Configuration. Inorganic Chemistry, 2013, 52, 13058-13067.	1.9	3
1308	Small Molecule Inhibitors of ERCC1-XPF Protein-Protein Interaction Synergize Alkylating Agents in Cancer Cells. Molecular Pharmacology, 2013, 84, 12-24.	1.0	80
1309	Synthesis, characterization, DNA interaction, cytotoxicity, and apoptosis induction of a mixed-ligand copper(II) complex. Journal of Coordination Chemistry, 2013, 66, 3891-3905.	0.8	17
1310	Diamide Linked Î³-Cyclodextrin Dimers as Molecular-Scale Delivery Systems for the Medicinal Pigment Curcumin to Prostate Cancer Cells. Molecular Pharmaceutics, 2013, 10, 4481-4490.	2.3	27
1311	Advances in Understanding the Complex Mechanisms of DNA Interstrand Cross-Link Repair. Cold Spring Harbor Perspectives in Biology, 2013, 5, a012732-a012732.	2.3	196
1312	Copper binding promotes the interaction of cisplatin with human copper chaperone Atox1. Chemical Communications, 2013, 49, 11197.	2.2	39
1313	Customâ€Fit Ruthenium(II) Metallopeptides: A New Twist to DNA Binding With Coordination Compounds. Chemistry - A European Journal, 2013, 19, 13369-13375.	1.7	22
1314	Utilizing Redox-Mediated Bergman Cyclization toward the Development of Dual-Action Metalloenediyne Therapeutics. Journal of the American Chemical Society, 2013, 135, 3826-3833.	6.6	21
1315	Structureï£¿Activity Relationship of Polypyridyl Ruthenium(II) Complexes as DNA Intercalators, DNA Photocleavage Reagents, and DNA Topoisomerase and RNA Polymerase Inhibitors. Chemistry and Biodiversity, 2013, 10, 367-384.	1.0	20
1316	Thymines in Single-Stranded Oligonucleotides and G-Quadruplex DNA Are Competitive with Guanines for Binding to an Organoruthenium Anticancer Complex. Inorganic Chemistry, 2013, 52, 11332-11342.	1.9	27
1317	Progress in Synthesis and Antitumor Activities of Estradiol-linked Platinum Complex. Mini-Reviews in Medicinal Chemistry, 2013, 13, 265-272.	1.1	0
1318	Markers of response to platinum-based chemotherapy in lung cancer. Lung Cancer Management, 2013, 2, 227-239.	1.5	4
1319	Electron scattering from gas phase cis-diamminedichloroplatinum(II): Quantum analysis of resonance dynamics. Journal of Chemical Physics, 2013, 138, 204308.	1.2	2

#	Article	IF	Citations
1320	Cisplatin Protects against Acute Liver Failure by Inhibiting Nuclear HMGB1 Release. International Journal of Molecular Sciences, 2013, 14, 11224-11237.	1.8	10
1321	Copper chaperone Atox1 interacts with the metal-binding domain of Wilson's disease protein in cisplatin detoxification. Biochemical Journal, 2013, 454, 147-156.	1.7	53
1322	Chiral Selectivity in the Binding of [4]Helicene Derivatives to Doubleâ€Stranded DNA. Chemistry - A European Journal, 2013, 19, 7173-7180.	1.7	43
1323	Euler buckling and nonlinear kinking of double-stranded DNA. Nucleic Acids Research, 2013, 41, 9881-9890.	6.5	36
1324	The Protective Effects of Acetyl L-Carnitine on Testis Gonadotoxicity Induced by Cisplatin in Rats. Balkan Medical Journal, 2013, 30, 235-241.	0.3	14
1325	Quantitative analysis of the flexibility effect of cisplatin on circular DNA. Physical Review E, 2013, 88, 042703.	0.8	5
1326	Synthesis, structure, spectroscopic, and DNA binding properties of Co(III) and Ni(II) complexes with ((E)-2-(amino((pyridin-2-ylmethylene)amino)methylene)maleonitrile). Journal of Coordination Chemistry, 2013, 66, 2465-2476.	0.8	5
1327	Diazido Mixedâ€Amine Platinum(IV) Anticancer Complexes Activatable by Visibleâ€Light Form Novel DNA Adducts. Chemistry - A European Journal, 2013, 19, 9578-9591.	1.7	90
1328	Photochemistry and DNA photocleavage by a new unsupported dirhodium(II,II) complex. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2013, 371, 20120128.	1.6	12
1329	Synthesis and crystal structure of a new dicopper(II) complex withN-benzoato-Nâ€²-(hydroxypropyl)oxamide as ligand: cytotoxic activities and reactivities towards DNA and BSA. Journal of Coordination Chemistry, 2013, 66, 1985-2003.	0.8	22
1330	Spontaneous Translocation of Antitumor Oxaliplatin, its Enantiomeric Analogue, and Cisplatin from One Strand to Another in Doubleâ€Helical DNA. Chemistry - A European Journal, 2013, 19, 11984-11991.	1.7	5
1331	Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer. International Journal of Molecular Medicine, 2013, 31, 33-42.	1.8	27
1332	Cytotoxicity of cyclometallated ruthenium complexes: the role of ligand exchange on the activity. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2013, 371, 20120135.	1.6	31
1333	GABAA receptor-binding protein promotes sensitivity to apoptosis induced by chemotherapeutic agents. International Journal of Oncology, 2013, 42, 1807-1814.	1.4	7
1334	Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Nuklearmedizin - NuclearMedicine, 2013, 52, 222-227.	0.3	19
1335	Molecular Mechanisms of Platinum Resistance in Ovarian Cancer. , 0, , .		26
1336	Synthesis, Characterization, and Interaction with Biomolecules of Platinum(II) Complexes with Shikimic Acid-Based Ligands. Bioinorganic Chemistry and Applications, 2013, 2013, 1-12.	1.8	6
1337	The Ganglioside GM3 Is Associated with Cisplatin-Induced Apoptosis in Human Colon Cancer Cells. PLoS ONE, 2014, 9, e92786.	1.1	33

#	Article	IF	Citations
1338	The Biological Side of Water-Soluble Arene Ruthenium Assemblies. Advances in Chemistry, 2014, 2014, 1-20.	1.1	16
1339	Carboplatin: molecular mechanisms of action associated with chemoresistance. Brazilian Journal of Pharmaceutical Sciences, 2014, 50, 693-701.	1.2	77
1340	Recent Advances in Multinuclear Complexes as Potential Anticancer and DNA Binding Agents. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 147-169.	0.9	36
1341	New Perspectives in Cancer Therapy: The Biotin-Antitumor Molecule Conjugates. , 2014, S, .		25
1342	Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncology Reviews, 2014, 8, 246.	0.8	42
1343	Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. Oncology Reviews, 2014, 8, 256.	0.8	65
1344	DNA Damage. , 2014, , 9-69.		0
1345	Identification of Agents That Promote Endoplasmic Reticulum Stress Using an Assay That Monitors Luciferase Secretion. Journal of Biomolecular Screening, 2014, 19, 575-584.	2.6	2
1346	Effects of oxaliplatin on DNA condensation. Science China: Physics, Mechanics and Astronomy, 2014, 57, 2114-2120.	2.0	2
1347	Drugs for Plant Chromosome and Chromatin Research. Cytogenetic and Genome Research, 2014, 143, 51-59.	0.6	36
1348	Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney International, 2014, 85, 547-560.	2.6	113
1349	Interaction of Classical Platinum Agents with the Monomeric and Dimeric Atox1 Proteins: A Molecular Dynamics Simulation Study. International Journal of Molecular Sciences, 2014, 15, 75-99.	1.8	5
1350	Current and emerging strategies to increase the efficacy of ionizing radiation in the treatment of cancer. Expert Opinion on Drug Discovery, 2014, 9, 167-181.	2.5	4
1351	Seleniumâ€“Platinum Coordination Compounds as Novel Anticancer Drugs: Selectively Killing Cancer Cells via a Reactive Oxygen Species (ROS)â€Mediated Apoptosis Route. Chemistry - an Asian Journal, 2014, 9, 2295-2302.	1.7	59
1352	Resolved P-Metalated Nucleoside Phosphoramidites. Inorganic Chemistry, 2014, 53, 12680-12682.	1.9	3
1353	Syntheses, structures, optical properties and biological activities of bimetallic complexes. RSC Advances, 2014, 4, 64725-64730.	1.7	14
1354	Optimizing the Electronic Properties of Photoactive Anticancer Oxypyridine-Bridged Dirhodium(II,II) Complexes. Journal of the American Chemical Society, 2014, 136, 17058-17070.	6.6	37
1355	A Single Subexcitationâ€Energy Electron Can Induce a Doubleâ€Strand Break in DNA Modified by Platinum Chemotherapeutic Drugs. ChemMedChem, 2014, 9, 1145-1149.	1.6	43

#	Article	IF	Citations
1356	The Prodrug Platinâ€A: Simultaneous Release of Cisplatin and Aspirin. Angewandte Chemie - International Edition, 2014, 53, 1963-1967.	7.2	230
1358	Structural Biology of Cisplatin Complexes with Cellular Targets: The Adduct with Human Copper Chaperone Atox1 in Aqueous Solution. Chemistry - A European Journal, 2014, 20, 11719-11725.	1.7	14
1359	Synthesis, crystal structures, DNA binding and cleavage properties and protein binding activities of three mononuclear cobalt(II) complexes. Applied Organometallic Chemistry, 2014, 28, 259-266.	1.7	17
1360	Antioxidative Activity of Diarylheptanoids from the Bark of Black Alder (Alnus glutinosa) and Their Interaction with Anticancer Drugs. Planta Medica, 2014, 80, 1088-1096.	0.7	15
1361	Synthesis, Structural Characterization, and Evaluation of the Biological Properties of Heteroleptic Palladium(II) Complexes. Bioinorganic Chemistry and Applications, 2014, 2014, 1-7.	1.8	0
1362	â€œTurn offâ€“onâ€•fluorescent sensor for platinum drugs-DNA interactions based on quantum dots. Biosensors and Bioelectronics, 2014, 52, 29-35.	5.3	54
1363	Bis-amide transition metal complexes: Isomerism and DNA interaction study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2014, 120, 428-436.	2.0	4
1364	Ca2+-mediated regulation of VDAC1 expression levels is associated with cell death induction. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2270-2281.	1.9	77
1365	The effect of lipocisplatin on cisplatin efficacy and nephrotoxicity in malignant breast cancer treatment. Biomaterials, 2014, 35, 6462-6472.	5.7	20
1366	Synthesis, characterization and cytotoxicity of a new palladium(II) complex with a coumarine-derived ligand. European Journal of Medicinal Chemistry, 2014, 74, 502-508.	2.6	29
1367	Synthesis and structural characterization of a few thiocarboxylatonickel(II) complexes. Inorganica Chimica Acta, 2014, 411, 119-127.	1.2	11
1368	Study on synthesis, crystal structure, antioxidant and DNA-binding of mono-, di- and poly-nuclear lanthanides complexes with bis(N-salicylidene)-3-oxapentane-1,5-diamine. Journal of Photochemistry and Photobiology B: Biology, 2014, 135, 33-43.	1.7	95
1369	Platinum(II) complexes of reduced amino acid ester Schiff bases: synthesis, characterization, and antitumor activity. Research on Chemical Intermediates, 2014, 40, 413-424.	1.3	6
1370	Synthesis and crystal structure of a new tetranuclear copper(II) complex with N-(2-hydroxyphenyl)-Nâ€²-(3-aminopropyl)oxamide ligand: cytotoxicity, DNA and BSA-binding studies. Structural Chemistry, 2014, 25, 103-114.	1.0	3
1371	Cisplatin binds to human copper chaperone Cox17: the mechanistic implication of drug delivery to mitochondria. Chemical Communications, 2014, 50, 2667-2669.	2.2	35
1372	DNA-Binding Studies and Antitumor Evaluation of Novel Water Soluble Organic pip and hpip Analogs. Applied Biochemistry and Biotechnology, 2014, 172, 248-262.	1.4	17
1373	Cytotoxicity of cyclometalated platinum complexes based on tridentate NCN and CNN-coordinating ligands: Remarkable coordination dependence. Journal of Inorganic Biochemistry, 2014, 134, 49-56.	1.5	27
1374	Evaluation of novel trans-sulfonamide platinum complexes against tumor cell lines. European Journal of Medicinal Chemistry, 2014, 76, 360-368.	2.6	22

#	Article	IF	Citations
1375	Biological Properties of 1H-1,2,3- and 2H-1,2,3-Triazoles. Topics in Heterocyclic Chemistry, 2014, , 117-165.	0.2	34
1376	Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agentÂthan is the parent inhibitor. European Journal of Medicinal Chemistry, 2014, 71, 366-373.	2.6	10
1377	InÂvitro cytotoxicity studies of palladacyclic complexes containing the symmetric diphosphine bridging ligand. Studies of their interactions with DNA and BSA. European Journal of Medicinal Chemistry, 2014, 73, 8-17.	2.6	69
1378	Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. European Journal of Medicinal Chemistry, 2014, 77, 422-487.	2.6	348
1379	Synthesis, crystal structures and characterization of late first row transition metal complexes derived from benzothiazole core: Anti-tuberculosis activity and special emphasis on DNA binding andÂcleavage property. European Journal of Medicinal Chemistry, 2014, 79, 47-56.	2.6	73
1380	Picolinic acid based Cu(II) complexes with heterocyclic bases â€“ Crystal structure, DNA binding and cleavage studies. European Journal of Medicinal Chemistry, 2014, 79, 117-127.	2.6	57
1381	Monitoring Cellular Uptake and Cytotoxicity of Copper(II) Complex Using a Fluorescent Anthracene Thiosemicarbazone Ligand. Bioconjugate Chemistry, 2014, 25, 102-114.	1.8	50
1382	Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine. European Journal of Medicinal Chemistry, 2014, 78, 54-64.	2.6	10
1383	Synthesis and structure of a new mononuclear copper(II) complex with 2,2Ê¹-bipyridine and picrate: molecular docking, DNA-binding, and in vitro anticancer activity. Journal of Coordination Chemistry, 2014, 67, 630-648.	0.8	25
1384	Enhanced anti-cancer efficacy to cancer cells by doxorubicin loaded water-soluble amino acid-modified Î²-cyclodextrin platinum complexes. Journal of Inorganic Biochemistry, 2014, 137, 31-39.	1.5	10
1385	A Comparative Study of In Vitro Cytotoxic, Antioxidant, and Antimicrobial Activity of Pt(II), Zn(II), Cu(II), and Co(III) Complexes with Nâ€heteroaromatic Schiff Base (E)â€2â€[Nâ€²â€(1â€pyridinâ€2â€ylâ€ethylidene)hydrazino]acetate. Journal of Biochemical and Molecular Toxicology, 2014, 28, 99-110.	1.4	10
1388	Palladium(II) Complexes with N â€Heteroaromatic Bidentate Hydrazone Ligands: The Effect of the Chelate Ring Size and Lipophilicity on in vitro Cytotoxic Activity. Chemical Biology and Drug Design, 2014, 84, 333-341.	1.5	14
1389	Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro-Oncology, 2014, 16, 1313-1323.	0.6	110
1390	Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics. Clinical Cancer Research, 2014, 20, 2831-2837.	3.2	349
1391	Platinated DNA oligonucleotides: new probes forming ultrastable conjugates with graphene oxide. Nanoscale, 2014, 6, 7079.	2.8	18
1392	Stereospecific ligands and their complexes. Part XII. Synthesis, characterization and in vitro antiproliferative activity of platinum(IV) complexes with some O,Oâ€²-dialkyl esters of (S,S)-ethylenediamine-N,Nâ€²-di-2-propanoic acid against colon cancer (HCT-116) and breast cancer (MDA-MB-231) cell lines. Journal of Molecular Structure, 2014, 1062, 21-28.	1.8	15
1393	Phenanthroline ligands are biologically more active than their corresponding ruthenium(<scp>ii</scp>) arene complexes. Dalton Transactions, 2014, 43, 2629-2645.	1.6	34
1394	New cyclometallated Ru(ii) complex for potential application in photochemotherapy?. Photochemical and Photobiological Sciences, 2014, 13, 272-280.	1.6	53

#	Article	IF	Citations
1395	Lasing the DNA fragments through Î²-diketimine framed Knoevenagel condensed Cu(II) and Zn(II) complexes â€“ An in vitro and in vivo approach. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2014, 118, 867-882.	2.0	10
1396	A first principles study of pristine and Al-doped boron nitride nanotubes interacting with platinum-based anticancer drugs. Physica E: Low-Dimensional Systems and Nanostructures, 2014, 57, 47-55.	1.3	39
1397	Synthesis, characterization and anti-proliferative activity of Cd(II) complexes with NNN type pyrazole-based ligand and pseudohalide ligands as coligand. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2014, 121, 282-287.	2.0	21
1398	Synthetic Methods for the Preparation of Platinum Anticancer Complexes. Chemical Reviews, 2014, 114, 4470-4495.	23.0	531
1399	Synthesis, in-vitro cytotoxic activity and DNA interactions of new dicarboxylatoplatinum(II) complexes with 2-hydroxymethylbenzimidazole as carrier ligands. Journal of Pharmacy and Pharmacology, 2014, 66, 1593-1605.	1.2	10
1400	Synthesis and X-ray structure of a new zinc(<scp>ii</scp>) coordination polymer: interaction with DNA and double stranded RNA and elucidation of the molecular aspects of the binding to bovine serum albumin. RSC Advances, 2014, 4, 57855-57868.	1.7	17
1401	Condensations of single DNA molecules induced by heptaplatin and its chiral isomer. AIP Advances, 2014, 4, .	0.6	2
1402	Synthesis, crystal structure and cytotoxicity studies of cis-dichloro(4,5-diazafluoren-9-one)platinum(II). Inorganica Chimica Acta, 2014, 423, 93-97.	1.2	10
1403	Design, synthesis and comparative cytotoxic investigation of platinum(II) complexes with some derivatives of 5-methyl-5-(4-pyridyl)hydantoin. Inorganica Chimica Acta, 2014, 423, 46-51.	1.2	7
1404	Binuclear ruthenium complexes containing mPTA and alkyl-bis(8-thiotheophylline) derivatives (mPTAÂ=ÂN-methyl-1,3,5-triaza-7-phosphaadamantane). Journal of Coordination Chemistry, 2014, 67, 2701-2710.	0.8	3
1405	Synthesis, biological evaluation and SAR studies of novel bicyclic antitumor platinum(IV) complexes. European Journal of Medicinal Chemistry, 2014, 83, 374-388.	2.6	21
1406	Identification and discrimination of binding sites of an organoruthenium anticancer complex to single-stranded oligonucleotides by mass spectrometry. Analyst, The, 2014, 139, 4491-4496.	1.7	11
1407	Bisindolines from the reaction of 3,5-dimethoxyaniline with vicinal diones. RSC Advances, 2014, 4, 1401-1411.	1.7	6
1408	Mixed ligand Î¼-phenoxo-bridged dinuclear copper(ii) complexes with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity. Dalton Transactions, 2014, 43, 6177.	1.6	89
1409	Enzyme-triggered supramolecular self-assembly of platinum prodrug with enhanced tumor-selective accumulation and reduced systemic toxicity. Journal of Materials Chemistry B, 2014, 2, 8303-8309.	2.9	40
1410	An H₂O₂-responsive nanocarrier for dual-release of platinum anticancer drugs and O₂: controlled release and enhanced cytotoxicity against cisplatin resistant cancer cells. Chemical Communications, 2014, 50, 9714-9717.	2.2	98
1411	A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex. Metallomics, 2014, 6, 1491-1501.	1.0	87
1412	A density functional reactivity theory (DFRT) based approach to understand the interaction of cisplatin analogues with protecting agents. Journal of Computer-Aided Molecular Design, 2014, 28, 1153-1173.	1.3	11

#	Article	IF	Citations
1413	Synthesis, Characterization, and DNA-Binding Properties of the Cadmium(II) Complex With 1,3-bis(1-methylbenzimidazol-2-yl)-2-oxopropane. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2014, 44, 545-551.	0.6	1
1414	Copper binding modulates the platination of human copper chaperone Atox1 by antitumor trans-platinum complexes. Metallomics, 2014, 6, 491-497.	1.0	13
1415	Kinetic and mechanistic studies of 1,3-bis(2-pyridylimino)isoindolate Pt(<scp>ii</scp>) derivatives. Experimental and new computational approach. Dalton Transactions, 2014, 43, 2549-2558.	1.6	25
1416	Amino acid-linked platinum(<scp>ii</scp>) analogues have altered specificity for RNA compared to cisplatin. Chemical Communications, 2014, 50, 3918-3920.	2.2	29
1417	Local conformation transitions of linear DNA induced by cisplatin. Science Bulletin, 2014, 59, 3085-3089.	1.7	7
1418	Marked Improvement in Photoinduced Cell Death by a New Tris-heteroleptic Complex with Dual Action: Singlet Oxygen Sensitization and Ligand Dissociation. Journal of the American Chemical Society, 2014, 136, 17095-17101.	6.6	169
1419	Formation of glutathione sulfenate and sulfinate complexes by an organoiridium(<scp>iii</scp>) anticancer complex. Inorganic Chemistry Frontiers, 2014, 1, 668-672.	3.0	13
1420	Solvent evaporation versus proton transfer in nucleobaseâ€“Pt(CN)4,62â^' dianion clusters: a collisional excitation and electronic laser photodissociation spectroscopy study. Physical Chemistry Chemical Physics, 2014, 16, 15490.	1.3	23
1421	Reactivity of kiteplatin with S-donor biomolecules and nucleotides. Dalton Transactions, 2014, 43, 12851-12859.	1.6	15
1422	Heteroleptic titanium(<scp>iv</scp>) catecholato/piperazine systems and their anti-cancer properties. Dalton Transactions, 2014, 43, 1380-1385.	1.6	14
1423	Novel in situ methodology to observe the interactions of chemotherapeutical Pt drugs with DNA under physiological conditions. Dalton Transactions, 2014, 43, 13839-13844.	1.6	18
1424	PIM2 Kinase Is Induced by Cisplatin in Ovarian Cancer Cells and Limits Drug Efficacy. Journal of Proteome Research, 2014, 13, 4970-4982.	1.8	22
1425	An Unusual Ligand Coordination Gives Rise to a New Family of Rhodium Metalloinsertors with Improved Selectivity and Potency. Journal of the American Chemical Society, 2014, 136, 14160-14172.	6.6	39
1426	Loss of Î±(E)-Catenin Potentiates Cisplatin-Induced Nephrotoxicity via Increasing Apoptosis in Renal Tubular Epithelial Cells. Toxicological Sciences, 2014, 141, 254-262.	1.4	17
1427	Molecular Recognition of Platinated DNA from Chromosomal HMGB1. Journal of Chemical Theory and Computation, 2014, 10, 3578-3584.	2.3	12
1428	Cisplatin Inhibits the Formation of a Reactive Intermediate during Copper-Catalyzed Oxidation of Amyloid Î² Peptide. Inorganic Chemistry, 2014, 53, 10003-10005.	1.9	11
1429	Labelling Herceptin with a novel oxaliplatin derivative: a computational approach towards the selective drug delivery. Journal of Molecular Modeling, 2014, 20, 2401.	0.8	24
1430	Discovery of a Highly Tumor-Selective Organometallic Ruthenium(II)â€“Arene Complex. Journal of Medicinal Chemistry, 2014, 57, 3546-3558.	2.9	60

#	Article	IF	Citations
1431	Targeting the Androgen Receptor with Steroid Conjugates. Journal of Medicinal Chemistry, 2014, 57, 8224-8237.	2.9	34
1432	Platinum-RNA Modifications Following Drug Treatment in S. cerevisiae Identified by Click Chemistry and Enzymatic Mapping. ACS Chemical Biology, 2014, 9, 2404-2411.	1.6	49
1433	Understanding the interaction of an antitumoral platinum(II) 7-azaindolate complex with proteins and DNA. BioMetals, 2014, 27, 1159-1177.	1.8	8
1434	Metallomics insights into the programmed cell death induced by metal-based anticancer compounds. Metallomics, 2014, 6, 978.	1.0	95
1435	Potential apoptosis inducing agents based on a new benzimidazole schiff base ligand and its dicopper(<scp>ii</scp>) complex. RSC Advances, 2014, 4, 41228-41236.	1.7	38
1436	The effect of Ïƒ-donation on the interactions of cis-diaqua(2-aminomethylpiperidine)platinum(II) complex with biomolecules in aqueous medium: synthesis, kinetic and mechanistic study. Transition Metal Chemistry, 2014, 39, 727-733.	0.7	4
1437	Copper Phenanthrene Oxidative Chemical Nucleases. Inorganic Chemistry, 2014, 53, 5392-5404.	1.9	72
1438	Mixed ligand copper(II) complexes of 2,9-dimethyl-1,10-phenanthroline: Tridentate 3N primary ligands determine DNA binding and cleavage and cytotoxicity. Journal of Inorganic Biochemistry, 2014, 140, 202-212.	1.5	74
1440	A new nano-structured Ni(II) Schiff base complex: synthesis, characterization, optical band gaps, and biological activity. Applied Physics A: Materials Science and Processing, 2014, 117, 877-890.	1.1	50
1441	Cisplatin handover between copper transporters: the effect of reducing agents. Journal of Biological Inorganic Chemistry, 2014, 19, 705-714.	1.1	13
1442	Characterising the atypical 5â€²-CG DNA sequence specificity of 9-aminoacridine carboxamide Pt complexes. Journal of Biological Inorganic Chemistry, 2014, 19, 997-1007.	1.1	10
1443	Effects of SOD/catalase mimetic platinum nanoparticles on radiation-induced apoptosis in human lymphoma U937 cells. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 1006-1016.	2.2	43
1444	Development of EGFR-Targeted Nanoemulsion for Imaging and Novel Platinum Therapy of Ovarian Cancer. Pharmaceutical Research, 2014, 31, 2490-2502.	1.7	36
1445	Novel Pt-loaded layered double hydroxide nanoparticles for efficient and cancer-cell specific delivery of a cisplatin prodrug. Journal of Materials Chemistry B, 2014, 2, 4868.	2.9	35
1446	Anticancer activity and DNA-binding properties of novel cationic Pt(II) complexes. International Journal of Biological Macromolecules, 2014, 66, 86-96.	3.6	48
1447	Mononuclear half-sandwich cyclic-Ï€-perimeter platinum group metal complexes having bithiazole ligands: Synthesis, molecular and anti-cancer studies. Inorganica Chimica Acta, 2014, 421, 349-358.	1.2	12
1448	Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10444-10449.	3.3	206
1449	Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery. Journal of the American Chemical Society, 2014, 136, 8790-8798.	6.6	362

#	Article	IF	Citations
1450	Mass Spectrometric Proteomics Reveals that Nuclear Protein Positive Cofactor PC4 Selectively Binds to Cross-Linked DNA by a trans-Platinum Anticancer Complex. Journal of the American Chemical Society, 2014, 136, 2948-2951.	6.6	32
1451	Detailed mechanistic study on ligand substitution reactions in dinuclear platinum(II) complexes: effect of alkanediamine linker. Transition Metal Chemistry, 2014, 39, 407-420.	0.7	11
1452	Synthesis, structure, redox properties and DNA interaction studies on mononuclear iron(III) complexes with amidate ligand. Inorganica Chimica Acta, 2014, 412, 20-26.	1.2	13
1453	Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(<scp>iv</scp>) prodrugs. Chemical Science, 2014, 5, 2265-2270.	3.7	70
1454	Visibleâ€Lightâ€Induced Annihilation of Tumor Cells with Platinumâ€“Porphyrin Conjugates. Angewandte Chemie - International Edition, 2014, 53, 6938-6941.	7.2	192
1455	Cisplatin Radiosensitization of DNA Irradiated with 2â€“20 eV Electrons: Role of Transient Anions. Journal of Physical Chemistry C, 2014, 118, 15516-15524.	1.5	32
1456	Cytotoxicity and NMR Studies of Platinum Complexes with Cyclooctadiene Ligands. Organometallics, 2014, 33, 4027-4034.	1.1	32
1457	Anticancer activity of organotin(IV) carboxylates. Inorganica Chimica Acta, 2014, 423, 14-25.	1.2	93
1458	Cisplatin Intrastrand Adducts Sensitize DNA to Base Damage by Hydrated Electrons. Journal of Physical Chemistry B, 2014, 118, 4803-4808.	1.2	24
1460	Synthesis, structure and molecular docking studies of dicopper(<scp>ii</scp>) complexes bridged by N-phenolato-Nâ€²-[2-(dimethylamino)ethyl]oxamide: the influence of terminal ligands on cytotoxicity and reactivity towards DNA and protein BSA. New Journal of Chemistry, 2014, 38, 2964-2978.	1.4	114
1461	Nuclease activity and protein-binding properties of a novel tetranuclear thiosemicarbazide Pt(<scp>ii</scp>) complex. Dalton Transactions, 2014, 43, 1663-1671.	1.6	21
1462	Synthesis, structure, and DNA-binding properties of manganese(II) and nickel(II) complexes with tris(N-ethylbenzimidazol-2-ylmethyl)amine ligand. Journal of Coordination Chemistry, 2014, 67, 660-669.	0.8	10
1463	Interaction of electrons with cisplatin and the subsequent effect on DNA damage: a density functional theory study. Physical Chemistry Chemical Physics, 2014, 16, 19290.	1.3	14
1464	Targeted Chemotherapy with Metal Complexes. Comments on Inorganic Chemistry, 2014, 34, 114-123.	3.0	31
1465	In vitro studies on the behavior of salmeterol xinafoate and its interaction with calf thymus DNA by multi-spectroscopic techniques. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2014, 132, 198-204.	2.0	21
1466	Photosensitive Pt(IV)â€“azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo. Journal of Controlled Release, 2014, 173, 11-17.	4.8	96
1467	Atomic Level Rendering of DNA-Drug Encounter. Biophysical Journal, 2014, 106, 421-429.	0.2	9
1468	New titanocene derivatives with high antiproliferative activity against breast cancer cells. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 136-140.	1.0	19

#	Article	IF	Citations
1469	Non-DSB clustered DNA lesions induced by ionizing radiation are largely responsible for the loss of plasmid DNA functionality in the presence of cisplatin. Chemico-Biological Interactions, 2014, 217, 9-18.	1.7	16
1470	Protective effects of schizandrin and schizandrin B towards cisplatin nephrotoxicity in vitro. Journal of Applied Toxicology, 2014, 34, 1311-1319.	1.4	20
1471	Synthesis, characterization, crystal structures and biological activity of set of Cu(II) benzothiazole complexes: Artificial nucleases with cytotoxic activities. Journal of Inorganic Biochemistry, 2014, 137, 1-11.	1.5	29
1472	Platinum drugs binding to human serum albumin: Effect of non-steroidal anti-inflammatory drugs. Journal of Photochemistry and Photobiology A: Chemistry, 2014, 289, 1-6.	2.0	26
1473	Understanding Intrinsically Irreversible, Non-Nernstian, Two-Electron Redox Processes: A Combined Experimental and Computational Study of the Electrochemical Activation of Platinum(IV) Antitumor Prodrugs. Journal of the American Chemical Society, 2014, 136, 8992-9000.	6.6	70
1474	Bispidine Analogues of Cisplatin, Carboplatin, and Oxaliplatin. Synthesis, Structures, and Cytotoxicity. Inorganic Chemistry, 2014, 53, 3371-3384.	1.9	38
1475	Raman spectroscopic evaluation of DNA adducts of a platinum containing anticancer drug. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2014, 130, 386-389.	2.0	9
1476	Assessing cisplatin-induced ototoxicity and otoprotection in whole organ culture of the mouse inner ear in simulated microgravity. Toxicology Letters, 2014, 227, 203-212.	0.4	14
1477	Synthesis, characterization and in vitro antitumor activity of new palladium(II) complexes with (S,S)-R2edda-type esters. Polyhedron, 2014, 80, 106-111.	1.0	17
1478	DNA binding, cytotoxicity and apoptosis induction activity of a mixed-ligand copper(II) complex with taurine Schiff base and imidazole. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2014, 128, 686-693.	2.0	20
1479	Î¼-Oxamido binuclear copper (II) complexes: Synthesis, crystal structure, DNA interaction and antibacterial studies. Polyhedron, 2014, 68, 172-179.	1.0	18
1480	Alpha-lipoic acid protects against cisplatin-induced ototoxicity via the regulation of MAPKs and proinflammatory cytokines. Biochemical and Biophysical Research Communications, 2014, 449, 183-189.	1.0	40
1481	Non-specificity and synergy at the binding site of the carboplatin-induced DNA adduct via molecular dynamics simulations of the MutSÎ±â€“DNA recognition complex. Journal of Biomolecular Structure and Dynamics, 2014, 32, 969-992.	2.0	15
1482	Antitumor effect of a copper (II) complex of a coumarin derivative and phenanthroline on lung adenocarcinoma cells and the mechanism of action. Molecular Medicine Reports, 2014, 10, 2477-2482.	1.1	15
1483	Spectroscopic and Molecular Dynamics Studies on Binding of Dimethylplatinum(II) Complex Drug to Human Serum Albumin. Bulletin of the Chemical Society of Japan, 2014, 87, 1094-1100.	2.0	3
1484	The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. International Journal of Oncology, 2015, 46, 1924-1934.	1.4	62
1485	Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma. Scientific Reports, 2015, 5, 17387.	1.6	23
1486	Impacto dos agentes antineoplÃ¡sicos sobre os folÃculos ovarianos e importÃ¢ncia das biotÃ©cnicas reprodutivas na preservaÃ§Ã£o da fertilidade humana. Reproducao E Climaterio, 2015, 30, 90-99.	0.1	0

#	Article	IF	Citations
1487	The formation of intracellular nanoparticles correlates with cisplatin resistance. Science China Materials, 2015, 58, 640-648.	3.5	3
1488	Evaluation of Hybrid Theoretical Approaches for Structural Determination of a Glycine-Linked Cisplatin Derivative via Infrared Multiple Photon Dissociation (IRMPD) Action Spectroscopy. Journal of Physical Chemistry A, 2015, 119, 10980-10987.	1.1	35
1489	Synthesis, spectral investigation and development of tetrahedral copper(II) complexes as artificial metallonucleases and antimalarial agents. Applied Organometallic Chemistry, 2015, 29, 357-367.	1.7	16
1490	Anticancer Organometallic Osmium(II)â€pâ€cymene Complexes. ChemMedChem, 2015, 10, 1539-1547.	1.6	23
1491	Combination of twoâ€dimensional gel electrophoresis and a fluorescent carboxyfluoresceinâ€diacetateâ€labeled cisplatin analogue allows the identification of intracellular cisplatinâ€"protein adducts. Electrophoresis, 2015, 36, 2811-2819.	1.3	13
1492	Recent Advancements in Calix[4]pyrroleâ€Based Anionâ€Receptor Chemistry. European Journal of Organic Chemistry, 2015, 2015, 3859-3885.	1.2	89
1493	Boneâ€Targeted Cisplatinâ€Complexed Poly(Î³â€benzylâ€<scp>L</scp>â€glutamate)â€"Poly(glutamic acid) Block Polymer Nanoparticles: An Electrochemical Approach. ChemElectroChem, 2015, 2, 748-754.	1.7	3
1494	Synthesis and Structure of a New Copper(II) Coordination Polymer Alternately Bridged by Oxamido and Carboxylate Groups: Evaluation of DNA/BSA Binding and Cytotoxic Activities. Journal of Biochemical and Molecular Toxicology, 2015, 29, 360-372.	1.4	3
1495	A Series of Dinuclear Complexes with a Flexible Naphthaleneâ€Spacer and MOMâ€Cleavage by Preâ€coordinated Lewis Acids. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2015, 641, 2157-2168.	0.6	9
1496	Cisplatin Targeting of Bacterial Ribosomal RNA Hairpins. International Journal of Molecular Sciences, 2015, 16, 21392-21409.	1.8	19
1497	EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. PLoS ONE, 2015, 10, e0125402.	1.1	72
1498	Carboxymethyl Hyaluronan-Stabilized Nanoparticles for Anticancer Drug Delivery. International Journal of Cell Biology, 2015, 2015, 1-14.	1.0	11
1501	Smart Biodecorated Hybrid Nanoparticles. Current Bionanotechnology, 2015, 1, 60-78.	0.6	1
1502	Rational evolution of Cd²⁺-specific DNAzymes with phosphorothioate modified cleavage junction and Cd²⁺sensing. Nucleic Acids Research, 2015, 43, 6125-6133.	6.5	136
1503	Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. Blood Coagulation and Fibrinolysis, 2015, 26, 36-45.	0.5	25
1504	Oxidovanadium(<scp>v</scp>) complexes of aroylhydrazones incorporating heterocycles: synthesis, characterization and study of DNA binding, photo-induced DNA cleavage and cytotoxic activities. RSC Advances, 2015, 5, 51852-51867.	1.7	45
1505	Synthesis and structure of nickel(<scp>ii</scp>) thiocarboxamide complexes: effect of ligand substitutions on DNA/protein binding, antioxidant and cytotoxicity. RSC Advances, 2015, 5, 46760-46773.	1.7	69
1506	An efficient synthesis and in vitro antibacterial evaluation of rutheniumâ€"quinolinol complexes. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2892-2896.	1.0	11

#	Article	IF	Citations
1507	Synthesis, characterization, and DNA interaction of novel Pt(<scp>ii</scp>) complexes and their cytotoxicity, apoptosis and molecular docking. RSC Advances, 2015, 5, 47798-47808.	1.7	16
1508	A novel azopyridine-based Ru(<scp>ii</scp>) complex with GSH-responsive DNA photobinding ability. Chemical Communications, 2015, 51, 10684-10686.	2.2	26
1509	Therapeutic Applications of Spherical Nucleic Acids. Cancer Treatment and Research, 2015, 166, 23-50.	0.2	32
1511	Multifunctional selenium nanoparticles: Chiral selectivity of delivering MDR-siRNA for reversal of multidrug resistance and real-time biofluorescence imaging. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1773-1784.	1.7	44
1512	V-shaped ligand 1,3-bis(1-ethylbenzimidazol-2-yl)-2-thiapropane and manganese(II), cobalt(II) and copper(II) complexes: Synthesis, crystal structure, DNA-binding properties and antioxidant activities. Journal of Photochemistry and Photobiology B: Biology, 2015, 148, 252-261.	1.7	46
1513	Fluorescence imaging of a new monofunctional platinum(ii) complex containing a thioflavin-T (ThT)-based fluorophore. New Journal of Chemistry, 2015, 39, 1592-1596.	1.4	10
1514	Anticancer activity studies of a ruthenium(II) polypyridyl complex against human hepatocellular (BEL-7402) cells. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2015, 150, 127-134.	2.0	12
1515	Antiangiogenic Activity of Mononuclear Copper(II) Polypyridyl Complexes for the Treatment of Cancers. Journal of Medicinal Chemistry, 2015, 58, 5226-5241.	2.9	94
1516	Some examples on the performance of density functional theory in the description of bioinorganic systems and processes. , 2015, , .		0
1517	Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell and Melanoma Research, 2015, 28, 501-519.	1.5	3
1518	The use of Resonant X-ray Emission Spectroscopy (RXES) for the electronic analysis of metal complexes and their interactions with biomolecules. Drug Discovery Today: Technologies, 2015, 16, 1-6.	4.0	2
1519	Computational metallomics of the anticancer drug cisplatin. Journal of Inorganic Biochemistry, 2015, 153, 231-238.	1.5	20
1520	Synthesis of biocompatible polymeric nano-capsules based on calcium carbonate: A potential cisplatin delivery system. Journal of Inorganic Biochemistry, 2015, 153, 284-292.	1.5	29
1521	Electrophilic Activation of Oxidized Sulfur Ligands and Implications for the Biological Activity of Ruthenium(II) Arene Anticancer Complexes. Inorganic Chemistry, 2015, 54, 11574-11580.	1.9	8
1522	REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. Oncology Reports, 2015, 34, 1460-1468.	1.2	28
1523	Glutathione selectively modulates the binding of platinum drugs to human copper chaperone Cox17. Biochemical Journal, 2015, 472, 217-223.	1.7	16
1524	Cytotoxicity of palladium(II) complexes with some alkyl derivates of thiosalicylic acid. Crystal structure of the bis(S-butyl-thiosalicylate)palladium(II) complex, [Pd(S-bu-thiosal)2]. Polyhedron, 2015, 90, 34-40.	1.0	6
1525	Synthesis and the characterization of Schiff-base copper complexes: Reactivity with DNA, 4-NPP and BNPP. Inorganica Chimica Acta, 2015, 428, 176-184.	1.2	7

#	Article	IF	Citations
1526	Synthesis and characterization of cobalt(II), nickel(II) and copper(II)-based potential photosensitizers: Evaluation of their DNA binding profile, cleavage and photocytotoxicity. Inorganica Chimica Acta, 2015, 428, 138-146.	1.2	38
1527	Structural changes of linear DNA molecules induced by cisplatin. Biochemical and Biophysical Research Communications, 2015, 457, 688-692.	1.0	14
1528	Rational Design of a Cytotoxic Dinuclear Cu₂ Complex That Binds by Molecular Recognition at Two Neighboring Phosphates of the DNA Backbone. Inorganic Chemistry, 2015, 54, 2679-2690.	1.9	47
1529	The induction of lysis in lysogenic strains of Escherichia coli by a new antitumor transplatin derivative and its DNA interactions. Dalton Transactions, 2015, 44, 3573-3582.	1.6	5
1530	BODIPY appended copper(<scp>ii</scp>) complexes of curcumin showing mitochondria targeted remarkable photocytotoxicity in visible light. MedChemComm, 2015, 6, 846-851.	3.5	54
1531	Mitochondria-Localized Fluorescent BODIPY-Platinum Conjugate. ACS Medicinal Chemistry Letters, 2015, 6, 430-433.	1.3	80
1532	Third row transition metals for the treatment of cancer. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2015, 373, 20140185.	1.6	82
1533	A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug. Biomaterials, 2015, 51, 12-21.	5.7	109
1534	Nephroprotective effects of ferulic acid, Z-ligustilide and E-ligustilide isolated from Angelica sinensis against cisplatin toxicity in vitro. Toxicology in Vitro, 2015, 29, 458-467.	1.1	52
1535	Dual-Functional Analogous cis-Platinum Complex with High Antitumor Activities and Two-Photon Bioimaging. Biochemistry, 2015, 54, 2177-2180.	1.2	12
1536	Synthesis, structural characterization, in-vitro antibiogram assay and efficient catalytic activities of transition metal(II) chelates incorporating (E)-(2-((2-hydroxybenzylidene)amino)phenyl)(phenyl)methanone ligand. Journal of Molecular Structure, 2015, 1086, 56-63.	1.8	4
1537	Enzymatic Synthesis of a DNA Triblock Copolymer that is Composed of Natural and Unnatural Nucleotides. Chemistry - an Asian Journal, 2015, 10, 455-460.	1.7	8
1538	Synthesis, DNA binding and docking studies of copper(II) complexes containing modified phenanthroline ligands. Journal of Coordination Chemistry, 2015, 68, 1374-1386.	0.8	33
1539	Potential nephroprotective effects of the Chinese herbAngelica sinensisagainst cisplatin tubulotoxicity. Pharmaceutical Biology, 2015, 53, 985-994.	1.3	14
1540	Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 685-698.	1.9	23
1541	Synthesis and crystal structure of new dicopper(II) complexes with N,Nâ€²-bis-(dipropylenetriamine)oxamide as bridging ligand: Effects of the counterions on DNA/protein-binding property and in vitro antitumor activity. Journal of Photochemistry and Photobiology B: Biology, 2015, 143, 148-162.	1.7	12
1542	Revealing DNA Interactions with Exogenous Agents by Surface-Enhanced Raman Scattering. Journal of the American Chemical Society, 2015, 137, 469-476.	6.6	88
1543	Synthesis and characterization of water-soluble, heteronuclear ruthenium(III)/ferrocene complexes and their interactions with biomolecules. Journal of Inorganic Biochemistry, 2015, 145, 41-50.	1.5	19

#	Article	IF	Citations
1545	Photoinduced interactions of two dirhodium complexes with d(GTCGAC)₂ probed by 2D NOESY. Dalton Transactions, 2015, 44, 3640-3646.	1.6	8
1546	Crystal structures and antimicrobial and cytotoxic activities of zinc(II), nickel(II) and copper(II) complexes of Nâ€(piperidylthiocarbonyl)benzamide. Applied Organometallic Chemistry, 2015, 29, 157-164.	1.7	13
1547	Necroptosis-Inducing Rhenium(V) Oxo Complexes. Journal of the American Chemical Society, 2015, 137, 2967-2974.	6.6	85
1548	Synthesis, crystal structures and characterization of late first row transition metal complexes derived from thiosemicarbazone hub: DNA binding/cleavage studies. Applied Organometallic Chemistry, 2015, 29, 280-289.	1.7	21
1549	Platinum (IV) coiled coil nanotubes selectively kill human glioblastoma cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 913-925.	1.7	17
1550	Reactivity of hexanuclear ruthenium metallaprisms towards nucleotides and a DNA decamer. Journal of Biological Inorganic Chemistry, 2015, 20, 49-59.	1.1	9
1551	Fluorometric imaging methods for palladium and platinum and the use of palladium for imaging biomolecules. Chemical Society Reviews, 2015, 44, 4769-4791.	18.7	92
1552	DNA Binding Properties of Water-Soluble Mixed Ligand Nickel(II) Complex with Calf-thymus DNA Using Different Instrumental Methods. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2015, 45, 1882-1888.	0.6	15
1553	Enhanced cancer cell killing of a Pt(iv) prodrug promoted by outer-sphere coordination with polyethyleneimines. Dalton Transactions, 2015, 44, 7135-7138.	1.6	5
1554	C 2 ,N-dimethylbenzylamine cyclopalladated compounds: evaluation of cytotoxic, mutagenic and antitubercular activities. Medicinal Chemistry Research, 2015, 24, 2879-2888.	1.1	11
1555	Combined chemotherapy and photodynamic therapy using a nanohybrid based on layered double hydroxides to conquer cisplatin resistance. Chemical Communications, 2015, 51, 11587-11590.	2.2	79
1556	Revealing Three Stages of DNA-Cisplatin Reaction by a Solid-State Nanopore. Scientific Reports, 2015, 5, 11868.	1.6	12
1557	Study on the interactions between anti-cancer drug oxaliplatin and DNA by atomic force microscopy. Micron, 2015, 76, 46-51.	1.1	8
1558	The reaction of a platinated methionine motif of CTR1 with cysteine and histidine is dependent upon the type of precursor platinum complex. Journal of Inorganic Biochemistry, 2015, 153, 239-246.	1.5	7
1559	Mass Spectrometric and Computational Investigation of the Protonated Carnosineâ€“Carboplatin Complex Fragmentation. Inorganic Chemistry, 2015, 54, 7885-7897.	1.9	5
1560	Radiosensitization of DNA by Cisplatin Adducts Results from an Increase in the Rate Constant for the Reaction with Hydrated Electrons and Formation of Pt^I. Journal of Physical Chemistry B, 2015, 119, 9496-9500.	1.2	17
1561	Evaluation of nanoparticle delivered cisplatin in beagles. Nanoscale, 2015, 7, 13822-13830.	2.8	35
1562	Mass spectrometry for the assessment of the occurrence and biological consequences of DNA adducts. Chemical Society Reviews, 2015, 44, 7829-7854.	18.7	114

#	Article	IF	Citations
1563	An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicology Letters, 2015, 237, 219-227.	0.4	353
1564	Adjusting the DNA Interaction and Anticancer Activity of Pt(II) N-Heterocyclic Carbene Complexes by Steric Shielding of the Trans Leaving Group. Journal of Medicinal Chemistry, 2015, 58, 6283-6292.	2.9	72
1565	Fluorescent mixed ligand copper(<scp>ii</scp>) complexes of anthracene-appended Schiff bases: studies on DNA binding, nuclease activity and cytotoxicity. Dalton Transactions, 2015, 44, 11997-12010.	1.6	69
1566	Five water-soluble zwitterionic copper(<scp>ii</scp>)-carboxylate polymers: role of dipyridyl coligands in enhancing the DNA-binding, cleaving and anticancer activities. Dalton Transactions, 2015, 44, 13369-13377.	1.6	26
1567	Synthesis, structure, DNA binding and cleavage activity of a new copper(II) complex of bispyridylpyrrolide. Journal of Central South University, 2015, 22, 1619-1625.	1.2	4
1568	Cisplatin-loaded polymeric nanoparticles: Characterization and potential exploitation for the treatment of non-small cell lung carcinoma. Acta Biomaterialia, 2015, 18, 68-76.	4.1	46
1569	A novel bioactive Cd(II) polymeric complex with mefenamic acid: Synthesis, crystal structure and biological evaluations. Inorganica Chimica Acta, 2015, 432, 176-184.	1.2	17
1570	Unusual Example of Chelate Ring Opening upon Coordination of the 9-Ethylguanine Nucleobase to [Pt(di-(6-methyl-2-picolyl)amine)Cl]Cl. Inorganic Chemistry, 2015, 54, 4895-4908.	1.9	11
1571	New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells. Biochemical Pharmacology, 2015, 95, 133-144.	2.0	78
1572	Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents. Journal of Biological Inorganic Chemistry, 2015, 20, 619-638.	1.1	36
1573	Polymeric Prodrugs Containing Metal-Based Anticancer Drugs. Journal of Inorganic and Organometallic Polymers and Materials, 2015, 25, 339-353.	1.9	9
1574	Single and double chain surfactantâ€“cobalt(<scp>iii</scp>) complexes: the impact of hydrophobicity on the interaction with calf thymus DNA, and their biological activities. RSC Advances, 2015, 5, 31746-31758.	1.7	46
1575	Synthesis and biological evaluation of copper(<scp>ii</scp>) pyrenethiosemicarbazone. RSC Advances, 2015, 5, 47476-47487.	1.7	19
1577	HMGB1 bound to cisplatinâ€“DNA adducts undergoes extensive acetylation and phosphorylation in vivo. Chemical Science, 2015, 6, 2074-2078.	3.7	26
1578	Insights into the structureâ€“activity relationships of chiral 1,2-diaminophenylalkane platinum(II) anticancer derivatives. Journal of Biological Inorganic Chemistry, 2015, 20, 841-853.	1.1	7
1579	Biologically active [Pd₂L₄]⁴⁺ quadruply-stranded helicates: stability and cytotoxicity. Dalton Transactions, 2015, 44, 11129-11136.	1.6	81
1580	Block Copolymer Nanostructures and Their Applications: A Review. Polymer-Plastics Technology and Engineering, 2015, 54, 1077-1095.	1.9	19
1581	Cytotoxicity in vitro, cell migration and apoptotic mechanism studies induced by ruthenium(<scp>ii</scp>) complexes. RSC Advances, 2015, 5, 24534-24543.	1.7	30

#	Article	IF	Citations
1582	Platinated oligomers of bovine pancreatic ribonuclease: Structure and stability. Journal of Inorganic Biochemistry, 2015, 146, 37-43.	1.5	24
1583	Mechanisms of chemotherapy-induced behavioral toxicities. Frontiers in Neuroscience, 2015, 9, 131.	1.4	133
1584	Unprecedented formation of organo-ruthenium(<scp>ii</scp>) complexes containing 2-hydroxy-1-naphthaldehyde S-benzyldithiocarbazate: synthesis, X-ray crystal structure, DFT study and their biological activities in vitro. Inorganic Chemistry Frontiers, 2015, 2, 620-639.	3.0	43
1585	Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes. European Journal of Pharmaceutical Sciences, 2015, 74, 95-102.	1.9	33
1586	Hydration of Two Cisplatin Aqua-Derivatives Studied by Quantum Mechanics and Molecular Dynamics Simulations. Journal of Chemical Theory and Computation, 2015, 11, 1735-1744.	2.3	28
1587	Modulating the Anticancer Activity of Ruthenium(II)â€“Arene Complexes. Journal of Medicinal Chemistry, 2015, 58, 3356-3365.	2.9	99
1588	Fluorescent sensing of monofunctional platinum species. Chemical Communications, 2015, 51, 6312-6314.	2.2	24
1589	Analysis of Platinum and Trace Metals in Treated Glioma Rat Cells by X-Ray Fluorescence Emission. Biological Trace Element Research, 2015, 163, 177-183.	1.9	10
1590	Synthesis, characterization, DNA/BSA interactions and anticancer activity of achiral and chiral copper complexes. Dalton Transactions, 2015, 44, 9516-9527.	1.6	47
1591	Coordination compounds in cancer: Past, present and perspectives. Journal of Applied Biomedicine, 2015, 13, 79-103.	0.6	113
1592	Homoleptic bisterpyridyl complexes: Synthesis, characterization, DNA binding, DNA cleavage and topoisomerase II inhibition activity. Inorganica Chimica Acta, 2015, 432, 71-80.	1.2	14
1593	Cisplatin binding to human serum albumin: a structural study. Chemical Communications, 2015, 51, 9436-9439.	2.2	115
1594	Pivotal Role of Nitric Oxide in Chemo and Immuno Sensitization of Resistant Tumor Cells to Apoptosis. , 2015, , 179-201.		0
1595	A dinuclear Ru(ii) complex capable of photoinduced ligand exchange at both metal centers. Chemical Communications, 2015, 51, 16522-16525.	2.2	10
1596	Empirical force field for cisplatin based on quantum dynamics data: case study of new parameterization scheme for coordination compounds. Journal of Molecular Modeling, 2015, 21, 268.	0.8	20
1597	Mixed copperâ€“platinum complex formation could explain synergistic antiproliferative effect exhibited by binary mixtures of cisplatin and copper-1,10-phenanthroline compounds: An ESIâ€“MS study. Journal of Inorganic Biochemistry, 2015, 151, 107-114.	1.5	23
1598	A Monofunctional Platinum Complex Coordinated to a Rhodium Metalloinsertor Selectively Binds Mismatched DNA in the Minor Groove. Inorganic Chemistry, 2015, 54, 9626-9636.	1.9	21
1599	Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells. Cell Death and Disease, 2015, 6, e1926-e1926.	2.7	10

#	Article	IF	Citations
1600	Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents. Journal of Biological Inorganic Chemistry, 2015, 20, 1263-1275.	1.1	16
1601	Azide vs Alkyne Functionalization in Pt(II) Complexes for Post-treatment Click Modification: Solid-State Structure, Fluorescent Labeling, and Cellular Fate. Journal of the American Chemical Society, 2015, 137, 15169-15175.	6.6	46
1602	Reduced toxicological manifestations of cisplatin following encapsulation in folate grafted albumin nanoparticles. Life Sciences, 2015, 142, 76-85.	2.0	19
1603	Nuclease activity and interaction studies of unsymmetrical binuclear Ni(ii) complexes with CT-DNA and BSA. Dalton Transactions, 2015, 44, 16361-16371.	1.6	26
1604	Repair of UV induced DNA lesions in ribosomal gene chromatin and the role of â€œOddâ€•RNA polymerases (I and III). DNA Repair, 2015, 36, 49-58.	1.3	9
1605	Synthesis, characterization and biological activity of platinum(II) complexes with a tetrapyrazole ligand. Polyhedron, 2015, 102, 321-328.	1.0	10
1606	12 Binding of Kinetically Inert Metal Ions to RNA: The Case of Platinum(II). , 2015, , 347-378.		0
1607	Computational study on mechanisms of the anticancer drug: Cisplatin and novel polynuclear platinum(II) interaction with sulfur-donor biomolecules and DNA purine bases. Computational and Theoretical Chemistry, 2015, 1074, 36-49.	1.1	9
1608	An Integrated Approach for Analysis of the DNA Damage Response in Mammalian Cells. Journal of Biological Chemistry, 2015, 290, 28812-28821.	1.6	31
1609	A Study on Spectro-Analytical Aspects, DNA â€“ Interaction, Photo-Cleavage, Radical Scavenging, Cytotoxic Activities, Antibacterial and Docking Properties of 3 â€“ (1 â€“ (6 â€“ methoxybenzo [d] thiazol â€“ 2) Tj ETQq1 1 0.78431 Fluorescence. 2015, 25, 1279-1296.	1.3	12
1610	Incorporation of cisplatin into the metalâ€“organic frameworks UiO66-NH₂ and UiO66 â€“ encapsulation vs. conjugation. RSC Advances, 2015, 5, 83648-83656.	1.7	62
1611	Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes. Experimental and Molecular Medicine, 2015, 47, e142-e142.	3.2	44
1612	Mono- and di-bromo platinum(iv) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity. Dalton Transactions, 2015, 44, 19918-19926.	1.6	24
1613	Luminescent europium and terbium complexes of dipyridoquinoxaline and dipyridophenazine ligands as photosensitizing antennae: structures and biological perspectives. Dalton Transactions, 2015, 44, 19844-19855.	1.6	53
1614	Design, synthesis and DNA interactions of a chimera between a platinum complex and an IHF mimicking peptide. Organic and Biomolecular Chemistry, 2015, 13, 11704-11713.	1.5	2
1615	Synthesis, spectroscopic, DFT, cytotoxicity and antimicrobial activity of Pd(II) and Pt(II) complexes of N,N-chelated benzimidazole derivatives. Inorganica Chimica Acta, 2015, 438, 76-84.	1.2	21
1616	Visualization of the spatial distribution of Pt+ ions in cisplatin-treated glioblastoma cells by time-of-flight secondary ion mass spectrometry. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2015, 9, 202-209.	0.3	11
1617	Photoactivatable platinum(II) compounds: in search of novel anticancer drugs. Theoretical Chemistry Accounts, 2015, 134, 1.	0.5	6

#	Article	IF	Citations
1618	Effects of antitumor derivatives of ineffective transplatin on bacterial cells: Is DNA a pharmacological target?. Journal of Inorganic Biochemistry, 2015, 153, 206-210.	1.5	9
1619	Synthesis, Structure, and Biological Activities of a New Î¼â€Oxamidoâ€Bridged Dicopper(II) Complex: The Influence of Hydrophobicity of Bridging Ligand on DNA Binding and Cytotoxic Activities. Journal of Biochemical and Molecular Toxicology, 2015, 29, 77-90.	1.4	1
1620	Fluorinated Fe(III) Salophene Complexes: Optimization of Tumor Cell Specific Activity and Utilization of Fluorine Labeling for in Vitro Analysis. Journal of Medicinal Chemistry, 2015, 58, 588-597.	2.9	24
1621	Stereospecific ligands and their complexes. XXII. Synthesis and antitumor activity of palladium(II) complexes with some esters of (S,S)-ethylenediamine-N,Nâ€²-di-(2,2â€²-di(4-hydroxy-benzyl))-acetic acid. Journal of Inorganic Biochemistry, 2015, 143, 111-116.	1.5	12
1622	InÂvitro anticancer activity of gold(III) complexes with some esters of (S,S)-ethylenediamine-N,Nâ€²-di-2-propanoic acid. European Journal of Medicinal Chemistry, 2015, 90, 766-774.	2.6	30
1623	An Alkyneâ€Appended, Clickâ€Ready Pt^{II} Complex with an Unusual Arrangement in the Solid State. Angewandte Chemie - International Edition, 2015, 54, 1032-1035.	7.2	11
1624	Synthesis and spectroscopic characterizations of noble metal complexes (gold, silver, platinum) in the presence of selenium, and their biological applications as antibacterial, antifungal, and anticancer. Research on Chemical Intermediates, 2015, 41, 965-1000.	1.3	7
1625	Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy. Coordination Chemistry Reviews, 2015, 282-283, 110-126.	9.5	342
1626	Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential. Dalton Transactions, 2015, 44, 659-668.	1.6	57
1627	(1-Methyl-2-(thiophen-2-yl)-1H-benzo[d]imidazole) and its three copper complexes: Synthesis, characterization and fluorescence properties. Journal of Molecular Structure, 2015, 1081, 304-310.	1.8	7
1628	Stress Response Pathways in Cancer. , 2015, , .		3
1629	Chemistry of 1,2,3-triazoles. Topics in Heterocyclic Chemistry, 2015, , .	0.2	32
1630	Metal complex interactions with DNA. Dalton Transactions, 2015, 44, 3505-3526.	1.6	314
1631	DNA-binding, topoisomerases I and II inhibition and in vitro cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)2L]2+ (L = dppz-11-CO2Me and dppz). Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2015, 135, 101-109.	2.0	29
1632	Effect of chirality in platinum drugs. Coordination Chemistry Reviews, 2015, 284, 286-297.	9.5	50
1633	Mixed-ligand copper(II) phenolate complexes: Synthesis, spectral characterization, phosphate-hydrolysis, antioxidant, DNA interaction and cytotoxic studies. Journal of Molecular Structure, 2015, 1080, 88-98.	1.8	33
1634	Synthesis, crystal structure and antitumor effect of a novel copper(II) complex bearing zoledronic acid derivative. European Journal of Medicinal Chemistry, 2015, 89, 42-50.	2.6	30
1635	Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation. Drug Development and Industrial Pharmacy, 2015, 41, 232-238.	0.9	51

#	Article	IF	Citations
1636	Design, synthesis and SAR studies of novel 1,2-bis(aminomethyl)cyclohexane platinum(II) complexes with cytotoxic activity. Studies of interaction with DNA of iodinated seven-membered 1,4-diaminoplatinocycles. Journal of Inorganic Biochemistry, 2015, 142, 15-27.	1.5	14
1637	SPECTRAL CHARACTERIZATION AND BIOCIDAL STUDIES OF 2, 2, 6, 6 -TETRAMETHYLPIPERIDIN-4-ONE AND THEIR PALLADIUM (II) COMPLEX. International Research Journal of Pharmacy, 2016, 7, 4-8.	0.0	0
1638	Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro. Genetics and Molecular Biology, 2016, 39, 129-134.	0.6	32
1639	Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 465-489.	0.9	165
1640	Protective Effects of Laminarin on Cisplatin-induced Ototoxicity in HEIOC1 Auditory Cells. Journal of Nutrition & Food Sciences, 2016, 6, .	1.0	2
1641	High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-17.	1.9	29
1642	Overexpression ofÎ²-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma. BioMed Research International, 2016, 2016, 1-11.	0.9	41
1643	New Look on 3-Hydroxyiminoflavanone and Its Palladium(II) Complex: Crystallographic and Spectroscopic Studies, Theoretical Calculations and Cytotoxic Activity. Molecules, 2016, 21, 455.	1.7	4
1644	Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS ONE, 2016, 11, e0146256.	1.1	13
1645	Half-Sandwich Ru(II) Halogenido, Valproato and 4-Phenylbutyrato Complexes Containing 2,2â€²-Dipyridylamine: Synthesis, Characterization, Solution Chemistry and In Vitro Cytotoxicity. Molecules, 2016, 21, 1725.	1.7	11
1646	Nanoparticle-mediated delivery of multinuclear platinum(IV) prodrugs with enhanced drug uptake and the activity of overcoming drug resistance. Anti-Cancer Drugs, 2016, 27, 77-83.	0.7	7
1647	A comparative study of the effectiveness of cisplatin and 5-fluorouracil on cutaneous squamous human carcinoma cell line: Potential chemotherapy alternative to surgery. Dermatologic Therapy, 2016, 29, 341-344.	0.8	6
1648	A Selective Na⁺ Aptamer Dissected by Sensitized Tb³⁺ Luminescence. ChemBioChem, 2016, 17, 1563-1570.	1.3	26
1649	Synergistic Effects of Metals in a Promising Ru^{II}â”Pt^{II} Assembly for a Combined Anticancer Approach: Theoretical Exploration of the Photophysical Properties. Chemistry - A European Journal, 2016, 22, 9162-9168.	1.7	34
1650	Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. Biochemical Pharmacology, 2016, 116, 22-38.	2.0	33
1651	Anticancer potential of a photoactivated transplatin derivative containing the methylazaindole ligand mediated by ROS generation and DNA cleavage. Dalton Transactions, 2016, 45, 13179-13186.	1.6	14
1652	Unique Use of Alkylation for Chemoâ€Redox Activity by a Pt^{IV} Prodrug. Chemistry - A European Journal, 2016, 22, 3029-3036.	1.7	24
1653	Fluorescence turnâ€on chemical sensor based on waterâ€soluble conjugated polymer/singleâ€walled carbon nanotube composite. Journal of Applied Polymer Science, 2016, 133, .	1.3	3

#	Article	IF	Citations
1654	Anticancer activity studies of ruthenium(II) polypyridyl complexes against human gastric carcinoma SGC-7901 cell. Inorganic Chemistry Communication, 2016, 70, 210-218.	1.8	8
1655	Glycosylated platinum(<scp>iv</scp>) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects. Dalton Transactions, 2016, 45, 11830-11838.	1.6	40
1657	Poly-carboxylic acids functionalized chitosan nanocarriers for controlled and targeted anti-cancer drug delivery. Biomedicine and Pharmacotherapy, 2016, 83, 201-211.	2.5	41
1658	An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance. Dalton Transactions, 2016, 45, 13052-13060.	1.6	58
1659	Internalization of Ineffective Platinum Complex in Nanocapsules Renders It Cytotoxic. Chemistry - A European Journal, 2016, 22, 2728-2735.	1.7	13
1660	Nucleotide Binding Preference of the Monofunctional Platinum Anticancer-Agent Phenanthriplatin. Chemistry - A European Journal, 2016, 22, 7574-7581.	1.7	33
1661	Thermodynamics of DNA: sensitizer recognition. Characterizing binding motifs with all-atom simulations. Physical Chemistry Chemical Physics, 2016, 18, 33180-33186.	1.3	10
1662	Evaluation of multidrug cancer chronotherapy based on cell cycle model under influences of circadian clock. , 2016, 2016, 1439-1442.		2
1663	Flap endonuclease 1 silencing is associated with increasing the cisplatin sensitivity of SGC-7901 gastric cancer cells. Molecular Medicine Reports, 2016, 13, 386-392.	1.1	16
1664	Chromatin folding and DNA replication inhibition mediated by a highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex. Scientific Reports, 2016, 6, 24712.	1.6	20
1665	Four Cu(<scp>ii</scp>) complexes based on antitumor chelators: synthesis, structure, DNA binding/damage, HSA interaction and enhanced cytotoxicity. Dalton Transactions, 2016, 45, 8036-8049.	1.6	44
1666	Synthesis of novel anticancer rutheniumâ€“arene pyridinylmethylene scaffolds via three-component reaction. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2695-2700.	1.0	24
1667	Specific interaction of platinated DNA and proteins by surface plasmon resonance imaging. RSC Advances, 2016, 6, 21900-21906.	1.7	10
1668	New trans dichloro (triphenylphosphine)platinum(II) complexes containing N -(butyl), N -(arylmethyl)amino ligands: Synthesis, cytotoxicity and mechanism of action. Bioorganic and Medicinal Chemistry, 2016, 24, 2929-2937.	1.4	19
1669	Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. Cancer Treatment Reviews, 2016, 48, 8-19.	3.4	26
1670	Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements. Biophysical Journal, 2016, 110, 2151-2161.	0.2	20
1671	More of a misunderstanding than a real mismatch? Platinum and its affinity for aqua, hydroxido, and oxido ligands. Coordination Chemistry Reviews, 2016, 327-328, 333-348.	9.5	38
1672	Structural Basis for the Structureâ€“Activity Behaviour of Oxaliplatin and its Enantiomeric Analogues: A Molecular Dynamics Study of Platinum-DNA Intrastrand Crosslink Adducts. Australian Journal of Chemistry, 2016, 69, 379.	0.5	2

#	Article	IF	Citations
1673	The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair. Cell Death and Differentiation, 2016, 23, 1198-1208.	5.0	62
1674	Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes. European Journal of Medicinal Chemistry, 2016, 114, 141-152.	2.6	15
1675	Graphene quantum dots enhance anticancer activity of cisplatin via increasing its cellular and nuclear uptake. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1997-2006.	1.7	71
1676	Activation and Reactivity of a Bispidine Analogue of Cisplatin: A Theoretical Investigation. Journal of Physical Chemistry A, 2016, 120, 5175-5186.	1.1	20
1677	A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene, 2016, 35, 5916-5927.	2.6	52
1678	Baseâ€Resolution Analysis of Cisplatinâ€“DNA Adducts at the Genome Scale. Angewandte Chemie - International Edition, 2016, 55, 14246-14249.	7.2	64
1679	Folic acid enhances the apoptotic and genotoxic activity of carboplatin in HeLa cell line. Toxicology in Vitro, 2016, 37, 142-147.	1.1	3
1680	Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11507-11512.	3.3	149
1681	Development of controlled-release cisplatin dry powders for inhalation against lung cancers. International Journal of Pharmaceutics, 2016, 515, 209-220.	2.6	46
1682	The Relationship Between Checkpoint Adaptation and Mitotic Catastrophe in Genomic Changes in Cancer Cells. , 2016, , 373-389.		8
1683	Selective speciation improves efficacy and lowers toxicity of platinum anticancer and vanadium antidiabetic drugs. Journal of Inorganic Biochemistry, 2016, 165, 56-70.	1.5	69
1684	Development of a controlled-release drug delivery system by encapsulating oxaliplatin into SPIO/MWNT nanoparticles for effective colon cancer therapy and magnetic resonance imaging. Biomaterials Science, 2016, 4, 1742-1753.	2.6	31
1686	Half-sandwich iridium^{III} complexes with pyrazole-substituted heterocyclic frameworks and their biological applications. New Journal of Chemistry, 2016, 40, 9968-9980.	1.4	16
1687	MiR-182-5p protects inner ear hair cells from cisplatin-induced apoptosis by inhibiting FOXO3a. Cell Death and Disease, 2016, 7, e2362-e2362.	2.7	36
1688	Cr³⁺ Binding to DNA Backbone Phosphate and Bases: Slow Ligand Exchange Rates and Metal Hydrolysis. Inorganic Chemistry, 2016, 55, 8193-8200.	1.9	29
1689	Î±â^'Nâ^'heterocyclic thiosemicarbazone Fe(III) complex: Characterization of its antitumor activity and identification of anticancer mechanism. European Journal of Medicinal Chemistry, 2016, 123, 354-364.	2.6	67
1690	Substitution reactions of [Pd(bipy)(malonate)] explored with a different set of ligands: Kinetic and mechanistic interpretation in aqueous medium and at pH 7.4. Journal of Chemical Sciences, 2016, 128, 1327-1335.	0.7	1
1691	Triphenylphosphane Pt(II) complexes containing biologically active natural polyphenols: Synthesis, crystal structure, molecular modeling and cytotoxic studies. Journal of Inorganic Biochemistry, 2016, 163, 346-361.	1.5	24

#	Article	IF	Citations
1692	Platinum(<scp>ii</scp>) O,S complexes as potential metallodrugs against Cisplatin resistance. Dalton Transactions, 2016, 45, 18876-18891.	1.6	15
1693	Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies. ChemMedChem, 2016, 11, 1199-1210.	1.6	104
1694	A Ruthenium(II) Polypyridyl Nucleoside as a Potential Photodynamic Therapy Agent. ChemistrySelect, 2016, 1, 793-797.	0.7	2
1695	CpG methylation increases the DNA binding of 9-aminoacridine carboxamide Pt analogues. Bioorganic and Medicinal Chemistry, 2016, 24, 4701-4710.	1.4	8
1696	Mass spectrometry based strategy for studies of binding sites and structural changes of cisplatin binding to myoglobin. Rapid Communications in Mass Spectrometry, 2016, 30, 2433-2441.	0.7	2
1697	Hydrogen Evolution Facilitates Reduction of DNA Guanine Residues at the Hanging Mercury Drop Electrode: Evidence for a Chemical Mechanism. Electroanalysis, 2016, 28, 2785-2790.	1.5	13
1698	Cisplatinâ€"Protein Interactions: Unexpected Drug Binding to N-Terminal Amine and Lysine Side Chains. Inorganic Chemistry, 2016, 55, 7814-7816.	1.9	26
1699	High stability and biological activity of the copper(II) complexes of alloferon 1 analogues containing tryptophan. Journal of Inorganic Biochemistry, 2016, 163, 147-161.	1.5	12
1700	Anti-tumor activity and mechanism of apoptosis of A549 induced by ruthenium complex. Journal of Biological Inorganic Chemistry, 2016, 21, 945-956.	1.1	14
1701	Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity. Journal of the American Chemical Society, 2016, 138, 12494-12501.	6.6	44
1702	Synthesis of silver(I) p-substituted phenyl diphenyl phosphine complexes with the evaluation of the toxicity on a SNO cancer cell line. Inorganica Chimica Acta, 2016, 453, 443-451.	1.2	10
1703	Structural study on the interactions of oxaliplatin and linear DNA. Scanning, 2016, 38, 880-888.	0.7	3
1704	Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position. Scientific Reports, 2016, 6, 29367.	1.6	56
1705	Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells. Scientific Reports, 2016, 6, 19449.	1.6	93
1706	Amberlite IR-120(H)-mediated â€œon waterâ€•synthesis of novel anticancer ruthenium(<scp>ii</scp>)â€"p-cymene 2-pyridinylbenzothiazole (BTZ), 2-pyridinylbenzoxazole (BOZ) & 2-pyridinylbenzimidazole (BIZ) scaffolds. New Journal of Chemistry, 2016, 40, 10333-10343.	1.4	24
1707	â€œHead-to-headâ€•double-hamburger-like structure of di-ruthenated d(GpG) adducts of mono-functional Ruâ€"arene anticancer complexes. Dalton Transactions, 2016, 45, 18676-18688.	1.6	8
1708	Influence of Water in the Photogeneration and Properties of a Bifunctional Quinone Methide. Journal of Physical Chemistry B, 2016, 120, 11132-11141.	1.2	8
1709	Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes. Scientific Reports, 2016, 6, 28474.	1.6	5

#	Article	IF	Citations
1710	Baseâ€Resolution Analysis of Cisplatinâ€“DNA Adducts at the Genome Scale. Angewandte Chemie, 2016, 128, 14458-14461.	1.6	14
1711	Exploration of biological activities of alkyne arms containing Cu(<scp>ii</scp>) and Ni(<scp>ii</scp>) complexes: syntheses, crystal structures and DFT calculations. RSC Advances, 2016, 6, 102482-102497.	1.7	13
1712	Molecular dynamics simulation and free energy analysis of the interaction of platinum-based anti-cancer drugs with DNA. Journal of Theoretical and Computational Chemistry, 2016, 15, 1650054.	1.8	2
1713	Amphiphilic Cyanineâ€“Platinum Conjugates as Fluorescent Nanodrugs. Chemistry - an Asian Journal, 2016, 11, 221-225.	1.7	15
1714	Investigation of the potential antitumor radioactive complex of platinum(II) with tetracycline. Journal of Radioanalytical and Nuclear Chemistry, 2016, 309, 85-89.	0.7	3
1715	Effective DNA binding and cleaving tendencies of malonic acid coupled transition metal complexes. Journal of Molecular Structure, 2016, 1123, 162-170.	1.8	21
1716	Synthesis, characterization and anticancer activity studies of ruthenium(II) polypyridyl complexes on A549 cells. Journal of Photochemistry and Photobiology B: Biology, 2016, 161, 295-303.	1.7	17
1717	Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes. BMC Cancer, 2016, 16, 333.	1.1	6
1718	Synthesis, characterization and biological evaluation of labile intercalative ruthenium(<scp>ii</scp>) complexes for anticancer drug screening. Dalton Transactions, 2016, 45, 13135-13145.	1.6	42
1719	Anticancer activity assessment of two novel binuclear platinum (II) complexes. Journal of Photochemistry and Photobiology B: Biology, 2016, 161, 345-354.	1.7	27
1720	A theoretical investigation on hydrolysis mechanism of biologically relevant Pt(II)/Pd(II) complexes with Ïƒ-donor and Ï€-acceptor carrier ligand. Chemical Physics Letters, 2016, 657, 148-155.	1.2	4
1721	Metal-ion nucleic-acid interactions: A personal account. Inorganica Chimica Acta, 2016, 452, 268-272.	1.2	11
1722	Kiteplatin: Differential binding between GSH and GMP. Inorganica Chimica Acta, 2016, 452, 130-136.	1.2	3
1723	Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents andÂCanines. Journal of Pharmaceutical Sciences, 2016, 105, 1891-1900.	1.6	7
1724	Photoactivation of Diiodidoâ€“Pt(IV) Complexes Coupled to Upconverting Nanoparticles. Molecular Pharmaceutics, 2016, 13, 2346-2362.	2.3	29
1725	Oxaliplatin Binding to Human Copper Chaperone Atox1 and Protein Dimerization. Inorganic Chemistry, 2016, 55, 6563-6573.	1.9	17
1726	Platinum(<scp>iv</scp>) N-heterocyclic carbene complexes: their synthesis, characterisation and cytotoxic activity. Dalton Transactions, 2016, 45, 11362-11368.	1.6	19
1727	[Pt(O,Oâ€²-acac)(Î³-acac)(DMS)] versus cisplatin: apoptotic effects in B50 neuroblastoma cells. Histochemistry and Cell Biology, 2016, 145, 587-601.	0.8	7

#	Article	IF	Citations
1728	Two-photon-absorption DNA sensitization via solvated electron production: unraveling photochemical pathways by molecular modeling and simulation. Physical Chemistry Chemical Physics, 2016, 18, 18598-18606.	1.3	20
1729	Parallel folding topology-selective label-free detection and monitoring of conformational and topological changes of different G-quadruplex DNAs by emission spectral changes via FRET of mPPE-Alaâ€“Pt(<scp>ii</scp>) complex ensemble. Chemical Science, 2016, 7, 2842-2855.	3.7	25
1730	Nanostructured materials functionalized with metal complexes: In search of alternatives for administering anticancer metallodrugs. Coordination Chemistry Reviews, 2016, 312, 67-98.	9.5	183
1731	Furan oxidation based cross-linking: a new approach for the study and targeting of nucleic acid and protein interactions. Chemical Communications, 2016, 52, 1539-1554.	2.2	43
1733	Cytotoxicity of electrophilic iron(II)â€“clathrochelates in human promyelocytic leukemia cell line. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 626-629.	1.0	23
1734	The deleterious effect of pyrollic-nitrogen on the substitution reactivity of tridentate N^C^N platinum(II) complexes. A kinetic and mechanistic study. Journal of Coordination Chemistry, 2016, 69, 389-403.	0.8	9
1735	Multifunctional Pt(II) Reagents: Covalent Modifications of Pt Complexes Enable Diverse Structural Variation and In-Cell Detection. Accounts of Chemical Research, 2016, 49, 56-66.	7.6	34
1736	Palladiumâ€“benzodiazepine derivatives as promising metallodrugs for the development of antiepileptic therapies. Journal of Inorganic Biochemistry, 2016, 155, 129-135.	1.5	6
1737	Cisplatin binding to proteins: A structural perspective. Coordination Chemistry Reviews, 2016, 315, 67-89.	9.5	126
1738	Rational design of dinuclear complexes binding at two neighboring phosphate esters of DNA. Inorganica Chimica Acta, 2016, 452, 62-72.	1.2	15
1739	DNA studies of newly synthesized heteroleptic platinum(II) complexes [Pt(bpy)(iip)]2+ and [Pt(bpy)(miip)]2+. Journal of Biological Inorganic Chemistry, 2016, 21, 163-175.	1.1	16
1740	Platinum(<scp>iv</scp>) prodrug conjugated Pd@Au nanoplates for chemotherapy and photothermal therapy. Nanoscale, 2016, 8, 5706-5713.	2.8	61
1741	Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA = 1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties. Journal of Inorganic Biochemistry, 2016, 160, 180-188.	1.5	23
1742	Synthesis of cis-[Cr(diimine)2(1-methylimidazole)2]3+ Complexes and an Investigation of Their Interaction with Mononucleotides and Polynucleotides. Inorganic Chemistry, 2016, 55, 1516-1526.	1.9	10
1743	The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chemical Reviews, 2016, 116, 3436-3486.	23.0	1,895
1744	Palladium complexes: new candidates for anti-cancer drugs. Journal of the Iranian Chemical Society, 2016, 13, 967-989.	1.2	60
1745	Syntheses, structures and biological activities of square planar Ni(II), Cu(II) complexes. Polyhedron, 2016, 107, 183-189.	1.0	47
1746	An upconversion nanoparticle/Ru(<scp>ii</scp>) polypyridyl complex assembly for NIR-activated release of a DNA covalent-binding agent. RSC Advances, 2016, 6, 23804-23808.	1.7	19

#	Article	IF	Citations
1747	Copper complexes based on chiral Schiff-base ligands: DNA/BSA binding ability, DNA cleavage activity, cytotoxicity and mechanism of apoptosis. European Journal of Medicinal Chemistry, 2016, 114, 244-256.	2.6	79
1748	Elucidating the reactivity of Pt(II) complexes with (O,S) bidentate ligands towards DNA model systems. Journal of Inorganic Biochemistry, 2016, 160, 198-209.	1.5	15
1749	Antiproliferative activity of cationic and neutral thiosemicarbazone copper(<scp>ii</scp>) complexes. RSC Advances, 2016, 6, 25082-25093.	1.7	70
1750	Targeting DNA mismatches with rhodium metalloinsertors. Inorganica Chimica Acta, 2016, 452, 3-11.	1.2	33
1751	Synthesis, characterization, DNA binding, cleavage activity, cytotoxicity and molecular docking of new nano water-soluble [M(5-CH₂PPh₃-3,4-salpyr)](ClO₄)₂(M = Ni, Zn) complexes. Dalton Transactions, 2016, 45, 6592-6611.	1.6	81
1752	Sexual differentiation and reproductive development of female rat offspring after paternal exposure to the anti-tumor pharmaceutical cisplatin. Reproductive Toxicology, 2016, 60, 112-122.	1.3	11
1753	Mass spectrometric studies on the interaction of cisplatin and insulin. Amino Acids, 2016, 48, 1033-1043.	1.2	11
1754	Substituent effect and wavelength dependence of the photoinduced Ruâ€“O homolysis in the [Ru(bpy)2(py-SO3)]+-type complexes. Dalton Transactions, 2016, 45, 2897-2905.	1.6	15
1755	Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases. Advances in Experimental Medicine and Biology, 2016, 893, 211-224.	0.8	7
1756	Rhodium complexes as therapeutic agents. Dalton Transactions, 2016, 45, 2762-2771.	1.6	41
1757	Anti-apoptotic and anti-inflammatory effects of naringin on cisplatin-induced renal injury in the rat. Chemico-Biological Interactions, 2016, 243, 1-9.	1.7	80
1758	miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance. Expert Review of Anticancer Therapy, 2016, 16, 57-70.	1.1	40
1759	High-affinity sequence-selective DNA binding by iridium(<scp>iii</scp>) polypyridyl organometallopeptides. Chemical Communications, 2016, 52, 1234-1237.	2.2	20
1760	Coordination chemistry of thiazoles, isothiazoles and thiadiazoles. Coordination Chemistry Reviews, 2016, 308, 32-55.	9.5	113
1761	Cationic Ru(II), Rh(III) and Ir(III) complexes containing cyclic -perimeter and 2-aminophenyl benzimidazole ligands: Synthesis, molecular structure, DNA and protein binding, cytotoxicity and anticancer activity. Journal of Organometallic Chemistry, 2016, 801, 68-79.	0.8	60
1762	Synthesis, characterization, X-ray structural determination and theoretical study of the complexes [RuCp(8MTT-ÎºS)LLâ€²] (8MTT=8-methylthio-theophyllinate; L,Lâ€²=PTA, mPTA; L=mPTA, Lâ€²=PPh3;) Tj ETQq1 1 0.784314 rgBT /Ov Chimica Acta, 2017, 455, 557-567.	1.2	3
1763	Synthesis, characterisation and dynamic behavior of photoactive bipyridyl ruthenium(II)-nicotinamide complexes. Inorganica Chimica Acta, 2017, 454, 240-246.	1.2	6
1764	Rutin ameliorates cisplatin-induced reproductive damage via suppression of oxidative stress and apoptosis in adult male rats. Andrologia, 2017, 49, e12593.	1.0	89

#	Article	IF	Citations
1765	Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 950-955.	3.3	44
1766	Synthesis, Characterization, Speciation, DNA Cleavage, and Cytotoxic Studies of the Pd[2â€(2â€Aminoethyl)â€1â€methylpyrrolidine]Cl₂ Complex with Reference to Carboplatin. European Journal of Inorganic Chemistry, 2017, 2017, 1877-1887.	1.0	9
1767	Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs. Non-coding RNA Research, 2017, 2, 1-17.	2.4	15
1768	The natural flavonoid apigenin sensitizes human CD44 + prostate cancer stem cells to cisplatin therapy. Biomedicine and Pharmacotherapy, 2017, 88, 210-217.	2.5	81
1769	A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War Against Cancer. Molecular Cancer Therapeutics, 2017, 16, 625-636.	1.9	47
1770	A platinum blue complex exerts its cytotoxic activity via DNA damage and induces apoptosis in cancer cells. Chemical Biology and Drug Design, 2017, 90, 210-224.	1.5	3
1771	Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. Radiation Research, 2017, 187, 147-160.	0.7	44
1772	Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines. BMC Cancer, 2017, 17, 49.	1.1	19
1773	Binding interactions of mixed ligand copper(II) amino acid Schiff base complexes with biological targets: Spectroscopic evaluation and molecular docking. Applied Organometallic Chemistry, 2017, 31, e3713.	1.7	35
1774	Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: Syntheses, characterization, and in vitro cytotoxicity studies. Inorganic Chemistry Communication, 2017, 78, 17-20.	1.8	5
1775	Green engineered biomolecule-capped silver and copper nanohybrids using Prosopis cineraria leaf extract: Enhanced antibacterial activity against microbial pathogens of public health relevance and cytotoxicity on human breast cancer cells (MCF-7). Microbial Pathogenesis, 2017, 105, 86-95.	1.3	77
1776	Cyclometalated Platinum(II) Complexes Comprising 2â€(Diphenylphosphino)pyridine and Various Thiolate Ligands: Synthesis, Spectroscopic Characterization, and Biological Activity. European Journal of Inorganic Chemistry, 2017, 2017, 2247-2254.	1.0	33
1777	Synthesis, structure and DNA interaction studies of bisphosphoramides: Theoretical and experimental insights. Inorganica Chimica Acta, 2017, 461, 84-91.	1.2	8
1778	New palladium(II) formamidine complexes: Preparation, characterization, theoretical calculations and cytotoxic activity. Journal of Molecular Structure, 2017, 1137, 453-460.	1.8	4
1779	Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery. ACS Applied Materials & Interfaces, 2017, 9, 9426-9436.	4.0	131
1780	Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. Journal of the American Chemical Society, 2017, 139, 3033-3044.	6.6	74
1781	Synthesis, characterization and in vitro cytotoxicity of platinum(II) complexes of selenones [Pt(selenone)₂Cl₂]. Journal of Coordination Chemistry, 2017, 70, 1020-1031.	0.8	12
1782	Near infrared BODIPY-Platinum conjugates for imaging, photodynamic therapy and chemotherapy. Dyes and Pigments, 2017, 141, 5-12.	2.0	40

#	Article	IF	Citations
1783	DNAâ€Targeted Inhibition of MGMT. ChemBioChem, 2017, 18, 894-898.	1.3	5
1784	Synthesis, Biological Evaluation, and Molecular Docking Studies on the DNA Binding Interactions of Platinum(II) Rollover Complexes Containing Phosphorus Donor Ligands. ChemMedChem, 2017, 12, 456-465.	1.6	34
1785	Study on electronic properties, thermodynamic and kinetic parameters of the selected platinum(II) derivatives interacting with guanine. Journal of Inorganic Biochemistry, 2017, 172, 100-109.	1.5	9
1786	Cisplatin Analogs Confer Protection against Cyanide Poisoning. Cell Chemical Biology, 2017, 24, 565-575.e4.	2.5	17
1787	Hydrolysis mechanism of (N, N) chelated cytotoxic Pt/Pd(II)-dichloro complexes: A theoretical approach. Chemical Physics Letters, 2017, 678, 241-249.	1.2	5
1788	Novel mononuclear Cu (II) terpyridine complexes: Impact of fused ringÂthiophene and thiazole head groups towards DNA/BSA interaction,Âcleavage and antiproliferative activity on HepG2 andÂtripleÂnegative CAL-51Âcell line. European Journal of Medicinal Chemistry, 2017, 135, 434-446.	2.6	48
1789	Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes. Journal of Inorganic Biochemistry, 2017, 173, 126-133.	1.5	22
1790	Specific Interactions of Antitumor Metallocenes with Deoxydinucleoside Monophosphates. Journal of the American Society for Mass Spectrometry, 2017, 28, 1901-1909.	1.2	5
1791	A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin. Journal of Inorganic Biochemistry, 2017, 173, 105-112.	1.5	15
1792	Cytotoxic platinum coordination compounds. DNA binding agents. Coordination Chemistry Reviews, 2017, 351, 2-31.	9.5	137
1793	Synthesis, Characterization, and Time-Dependent NMR Spectroscopy Studies of (SP-4-2)-[(trans-1R,2R/1S,2S-15N2)-Cyclohexane-1,2-diamine][(13C2)oxalato]platinum(II). European Journal of Inorganic Chemistry, 2017, 2017, 2347-2354.	1.0	6
1794	Synergistic effects of a novel lipid-soluble extract from Pinellia pedatisecta Schott and cisplatin on human cervical carcinoma cell lines through the regulation of DNA damage response signaling pathway. Oncology Letters, 2017, 13, 2121-2128.	0.8	11
1795	High BIM mRNA levels are associated with longer survival in advanced gastric cancer. Oncology Letters, 2017, 13, 1826-1834.	0.8	10
1796	Ruthenium(II/III) complexes of redox non-innocent bis(thiosemicarbazone) ligands: Synthesis, X-ray crystal structures, electrochemical, DNA binding and DFT studies. Polyhedron, 2017, 131, 74-85.	1.0	18
1797	Deciphering of interactions between platinated DNA and HMGB1 by hydrogen/deuterium exchange mass spectrometry. Dalton Transactions, 2017, 46, 6187-6195.	1.6	3
1798	Quantitative Examination of the Active Targeting Effect: The Key Factor for Maximal Tumor Accumulation and Retention of Short-Circulated Biopolymeric Nanocarriers. Bioconjugate Chemistry, 2017, 28, 1351-1355.	1.8	8
1799	Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radical Biology and Medicine, 2017, 102, 274-286.	1.3	110
1800	A micellar cisplatin prodrug simultaneously eliminates both cancer cells and cancer stem cells in lung cancer. Biomaterials Science, 2017, 5, 1612-1621.	2.6	24

#	Article	IF	Citations
1801	The Exploitation of Low-Energy Electrons in Cancer Treatment. Radiation Research, 2017, 188, 123-143.	0.7	42
1802	TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/Î²-catenin signaling pathway and promoting the epithelial mesenchymal transition. Cancer Letters, 2017, 402, 117-130.	3.2	42
1803	Enhanced anti-cancer efficacy to cancer cells by a novel monofunctional mononuclear platinum(ii) complex containing a mixed S,N,S-donor ligand. New Journal of Chemistry, 2017, 41, 6760-6768.	1.4	8
1804	Metal Sensing by DNA. Chemical Reviews, 2017, 117, 8272-8325.	23.0	713
1805	Cisplatin selects short forms of the mitochondrial DNA OriB variant (16184â€“16193 poly-cytosine tract), which confer resistance to cisplatin. Scientific Reports, 2017, 7, 46240.	1.6	3
1806	siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells. Oncology Letters, 2017, 13, 3014-3024.	0.8	20
1807	Binding of Copper and Cisplatin to Atox1 Is Mediated by Glutathione through the Formation of Metalâ€“Sulfur Clusters. Biochemistry, 2017, 56, 3129-3141.	1.2	27
1809	Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?. European Journal of Pharmacology, 2017, 811, 125-128.	1.7	37
1810	Synthesis, characterization and cytotoxicity of a new palladium(II) complex with a coumarin-derived ligand 3-(1-(3-hydroxypropylamino)ethylidene)chroman-2,4-dione. Crystal structure of the 3-(1-(3-hydroxypropylamino)ethylidene)-chroman-2,4-dione. Inorganica Chimica Acta, 2017, 466, 188-196.	1.2	23
1811	Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery. Journal of Medicinal Chemistry, 2017, 60, 5736-5748.	2.9	87
1812	BERing the burden of damage: Pathway crosstalk and posttranslational modification of base excision repair proteins regulate DNA damage management. DNA Repair, 2017, 56, 51-64.	1.3	44
1813	An omics perspective to the molecular mechanisms of anticancer metallo-drugs in the computational microscope era. Expert Opinion on Drug Discovery, 2017, 12, 1-13.	2.5	14
1814	Synthesis, X-ray crystal structure, DNA/BSA binding, DNA cleavage and cytotoxicity studies of phenanthroline based copper(II)/zinc(II) complexes. BioMetals, 2017, 30, 575-587.	1.8	16
1815	A review on acridinylthioureas and its derivatives: biological and cytotoxic activity. Journal of Applied Toxicology, 2017, 37, 1132-1139.	1.4	20
1816	Role of Knoevenagel condensate pyrazolone derivative Schiff base ligated transition metal complexes in biological assay and cytotoxic efficacy. Applied Organometallic Chemistry, 2017, 31, e3792.	1.7	10
1817	Mass Spectrometry Based Proteomics Study of Cisplatin-Induced DNAâ€“Protein Cross-Linking in Human Fibrosarcoma (HT1080) Cells. Chemical Research in Toxicology, 2017, 30, 980-995.	1.7	35
1818	Synthesis characterization and cytotoxicity studies of platinum(II) complexes with reduced amino pyridine schiff base and its derivatives as ligands. Bioscience, Biotechnology and Biochemistry, 2017, 81, 1081-1089.	0.6	13
1819	Synthesis, structural characterization and cytotoxicity evaluation of platinum(II) complexes of heterocyclic selenones. Polyhedron, 2017, 128, 2-8.	1.0	14

#	Article	IF	Citations
1820	Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-Î¹B pathways. Biochemical Pharmacology, 2017, 135, 50-68.	2.0	31
1821	Crystal structure and antimicrobial activity of a transplatin adduct of N,Nâ€²-dimethylthiourea, trans-[Pt(NH3)2(dmtu)2]Cl2. Monatshefte FÃ¼r Chemie, 2017, 148, 669-674.	0.9	4
1822	Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor. Bioconjugate Chemistry, 2017, 28, 461-470.	1.8	12
1823	The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines. Redox Biology, 2017, 11, 170-175.	3.9	34
1824	Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structureâ€“Activity Relationship and Application as Orally Available Prodrugs. ChemMedChem, 2017, 12, 300-311.	1.6	46
1825	Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties. International Journal of Pharmaceutics, 2017, 517, 359-372.	2.6	19
1826	Synthesis, characterization and cytotoxicity of platinum(II) complexes containing reduced amino acid ester Schiff bases. Applied Organometallic Chemistry, 2017, 31, e3689.	1.7	7
1827	Specific Conformational Change in Giant DNA Caused by Anticancer Tetrazolato-Bridged Dinuclear Platinum(II) Complexes: Middle-Length Alkyl Substituents Exhibit Minimum Effect. Inorganic Chemistry, 2017, 56, 802-811.	1.9	18
1828	Interaction of DDP with bovine serum albumin facilitates formation of the protein dimers. Journal of Molecular Structure, 2017, 1140, 148-153.	1.8	7
1829	A computational mechanistic investigation into the reduction of Pt(<scp>iv</scp>) prodrugs with two axial chlorides by biological reductants. Chemical Communications, 2017, 53, 1413-1416.	2.2	19
1830	Four mononuclear platinum(II) complexes: synthesis, DNA/BSA binding, DNA cleavage and cytotoxicity. BioMetals, 2017, 30, 17-26.	1.8	16
1831	Three structurally related Copper complexes with two isomers: DNA/BSA binding ability, DNA cleavage activity and excellent cytotoxicity. Inorganica Chimica Acta, 2017, 457, 7-18.	1.2	25
1832	Contemporary Oral Oncology. , 2017, , .		7
1833	A theoretical investigation on bio-transformation of third generation anti-cancer drug Heptaplatin and its interaction with DNA purine bases. Chemical Physics Letters, 2017, 690, 105-115.	1.2	3
1834	Synthesis and crystal structure of new monometallic Ni(<scp>ii</scp>) and Co(<scp>ii</scp>) complexes with an asymmetrical aroylhydrazone: effects of the complexes on DNA/protein binding property, molecular docking, and in vitro anticancer activity. RSC Advances, 2017, 7, 49404-49422.	1.7	55
1835	Kinetic aspects of platinum anticancer agents. Polyhedron, 2017, 138, 109-124.	1.0	47
1836	Design, structural characterization and cytotoxic properties of copper(I) and copper(II) complexes formed by vitamin B 3 type. Polyhedron, 2017, 138, 277-286.	1.0	6
1837	DNA interaction with platinum-based cytostatics revealed by DNA sequencing. Analytical Biochemistry, 2017, 539, 22-28.	1.1	4

#	Article	IF	Citations
1838	Interactions between human copper chaperone Atox1 and cisplatin, carboplatin, nedaplatin and oxaliplatin studied by ESI mass spectrometry. Inorganic Chemistry Communication, 2017, 86, 82-86.	1.8	2
1839	Synthesis, spectroscopic characterization and in vitro anticancer activity of new platinum(II) complexes with some thione ligandsÂin the presence of triethylphosphine. BioMetals, 2017, 30, 787-795.	1.8	5
1840	Effects of electrochemotherapy with cisplatin and peritumoral IL-12 gene electrotransfer on canine mast cell tumors: a histopathologic and immunohistochemical study. Radiology and Oncology, 2017, 51, 286-294.	0.6	27
1841	Investigation of DNA Binding Interaction of Newly Synthesized Nickel(II) and Palladium(II) Complexes Containing Ferrocenyl Schiff Base Ligand. Journal of the Chinese Chemical Society, 2017, 64, 1524-1531.	0.8	3
1842	In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes. Journal of the American Chemical Society, 2017, 139, 14302-14314.	6.6	147
1843	VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells. Tumor Biology, 2017, 39, 101042831771165.	0.8	0
1844	Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(<scp>ii</scp>) polypyridyl complexes as anticancer drug candidates. Chemical Society Reviews, 2017, 46, 7317-7337.	18.7	174
1845	Targeted killing of prostate cancer cells using antibodyâ€“drug conjugated carbon nanohorns. Journal of Materials Chemistry B, 2017, 5, 8821-8832.	2.9	20
1846	Ni(<scp>ii</scp>) and Co(<scp>ii</scp>) complexes of an asymmetrical aroylhydrazone: synthesis, molecular structures, DNA binding, protein interaction, radical scavenging and cytotoxic activity. RSC Advances, 2017, 7, 41527-41539.	1.7	62
1847	Functional metal-organic quadrangular macrocycle as luminescent sensor for ATP in aqueous media. Inorganic Chemistry Communication, 2017, 84, 195-199.	1.8	9
1848	Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice. Clinical Cancer Research, 2017, 23, 7020-7033.	3.2	20
1849	A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells. Molecular BioSystems, 2017, 13, 2268-2276.	2.9	28
1850	Catalysis of a 1,3-dipolar reaction by distorted DNA incorporating a heterobimetallic platinum(<scp>ii</scp>) and copper(<scp>ii</scp>) complex. Chemical Science, 2017, 8, 7038-7046.	3.7	6
1851	Synergistic Effects in Pt^{II}â€“Porphyrinoid Dyes as Candidates for a Dualâ€Action Anticancer Therapy: A Theoretical Exploration. Chemistry - A European Journal, 2017, 23, 15124-15132.	1.7	24
1852	Monomeric and Dimeric Oxidomolybdenum(V and VI) Complexes, Cytotoxicity, and DNA Interaction Studies: Molybdenum Assisted Câ•N Bond Cleavage of Salophen Ligands. Inorganic Chemistry, 2017, 56, 11190-11210.	1.9	52
1853	DNA incision evaluation, binding investigation and biocidal screening of Cu(II), Ni(II) and Co(II) complexes with isoxazole Schiff bases. Journal of Photochemistry and Photobiology B: Biology, 2017, 175, 132-140.	1.7	44
1855	Force spectroscopy unravels the role of ionic strength on DNA-cisplatin interaction: Modulating the binding parameters. Physical Review E, 2017, 96, 032408.	0.8	21
1856	Anticancer kiteplatin pyrophosphate derivatives show unexpected target selectivity for DNA. Dalton Transactions, 2017, 46, 14139-14148.	1.6	11

#	Article	IF	Citations
1857	An Ultraviolet Resonance Raman Spectroscopic Study of Cisplatin and Transplatin Interactions with Genomic DNA. Journal of Physical Chemistry B, 2017, 121, 8975-8983.	1.2	6
1858	Substance P Mediated DGLs Complexing with DACHPt for Targeting Therapy of Glioma. ACS Applied Materials & Interfaces, 2017, 9, 34603-34617.	4.0	15
1859	Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy. Journal of Controlled Release, 2017, 266, 36-46.	4.8	54
1860	Siteâ€Selective Labeling of Chromium(III) as a Quencher on DNA for Molecular Beacons. ChemPlusChem, 2017, 82, 1224-1230.	1.3	9
1861	Cisplatin and transplatin interaction with methionine: bonding motifs assayed by vibrational spectroscopy in the isolated ionic complexes. Physical Chemistry Chemical Physics, 2017, 19, 26697-26707.	1.3	26
1862	Breast Cancer Spheroids Reveal a Differential Cancer Stem Cell Response to Chemotherapeutic Treatment. Scientific Reports, 2017, 7, 10382.	1.6	112
1863	Selfâ€Assembly of Nucleobase, Nucleoside and Nucleotide Coordination Polymers: From Synthesis to Applications. ChemNanoMat, 2017, 3, 670-684.	1.5	54
1864	Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics. Expert Review of Anticancer Therapy, 2017, 17, 815-825.	1.1	15
1865	Catalytic Metallodrugs: Substrateâ€Selective Metal Catalysts as Therapeutics. Chemistry - A European Journal, 2017, 23, 14113-14127.	1.7	49
1866	Chemoradiation Cancer Therapy: Molecular Mechanisms of Cisplatin Radiosensitization. Journal of Physical Chemistry C, 2017, 121, 17505-17513.	1.5	20
1867	Versatile coordination ability of thioamide ligand in Ru(<scp>ii</scp>) complexes: synthesis, computational studies, in vitro anticancer activity and apoptosis induction. New Journal of Chemistry, 2017, 41, 9130-9141.	1.4	13
1868	Cytotoxic (salen)ruthenium(<scp>iii</scp>) anticancer complexes exhibit different modes of cell death directed by axial ligands. Chemical Science, 2017, 8, 6865-6870.	3.7	46
1869	Molecular efficacy of radio- and chemotherapy sequences from direct DNA damage measurements. International Journal of Radiation Biology, 2017, 93, 1274-1282.	1.0	5
1870	Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. Scientific Reports, 2017, 7, 16231.	1.6	64
1872	Injectable Thermosensitive Polypeptide-Based CDDP-Complexed Hydrogel for Improving Localized Antitumor Efficacy. Biomacromolecules, 2017, 18, 4341-4348.	2.6	33
1873	Toxicity of Metal Compounds: Knowledge and Myths. Organometallics, 2017, 36, 4071-4090.	1.1	467
1874	Mononuclear palladium(<scp>ii</scp>) and platinum(<scp>ii</scp>) complexes of P,C-donor ligands: synthesis, crystal structures, cytotoxicity, and mechanistic studies of a highly stereoselective Mizorokiâ€“Heck reaction. Inorganic Chemistry Frontiers, 2017, 4, 2107-2118.	3.0	16
1875	Synergistic enhancement of breast cancer cell death using ultrasound-microbubbles in combination with cisplatin. AIP Conference Proceedings, 2017, , .	0.3	1

#	Article	IF	Citations
1876	Crystal and molecular structure of a new palladium(II) complex with a coumarin-valine derivate. Journal of Structural Chemistry, 2017, 58, 550-557.	0.3	5
1877	Enzymes in the Base Excision Repair Pathway as Targets for Small Molecule Mediated Therapeutics. , 2017, , 663-729.		0
1878	Coordination self-assembly of platinumâ€“bisphosphonate polymerâ€“metal complex nanoparticles for cisplatin delivery and effective cancer therapy. Nanoscale, 2017, 9, 10002-10019.	2.8	32
1879	Direct measurement of interaction forces between a platinum dichloride complex and DNA molecules. Journal of Biological Physics, 2017, 43, 355-365.	0.7	1
1880	Association of a Platinum Complex to a G-Quadruplex Ligand Enhances Telomere Disruption. Chemical Research in Toxicology, 2017, 30, 1629-1640.	1.7	13
1881	On the binding modes of metal NHC complexes with DNA secondary structures: implications for therapy and imaging. Chemical Communications, 2017, 53, 8249-8260.	2.2	64
1882	The development of anticancer ruthenium(<scp>ii</scp>) complexes: from single molecule compounds to nanomaterials. Chemical Society Reviews, 2017, 46, 5771-5804.	18.7	793
1883	Structural, spectral, DFT and biological studies on macrocyclic mononuclear ruthenium (II) complexes. Journal of Molecular Structure, 2017, 1147, 502-514.	1.8	16
1884	Platinum complexes containing adenine-based ligands: An overview of selected structural features. Coordination Chemistry Reviews, 2017, 332, 1-29.	9.5	17
1885	Cell and Cellâ€Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties. European Journal of Inorganic Chemistry, 2017, 2017, 1737-1744.	1.0	17
1886	Bis(pyridazine-5-olate-4-carboxylate)manganese hydrate: Synthesis, characterization, and in vitro antitumor activities. Inorganic and Nano-Metal Chemistry, 2017, 47, 703-707.	0.9	4
1887	Synthesis and structure of a new trinuclear nickel(II) complex bridged by Nâ€[3â€(Dimethylamino)propyl]â€Nâ€²â€(2â€hydroxyphenyl)oxamido: in vitro anticancer activities and reactivities toward DNA and protein. Journal of Biochemical and Molecular Toxicology, 2017, 31, 1-11.	1.4	5
1888	Synthesis, crystal structure, DNA binding, cleavage and cytotxicity, antimicrobial activity of new copper(II) complex with L-ornithine and 1,10-phenanthroline. Inorganic and Nano-Metal Chemistry, 2017, 47, 269-277.	0.9	10
1889	Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents. European Journal of Medicinal Chemistry, 2017, 125, 372-384.	2.6	24
1890	Crystal structure, DFT study, antimicrobial properties and DNA cleavage potential and thermal behavior of some new mercury complexes. Journal of the Iranian Chemical Society, 2017, 14, 297-312.	1.2	6
1891	Ecotoxicological assessment of the anticancer drug cisplatin in the polychaete Nereis diversicolor. Science of the Total Environment, 2017, 575, 162-172.	3.9	43
1892	Cu(I) complexes of bis(methyl)(thia/selena) salen ligands: Synthesis, characterization, redox behavior and DNA binding studies. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017, 171, 18-24.	2.0	30
1893	Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1301-1307.	1.7	19

#	Article	IF	Citations
1894	Filipendula ulmaria extracts attenuate cisplatin-induced liver and kidney oxidative stress in rats: InÂvivo investigation and LC-MS analysis. Food and Chemical Toxicology, 2017, 99, 86-102.	1.8	38
1895	A multi-functional PEGylated gold(<scp>iii</scp>) compound: potent anti-cancer properties and self-assembly into nanostructures for drug co-delivery. Chemical Science, 2017, 8, 1942-1953.	3.7	56
1896	The impact of erdosteine on cisplatin-induced ototoxicity: a proteomics approach. European Archives of Oto-Rhino-Laryngology, 2017, 274, 1365-1374.	0.8	6
1897	Drug-Triggered Self-Assembly of Linear Polymer into Nanoparticles for Simultaneous Delivery of Hydrophobic and Hydrophilic Drugs in Breast Cancer Cells. ACS Omega, 2017, 2, 8730-8740.	1.6	13
1898	Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression. Scientific Reports, 2017, 7, 17724.	1.6	34
1899	Synthesis, biological activity of a new long-chain di-Schiff base ligand and Ru(II) complex in solvent-free conditions. Main Group Chemistry, 2017, 16, 255-266.	0.4	5
1900	Mononuclear copper(II) and binuclear cobalt(II) complexes with halides and tetradentate nitrogen coordinate ligand: Synthesis, structures and bioactivities. Inorganica Chimica Acta, 2017, 466, 219-227.	1.2	20
1902	MutSÎ±'s Multi-Domain Allosteric Response to Three DNA Damage Types Revealed by Machine Learning. Frontiers in Physics, 2017, 5, .	1.0	8
1903	Under-Reported Aspects of Platinum Drug Pharmacology. Molecules, 2017, 22, 382.	1.7	15
1904	Role of nanostructure molecules in enhancing the bioavailability of oral drugs. , 2017, , 375-407.		8
1905	The Protective Effects of p-Coumaric Acid on Acute Liver and Kidney Damages Induced by Cisplatin. Biomedicines, 2017, 5, 18.	1.4	80
1906	Inhibition of Mitochondrial Division Attenuates Cisplatin-Induced Toxicity in the Neuromast Hair Cells. Frontiers in Cellular Neuroscience, 2017, 11, 393.	1.8	16
1907	The Analysis of Therapeutic Metal Complexes and Their Biomolecular Interactions. , 2017, , 355-386.		0
1908	Nitric Oxide Donors Sensitize Resistant Cancer Cells to Apoptosis Induced by Chemotherapy: Molecular Mechanisms of Sensitization. , 2017, , 15-34.		2
1909	New perspectives of cobalt tris(bipyridine) system: anti-cancer effect and its collateral sensitivity towards multidrug-resistant (MDR) cancers. Oncotarget, 2017, 8, 55003-55021.	0.8	27
1910	DNA Minor Groove Binders as Therapeutic Agents. , 2017, , 149-178.		4
1911	Inhibitory Effects of Total Triterpenoid Saponins Isolated from the Seeds of the Tea Plant (Camellia) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.7	20
1912	A fluorophore-labelled copper complex: crystal structure, hybrid cyclic waterâ€“perchlorate cluster and biological properties. Acta Crystallographica Section C, Structural Chemistry, 2017, 73, 710-717.	0.2	7

#	Article	IF	Citations
1913	Titanium-Phenolato-Based Anticancer Chemotherapy: Developmental Stages. , 2017, , .		0
1914	Insight into the Electrochemical Reduction Mechanism of Pt(IV) Anticancer Complexes. Inorganic Chemistry, 2018, 57, 3411-3419.	1.9	33
1915	Molecular Mechanism, Dynamics, and Energetics of Protein-Mediated Dinucleotide Flipping in a Mismatched DNA: A Computational Study of the RAD4-DNA Complex. Journal of Chemical Information and Modeling, 2018, 58, 647-660.	2.5	3
1916	Metal-Based Therapy in Traditional and Modern Medicine Systems. , 2018, , 195-211.		4
1917	Biomedical Applications of Metals. , 2018, , .		6
1918	The effect of geometric isomerism on the anticancer activity of the monofunctional platinum complextrans-[Pt(NH₃)₂(phenanthridine)Cl]NO₃. Chemical Communications, 2018, 54, 2788-2791.	2.2	23
1919	Optimized twoâ€dimensional gel electrophoresis in an alkaline pH range improves the identification of intracellular CFDAâ€cisplatinâ€protein adducts in ovarian cancer cells. Electrophoresis, 2018, 39, 1488-1496.	1.3	7
1920	Cisplatin-stitched Î±-poly(glutamatic acid) nanoconjugate for enhanced safety and effective tumor inhibition. European Journal of Pharmaceutical Sciences, 2018, 119, 189-199.	1.9	9
1921	Reviewing Gold(III) complexes as effective biological operators. Main Group Chemistry, 2018, 17, 35-52.	0.4	13
1922	Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1. Metallomics, 2018, 10, 745-750.	1.0	10
1923	A Computational Mechanistic Investigation into Reduction of Gold(III) Complexes by Amino Acid Glycine: A New Variant for Amine Oxidation. Chemistry - A European Journal, 2018, 24, 8361-8368.	1.7	14
1924	Titanocene binding to oligonucleotides. Journal of Inorganic Biochemistry, 2018, 184, 1-7.	1.5	3
1925	LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions. Biomedicine and Pharmacotherapy, 2018, 102, 549-554.	2.5	19
1926	In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. Genome Research, 2018, 28, 654-665.	2.4	126
1927	Identification of cisplatin-binding sites on the large cytoplasmic loop of the Na⁺/K⁺-ATPase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 701-706.	2.5	10
1928	7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS. , 2018, 18, 199-218.		82
1929	DNA binding, crystal structure, molecular docking studies and anticancer activity evaluation of a copper(II) complex. Transition Metal Chemistry, 2018, 43, 259-271.	0.7	24
1930	Simultaneous detection of nucleotide excision repair events and apoptosis-induced DNA fragmentation in genotoxin-treated cells. Scientific Reports, 2018, 8, 2265.	1.6	9

#	Article	IF	Citations
1931	Lysozyme and DNA binding affinity of Pd(<scp>ii</scp>) and Pt(<scp>ii</scp>) complexes bearing charged N,N-pyridylbenzimidazole bidentate ligands. Dalton Transactions, 2018, 47, 3459-3468.	1.6	41
1932	Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nature Communications, 2018, 9, 508.	5.8	127
1933	The Development of a Nano-based Approach to Alleviate Cisplatin-Induced Ototoxicity. JARO - Journal of the Association for Research in Otolaryngology, 2018, 19, 123-132.	0.9	8
1934	A Low-Toxicity DNA-Alkylating N-Mustard-Quinoline Conjugate with Preferential Sequence Specificity Exerts Potent Antitumor Activity Against Colorectal Cancer. Neoplasia, 2018, 20, 119-130.	2.3	8
1935	Synthesis, characterization and anticancer evaluation of transplatin derivatives with heterocyclic thiones. Polyhedron, 2018, 141, 360-368.	1.0	14
1936	Synthesis, characterization, antimicrobial and antitumor reactivity of new palladium(II) complexes with methionine and tryptophane coumarine derivatives. Journal of Molecular Structure, 2018, 1157, 425-433.	1.8	13
1937	Peanut testa extracts possessing histone deacetylase inhibitory activity induce apoptosis in cholangiocarcinoma cells. Biomedicine and Pharmacotherapy, 2018, 98, 233-241.	2.5	9
1938	Imaging of a clickable anticancer iridium catalyst. Journal of Inorganic Biochemistry, 2018, 180, 179-185.	1.5	23
1939	Coordination-driven self-assembly of a Pt(<scp>iv</scp>) prodrug-conjugated supramolecular hexagon. Chemical Communications, 2018, 54, 731-734.	2.2	45
1940	Luminescent cyclometallated platinum(<scp>ii</scp>) complexes: highly promising EGFR/DNA probes and dual-targeting anticancer agents. Inorganic Chemistry Frontiers, 2018, 5, 413-424.	3.0	41
1941	Kinetically-inert polypyridylruthenium(II) complexes as therapeutic agents. Coordination Chemistry Reviews, 2018, 375, 134-147.	9.5	39
1942	Anticancer platinumâ€based complexes with nonâ€classical structures. Applied Organometallic Chemistry, 2018, 32, e4228.	1.7	31
1943	First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?. Cancer Chemotherapy and Pharmacology, 2018, 81, 443-453.	1.1	10
1944	Cascade-Promoted Photo-Chemotherapy against Resistant Cancers by Enzyme-Responsive Polyprodrug Nanoplatforms. Chemistry of Materials, 2018, 30, 3486-3498.	3.2	79
1945	Structural Basis for Human DNA Polymerase Kappa to Bypass Cisplatin Intrastrand Cross-Link (Pt-GG) Lesion as an Efficient and Accurate Extender. Journal of Molecular Biology, 2018, 430, 1577-1589.	2.0	17
1946	Coordination of GMP ligand with Cu to enhance the multiple enzymes stability and substrate specificity by co-immobilization process. Biochemical Engineering Journal, 2018, 136, 102-108.	1.8	31
1947	Synergic highly effective photothermal-chemotherapy with platinum prodrug linked melanin-like nanoparticles. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 356-363.	1.9	12
1948	Cycloplatinated(<scp>ii</scp>) complexes bearing an O,S-heterocyclic ligand: search for anticancer drugs. New Journal of Chemistry, 2018, 42, 7177-7187.	1.4	15

#	Article	IF	Citations
1949	Solvent Effects on the Structure And Spectroscopic Properties of the Second-Generation Anticancer Drug Carboplatin: A Theoretical Insight. Journal of Structural Chemistry, 2018, 59, 245-251.	0.3	20
1950	Effect of lipophilicity of amylamine and amylglycine ligands on biological activity of new anticancer cisplatin analog. Journal of Biomolecular Structure and Dynamics, 2018, 36, 893-905.	2.0	17
1951	Cisplatin nephrotoxicity: a review of the literature. Journal of Nephrology, 2018, 31, 15-25.	0.9	437
1952	Potentiation of cytotoxic action of cis -[PtCl 2 (NH 3)(1M7AI)] by UVA irradiation. Mechanistic insights. Inorganica Chimica Acta, 2018, 472, 199-206.	1.2	6
1953	Comparing Pt II - and Pd II -nucleobase coordination chemistry: Why Pd II not always is a good substitute for Pt II. Inorganica Chimica Acta, 2018, 472, 207-213.	1.2	15
1954	Synthesis, structure, and biological evaluation of a platinumâ€carbazole conjugate. Chemical Biology and Drug Design, 2018, 91, 116-125.	1.5	3
1955	Review of direct chemical and biochemical transformations of starch. Carbohydrate Polymers, 2018, 181, 460-476.	5.1	56
1956	Synthesis, crystal structure and anticancer activity of tetrakis(N-isopropylimidazolidine-2-selenone)platinum(II) chloride. Journal of Molecular Structure, 2018, 1152, 232-236.	1.8	8
1957	New organotin supramolecular complexes based on copper cyanide and auxiliary Nâ€donor ligands as potent inhibitors of cancer cell lines: In vitro and antioxidant experiments. Applied Organometallic Chemistry, 2018, 32, e4053.	1.7	10
1958	Regulation of metalâ€“metal interactions and chromic phenomena of multi-decker platinum complexes having Ï€-systems. Coordination Chemistry Reviews, 2018, 355, 101-115.	9.5	132
1959	Covalent bonding of magnetic Fe 3 O 4 nanoparticles to aminopropylâ€functionalized magnesium phyllosilicate clay: Synthesis and cytotoxic potential investigation. Applied Organometallic Chemistry, 2018, 32, e4036.	1.7	4
1960	Cytotoxicity modulation of ruthenium(II) tris-bathophenanthroline complexes with systematically varied charge. Journal of Photochemistry and Photobiology A: Chemistry, 2018, 351, 59-68.	2.0	16
1961	Controlling with light the interaction betweentrans-tetrapyridyl ruthenium complexes and an oligonucleotide. Dalton Transactions, 2018, 47, 507-516.	1.6	8
1962	Benzothiazoleâ€Based Cycloplatinated Chromophores: Synthetic, Optical, and Biological Studies. Chemistry - A European Journal, 2018, 24, 2440-2456.	1.7	33
1963	Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase. BioMetals, 2018, 31, 29-43.	1.8	9
1964	Structural basis for the recognition and processing of DNA containing bulky lesions by the mammalian nucleotide excision repair system. DNA Repair, 2018, 61, 86-98.	1.3	7
1965	Synthesis, Structural Characterization and Antiâ€Proliferative Activity of (Î¹¹â€C)â€and (Î¹²â€C,S)â€Pt^{II} Complexes Bearing Thioetherâ€Functionalized Nâ€Heterocyclic Carbenes. European Journal of Inorganic Chemistry, 2018, 2018, 159-166.	1.0	16
1966	The effect of alkyl chain tethers on the kinetics and mechanistic behaviour of bifunctional dinuclear platinum(<scp>ii</scp>) complexes bearing N,Nâ€²-dipyridylamine ligands. New Journal of Chemistry, 2018, 42, 214-227.	1.4	7

#	Article	IF	Citations
1967	Identification of cisplatin sensitizers through high-throughput combinatorial screening. International Journal of Oncology, 2018, 53, 1237-1246.	1.4	5
1968	Cisplatin-induced cardiotoxicity with midrange ejection fraction. Medicine (United States), 2018, 97, e13807.	0.4	39
1969	Platinum-Based Antitumor Drugs and Their Liposomal Formulations in Clinical Trials. Russian Journal of Bioorganic Chemistry, 2018, 44, 619-630.	0.3	5
1970	The AT Interstrand Cross-Link: Structure, Electronic Properties, and Influence on Charge Transfer in dsDNA. Molecular Therapy - Nucleic Acids, 2018, 13, 665-685.	2.3	10
1971	Synthesis, cytotoxic activity and DNA interaction studies of new dinuclear platinum(<scp>ii</scp>) complexes with an aromatic 1,5-naphthyridine bridging ligand: DNA binding mode of polynuclear platinum(<scp>ii</scp>) complexes in relation to the complex structure. Dalton Transactions, 2018, 47, 15091-15102.	1.6	19
1972	ATR-FTIR spectroscopy shows changes in ovarian cancer cells after incubation with novel organoamidoplatinum(<scp>ii</scp>) complexes. Analyst, The, 2018, 143, 6087-6094.	1.7	19
1973	COMBINATION OF HEDYOTIS CORYMBOSA L. AND TINOSPORA CRISPA ETHANOLIC EXTRACT INCREASE CISPLATIN CYTOTOXICITY ON T47D BREAST CANCER CELLS. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 171.	0.3	2
1974	Relations between approved platinum drugs and non-coding RNAs in mesothelioma. Non-coding RNA Research, 2018, 3, 161-173.	2.4	11
1975	The interactions of novel mononuclear platinum-based complexes with DNA. BMC Cancer, 2018, 18, 1284.	1.1	15
1976	Therapeutic Potential of Nitrogen Mustard Based Hybrid Molecules. Frontiers in Pharmacology, 2018, 9, 1453.	1.6	61
1977	The Application of ATR-FTIR Spectroscopy and the Reversible DNA Conformation as a Sensor to Test the Effectiveness of Platinum(II) Anticancer Drugs. Sensors, 2018, 18, 4297.	2.1	11
1978	The induction of apoptosis in BEL-7402 cells by an iridium(III) complex through lysosomeâ€“mitochondria pathway. Polyhedron, 2018, 156, 320-331.	1.0	5
1979	Squaramide-Based Pt(II) Complexes as Potential Oxygen-Regulated Light-Triggered Photocages. Inorganic Chemistry, 2018, 57, 15517-15525.	1.9	7
1980	Analysis of the Interaction Between the C20 Cage and cis-Ptcl2(NH3)2: A DFT Investigation of the Solvent Effect, Structures, Properties, and Topologies. Journal of Structural Chemistry, 2018, 59, 1044-1051.	0.3	7
1981	Antineoplastic Agents. , 2018, , 219-232.		0
1982	Effect of Torsion on Cisplatin-Induced DNA Condensation. Chinese Physics Letters, 2018, 35, 118701.	1.3	2
1983	Platinum(II) Complexes with Sterically Expansive Tetraarylethylene Ligands as Probes for Mismatched DNA. Inorganic Chemistry, 2018, 57, 12641-12649.	1.9	10
1984	Photodamaging of Mitochondrial DNA to Overcome Cisplatin Resistance by a Ru^{II}â€“Pt^{II} Bimetallic Complex. Chemistry - A European Journal, 2018, 24, 18971-18980.	1.7	35

#	Article	IF	Citations
1985	Pt-induced crosslinks promote target enrichment and protection from serum nucleases. Journal of Inorganic Biochemistry, 2018, 189, 124-133.	1.5	6
1986	The curcuminoid, EF-24, reduces cisplatin-mediated reactive oxygen species in zebrafish inner ear auditory and vestibular tissues. Journal of Clinical Neuroscience, 2018, 57, 152-156.	0.8	11
1987	PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection. Pharmacological Research, 2018, 137, 104-113.	3.1	38
1988	DNA binding, cleavage and cytotoxicity studies of three mononuclear Cu(II) chloro-complexes containing Nâ€“S donor Schiff base ligands. Journal of Biological Inorganic Chemistry, 2018, 23, 1331-1349.	1.1	22
1989	Modes of Chemically Induced Cell Death. , 2018, , 229-253.		1
1990	Exogenous spermidine ameliorates tubular necrosis during cisplatin nephrotoxicity. Anatomy and Cell Biology, 2018, 51, 189.	0.5	12
1991	EGCG inhibits CSCâ€like properties through targeting miRâ€485/CD44 axis in A549â€cisplatin resistant cells. Molecular Carcinogenesis, 2018, 57, 1835-1844.	1.3	38
1992	Effect of Substituents on the Biological Activities of Piano Stool Î·5-Cyclopentadienyl Rh(III) and Ir(III) Complexes. Journal of Inorganic and Organometallic Polymers and Materials, 2018, 28, 2749-2758.	1.9	11
1993	Phosphorescent cyclometalated iridium(<scp>iii</scp>) complexes: synthesis, photophysics, DNA interaction, cellular internalization, and cytotoxic activity. New Journal of Chemistry, 2018, 42, 16846-16854.	1.4	11
1994	A new C,N-cyclometalated osmium(<scp>ii</scp>) arene anticancer scaffold with a handle for functionalization and antioxidative properties. Chemical Communications, 2018, 54, 11120-11123.	2.2	12
1995	Drug-Induced Nephrotoxicity: Pathogenic Mechanisms, Biomarkers and Prevention Strategies. Current Drug Metabolism, 2018, 19, 559-567.	0.7	74
1996	Zinc(II)â€N₂O₂ ligation complexâ€based DNA/protein binder and cleaver having enhanced cytotoxic and phosphatase activity. Applied Organometallic Chemistry, 2018, 32, e4400.	1.7	4
1997	A novel water-soluble tetranuclear copper (II) Schiff base cluster bridged by 2, 6-bis-[(2-hydroxyethylimino)methyl]-4-methylphenol in interaction with BSA: Synthesis, X-ray crystallography, docking and cytotoxicity studies. Journal of Photochemistry and Photobiology A: Chemistry, 2018, 361, 93-104.	2.0	16
1998	Enantioselective Iridium-Catalyzed Ring Opening of Low-Activity Azabenzonorbornadienes with Amines. Organometallics, 2018, 37, 1652-1655.	1.1	3
1999	DNA Binding, amelioration of oxidative stress, and molecular docking study of Zn(II) metal complex of a new Schiff base ligand. Journal of Coordination Chemistry, 2018, 71, 2165-2182.	0.8	32
2000	Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism. Toxicology Letters, 2018, 295, 88-98.	0.4	12
2001	Bifunctional cross-linking approaches for mass spectrometry-based investigation of nucleic acids and protein-nucleic acid assemblies. Methods, 2018, 144, 64-78.	1.9	12
2002	Chiralityâ€Induced Variation in Interaction of Two Similar Copper(II) Coordination Polymers with Calf Thymus DNA: Exploration of Their Antimicrobial Activity and Cytotoxicity. ChemistrySelect, 2018, 3, 7112-7122.	0.7	11

#	Article	IF	Citations
2003	Metalâ€“ligand interactions in drug design. Nature Reviews Chemistry, 2018, 2, 100-112.	13.8	124
2004	Role of a 2,3-bis(pyridyl)pyrazinyl chelate bridging ligand in the reactivity of Ru(<scp>ii</scp>)â€“Pt(<scp>ii</scp>) dinuclear complexes on the substitution of chlorides by thiourea nucleophiles â€“ a kinetic study. New Journal of Chemistry, 2018, 42, 12557-12569.	1.4	15
2005	Exploring the interactions between model proteins and Pd(<scp>ii</scp>) or Pt(<scp>ii</scp>) compounds bearing chargedN,N-pyridylbenzimidazole bidentate ligands by X-ray crystallography. Dalton Transactions, 2018, 47, 10130-10138.	1.6	20
2006	In Vivo 6-([¹⁸F]Fluoroacetamido)-1-hexanoicanilide PET Imaging of Altered Histone Deacetylase Activity in Chemotherapy-Induced Neurotoxicity. Contrast Media and Molecular Imaging, 2018, 2018, 1-12.	0.4	7
2007	In Vitro Study of Antitumor Effect of Antimicrobial Peptide Tachyplesin I in Combination with Cisplatin. Bulletin of Experimental Biology and Medicine, 2018, 165, 220-224.	0.3	11
2008	Synthesis, characterization, electrochemical and biological activities of mixed ligand copper(II) complexes with dimethylglyoxime and amino acids. Journal of Molecular Structure, 2018, 1173, 280-290.	1.8	22
2009	ER-Î±36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway. Journal of Experimental and Clinical Cancer Research, 2018, 37, 123.	3.5	18
2010	Recent progress in polymer-based platinum drug delivery systems. Progress in Polymer Science, 2018, 87, 70-106.	11.8	144
2011	Theaflavin-3,3â€²-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 117.	1.8	23
2012	Antitumor effect of a Pt-loaded nanocomposite based on graphene quantum dots combats hypoxia-induced chemoresistance of oral squamous cell carcinoma. International Journal of Nanomedicine, 2018, Volume 13, 1505-1524.	3.3	47
2013	Carboplatin as an alternative to Cisplatin in chemotherapies: New insights at single molecule level. Biophysical Chemistry, 2018, 241, 8-14.	1.5	15
2014	Thiabendazole-based Rh(III) and Ir(III) biscyclometallated complexes with mitochondria-targeted anticancer activity and metal-sensitive photodynamic activity. European Journal of Medicinal Chemistry, 2018, 157, 279-293.	2.6	41
2015	Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. European Journal of Medicinal Chemistry, 2018, 156, 666-679.	2.6	30
2016	Monitoring Interactions Inside Cells by Advanced Spectroscopies: Overview of Copper Transporters and Cisplatin. Current Medicinal Chemistry, 2018, 25, 462-477.	1.2	15
2017	Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy. International Journal of Molecular Sciences, 2018, 19, 1818.	1.8	10
2018	Evaluation of Transition Metal Complexes of Benzimidazole-Derived Scaffold as Promising Anticancer Chemotherapeutics. Molecules, 2018, 23, 1232.	1.7	32
2019	DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system. Oncology Letters, 2018, 16, 1869-1875.	0.8	14
2020	DNA interaction and anticancer evaluation of new palladium(II), platinum(II) and silver(I) complexes based on (Î”)- and (Î›)-1,2â€“bis-(1H-benzimidazol-2-yl)-1,2-ethanediol enantiomers. Polyhedron, 2018, 154, 156-172.	1.0	13

#	Article	IF	Citations
2021	Palladium and Platinum 2,4-cis-amino Azetidine and Related Complexes. Frontiers in Chemistry, 2018, 6, 211.	1.8	5
2022	Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop. Phytomedicine, 2018, 48, 51-61.	2.3	43
2023	Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. Journal of Translational Medicine, 2018, 16, 96.	1.8	133
2024	Trypanosoma cruzi biochemical changes and cell death induced by an organometallic platinumâ€based compound. Chemical Biology and Drug Design, 2018, 92, 1657-1669.	1.5	21
2025	Photochemotherapy of Infrared Active BODIPY-Appended Iron(III) Catecholates for in Vivo Tumor Growth Inhibition. ACS Omega, 2018, 3, 9333-9338.	1.6	16
2026	New Silver Complexes with Mixed Thiazolidine and Phosphine Ligands as Highly Potent Antimalarial and Anticancer Agents. Journal of Chemistry, 2018, 2018, 1-10.	0.9	12
2027	Platinum Complexes Can Bind to Telomeres by Coordination. International Journal of Molecular Sciences, 2018, 19, 1951.	1.8	5
2028	Turning intercalators into groove binders: synthesis, photophysics and DNA binding properties of tetracationic mononuclear ruthenium(<scp>ii</scp>)-based chromophoreâ€“quencher complexes. Dalton Transactions, 2018, 47, 12300-12307.	1.6	4
2029	Imineâ€Nâ€Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) pâ€Cymene Anticancer Complexes: A Structureâ€“Activity Relationship Study. Chemistry - an Asian Journal, 2018, 13, 2923-2933.	1.7	43
2030	Computational Evaluation of Novel Schiff base Complexes as Anti-Dengue and Anti-cancer Agent. Oriental Journal of Chemistry, 2018, 34, 1411-1419.	0.1	1
2031	Targeting BER enzymes in cancer therapy. DNA Repair, 2018, 71, 118-126.	1.3	43
2032	Emerging role of long non-coding RNAs in cisplatin resistance. OncoTargets and Therapy, 2018, Volume 11, 3185-3194.	1.0	69
2033	Pre-/post-functionalization in dipyrrin metal complexes â€“ antitumor and antibacterial activity of their glycosylated derivatives. Dalton Transactions, 2018, 47, 12373-12384.	1.6	19
2034	Binding of Organometallic Ruthenium Anticancer Complexes to DNA: Thermodynamic Base and Sequence Selectivity. International Journal of Molecular Sciences, 2018, 19, 2137.	1.8	10
2035	Dual Chemodrug-Loaded Single-Walled Carbon Nanohorns for Multimodal Imaging-Guided Chemo-Photothermal Therapy of Tumors and Lung Metastases. Theranostics, 2018, 8, 1966-1984.	4.6	79
2036	Analysis of single, cisplatinâ€induced DNA bends by atomic force microscopy and simulations. Journal of Molecular Recognition, 2018, 31, e2731.	1.1	17
2037	Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin. Journal of Biological Inorganic Chemistry, 2018, 23, 833-848.	1.1	10
2038	Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium. Dalton Transactions, 2018, 47, 9934-9974.	1.6	207

#	Article	IF	Citations
2039	Protective Effect of Nanoceria on Cisplatin-Induced Nephrotoxicity by Amelioration of Oxidative Stress and Pro-inflammatory Mechanisms. Biological Trace Element Research, 2019, 189, 145-156.	1.9	47
2040	Substituted effect on some water-soluble Mn(II) salen complexes: DNA binding, cytotoxicity, molecular docking, DFT studies and theoretical IR & UV studies. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 206, 278-294.	2.0	32
2041	Synthesis, structure and DNA binding properties of a homodinuclear Cu(II) complex: An experimental and theoretical approach. Journal of Molecular Structure, 2019, 1176, 283-289.	1.8	24
2042	Oxaliplatin effects on the DNA molecule studied by force spectroscopy. Biomedical Physics and Engineering Express, 2019, 5, 055009.	0.6	2
2043	A Nanobodyâ€Conjugated DNA Nanoplatform for Targeted Platinumâ€Drug Delivery. Angewandte Chemie, 2019, 131, 14362-14366.	1.6	21
2044	Doxorubicin/cisplatin co-loaded hyaluronic acid/chitosan-based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer. Carbohydrate Polymers, 2019, 225, 115206.	5.1	57
2045	Imaging and proteomic study of a clickable iridium complex. Metallomics, 2019, 11, 1344-1352.	1.0	11
2046	Celastrol pretreatment as a therapeutic option against cisplatin-induced nephrotoxicity. Toxicology Research, 2019, 8, 723-730.	0.9	4
2047	Mammalian DNA Polymerase Kappa Activity and Specificity. Molecules, 2019, 24, 2805.	1.7	28
2048	A Nanobodyâ€Conjugated DNA Nanoplatform for Targeted Platinumâ€Drug Delivery. Angewandte Chemie - International Edition, 2019, 58, 14224-14228.	7.2	135
2049	Lobaplatin-Induced Apoptosis Requires p53-Mediated p38MAPK Activation Through ROS Generation in Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 538.	1.3	15
2050	Glyconanoparticles for Targeted Tumor Therapy of Platinum Anticancer Drug. Biomacromolecules, 2019, 20, 2962-2972.	2.6	25
2051	Synthesis, structure and biological evaluation of mixed ligand oxidovanadium(<scp>iv</scp>) complexes incorporating 2-(arylazo)phenolates. New Journal of Chemistry, 2019, 43, 17711-17725.	1.4	21
2052	Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs. Journal of the American Chemical Society, 2019, 141, 12109-12120.	6.6	24
2053	Luminescent anticancer ruthenium(<scp>ii</scp>)-p-cymene complexes of extended imidazophenanthroline ligands: synthesis, structure, reactivity, biomolecular interactions and live cell imaging. Dalton Transactions, 2019, 48, 12257-12271.	1.6	30
2054	Beyond cisplatin: Combination therapy with arsenic trioxide. Inorganica Chimica Acta, 2019, 496, 119030.	1.2	20
2055	Enhanced Activity of Variant DNA Polymerase Î² (D160G) Contributes to Cisplatin Therapy by Impeding the Efficiency of NER. Molecular Cancer Research, 2019, 17, 2077-2088.	1.5	12
2056	Advances in Toxicological Research of the Anticancer Drug Cisplatin. Chemical Research in Toxicology, 2019, 32, 1469-1486.	1.7	215

#	Article	IF	Citations
2057	Synergistic effect of meta-tetra(hydroxyphenyl)chlorin-based photodynamic therapy followed by cisplatin on malignant Hep-2 cells . OncoTargets and Therapy, 2019, Volume 12, 5525-5536.	1.0	6
2058	The modulatory effect of green tea catechin on drug resistance in human ovarian cancer cells. Medicinal Chemistry Research, 2019, 28, 657-667.	1.1	19
2059	ATR inhibition sensitizes HPVâ^' and HPV+ head and neck squamous cell carcinoma to cisplatin. Oral Oncology, 2019, 95, 35-42.	0.8	34
2060	Comparative solution equilibria studies of complex formation between Ir(III) ion and antituberculosis drug analogues: Spectroscopic, potentiometric and conductometric approach. Journal of Molecular Liquids, 2019, 296, 111887.	2.3	4
2061	ILâ€7â€“Mediated ILâ€7Râ€JAK3/STAT5 signalling pathway contributes to chemotherapeutic sensitivity in nonâ€“smallâ€cell lung cancer. Cell Proliferation, 2019, 52, e12699.	2.4	8
2062	Poly (ADP-Ribose) Polymerase-1 (PARP1) Deficiency and Pharmacological Inhibition by Pirenzepine Protects From Cisplatin-Induced Ototoxicity Without Affecting Antitumor Efficacy. Frontiers in Cellular Neuroscience, 2019, 13, 406.	1.8	5
2063	Oxidative DNA Cleavage, Formation of Î¼-1,1-Hydroperoxo Species, and Cytotoxicity of Dicopper(II) Complex Supported by a p-Cresol-Derived Amide-Tether Ligand. Inorganic Chemistry, 2019, 58, 14294-14298.	1.9	10
2064	Copper(<scp>ii</scp>) complexes with 4-acyl pyrazolone derivatives and diimine coligands: synthesis, structural characterization, DNA binding and antitumor activity. New Journal of Chemistry, 2019, 43, 2529-2539.	1.4	20
2065	Synthesis and Structure of Î±-Aminophosphate and Its Interaction with DNA/BSA. Journal of Applied Spectroscopy, 2019, 86, 955-960.	0.3	1
2066	CpRu Complexes Containing Water Soluble Phosphane PTA and Natural Purines Adenine, Guanine and Theophylline: Synthesis, Characterization, and Antiproliferative Properties. European Journal of Inorganic Chemistry, 2019, 2019, 4078-4086.	1.0	11
2067	(â^')-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells. Cancer Cell International, 2019, 19, 266.	1.8	21
2068	Breast Cancer Metastasis and Drug Resistance. Advances in Experimental Medicine and Biology, 2019, , .	0.8	38
2069	Amino acid-linked platinum(II) compounds: non-canonical nucleoside preferences and influence on glycosidic bond stabilities. Journal of Biological Inorganic Chemistry, 2019, 24, 985-997.	1.1	4
2070	DNA- and DNA-Protein-Crosslink Repair in Plants. International Journal of Molecular Sciences, 2019, 20, 4304.	1.8	15
2071	Discovery of Inhibitors for Proliferating Cell Nuclear Antigen Using a Computational-Based Linked-Multiple-Fragment Screen. ACS Omega, 2019, 4, 15181-15196.	1.6	11
2072	Protein-mediated disproportionation of Au(<scp>i</scp>): insights from the structures of adducts of Au(<scp>iii</scp>) compounds bearingN,N-pyridylbenzimidazole derivatives with lysozyme. Dalton Transactions, 2019, 48, 14027-14035.	1.6	17
2073	Oxidation of Human Copper Chaperone Atox1 and Disulfide Bond Cleavage by Cisplatin and Glutathione. International Journal of Molecular Sciences, 2019, 20, 4390.	1.8	3
2074	Synthesis and characterization of mixed-ligand Zn(II) and Cu(II) complexes including polyamines and dicyano-dithiolate(2-): In vitro cytotoxic activity of Cu(II) compounds. Inorganica Chimica Acta, 2019, 498, 119098.	1.2	21

#	Article	IF	Citations
2075	Synthesis, physico-chemical studies and biological evaluation of new metal complexes with some pyrazolone derivatives. Journal of Saudi Chemical Society, 2019, 23, 1192-1205.	2.4	10
2076	Multifunctional, heterometallic ruthenium-platinum complexes with medicinal applications. Coordination Chemistry Reviews, 2019, 401, 213067.	9.5	36
2077	DNA cleavage, DNA/HSA binding study, and antiproliferative activity of a phenolate-bridged binuclear copper(II) complex. BioMetals, 2019, 32, 227-240.	1.8	10
2078	Synthesis, characterization and biological investigation of platinum(<scp>ii</scp>) complexes with asparagusic acid derivatives as ligands. Dalton Transactions, 2019, 48, 936-944.	1.6	14
2079	Experimental and theoretical investigation of cyclometallated platinum(<scp>ii</scp>) complex containing adamantanemethylcyanamide and 1,4-naphthoquinone derivative as ligands: synthesis, characterization, interacting with guanine and cytotoxic activity. RSC Advances, 2019, 9, 287-300.	1.7	10
2080	Reaction with Proteins of a Five-Coordinate Platinum(II) Compound. International Journal of Molecular Sciences, 2019, 20, 520.	1.8	6
2081	Crocin, a carotenoid, suppresses spindle microtubule dynamics and activates the mitotic checkpoint by binding to tubulin. Biochemical Pharmacology, 2019, 163, 32-45.	2.0	15
2082	pH/redox dual-sensitive platinum (IV)-based micelles with greatly enhanced antitumor effect for combination chemotherapy. Journal of Colloid and Interface Science, 2019, 541, 30-41.	5.0	44
2083	Tandem mass spectrometry characterization of a conjugate between oleuropein and hydrated cisâ€diammineplatinum(II). Rapid Communications in Mass Spectrometry, 2019, 33, 657-666.	0.7	5
2084	Synthesis and crystal structure of bicopper(II) complexes: The influence of bridging ligands on DNA/BSA binding behaviors and in vitro antitumor activity. Inorganica Chimica Acta, 2019, 488, 219-228.	1.2	9
2085	Synthesis, characterisation, molecular docking, biomolecular interaction and cytotoxicity studies of novel ruthenium(<scp>ii</scp>)â€“arene-2-heteroarylbenzoxazole complexes. New Journal of Chemistry, 2019, 43, 3291-3302.	1.4	31
2086	Contribution of Base Damages to the Molecular Radiosensitization Mechanism of Platinum Chemotherapeutic Drugs. ChemistrySelect, 2019, 4, 1084-1091.	0.7	3
2087	Synthesis, crystal structures, and antiglioma activity evaluation of two novel Ho(III) metal-organic complexes. Journal of Coordination Chemistry, 2019, 72, 716-726.	0.8	2
2088	Studies on the synthesis, characterization, cytotoxic activities and plasmid DNA binding of platinum(II) complexes having 2-subsituted benzimidazole ligands. Polyhedron, 2019, 161, 298-308.	1.0	12
2089	Facile synthesis of superhydrophobic three-metal-component layered double hydroxide films on aluminum foils for highly improved corrosion inhibition. New Journal of Chemistry, 2019, 43, 2289-2298.	1.4	24
2090	Chlorambucil targets <scp>BRCA</scp> 1/2â€deficient tumours and counteracts <scp>PARP</scp> inhibitor resistance. EMBO Molecular Medicine, 2019, 11, e9982.	3.3	26
2091	Synthesis, Structure and In Vitro Anti-gastric Cancer Activity of Two New Mixed-Ligand Cu(II) and Cd(II)-Coordination Polymers. Journal of Inorganic and Organometallic Polymers and Materials, 2019, 29, 1184-1191.	1.9	7
2092	Systematic investigation of the antiproliferative activity of a series of ruthenium terpyridine complexes. Journal of Inorganic Biochemistry, 2019, 198, 110752.	1.5	47

#	Article	IF	Citations
2093	Current Applications of Nanoemulsions in Cancer Therapeutics. Nanomaterials, 2019, 9, 821.	1.9	147
2094	A Pt(IV) prodrug of kiteplatin with the bone-targeting pyrophosphate ligand. Inorganica Chimica Acta, 2019, 494, 98-104.	1.2	6
2095	Palladium(ii) and platinum(ii) complexes of glyoxalbis(N-aryl)osazone: molecular and electronic structures, anti-microbial activities and DNA-binding study. New Journal of Chemistry, 2019, 43, 9891-9901.	1.4	5
2096	Absolute cross sections for chemoradiation therapy: Damages to cisplatin-DNA complexes induced by 10 eV electrons. Journal of Chemical Physics, 2019, 150, 195101.	1.2	5
2097	Adsorption and Diffusion of Cisplatin Molecules in Nanoporous Materials: A Molecular Dynamics Study. Biomolecules, 2019, 9, 204.	1.8	11
2098	Novel Amphiphilic Cyclobutene and Cyclobutane cis-C18 Fatty Acid Derivatives Inhibit Mycobacterium avium subsp. paratuberculosis Growth. Veterinary Sciences, 2019, 6, 46.	0.6	5
2099	Unprecedented isolation of a dinuclear tin (II) complex stabilized by pyridineâ€2,6â€dimethanol: structure, DFT and in vitro screening of cytotoxic properties. Applied Organometallic Chemistry, 2019, 33, e5006.	1.7	13
2100	New Heteroleptic Ruthenium(II) Complexes with Sulfamethoxypyridazine and Diimines as Potential Antitumor Agents. Molecules, 2019, 24, 2154.	1.7	9
2101	Pyridylbenzimidazole-Based Gold(III) Complexes: Lysozyme Metalation, DNA Binding Studies, and Biological Activity. European Journal of Inorganic Chemistry, 2019, 2019, 2830-2838.	1.0	14
2102	Has vitamin E any shreds of evidence in cisplatinâ€induced toxicity. Journal of Biochemical and Molecular Toxicology, 2019, 33, e22349.	1.4	22
2103	Advances in the relationship between glycosyltransferases and multidrug resistance in cancer. Clinica Chimica Acta, 2019, 495, 417-421.	0.5	25
2104	Propofol alleviates cisplatin-related cognitive impairment. Neurological Sciences, 2019, 40, 1645-1649.	0.9	9
2105	Wogonin pre-treatment attenuates cisplatin-induced nephrotoxicity in rats: Impact on PPAR-Î³, inflammation, apoptosis and Wnt/Î²-catenin pathway. Chemico-Biological Interactions, 2019, 308, 137-146.	1.7	39
2106	Synthesis and structure characterization of Pt(IV) and Cd(II) 1,10-phenanthroline complexes; fluorescence, antitumor and photocatalytic property. Journal of Molecular Structure, 2019, 1192, 230-240.	1.8	16
2107	Tripodal Oâ€Nâ€O Bisâ€Phenolato Amine Titanium(IV) Complexes Show High in vitro Antiâ€Cancer Activity. European Journal of Inorganic Chemistry, 2019, 2019, 2774-2780.	1.0	8
2108	Radicalic cleavage pathway and DNA docking studies of novel chemotherapic platinum agent of 5,6-di-2-ithienyl-2,3-dihydropyrazine. Polyhedron, 2019, 170, 25-33.	1.0	4
2109	Novel pyridine-derived platinum complexes. Journal of Thermal Analysis and Calorimetry, 2019, 138, 297-307.	2.0	5
2110	Discovery of Cisplatin Binding to Thymine and Cytosine on a Single-Stranded Oligodeoxynucleotide by High Resolution FT-ICR Mass Spectrometry. Molecules, 2019, 24, 1852.	1.7	20

#	Article	IF	Citations
2111	Platinum(II) complexes containing hydrazideâ€based aminophosphine ligands: Synthesis, molecular structures, computational investigation and evaluation as antitumour agents. Applied Organometallic Chemistry, 2019, 33, e4873.	1.7	4
2112	Roles of volume-regulatory anion channels, VSOR and Maxi-Cl, in apoptosis, cisplatin resistance, necrosis, ischemic cell death, stroke and myocardial infarction. Current Topics in Membranes, 2019, 83, 205-283.	0.5	34
2113	Platinum (II) Nâ€heterocyclic carbene complexes: Synthesis, characterization and cytotoxic properties. Applied Organometallic Chemistry, 2019, 33, e4851.	1.7	7
2114	Theoretical Study of the Interaction between Graphyne and cis-PtCl2(NH3)2 Complex. Russian Journal of Inorganic Chemistry, 2019, 64, 369-376.	0.3	1
2115	Phosphineâ€“copper(I) complexes as anticancer agents: design, synthesis, and physicochemical characterization. Part I. , 2019, , 61-82.		6
2116	Proteomic Strategy for Identification of Proteins Responding to Cisplatin-Damaged DNA. Analytical Chemistry, 2019, 91, 6035-6042.	3.2	14
2117	Reaction of Histone H1 with trans-Platinum Complexes and the Effect on DNA Platination. Inorganic Chemistry, 2019, 58, 6485-6494.	1.9	2
2118	An unexpected mixed valence tetranuclear copper(I/II) complex: Synthesis, structural characterization, DNA/protein binding, antioxidant and anticancer properties. Polyhedron, 2019, 167, 137-150.	1.0	24
2119	New insights into germ cell tumor genomics. Andrology, 2019, 7, 507-515.	1.9	23
2120	Mixed ligand ternary complexes of Co(II), Ni(II), Cu(II) and Zn(II) and their structural characterization, electrochemical, theoretical and biological studies. Journal of Molecular Structure, 2019, 1187, 108-120.	1.8	13
2121	Four-component relativistic ³¹P NMR calculations for trans-platinum(<scp>ii</scp>) complexes: importance of the solvent and dynamics in spectral simulations. Dalton Transactions, 2019, 48, 8076-8083.	1.6	18
2122	The comparative study of the DNA binding and biological activities of the quaternized dicnq as a dicationic form and its platinum(II) heteroleptic cationic complex. Bioorganic Chemistry, 2019, 87, 70-77.	2.0	16
2123	Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models. Theranostics, 2019, 9, 1426-1452.	4.6	53
2124	Anticancer Ir III â€“Aspirin Conjugates for Enhanced Metabolic Immunoâ€Modulation and Mitochondrial Lifetime Imaging. Chemistry - A European Journal, 2019, 25, 7012-7022.	1.7	24
2125	Fibroblasts from patients with idiopathic pulmonary fibrosis are resistant to cisplatin-induced cell death via enhanced CK2-dependent XRCC1 activity. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 499-510.	2.2	11
2126	Enhancement of chemoradiation by coâ€incorporation of gold nanoparticles and cisplatin into alginate hydrogel. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2019, 107, 2658-2663.	1.6	55
2127	In Vitro Cytotoxicity and In Vivo Antitumor Efficacy of Tetrazolato-Bridged Dinuclear Platinum(II) Complexes with a Bulky Substituent at Tetrazole C5. Inorganics, 2019, 7, 5.	1.2	7
2128	Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry, 2019, 88, 102925.	2.0	961

#	Article	IF	Citations
2129	A combined experimental and theoretical approach to investigate the structure, magnetic properties and DNA binding affinity of a homodinuclear Cu(<scp>ii</scp>) complex. New Journal of Chemistry, 2019, 43, 7511-7519.	1.4	23
2130	The ameliorative effects of ceftriaxone and vitamin E against cisplatin-induced nephrotoxicity. Environmental Science and Pollution Research, 2019, 26, 15248-15254.	2.7	28
2131	Synthesis, characterization, lipophilicity and cytotoxic properties of novel bis(carboxylato)oxalatobis(1-propylamine)platinum(IV) complexes. Inorganica Chimica Acta, 2019, 491, 76-83.	1.2	3
2132	A nuclear permeable Ru(ii)-based photoactivated chemotherapeutic agent towards a series of cancer cells: in vitro and in vivo studies. Dalton Transactions, 2019, 48, 6492-6500.	1.6	26
2133	Dinuclear platinum(II) complexes of imidazophenanthroline-based bridging ligands as potential anticancer agents: synthesis, characterization, and in vitro cytotoxicity studies. Journal of Biological Inorganic Chemistry, 2019, 24, 405-418.	1.1	10
2134	Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes. Molecular Human Reproduction, 2019, 25, 433-444.	1.3	77
2135	Recent Advances and Developments of inâ€...vitro Evaluation of Heterocyclic Moieties on Cancer Cell Lines. Chemical Record, 2019, 19, 362-393.	2.9	30
2136	Co-delivery of Cisplatin(IV) and Capecitabine as an Effective and Non-toxic Cancer Treatment. Frontiers in Pharmacology, 2019, 10, 110.	1.6	13
2137	Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics. Molecules, 2019, 24, 581.	1.7	19
2138	In vitro cytotoxic and apoptotic effect of vicâ€dioxime ligand and its metal complexes. Applied Organometallic Chemistry, 2019, 33, e4818.	1.7	4
2139	Cisplatin, glutathione and the third wheel: a copper-(1,10-phenanthroline) complex modulates cisplatinâ€“GSH interactions from antagonism to synergism in cancer cells resistant to cisplatin. RSC Advances, 2019, 9, 5362-5376.	1.7	9
2140	Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators. Journal of Inorganic Biochemistry, 2019, 195, 130-140.	1.5	23
2141	Preparation, spectral, antimicrobial properties and anticancer molecular docking studies of new metal complexes [M(caffeine)4] (PF6)2; MÂ= Fe(II), Co(II), Mn(II), Cd(II), Zn(II), Cu(II), Ni(II). Journal of Molecular Structure, 2019, 1184, 262-270.	1.8	26
2142	Self-assembled ruthenium (II) metallacycles and metallacages with imidazole-based ligands and their in vitro anticancer activity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4090-4098.	3.3	33
2143	Platinum Polyoxoniobates Form Adducts with DNA. Russian Journal of Bioorganic Chemistry, 2019, 45, 641-646.	0.3	4
2144	FTIR Study of the Secondary Structure of DNA in Complexes with Platinum Coordination Compounds. Journal of Physics: Conference Series, 2019, 1400, 033004.	0.3	3
2145	Ruthenium(<scp>ii</scp>) and palladium(<scp>ii</scp>) homo- and heterobimetallic complexes: synthesis, crystal structures, theoretical calculations and biological studies. Dalton Transactions, 2019, 48, 15869-15887.	1.6	8
2146	Synthesis, characterisation and potent cytotoxicity of unconventional platinum(<scp>iv</scp>) complexes with modified lipophilicity. Dalton Transactions, 2019, 48, 17217-17227.	1.6	16

#	Article	IF	Citations
2147	Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(<scp>iv</scp>) prodrugs as potent anticancer agents. Dalton Transactions, 2019, 48, 17228-17240.	1.6	30
2148	Beclin1 affected by DN604 upregulates chemo-sensitivity of cervix SiHa cancer cells via inhibiting CK2-MRN-DSBs repair. Anti-Cancer Drugs, 2019, 30, 774-783.	0.7	0
2149	Zinc(II) Terpyridine Complexes: Substituent Effect on Photoluminescence, Antiproliferative Activity, and DNA Interaction. Molecules, 2019, 24, 4519.	1.7	27
2150	Synthesis, DNA binding and in vitro cytotoxicity studies of a mononuclear copper(II) complex containing N2S(thiolate)Cu core and 1,10-phenanthroline as a coligand. Inorganica Chimica Acta, 2019, 484, 219-226.	1.2	18
2151	Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials. Advanced Materials, 2019, 31, e1802725.	11.1	230
2152	Synthesis, X-ray structure and in vitro cytotoxicity of trans-diammineplatinum(II) complexes of selenones, trans-[Pt(NH3)2(selenone)2](NO3)2. Polyhedron, 2019, 158, 234-240.	1.0	8
2153	Amine-fnctionalized silver and gold N-heterocyclic carbene complexes: Synthesis, characterization and antitumor properties. Journal of Organometallic Chemistry, 2019, 882, 26-32.	0.8	26
2154	Luminescent Cycloplatinated Complexes with Biologically Relevant Phosphine Ligands: Optical and Cytotoxic Properties. Inorganic Chemistry, 2019, 58, 1657-1673.	1.9	30
2155	Exploring the Cytotoxicity, Uptake, Cellular Response, and Proteomics of Mono- and Dinuclear DNA Light-Switch Complexes. Journal of the American Chemical Society, 2019, 141, 2925-2937.	6.6	53
2156	Some divalent metal(II) complexes of salicylaldehydeâ€derived Schiff bases: Synthesis, spectroscopic characterization, antimicrobial and in vitro anticancer studies. Applied Organometallic Chemistry, 2019, 33, e4693.	1.7	64
2157	Electron impact ionisation cross sections of cis- and trans-diamminedichloridoplatinum(II) and its hydrolysis products. Molecular Physics, 2019, 117, 2233-2240.	0.8	6
2158	Global Folding of a Na⁺â€Specific DNAzyme Studied by FRET. ChemBioChem, 2019, 20, 385-393.	1.3	3
2159	Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands. Journal of Inorganic Biochemistry, 2019, 191, 1-7.	1.5	26
2160	Apocynin alleviates cisplatinâ€induced testicular cytotoxicity by regulating oxidative stress and apoptosis in rats. Andrologia, 2019, 51, e13227.	1.0	31
2161	Synthesis and structureâ€“activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes: A small modification at tetrazole C5 markedly influences the in vivo antitumor efficacy. Journal of Inorganic Biochemistry, 2019, 192, 82-86.	1.5	9
2162	Synthesis and computational study of new meta- and para-substituted ferrocenyl thioureas as potent protein kinase inhibitors and cytotoxic agents. Inorganica Chimica Acta, 2019, 488, 8-18.	1.2	1
2163	New bioactive ferrocene-substituted heteroleptic copper(I) complex: Synthesis, structural elucidation, DNA interaction, and DFT study. Journal of Organometallic Chemistry, 2019, 879, 60-68.	0.8	11
2164	Diffusion of cisplatin molecules in silica nanopores: Molecular dynamics study of a targeted drug delivery system. Journal of Molecular Graphics and Modelling, 2019, 86, 228-234.	1.3	13

#	Article	IF	Citations
2165	New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules. BioMetals, 2019, 32, 33-47.	1.8	13
2166	Synthesis, characterization and biological activity of mixed ligands complexes of quinolin-8-ol and substituted chromones with Mn(II), Co(II), Ni(II) and Cu(II) metal ions. Research on Chemical Intermediates, 2019, 45, 973-996.	1.3	9
2167	Mass spectrometric discrimination of phospholipid patterns in cisplatinâ€resistant and â€sensitive cancer cells. Rapid Communications in Mass Spectrometry, 2019, 33, 97-106.	0.7	6
2168	A novel binuclear hydrazone-based Cd(II) complex is a strong pro-apoptotic inducer with significant activity against 2D and 3D pancreatic cancer stem cells. Journal of Inorganic Biochemistry, 2019, 190, 45-66.	1.5	8
2169	Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Acta Biomaterialia, 2019, 84, 367-377.	4.1	101
2170	Development of novel Cu(I) compounds with vitamin B1 derivative and their potential application as anticancer drugs. Inorganica Chimica Acta, 2019, 487, 287-294.	1.2	2
2171	Synthesis, spectroscopic characterization and in vitro cytotoxic as well as docking studies of cis-diammine platinum(II) complexes of thiones. Inorganica Chimica Acta, 2019, 484, 347-351.	1.2	5
2172	Molecular and Cellular Basis of Chemoresistance in Ovarian Cancer. , 2019, , 575-593.		2
2173	Association Between Dose and Duration of Cisplatin Exposure with Cytotoxicity Effect on Nasopharyngeal Carcinoma Stem Cell. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, 71, 373-377.	0.3	2
2174	Raman spectroscopy: A novel experimental approach to evaluating cisplatin induced tissue damage. Talanta, 2020, 207, 120343.	2.9	10
2175	A novel Cu(II) distorted cubane complex containing Cu4O4 core as the first tetranuclear catalyst for temperature dependent oxidation of 3,5-di-tert-butyl catechol and in interaction with DNA & protein (BSA). Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 227, 117593.	2.0	22
2176	Yb(III), Sm(III) and La(III) complexes of a tetradentate pyridoxal Schiff base ligand: Their DNA-binding activity and bio-imaging applications. Polyhedron, 2020, 175, 114167.	1.0	4
2177	Crystal structure, DNA crosslinking and photo-induced cytotoxicity of oxovanadium(IV) conjugates of boron-dipyrromethene. Journal of Inorganic Biochemistry, 2020, 202, 110817.	1.5	10
2178	Bioactive vitaminâ€“metal compounds: other potential applications of vitamins. , 2020, , 33-49.		2
2179	Cisplatinâ€induced alteration on membrane composition of A549 cells revealed by ToFâ€SIMS. Surface and Interface Analysis, 2020, 52, 256-263.	0.8	9
2180	Pt(II) and Pd(II) complexes with a thiazoline derivative ligand: Synthesis, structural characterization, antiproliferative activity and evaluation of pro-apoptotic ability in tumor cell lines HT-29 and U-937. Journal of Inorganic Biochemistry, 2020, 202, 110870.	1.5	12
2181	Synthesis, characterization, DNA binding, topoisomerase inhibition, and apoptosis induction studies of a novel cobalt(III) complex with a thiosemicarbazone ligand. Journal of Inorganic Biochemistry, 2020, 203, 110907.	1.5	21
2182	Rationalization of the Superior Anticancer Activity of Phenanthriplatin: An Inâ€Depth Computational Exploration. Chemistry - A European Journal, 2020, 26, 259-268.	1.7	17

#	Article	IF	Citations
2183	Fiveâ€Coordinate Platinum(II) Compounds as Potential Anticancer Agents. European Journal of Inorganic Chemistry, 2020, 2020, 918-929.	1.0	24
2184	Water-soluble conjugated polymeric micelles as a carrier for studying Pt(<scp>iv</scp>) release and imaging in living cells. Polymer Chemistry, 2020, 11, 1720-1726.	1.9	2
2185	NAMI-A preferentially reacts with the Sp1 protein: understanding the anti-metastasis effect of the drug. Chemical Communications, 2020, 56, 1397-1400.	2.2	13
2186	A novel molecularly imprinted polymer decorated by CQDs@HBNNS nanocomposite and UiO-66-NH2 for ultra-selective electrochemical sensing of Oxaliplatin in biological samples. Sensors and Actuators B: Chemical, 2020, 307, 127614.	4.0	53
2187	Recent advances in synthesis, metal complexes and biological evaluation of 2-aryl, 2-pyridyl and 2-pyrimidylbenzothiazoles as potential chemotherapeutics. Inorganica Chimica Acta, 2020, 502, 119302.	1.2	21
2188	Near-Infrared Light Irradiation Induced Mild Hyperthermia Enhances Glutathione Depletion and DNA Interstrand Cross-Link Formation for Efficient Chemotherapy. ACS Nano, 2020, 14, 14831-14845.	7.3	67
2189	Encapsulation of a Ru(Î·⁶-p-cymene) complex of the antibacterial drug trimethoprim into a polydiacetylene-phospholipid assembly to enhance its in vitro anticancer and antibacterial activities. New Journal of Chemistry, 2020, 44, 20047-20059.	1.4	9
2190	(Î·6-Arene) ruthenium(II) complexes with ferrocene-tethered salicylaldimine ligands: Synthesis, characterization and anti-cancer properties. Polyhedron, 2020, 192, 114829.	1.0	6
2191	A comparative computational mechanistic study on derivatives of pyriplatin, modified with the â€“CH2Ph3P+ group, as anticancer complexes targeting mitochondria. Inorganica Chimica Acta, 2020, 512, 119863.	1.2	3
2192	Biological properties of a benzothiazole-based mononuclear platinum(II) complex as a potential anticancer agent. Journal of Coordination Chemistry, 2020, 73, 1817-1832.	0.8	8
2193	Photoactivatable diazido Pt(iv) anticancer complex can bind to and oxidize all four nucleosides. Dalton Transactions, 2020, 49, 17157-17163.	1.6	7
2194	MicroRNA-1291-5p Sensitizes Pancreatic Carcinoma Cells to Arginine Deprivation and Chemotherapy through the Regulation of Arginolysis and Glycolysis. Molecular Pharmacology, 2020, 98, 686-694.	1.0	21
2195	Effects of Substituent Groups on the Crystal Structures and Anti-Cervical Cancer Activity of Zero-/Two-Dimensional Cu(II) Complexes. Journal of Structural Chemistry, 2020, 61, 133-140.	0.3	1
2196	A recombinant platform to characterize the role of transmembrane protein hTMEM205 in Pt(ii)-drug resistance and extrusion. Metallomics, 2020, 12, 1542-1554.	1.0	2
2197	Interaction of CT-DNA with Ruthenium(II) Metallosurfactant Complexes: Synthesis, CMC Determination, Antitumour and Antimicrobial Activities. Asian Journal of Chemistry, 2020, 32, 665-677.	0.1	4
2198	Titanium Tackles the Endoplasmic Reticulum: A First Genomic Study on a Titanium Anticancer Metallodrug. IScience, 2020, 23, 101262.	1.9	18
2199	Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs. International Journal of Molecular Sciences, 2020, 21, 4741.	1.8	7
2200	Reactions of a photoactivatable diazido Pt(iv) anticancer complex with a single-stranded oligodeoxynucleotide. Dalton Transactions, 2020, 49, 11249-11259.	1.6	7

#	Article	IF	Citations
2201	Enolate-forming compounds provide protection from platinum neurotoxicity. Chemico-Biological Interactions, 2020, 317, 108961.	1.7	1
2202	Newly Synthesized Imino-Derivatives Analogues of Resveratrol Exert Inhibitory Effects in Breast Tumor Cells. International Journal of Molecular Sciences, 2020, 21, 7797.	1.8	21
2203	Visualization of uracils created by APOBEC3A using UdgX shows colocalization with RPA at stalled replication forks. Nucleic Acids Research, 2020, 48, e118-e118.	6.5	19
2204	Inhibition of histone deacetylases, topoisomerases and epidermal growth factor receptor by metal-based anticancer agents: Design & synthetic strategies and their medicinal attributes. Bioorganic Chemistry, 2020, 105, 104396.	2.0	15
2205	Targeting SKA3 suppresses the proliferation and chemoresistance of laryngeal squamous cell carcinoma via impairing PLK1â€“AKT axis-mediated glycolysis. Cell Death and Disease, 2020, 11, 919.	2.7	38
2206	In vitro reactions of a cyanocobalaminâ€“cisplatin conjugate with nucleoside monophosphates. Rapid Communications in Mass Spectrometry, 2020, 34, e8945.	0.7	1
2207	Reactive Pt(II) center as part of redox-active quinoline-based heterocyclic scaffolds toward new anticancer leads. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127594.	1.0	6
2208	Antioxidant effect of acetyl-l-carnitine against cisplatin-induced cardiotoxicity. Journal of International Medical Research, 2020, 48, 030006052095139.	0.4	14
2209	Cisplatin adducts of DNA as precursors for nanostructured catalyst materials. Nanoscale Advances, 2020, 2, 4491-4497.	2.2	4
2210	The Synergistic Anticancer Effect of Dual Drug- (Cisplatin/Epigallocatechin Gallate) Loaded Gelatin Nanoparticles for Lung Cancer Treatment. Journal of Nanomaterials, 2020, 2020, 1-15.	1.5	15
2211	SYNTHESIS, CRYSTAL STRUCTURE, AND ANTI-GASTRIC CANCER ACTIVITY OF A Zn(II) COORDINATION POLYMER WITH A 4,4â€²-BIS(1-IMIDAZOLYL)BIPHENYL LIGAND. Journal of Structural Chemistry, 2020, 61, 1103-1110.	0.3	1
2212	Stronger Cytotoxicity for Cancer Cells Than for Fast Proliferating Human Stem Cells by Rationally Designed Dinuclear Complexes. Inorganic Chemistry, 2020, 59, 14464-14477.	1.9	7
2213	Tandem Mass Spectrometry Reveals Preferential Ruthenation of Thymines in Human Telomeric G-Quadruplex DNA by an Organometallic Ruthenium Anticancer Complex. Organometallics, 2020, 39, 3315-3322.	1.1	6
2214	Synthesis and Biological Studies on Dinuclear Gold(I) Complexes with Di-(N-Heterocyclic Carbene) Ligands Functionalized with Carbohydrates. Molecules, 2020, 25, 3850.	1.7	6
2215	Next-generation DNA damage sequencing. Chemical Society Reviews, 2020, 49, 7354-7377.	18.7	56
2217	Phosphorescent Trinuclear Ptâ€“Irâ€“Pt Complexes: Insights into the Photophysical and Electrochemical Properties and Interaction with Guanine Nucleobase. Chemistry - A European Journal, 2020, 26, 14987-14995.	1.7	8
2218	DNA Nanostructures as Pt(IV) Prodrug Delivery Systems to Combat Chemoresistance. Small, 2020, 16, e2003646.	5.2	25
2219	A New Ni(II)-Containing Coordination Complex Based on Carboxylate and Multinitrogen Co-Ligands: Crystal Structure and Protective Effect on Type 2 Diabetes by Down-Regulating PKC and MAPK Activation. Journal of Structural Chemistry, 2020, 61, 955-962.	0.3	0

#	Article	IF	Citations
2220	Reactivity towards DNA and protein, cellular uptake, cytotoxic activity of a mononuclear copper(II) complex of the thioflavin-T (ThT)-based derivative. Journal of Coordination Chemistry, 2020, 73, 1987-2003.	0.8	3
2221	Molecular dynamics simulation of non-covalent interactions between polynuclear platinum(II) complexes and DNA. Journal of Biological Inorganic Chemistry, 2020, 25, 963-978.	1.1	6
2222	Hypoxia efficient and glutathione-resistant cytoselective ruthenium(<scp>ii</scp>)-p-cymene-arylimidazophenanthroline complexes: biomolecular interaction and live cell imaging. Dalton Transactions, 2020, 49, 12865-12878.	1.6	20
2223	Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints. Nature Communications, 2020, 11, 4124.	5.8	20
2224	Inhibition of Type IV Secretion Activity and Growth of Helicobacter pylori by Cisplatin and Other Platinum Complexes. Frontiers in Cellular and Infection Microbiology, 2020, 10, 602958.	1.8	11
2225	Cisplatin-Induced Giant Cells Formation Is Involved in Chemoresistance of Melanoma Cells. International Journal of Molecular Sciences, 2020, 21, 7892.	1.8	10
2226	In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma. International Journal of Molecular Sciences, 2020, 21, 7826.	1.8	2
2227	Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies. Bioorganic Chemistry, 2020, 105, 104430.	2.0	17
2228	Two new coordination polymers based on the 2,4,6-tri(1H-imidazol-1-yl)-1,3,5-triazine ligand: Structures and anticancer activity on human osteogenic sarcoma cell. Main Group Chemistry, 2020, 19, 19-29.	0.4	0
2229	Recent advances in anticancer ruthenium Schiff base complexes. Applied Organometallic Chemistry, 2020, 34, e5687.	1.7	49
2230	Development of highly potent Arene-Ru (II)-ninhydrin complexes for inhibition of cancer cell growth. Inorganica Chimica Acta, 2020, 508, 119641.	1.2	8
2231	Glycoconjugated Metallohelices have Improved Nuclear Delivery and Suppress Tumour Growth In Vivo. Angewandte Chemie - International Edition, 2020, 59, 14677-14685.	7.2	10
2232	Duplication and divergence: New insights into AXR1 and AXL functions in DNA repair and meiosis. Scientific Reports, 2020, 10, 8860.	1.6	8
2233	Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies. Advances in Medical Sciences, 2020, 65, 265-285.	0.9	29
2234	Modified pyrazole platinum(II) complex can circumvent albumin and glutathione: Synthesis, structure and cytotoxic activity. Bioorganic Chemistry, 2020, 100, 103936.	2.0	11
2235	Unexpected Thymine Oxidation and Collision-Induced Thymine-Pt-guanine Cross-Linking on 5â€²-TpG and 5â€²-GpT by a Photoactivatable Diazido Pt(IV) Anticancer Complex. Inorganic Chemistry, 2020, 59, 8468-8480.	1.9	10
2236	Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(<scp>iv</scp>) prodrugs with prolonged circulation time in blood. Dalton Transactions, 2020, 49, 8107-8113.	1.6	10
2237	Two photoactive Ru (II) compounds based on tetrazole ligands for photodynamic therapy. Journal of Inorganic Biochemistry, 2020, 210, 111127.	1.5	15

#	Article	IF	Citations
2239	The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicology and Applied Pharmacology, 2020, 401, 115091.	1.3	6
2240	Glycoconjugated Metallohelices have Improved Nuclear Delivery and Suppress Tumour Growth In Vivo. Angewandte Chemie, 2020, 132, 14785-14793.	1.6	1
2241	Synthesis, DNA binding and antimicrobial studies on rhodium(II) complexes of dicyandiamide. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 923-942.	0.4	4
2242	Multiparametric analysis of the effectiveness of cisplatin on cutaneous squamous carcinoma cellsÂusing two different types of adjuvants. PLoS ONE, 2020, 15, e0230022.	1.1	4
2244	Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action. Journal of Inorganic Biochemistry, 2020, 207, 111070.	1.5	61
2245	Reduction of the Cisplatin Toxicity by Its Conjugation with Arabinogalactan. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2020, 14, 61-66.	0.3	1
2246	Synthesis, characterization, photoluminescence, antiproliferative activity, and DNA interaction of cadmium(II) substituted 4â€²-phenyl-terpyridine compounds. Journal of Inorganic Biochemistry, 2020, 210, 111165.	1.5	19
2247	Blue moon ensemble simulation of aquation free energy profiles applied to mono and bifunctional platinum anticancer drugs. Journal of Computational Chemistry, 2020, 41, 1973-1984.	1.5	7
2248	NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation. Nature Communications, 2020, 11, 3256.	5.8	56
2249	Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects. Molecular Pharmaceutics, 2020, 17, 3009-3023.	2.3	8
2250	Different Effects of Cisplatin and Transplatin on the Higher-Order Structure of DNA and Gene Expression. International Journal of Molecular Sciences, 2020, 21, 34.	1.8	18
2251	Inhibition of thioredoxin reductase 1 correlates with platinum-based chemotherapeutic induced tissue injury. Biochemical Pharmacology, 2020, 175, 113873.	2.0	16
2252	DNA Structural Distortions Induced by a Monofunctional Trinuclear Platinum Complex with Various Cross-Links Using Molecular Dynamics Simulation. Journal of Chemical Information and Modeling, 2020, 60, 1700-1708.	2.5	11
2253	Interactions of Cisplatin and Daunorubicin at the Chromatin Level. Scientific Reports, 2020, 10, 1107.	1.6	8
2254	Anticancer drug and ionizing radiation-induced DNA damage differently influences transcription activity and DDR-related stress responses of an endothelial monolayer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118678.	1.9	7
2255	Synthesis, characterization and antitumor properties of novel silver(I) and gold(I) N-heterocyclic carbene complexes. Inorganica Chimica Acta, 2020, 506, 119530.	1.2	22
2256	Synthesis, characterization, biological determination and catalytic evaluation of ruthenium(ii) complexes bearing benzimidazole-based NHC ligands in transfer hydrogenation catalysis. New Journal of Chemistry, 2020, 44, 5309-5323.	1.4	18
2257	Anticancer palladium-doped magnesia nanoparticles: synthesis, characterization, and in vitro study. Nanomedicine, 2020, 15, 547-561.	1.7	8

#	Article	IF	Citations
2258	Increasing the Cytotoxicity of Ru(II) Polypyridyl Complexes by Tuning the Electronic Structure of Dioxo Ligands. Journal of the American Chemical Society, 2020, 142, 6066-6084.	6.6	44
2259	Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells. Molecular Oncology, 2020, 14, 686-703.	2.1	5
2260	Metalloimmunology: The metal ion-controlled immunity. Advances in Immunology, 2020, 145, 187-241.	1.1	148
2261	Osmium-Promoted Ïƒ-Bond Activation Reactions on Nucleosides. Organometallics, 2020, 39, 312-323.	1.1	20
2262	Sensitive CometChip assay for screening potentially carcinogenic DNA adducts by trapping DNA repair intermediates. Nucleic Acids Research, 2020, 48, e13-e13.	6.5	29
2263	Forensic touch DNA recovery from metal surfaces â€“ A review. Science and Justice - Journal of the Forensic Science Society, 2020, 60, 206-215.	1.3	46
2264	Protein binding studies with human serum albumin, molecular docking and in vitro cytotoxicity studies using HeLa cervical carcinoma cells of Cu(<scp>ii</scp>)/Zn(<scp>ii</scp>) complexes containing a carbohydrazone ligand. Dalton Transactions, 2020, 49, 2947-2965.	1.6	33
2265	Synthesis, structural characterization and in vitro anticancer activity of two new nickel complexes bearing imine bonds. Inorganic Chemistry Communication, 2020, 114, 107824.	1.8	7
2266	Trans-Pd/Pt(II) saccharinate complexes with a phosphine ligand: Synthesis, cytotoxicity and structure-activity relationship. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127077.	1.0	12
2267	Synthesis and in vitro cytotoxicity studies of Pd(II) and Pt(II) acetamide complexes: Molecular structures of trans-[PdCl2(bzmta)2].DMF (bzmtaÂ=Â2-acetylamino-6-methylbenzothiazole) and cis-[PtCl2(bzta)2].2DMF (bztaÂ=Â2-acetylaminobenzothiazole). Polyhedron, 2020, 185, 114591.	1.0	4
2268	Docking and in vitro molecular biology studies of p-anisidine-appended 1-hydroxy-2-acetonapthanone Schiff base lanthanum(<scp>iii</scp>) complexes. RSC Advances, 2020, 10, 16457-16472.	1.7	6
2269	First dinuclear rhodium(II) complexes with triazolopyrimidines and the prospect of their potential biological use. Journal of Inorganic Biochemistry, 2020, 210, 111072.	1.5	9
2270	Links between cancer metabolism and cisplatin resistance. International Review of Cell and Molecular Biology, 2020, 354, 107-164.	1.6	48
2271	Role of Transient Anions in Chemoradiation Therapy: Base Modifications, Cross-Links, and Cluster Damages Induced to Cisplatin-DNA Complexes by 1â€“20 eV Electrons. Journal of Physical Chemistry B, 2020, 124, 3315-3325.	1.2	8
2272	Reduced amino acid Schiff base containing ruthenium(III) complexes: Synthesis, characterization, DNA interaction, and in vitro cytotoxicity. Journal of Biochemical and Molecular Toxicology, 2020, 34, e22510.	1.4	4
2273	Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs. Biochemical Pharmacology, 2020, 176, 113913.	2.0	29
2274	Synthesis of (-)-epigallocatechin-3-gallate derivative containing a triazole ring and combined with cisplatin/paclitaxel inhibits NSCLC cancer cells by decreasing phosphorylation of the EGFR. Journal of Chemical Research, 2020, 44, 586-591.	0.6	5
2275	The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Frontiers in Pharmacology, 2020, 11, 343.	1.6	258

#	Article	IF	Citations
2276	Cross-linking of the DNA repair protein O6-alkylguanine DNA alkyltransferase to DNA in the presence of cisplatin. DNA Repair, 2020, 89, 102840.	1.3	5
2277	Ru(<scp>ii</scp>)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer. Dalton Transactions, 2020, 49, 16193-16203.	1.6	22
2278	A DNA-based nanocarrier for efficient cancer therapy. Journal of Pharmaceutical Analysis, 2021, 11, 330-339.	2.4	20
2279	Targeted Engineering of Medicinal Chemistry for Cancer Therapy: Recent Advances and Perspectives. Angewandte Chemie - International Edition, 2021, 60, 5626-5643.	7.2	47
2280	Zielgerichtete Wirkstoffe fÃ¼r die Krebstherapie: Aktuelle Entwicklungen und Perspektiven. Angewandte Chemie, 2021, 133, 5686-5705.	1.6	3
2281	Intracellular RNA and nuclear DNA-dual-targeted tumor therapy via upconversion nanoplatforms with UCL/MR dual-mode bioimaging. Chemical Engineering Journal, 2021, 405, 126606.	6.6	14
2282	Activatable Mitochondriaâ€Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy. Angewandte Chemie - International Edition, 2021, 60, 1403-1410.	7.2	81
2283	Activatable Mitochondriaâ€Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy. Angewandte Chemie, 2021, 133, 1423-1430.	1.6	7
2284	Probing the structure of Copper(II)-Casiopeina type coordination complexes [Cu(O-O)(N-N)]+ by EPR and ENDOR spectroscopy. Journal of Catalysis, 2021, 394, 220-227.	3.1	5
2285	Gold nanoparticles induced apoptosis via oxidative stress and mitochondrial dysfunctions in MCFâ€7 breast cancer cells. Applied Organometallic Chemistry, 2021, 35, .	1.7	25
2286	Cu (II) and Co (II/III) complexes of N,Oâ€chelated Schiff base ligands: DNA interaction, protein binding, cytotoxicity, cell death mechanism and reactive oxygen species generation studies. Applied Organometallic Chemistry, 2021, 35, .	1.7	11
2287	Luminescent ruthenium(II)-para-cymene complexes of aryl substituted imidazo-1,10-phenanthroline as anticancer agents and the effect of remote substituents on cytotoxic activities. Inorganica Chimica Acta, 2021, 515, 120066.	1.2	15
2288	Antioxidant, antimicrobial, DNA binding and cleavage studies of novel Co(II), Ni(II) and Cu(II) complexes of N, O donor Schiff bases: Synthesis and spectral characterization. Journal of Molecular Structure, 2021, 1229, 129606.	1.8	12
2289	Drive to organoruthenium and organoiridium complexes from organoplatinum: Next-generation anticancer metallotherapeutics. Inorganic Chemistry Communication, 2021, 124, 108364.	1.8	12
2290	Synthesis, characterization, DNA binding/cleavage, cytotoxic, apoptotic, and antibacterial activities of V(IV), Mo(VI), and Ru(II) complexes containing a bioactive ONSâ€donor chelating agent. Applied Organometallic Chemistry, 2021, 35, e6082.	1.7	8
2291	Cisplatin under oriented external electric fields: A deeper insight into electrochemotherapy at the molecular level. International Journal of Quantum Chemistry, 2021, 121, e26578.	1.0	4
2292	Cancer cell-targeted cisplatin prodrug delivery in vivo via metabolic labeling and bioorthogonal click reaction. Biomaterials Science, 2021, 9, 1301-1312.	2.6	11
2293	Cyanide Bridged Platinumâ€Iron Complexes as Cisplatin Prodrug Systems: Design and Computational Study. ChemPhysChem, 2021, 22, 106-111.	1.0	1

#	Article	IF	Citations
2294	Pd(II) and Pt(II) complexes with N-(1,3-benzothiazol-2-yl)acetamide ligands, spectroscopic characterization, DFT computational and in-vitro cytotoxicity studies. Materials Today: Proceedings, 2021, 43, 977-985.	0.9	6
2295	Simple Synthesis of a Heterocyclophane Exhibiting Antiâ€câ€Met Activity by Acting as a Hatch Blocking Access to the Active Site**. Chemistry - A European Journal, 2021, 27, 1648-1654.	1.7	1
2296	Pyrrolidinyl Peptide Nucleic Acid Probes Capable of Crosslinking with DNA: Effects of Terminal and Internal Modifications on Crosslink Efficiency. ChemBioChem, 2021, 22, 241-252.	1.3	5
2297	A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms. Mutagenesis, 2021, 36, 75-86.	1.0	19
2298	Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits. Theranostics, 2021, 11, 3109-3130.	4.6	57
2299	Platinum-based chemotherapyviananocarriers and co-delivery of multiple drugs. Biomaterials Science, 2021, 9, 6023-6036.	2.6	19
2300	Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance. Cells, 2021, 10, 260.	1.8	4
2302	Nitrile-containing copper(<scp>ii</scp>) porphyrin coordination complexes for efficient anticancer activity and mechanism research. New Journal of Chemistry, 2021, 45, 5221-5227.	1.4	6
2303	Multilayered Modelling of the Metallation of Biological Targets. Lecture Notes in Computer Science, 2021, , 398-412.	1.0	14
2304	HIF in Nephrotoxicity during Cisplatin Chemotherapy: Regulation, Function and Therapeutic Potential. Cancers, 2021, 13, 180.	1.7	9
2305	Synthesis, characterization, crystal structure, DNA and human serum albumin interactions, as well as antiproliferative activity of a Cu(II) complex containing a Schiff base ligand formed in situ from the Cu(II)â€induced cyclization of 1,5â€bis(salicylidene)thiocarbohydrazide. Applied Organometallic Chemistry, 2021, 35, e6152.	1.7	11
2306	Synthesis, structural characterization, and density functional theory calculations of the two new Zn (II) complexes as antibacterial and anticancer agents with a neutral flexible tetradentate pyrazoleâ€based ligand. Applied Organometallic Chemistry, 2021, 35, e6173.	1.7	18
2307	Single cell imaging reveals cisplatin regulating interactions between transcription (co)factors and DNA. Chemical Science, 2021, 12, 5419-5429.	3.7	14
2308	Theoretical Determination of Influence of the Metallic State of Oxidation toward Cytotoxic Activity: Case of Ruthenium Complexes. Computational Chemistry, 2021, 09, 97-119.	0.2	2
2309	GSH-resistant and highly cytoselective ruthenium(<scp>ii</scp>)-p-cymene-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol complexes as potential anticancer agents. Dalton Transactions, 2021, 50, 10369-10373.	1.6	15
2310	Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance. Journal of Materials Chemistry B, 2021, 9, 5173-5194.	2.9	42
2311	Structural determination of arginine-linked cisplatin complexes via IRMPD action spectroscopy: arginine binds to platinum via NO^{â˜} binding mode. Physical Chemistry Chemical Physics, 2021, 23, 21959-21971.	1.3	6
2312	Formation of negative and positive ions in the radiosensitizer nimorazole upon low-energy electron collisions. Journal of Chemical Physics, 2021, 154, 074306.	1.2	9

#	Article	IF	Citations
2313	The safety of current pharmacotherapeutic strategies for osteosarcoma. Expert Opinion on Drug Safety, 2021, 20, 427-438.	1.0	11
2314	Mononuclear iron(III) complexes derived from tridentate ligands containing nonâ€innocent phenolato donors: Selfâ€activated nuclease, protease, and phenoxazinone synthase activity studies. Applied Organometallic Chemistry, 2021, 35, e6185.	1.7	3
2315	Spatiotemporal Concurrent Liberation of Cytotoxins from Dual-Prodrug Nanomedicine for Synergistic Antitumor Therapy. ACS Applied Materials & Interfaces, 2021, 13, 6053-6068.	4.0	17
2316	Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. BMC Cancer, 2021, 21, 174.	1.1	28
2317	Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. Journal of Experimental Pharmacology, 2021, Volume 13, 303-328.	1.5	146
2318	Intramolecular interactions in a target specific anti-tumor nanodrug: a theoretical study. Journal of Physics Communications, 2021, 5, 035004.	0.5	0
2319	Combining Gold Nanoparticles with Other Radiosensitizing Agents for Unlocking the Full Potential of Cancer Radiotherapy. Pharmaceutics, 2021, 13, 442.	2.0	18
2320	SYNTHESIS OF SILVER- AND GOLD-N-HETEROCYCLIC CARBENE COMPLEXES INCLUDING STRONG METAL-CARBON BINDING. Hacettepe Journal of Biology and Chemistry, 0, , .	0.3	1
2321	Anticancer effect of sodium metavanadate on murine breast cancer both in vitro and in vivo. BioMetals, 2021, 34, 557-571.	1.8	1
2322	A Microfluidic Multisize Spheroid Array for Multiparametric Screening of Anticancer Drugs and Bloodâ€“Brain Barrier Transport Properties. Advanced Science, 2021, 8, e2004856.	5.6	46
2323	Pt(IV) Prodrugs with NSAIDs as Axial Ligands. International Journal of Molecular Sciences, 2021, 22, 3817.	1.8	38
2324	Role of <scp>FOXO</scp> protein's abnormal activation through <scp>PI3K</scp>/<scp>AKT</scp> pathway in platinum resistance of ovarian cancer. Journal of Obstetrics and Gynaecology Research, 2021, 47, 1946-1957.	0.6	8
2325	Resistin increases cisplatin-induced cytotoxicity in lung adenocarcinoma A549 cells via a mitochondria-mediated pathway. Medical Oncology, 2021, 38, 65.	1.2	3
2326	Polymeric Encapsulation of a Ru(II)-Based Photosensitizer for Folate-Targeted Photodynamic Therapy of Drug Resistant Cancers. Journal of Medicinal Chemistry, 2021, 64, 4612-4622.	2.9	26
2327	Protein-Based Nanomedicine for Therapeutic Benefits of Cancer. ACS Nano, 2021, 15, 8001-8038.	7.3	59
2328	Pt(IV) Prodrugs Designed to Embed in Nanotubes of a Polysaccharide for Drug Delivery. ACS Applied Bio Materials, 2021, 4, 4841-4848.	2.3	5
2329	Ru complexes containing Cp, mPTA and natural purine bases (mPTAÂ=Âmethyl-N-1,3,5-triaza-7-phosphaadamantane): Evaluation of their antiproliferative activity, solubility and redox properties. Journal of Inorganic Biochemistry, 2021, 218, 111404.	1.5	8
2330	Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas. International Journal of Molecular Sciences, 2021, 22, 5111.	1.8	18

#	Article	IF	Citations
2331	An Oligonucleotideâ€Distortionâ€Responsive Organic Transistor for Platinumâ€Drugâ€Induced DNAâ€Damage Detection. Advanced Materials, 2021, 33, e2100489.	11.1	10
2332	Rutheniumâ€based Photoactive Metalloantibiotics^{â€}. Photochemistry and Photobiology, 2022, 98, 6-16.	1.3	23
2333	Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential. Journal of Inorganic Biochemistry, 2021, 218, 111403.	1.5	7
2334	miRNAs Modulate the Dichotomy of Cisplatin Resistance or Sensitivity in Breast Cancer: An Update of Therapeutic Implications. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 1069-1081.	0.9	7
2335	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. Translational Oncology, 2021, 14, 101056.	1.7	17
2336	Synthesis and crystal growth of cadmium naphthoate crystal for second order non-linear optics and cytotoxic activity. Journal of Dispersion Science and Technology, 0, , 1-17.	1.3	11
2337	The intravenous administration of skin-derived mesenchymal stem cells ameliorates hearing loss and preserves cochlear hair cells in cisplatin-injected mice. Hearing Research, 2022, 413, 108254.	0.9	4
2338	Targeted nanomedicine modalities for prostate cancer treatment. Drug Resistance Updates, 2021, 56, 100762.	6.5	20
2339	Interaction between carboplatin with B12P12 and Al12P12 nano-clusters: A computational investigation. Phosphorus, Sulfur and Silicon and the Related Elements, 2021, 196, 751-759.	0.8	10
2340	Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. Communications Biology, 2021, 4, 638.	2.0	12
2341	The Permeation Mechanism of Cisplatin Through a Dioleoylphosphocholine Bilayer**. ChemPhysChem, 2021, 22, 1251-1261.	1.0	7
2342	BODIPY-Appended Pt(II) Complexes with High Toxicities and Anti-chemoresistance Performances in a Cisplatin Resistant In Vivo Model. Inorganic Chemistry, 2021, 60, 10047-10055.	1.9	3
2343	Is the cytotoxic activity of phenanthriplatin dependent on the specific size of the phenanthridine ligand Ï€ system?. Journal of Inorganic Biochemistry, 2021, 219, 111447.	1.5	9
2344	Co-Loading of Cisplatin and Methotrexate in Nanoparticle-Based PCL-PEG System Enhances Lung Cancer Chemotherapy Effects. Journal of Cluster Science, 2022, 33, 1751-1762.	1.7	14
2345	SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner. Translational Oncology, 2021, 14, 101075.	1.7	6
2346	Anticancer Activity, DNA Binding, and Photodynamic Properties of a Nâˆ§Câˆ§N-Coordinated Pt(II) Complex. Inorganic Chemistry, 2021, 60, 10350-10360.	1.9	16
2347	The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis. Biochemical Pharmacology, 2021, 188, 114542.	2.0	12
2348	Coordination-based molecular nanomaterials for biomedically relevant applications. Coordination Chemistry Reviews, 2021, 438, 213752.	9.5	17

#	Article	IF	Citations
2349	Ruthenium Complexes as Promising Candidates against Lung Cancer. Molecules, 2021, 26, 4389.	1.7	32
2350	Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. Cancers, 2021, 13, 3697.	1.7	41
2351	Nanopore Sequencing Accurately Identifies the Cisplatin Adduct on DNA. ACS Sensors, 2021, 6, 3082-3092.	4.0	14
2352	From Preassociation to Chelation: A Survey of Cisplatin Interaction with Methionine at Molecular Level by IR Ion Spectroscopy and Computations. Journal of the American Society for Mass Spectrometry, 2021, 32, 2206-2217.	1.2	7
2353	Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy. International Journal of Molecular Sciences, 2021, 22, 8885.	1.8	57
2354	Systematic Identification of Proteins Binding with Cisplatin in Blood by Affinity Chromatography and a Four-Dimensional Proteomic Method. Journal of Proteome Research, 2021, 20, 4553-4565.	1.8	6
2355	The role of both intercalation and groove binding at AT-rich DNA regions in the interaction process of a dinuclear Cu(I) complex probed by spectroscopic and simulation analysis. Journal of Molecular Liquids, 2021, 335, 116290.	2.3	8
2356	N-heterocyclic carbene metal complexes as therapeutic agents: a patent review. Expert Opinion on Therapeutic Patents, 2022, 32, 47-61.	2.4	12
2357	DNA binding, molecular docking study and antitumor activity of [PdCl2(R2-(S,S)-eddtrp)] complexes. Monatshefte FÃ¼r Chemie, 2021, 152, 951-958.	0.9	2
2358	Photoactivated cytotoxicity induced by heterobimetallic Ru(II)-Pt(II) polypyridyl complexes in MCF-7 cells. Journal of Chemical Sciences, 2021, 133, 1.	0.7	3
2359	Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine, 2021, 38, 101031.	3.2	2
2360	Implications of inhibition of Rev1 interaction with Y family DNA polymerases for cisplatin chemotherapy. Genes and Development, 2021, 35, 1256-1270.	2.7	6
2361	Advancements in the Use of Platinum Complexes as Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 821-835.	0.9	8
2362	Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury. Antioxidants, 2021, 10, 1329.	2.2	25
2363	Synthesis, characterization, biological evaluation, and molecular docking approach of nickel (II) complexes containing O, Nâ€donor chelation pattern of sulfonamideâ€based Schiff bases. Applied Organometallic Chemistry, 2021, 35, e6412.	1.7	9
2364	Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells. Scientific Reports, 2021, 11, 17997.	1.6	9
2365	Atomic force microscopyâ€"A tool for structural and translational DNA research. APL Bioengineering, 2021, 5, 031504.	3.3	23
2366	Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. EBioMedicine, 2021, 71, 103560.	2.7	62

#	Article	IF	Citations
2367	Translesion activity of PrimPol on DNA with cisplatin and DNAâ€“protein cross-links. Scientific Reports, 2021, 11, 17588.	1.6	14
2368	Analytical methods for the quantification of cisplatin, carboplatin, and oxaliplatin in various matrices over the last two decades. Current Pharmaceutical Analysis, 2021, 18, .	0.3	2
2369	The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin. Frontiers in Pharmacology, 2021, 12, 684545.	1.6	5
2370	Synthesis and anticancer activity of Pt(0)â€olefin complexes bearing 1,3,5â€triazaâ€7â€phosphaadamantane and Nâ€heterocyclic carbene ligands. Applied Organometallic Chemistry, 2021, 35, e6438.	1.7	3
2371	Mononuclear Ï€-complexes of Pd(II) and Pt(II) with 1-allyl-3-(2-hydroxyethyl)thiourea: Synthesis, structure, molecular docking, DNA binding ability and genotoxic activity. Polyhedron, 2021, 210, 115477.	1.0	3
2372	Biomedical applications of Pt(II) metallacycle/metallacage-based agents: From mono-chemotherapy to versatile imaging contrasts and theranostic platforms. Coordination Chemistry Reviews, 2021, 443, 214017.	9.5	57
2373	Thioflavin T fluorescence and NMR spectroscopy suggesting a non-G-quadruplex structure for a sodium binding aptamer embedded in DNAzymes. Canadian Journal of Chemistry, 0, , 1-7.	0.6	1
2374	PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy. Frontiers in Immunology, 2021, 12, 714244.	2.2	7
2375	Lanthanide complexes as anticancer agents: A review. Polyhedron, 2021, 207, 115387.	1.0	29
2376	Synthesis, characterization of ruthenium(II), nickel(II), palladium(II), and platinum(II) triphenylphosphine-based complexes bearing an ONS-donor chelating agent: Interaction with biomolecules, antioxidant, in vitro cytotoxic, apoptotic activity and cell cycle analysis. Journal of Inorganic Biochemistry, 2021, 223, 111549.	1.5	44
2377	Synthesis, structural characterization, CT-DNA interaction study and antithrombotic activity of new ortho-vanillin-based chiral (Se,N,O) donor ligands and their Pd complexes. Inorganica Chimica Acta, 2021, 528, 120609.	1.2	2
2378	Multifunctional Pt(<scp>iv</scp>) prodrug candidates featuring the carboplatin core and deferoxamine. Dalton Transactions, 2021, 50, 8167-8178.	1.6	9
2379	DNA structures embedded with functionalized nanomaterials for biophysical applications. Journal of the Korean Physical Society, 2021, 78, 449-460.	0.3	3
2380	Cancer theranostic platforms based on injectable polymer hydrogels. Biomaterials Science, 2021, 9, 3543-3575.	2.6	16
2381	Synthesis, structural characterization, protein binding, DNA cleavage and anticancer activity of fluorophore labelled copper(<scp>ii</scp>) complexes based on 1,8-naphthalimide conjugates. New Journal of Chemistry, 2021, 45, 16319-16332.	1.4	9
2385	DNA-Mediated Assembly of Metal Nanoparticles: Fabrication, Structural Features, and Electrical Properties. Nanostructure Science and Technology, 2009, , 11-41.	0.1	3
2386	Charge Transport of Solute Oligonucleotides In Metallic Nanogaps â€“ Observations and Some Puzzles. , 2008, , 161-205.		4
2387	Application of Anomalous Diffraction Methods to the Study of DNA and DNA-Complexes. Methods in Molecular Biology, 2010, 613, 133-152.	0.4	3

#	Article	IF	Citations
2388	Possible Incorporation of Free N7-Platinated Guanines in DNA by DNA Polymerases, Relevance for the Cisplatin Mechanism of Action. , 2009, , 125-132.		5
2389	X-ray Crystal Structure of a Monofunctional Platinumâ€“DNA Adduct, cis-{Pt(NH3)2-(Pyridine)}2+ Bound to Deoxyguanosine in a Dodecamer Duplex. , 2009, , 67-72.		4
2390	Current State of Platinum Complexes for theÂTreatment of Advanced and Drug-Resistant Breast Cancers. Advances in Experimental Medicine and Biology, 2019, 1152, 253-270.	0.8	6
2391	Applications of Fluorescence Spectroscopy and Confocal Microscopy. , 2011, , 235-272.		1
2392	Antitumor Monoterpenes. , 2015, , 175-200.		2
2393	Molecular pathways involved in cell death after chemically induced DNA damage. Exs, 2009, 99, 209-230.	1.4	4
2394	Metal Ion-Promoted Conformational Changes of Oligonucleotides. Metal Ions in Life Sciences, 2012, 10, 103-118.	2.8	1
2395	DNA Modifications by Novel Antitumor Platinum Drugs. , 2002, , 229-250.		2
2396	195Pt NMR-Fourier Spectroscopy in the Analysis of the Mechanism of the Cytostatic Activity of Platinum Complexes. , 2002, , 615-623.		1
2397	Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation. Inorganica Chimica Acta, 2018, 470, 318-324.	1.2	8
2398	A Pd(II) complex derived from pyridine-2-carbaldehyde oxime ligand: Synthesis, characterization, DNA and BSA interaction studies and inÂvitro anticancer activity. Journal of Molecular Structure, 2020, 1219, 128479.	1.8	24
2399	In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. , 0, .		5
2400	Binding of Kinetically Inert Metal Ions to RNA: The Case of Platinum(II). Metal Ions in Life Sciences, 2011, 9, 347-377.	1.0	17
2401	Combining vitamin B₁₂ and cisplatin-loaded porous silica nanoparticles via coordination: a facile approach to prepare a targeted drug delivery system. New Journal of Chemistry, 2017, 41, 13823-13829.	1.4	19
2402	Kinetics and Mechanistic Study on the Reaction of Iodo(diethylenetriamine) Platinum(II) with L-Cystine. Australian Journal of Chemistry, 2009, 62, 493.	0.5	6
2403	Green engineering of biomolecule-coated metallic silver nanoparticles and their potential cytotoxic activity against cancer cell lines. Advances in Natural Sciences: Nanoscience and Nanotechnology, 2017, 8, 025001.	0.7	40
2404	Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation. JCI Insight, 2016, 1, e83654.	2.3	23
2405	Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. Journal of Leukocyte Biology, 2009, 86, 625-632.	1.5	27

#	Article	IF	Citations
2406	Inhibiting microRNA-449 Attenuates Cisplatin-Induced Injury in NRK-52E Cells Possibly via Regulating the SIRT1/P53/BAX Pathway. Medical Science Monitor, 2016, 22, 818-823.	0.5	29
2407	Next-Generation Sequencing Analysis of mRNA Profile in Cisplatin-Resistant Gastric Cancer Cell Line SGC7901. Medical Science Monitor, 2019, 25, 2386-2396.	0.5	8
2408	Potentiating Effect of UVA Irradiation on Anticancer Activity of Carboplatin Derivatives Involving 7-Azaindoles. PLoS ONE, 2015, 10, e0123595.	1.1	12
2409	Anti-cancer characteristics and ototoxicity of platinum(II) amine complexes with only one leaving ligand. PLoS ONE, 2018, 13, e0192505.	1.1	20
2410	Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective. World Journal of Oncology, 2014, 5, 97-108.	0.6	15
2411	Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. Journal of Translational Science, 2016, 2, 117-124.	0.2	6
2412	Radio-frequency plasma polymerized biodegradable carrier for in vivo release of cis-platinum. Oncotarget, 2016, 7, 58121-58132.	0.8	8
2413	MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1. Oncotarget, 2017, 8, 22003-22013.	0.8	58
2414	Enhanced antitumor effect of biodegradable cationic heparin-polyethyleneimine nanogels delivering FILIP1LÎ”C103 gene combined with low-dose cisplatin on ovarian cancer. Oncotarget, 2017, 8, 76432-76442.	0.8	2
2415	The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro. Oncotarget, 2017, 8, 76935-76948.	0.8	5
2416	FOXO3 induces ubiquitylation of AKT through MUL1 regulation. Oncotarget, 2017, 8, 110474-110489.	0.8	16
2417	The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models. Oncotarget, 2018, 9, 14524-14538.	0.8	49
2418	Intrinsic TGF-Î²2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells. Oncotarget, 2015, 6, 1008-1019.	0.8	27
2419	Enhanced nucleotide excision repair capacity in lung cancer cells by preconditioning with DNA-damaging agents. Oncotarget, 2015, 6, 22575-22586.	0.8	21
2420	Nanocarriers for Tracking and Treating Diseases. Current Medicinal Chemistry, 2013, 20, 3500-3514.	1.2	33
2421	Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Current Medicinal Chemistry, 2017, 24, 1586-1606.	1.2	89
2422	Platinum Compounds: A Hope for Future Cancer Chemotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 296-306.	0.9	172
2423	Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer. Anticancer Research, 2016, 36, 6005-6010.	0.5	10

#	Article	IF	Citations
2424	Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences. Asian Pacific Journal of Cancer Prevention, 2017, 18, 295-314.	0.5	33
2425	Antiproliferative properties of iron supramolecular cylinders. Chemistry Squared, 0, 2, 4.	0.0	5
2426	Daphnetin Attenuated Cisplatin-Induced Acute Nephrotoxicity With Enhancing Antitumor Activity of Cisplatin by Upregulating SIRT1/SIRT6-Nrf2 Pathway. Frontiers in Pharmacology, 2020, 11, 579178.	1.6	20
2427	Investigation into the Effect of Photodynamic Therapy and Cisplatin on the Cervical Cancer Cell Line (A2780). Journal of Lasers in Medical Sciences, 2020, 11, S85-S91.	0.4	5
2428	Effects of Terminalia arjuna bark extract on apoptosis of human hepatoma cell line HepG2. World Journal of Gastroenterology, 2006, 12, 1018.	1.4	41
2429	Apurinic endonuclease 1 promotes the cisplatin resistance of lung cancer cells by inducing Parkinâ€‘mediated mitophagy. Oncology Reports, 2019, 42, 2245-2254.	1.2	15
2430	Antimicrobial, Antioxidant and T47D Cytotoxic Activities of Trichaptum sp., A Fungal Endophyte from Phyllantus niruri Linn.: In vitro and in silico Studies. Asian Journal of Cell Biology, 2016, 12, 1-19.	0.4	3
2431	New Roles of Mitochondrial Transcription Factor A in Cancer. , 2012, 01, .		3
2432	Mechanistic Insights into in vitro DNA Adduction of Oxaliplatin. Bulletin of the Korean Chemical Society, 2010, 31, 2043-2046.	1.0	10
2433	Synthesis, crystal structure and in vitro anticancer studies of two bis(8-quinolinolato-N,O)-platinum(II) complexes. European Journal of Chemistry, 2019, 10, 37-44.	0.3	2
2434	Nâ€“nitrosamines are associated with shorter telomere length. Scandinavian Journal of Work, Environment and Health, 2011, 37, 316-324.	1.7	44
2435	Chitosan-Coated Fe₃O₄ Magnetic Nanoparticles as Carrier of Cisplatin for Drug Delivery. Fisheries and Aquatic Sciences, 2015, 18, 89-98.	0.3	20
2437	Model DNA for investigation of mechanism of nucleotide excision repair. Biopolymers and Cell, 2014, 30, 167-183.	0.1	3
2438	Platinum-based anticancer drugs encapsulated liposome and polymeric micelle formulation in clinical trials. Biochemical Compounds, 2016, 4, 1.	0.7	18
2439	In vitro Cytotoxic Activity of New Triphenyltin (IV) Alkyl-isopropyl-di-thiocarbamate Compounds on Human Acute T-Lymphoblastic Cell Line. Journal of Applied Pharmaceutical Science, 0, , 7-11.	0.7	6
2440	Advances in drug delivery system for platinum agents based combination therapy. Cancer Biology and Medicine, 2015, 12, 362-74.	1.4	36
2441	Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. ELife, 2020, 9, .	2.8	7
2442	Cancer molecular biology and strategies for the design of cytotoxic gold(<scp>i</scp>) and gold(<scp>iii</scp>) complexes: a tutorial review. Dalton Transactions, 2021, 50, 17413-17437.	1.6	17

#	Article	IF	Citations
2443	Anaphylaxis to Cisplatin after Carboplatin Hypersensitivity Reaction in Advanced Non-Small Cell Lung Cancer. Case Reports in Clinical Medicine, 2021, 10, 295-302.	0.1	1
2444	Synthesis, crystal structure, DFT analysis, and DNA studies of a binuclear copper(II) complex with 2,2â€²-bipyridine and 4-aminobenzoate. Journal of Coordination Chemistry, 2021, 74, 2764-2779.	0.8	2
2445	Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies. Frontiers in Oncology, 2021, 11, 764119.	1.3	20
2446	Synthesis and characterization of new platinum(II) complexes with cyclic iminoether-type ligands having the azomethine group out of cycle. Inorganica Chimica Acta, 2022, 530, 120655.	1.2	1
2447	Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer. Life Sciences, 2021, 286, 120029.	2.0	8
2448	Covalent and noncovalent interactions of coordination compounds with DNA: An overview. Journal of Inorganic Biochemistry, 2021, 225, 111624.	1.5	26
2449	Structural Aspects of Pt-DNA Adduct Recognition by Proteins. , 2005, , .		0
2450	Chapter 8. Covalent Interactions of Nucleic Acids with Small Molecules and Their Repair. , 2007, , 295-340.		0
2451	Metal Ionâ€“Nucleic Acid Interactions in Disease and Medicine. RSC Biomolecular Sciences, 2008, , 350-416.	0.4	1
2452	DNA Metallo-Intercalators with Leishmanicidal Activity. , 2008, , 59-73.		1
2454	Chapter 12. Monitoring the Effects of Cisplatin Uptake in Rat Glioma Cells: A Preliminary Study Using Fourier Transform Infrared Synchrotron Microspectroscopy. Metal Ions in Life Sciences, 2010, , 339-350.	1.0	0
2455	The Synthesis of Platinum(II) Intercalators. , 2011, , 69-100.		0
2456	Molecular Mechanism of Cisplatin Resistance in Head and Neck Cancers. Practica Otologica, 2011, 104, 161-170.	0.0	0
2457	Traditional Chinese Medicine Active Ingredient-Metal Based Anticancer Agents. , 0, , .		1
2459	PROL4 Elevates The Sensitivity of Lung Cancer Cell LTEP-a-2 to Cisplatin Treatment*. Progress in Biochemistry and Biophysics, 2012, 39, 919-925.	0.3	0
2460	Biomolecular Interactions of Platinum Complexes. Monographs in Supramolecular Chemistry, 2013, , 260-299.	0.2	3
2461	Platinum Resistance: The Role of Molecular, Genetic and Epigenetic Factors. Journal of Medical Sciences (Faisalabad, Pakistan), 2013, 13, 160-168.	0.0	0
2462	CHAPTER 15. Platinum. 2-Oxoglutarate-Dependent Oxygenases, 2014, , 429-460.	0.8	3

#	Article	IF	Citations
2463	Integrating Proteotoxic Stress Response Pathways for Induction of Cell Death in Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities. , 2015, , 183-202.		0
2464	Hypersensitivity and cross-reactivity to cisplatin and carboplatin. Journal of Emergency Practice and Trauma, 2016, 2, 58-61.	0.3	0
2465	Sphingolipid metabolism affects the anticancer effect of cisplatin. World Journal of Translational Medicine, 2016, 5, 37.	3.5	2
2466	Elucidation of Glutathione-S-transferase Activity Induced by Pectin- Cisplatin Nano-conjugates for Optimization of New Therapeutic Strategies. Journal of Nanomedicine & Nanotechnology, 2016, 7, .	1.1	0
2467	Current and Emerging Role of Chemotherapy in Oral Cancer. , 2017, , 127-146.		1
2469	Metal-Based Drug-DNA Interactions. Journal of the Mexican Chemical Society, 2017, 57, .	0.2	3
2472	The Zn(S-pr-thiosal)₂ complex attenuates murine breast cancer growth by inducing apoptosis and G1/S cell cycle arrest. Future Medicinal Chemistry, 2020, 12, 897-914.	1.1	7
2473	Anticancer Activity of Platinum (II) Complex with 2-Benzoylpyridine by Induction of DNA Damage, S-Phase Arrest, and Apoptosis. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 504-517.	0.9	2
2475	Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspaseâ€'3 pathway in oral cancer. Oncology Letters, 2020, 20, 1-1.	0.8	1
2478	Synthesis, Structural Characterization and Hirshfeld Surface Analysis of Mixed Ligand Copper(II) Complex. Chemical Data Collections, 2020, 28, 100374.	1.1	1
2479	Anticancer potential of Pd and Pt metallo-macrocycles of phosphines and 4,4Î„-dipyridyldiselenide. Polyhedron, 2022, 211, 115547.	1.0	4
2481	Determination of the anticancer properties of cis- and trans-diadamanthylcarboxylates of dirhenium(III). ScienceRise Biological Science, 2020, , 8-12.	0.1	1
2482	Controlling the reactivity of [Pd(II)(N^N^N)Cl]+ complexes using 2,6-bis(pyrazol-2-yl)pyridine ligands for biological application: Substitution reactivity, CT-DNA interactions and in vitro cytotoxicity study. Journal of Inorganic Biochemistry, 2020, 213, 111261.	1.5	6
2483	Ferrocene-functionalized anilines as potent anticancer and antidiabetic agents: Synthesis, spectroscopic elucidation, and DFT calculations. Journal of Molecular Structure, 2022, 1249, 131632.	1.8	7
2484	Review of Ototoxic Drugs and Treatment Strategies for Reducing Hearing Loss. , 2020, , 51-87.		0
2485	Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) Warheads*. , 2020, , 1585-1591.		0
2486	Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) Warheads*. , 2020, , 1585-1591.		0
2487	Enzymeless DNA Base Identification by Chemical Stepping in a Nanopore. Journal of the American Chemical Society, 2021, 143, 18181-18187.	6.6	17

#	Article	IF	Citations
2488	Mixed ligand copper(II) complexes of diimine co-ligands: Synthesis, characterization, DNA binding and DNA cleavage activity. Materials Today: Proceedings, 2022, 50, 358-364.	0.9	1
2489	Anticancer Activity Assessment and DNA Binding Properties of Two Binuclear Platinum (II) Complexes using Spectroscopic and Molecular Simulation Approaches. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 2066-2073.	0.9	1
2491	Knock down of p53 or its ubiquitin ligase E6AP does not affect the sensitivity of human papillomavirus-positive cervical cancer cells to cisplatin. American Journal of Cancer Research, 2012, 2, 309-21.	1.4	5
2493	Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Annals of Gastroenterology, 2012, 25, 106-118.	0.4	119
2496	Geranylgeranylacetone attenuates cisplatin-induced reductions in cell viability by suppressing the elevation of intracellular p53 content without heat shock protein induction. Nagoya Journal of Medical Science, 2012, 74, 123-31.	0.6	6
2497	Lipocalin2 Protects Human Embryonic Kidney Cells against Cisplatin-Induced Genotoxicity. Iranian Journal of Pharmaceutical Research, 2018, 17, 147-154.	0.3	8
2498	It's About Time: Advances in Understanding the Circadian Regulation of DNA Damage and Repair in Carcinogenesis and Cancer Treatment Outcomes. Yale Journal of Biology and Medicine, 2019, 92, 305-316.	0.2	16
2500	Harnessing Focal Adhesions to Accelerate p53 Accumulation and Anoikis of A549 Cells Using Colloidal Self-Assembled Patterns (cSAPs). ACS Applied Bio Materials, 2022, 5, 322-333.	2.3	6
2501	A mechanistic approach for inâ€vitro anticancer activity via nucleic acid fragmentation by copper(II) complex anchored on MCMâ€41. Applied Organometallic Chemistry, 2022, 36, .	1.7	3
2502	Synthesis, Characterization, Crystal Structure, DNA and HSA Interactions, and Anticancer Activity of a Mononuclear Cu(II) Complex with a Schiff Base Ligand Containing a Thiadiazoline Moiety. ACS Omega, 2022, 7, 2881-2896.	1.6	35
2503	New [Pt(S2CNR2)Cl(PAr3)] complexes as anticancer agents. Inorganic Chemistry Communication, 2022, 136, 109142.	1.8	4
2504	Platinum(II) and Copper(II) complexes of asymmetric halogen-substituted [NNÊ¹O] ligands: Synthesis, characterization, structural investigations and antiproliferative activity. Bioorganic Chemistry, 2022, 119, 105556.	2.0	3
2505	New ferrocene-integrated multifunctional guanidine surfactants: synthesis, spectroscopic elucidation, DNA interaction studies, and DFT calculations. New Journal of Chemistry, 2021, 46, 185-198.	1.4	3
2506	Novel Mononuclear Zinc(II) Complex with Niacin: Crystal Structure, DNA/Protein Interaction, and Cytotoxicity Studies. Journal of Applied Spectroscopy, 2022, 88, 1247-1256.	0.3	0
2507	Synthesis, Characterization, Thermal Analysis, DFT, and Cytotoxicity of Palladium Complexes with Nitrogen-Donor Ligands. Molecules, 2022, 27, 964.	1.7	4
2508	Evaluation of the binding mode of a cytotoxic dinuclear nickel complex to two neighboring phosphates of the DNA backbone. Dalton Transactions, 2022, 51, 2863-2875.	1.6	4
2509	Oxidative Stress in Cancer Therapy: Friend or Enemy?. ChemBioChem, 2022, 23, .	1.3	49
2510	Silybin B exerts protective effect on cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. Journal of Ethnopharmacology, 2022, 288, 114938.	2.0	8

#	Article	IF	Citations
2511	The MÃ¶ssbauer effect using ⁵⁷Fe-ferrabisdicarbollide ([o-⁵⁷FESAN]^{â¯}): a glance into the potential of a low-dose approach for glioblastoma radiotherapy. Inorganic Chemistry Frontiers, 2022, 9, 1490-1503.	3.0	8
2512	Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatinâ€“DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model. International Journal of Molecular Sciences, 2022, 23, 1868.	1.8	4
2513	Polymorphic mutations in the polb gene promoter and their impact on transcriptional activity. Thoracic Cancer, 2022, 13, 853-857.	0.8	1
2514	Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives. Inorganic Chemistry Frontiers, 2022, 9, 2424-2453.	3.0	33
2515	Nanoemulsions for antitumor activity. , 2022, , 435-454.		0
2516	Iridium(<scp>iii</scp>)â€“Cp*-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol analogues as hypoxia active, GSH-resistant cancer cytoselective and mitochondria-targeting cancer stem cell therapeutic agents. Dalton Transactions, 2022, 51, 5494-5514.	1.6	3
2517	Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI. International Journal of Molecular Sciences, 2022, 23, 2638.	1.8	7
2518	Swelling triggered release of cisplatin from gelatin coated gold nanoparticles. Inorganic and Nano-Metal Chemistry, 2022, 52, 961-973.	0.9	1
2519	Development of Novel ¹⁹¹Pt-Labeled Hoechst33258: ¹⁹¹Pt Is More Suitable than ¹¹¹In for Targeting DNA. Journal of Medicinal Chemistry, 2022, 65, 5690-5700.	2.9	3
2520	Recent Advances of Pyridinone in Medicinal Chemistry. Frontiers in Chemistry, 2022, 10, 869860.	1.8	20
2521	Metallodrugs: Mechanisms of Action, Molecular Targets and Biological Activity. International Journal of Molecular Sciences, 2022, 23, 3504.	1.8	6
2522	Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity. Pharmaceutics, 2022, 14, 787.	2.0	16
2523	Platinum-based Cancer Chemotherapeutics: Recent Trends and Future Perspectives. Current Chinese Science, 2022, 2, 275-293.	0.2	2
2524	Therapeutic Effect of Teneligliptin in Drug-Induced Nephrotoxicity: An In-Vitro Study. Cureus, 2022, 14, e23871.	0.2	0
2525	DNA, a target of mixed chelate copper(II) compounds (CasiopeinasÂ®) studied by electrophoresis, UVâ€“vis and circular dichroism techniques.. Journal of Inorganic Biochemistry, 2022, 231, 111772.	1.5	21
2526	How can the cisplatin analogs with different amine act on DNA during cancer treatment theoretically?. Journal of Molecular Modeling, 2022, 28, 2.	0.8	7
2527	Pharmacologic inhibition of ataxia telangiectasia and Rad3â€related (ATR) in the treatment of head and neck squamous cell carcinoma. Molecular Carcinogenesis, 2022, 61, 225-238.	1.3	9
2528	Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancerâ€”From Bench to Bedside. Cancers, 2022, 14, 1615.	1.7	7

#	Article	IF	Citations
2529	Pure DNA scaffolded drug delivery systems for cancer therapy. Biomaterials, 2022, 285, 121532.	5.7	9
2530	Rational design and synthesis of one-dimensional platinum-based nanostructures for oxygen-reduction electrocatalysis. Chinese Journal of Catalysis, 2022, 43, 1459-1472.	6.9	95
2538	Cytotoxicity of Metal-Based Photoactivated Chemotherapy (PACT) Compounds. Methods in Molecular Biology, 2022, 2451, 245-258.	0.4	2
2539	Analysis of Changes in the Structure of DNA when Interacting with Platinum Coordination Compounds by IR Spectroscopy. Biophysics (Russian Federation), 2022, 67, 15-21.	0.2	2
2541	Supporting Cells and Their Potential Roles in Cisplatin-Induced Ototoxicity. Frontiers in Neuroscience, 2022, 16, 867034.	1.4	7
2542	New mixed ligand oxidovanadium(IV) complexes: Solution behavior, protein interaction and cytotoxicity. Journal of Inorganic Biochemistry, 2022, 233, 111853.	1.5	10
2543	Solasonine induces apoptosis of the SGCâ€7901 human gastric cancer cell line in vitro via the mitochondriaâ€mediated pathway. Journal of Cellular and Molecular Medicine, 2022, 26, 3387-3395.	1.6	12
2544	Rapid DNA interstrand cross-linking of Pt(IV) compound. European Journal of Pharmacology, 2022, 925, 174985.	1.7	6
2545	New Rh(III) chloro complex of a tetradentate S-picolyl azo ligand of acetyl acetone: Synthesis, X-ray structure, spectral characterization, electrochemistry, DFT computation and interaction with DNA. Journal of Molecular Structure, 2022, 1263, 133215.	1.8	0
2546	Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model. Chemical Science, 2022, 13, 6899-6919.	3.7	13
2547	Low-intensity low-frequency pulsed ultrasound ameliorates sciatic nerve dysfunction in a rat model of cisplatin-induced peripheral neuropathy. Scientific Reports, 2022, 12, 8125.	1.6	6
2548	A two-step strategy to synthesis new aminoguanidinium complexes: cytotoxic effect and perspectives. Inorganic and Nano-Metal Chemistry, 0, , 1-19.	0.9	3
2549	Platinum(IV) Prodrugs with Cancer Stem Cell Inhibitory Effects on Lung Cancer for Overcoming Drug Resistance. Journal of Medicinal Chemistry, 2022, 65, 7933-7945.	2.9	21
2551	Structure and Function of SNM1 Family Nucleases. Advances in Experimental Medicine and Biology, 2022, , 1-26.	0.8	2
2552	Mixed Ligand Mononuclear Copper(II) Complex as a Promising Anticancer Agent: Interaction Studies with DNA/HSA, Molecular Docking, and In Vitro Cytotoxicity Studies. ACS Omega, 2022, 7, 21961-21977.	1.6	8
2553	Dual-platination and induced oxidation of uridine by a photoactivatable diazido Pt(IV) anticancer prodrug. Dalton Transactions, 0, , .	1.6	3
2554	Neurotoxicity of Cisplatin as Monotherapy or Combined Chemotherapy in Cancer Treatment. Clinical Cancer Drugs, 2022, 9, .	0.3	1
2555	Diastereomeric Separation of Chiral fac-Tricarbonyl(iminopyridine) Rhenium(I) Complexes and Their Cytotoxicity Studies: Approach toward an Action Mechanism against Glioblastoma. Journal of Medicinal Chemistry, 2022, 65, 9281-9294.	2.9	8

#	Article	IF	Citations
2556	Heavy-Metal Trojan Horse: Enterobactin-Directed Delivery of Platinum(IV) Prodrugs toEscherichia coli. Journal of the American Chemical Society, 2022, 144, 12756-12768.	6.6	26
2558	In vitro and in vivo antitumor studies of potential anticancer agents of platinum(II) complexes of dicyclopentadiene and dithiocarbamates. Metallomics, 2022, 14, .	1.0	6
2559	CasiopeinasÂ® third generation, with indomethacin: synthesis, characterization, DFT studies, antiproliferative activity, and nanoencapsulation. RSC Advances, 2022, 12, 21662-21673.	1.7	2
2560	Heterodinuclear Ruâ€“Pt Complexes Bridged with 2,3-Bis(pyridyl)pyrazinyl Ligands: Studies on Kinetics, Deoxyribonucleic Acid/Bovine Serum Albumin Binding and Cleavage, In Vitro Cytotoxicity, and In Vivo Toxicity on Zebrafish Embryo Activities. ACS Omega, 2022, 7, 26226-26245.	1.6	11
2561	Nucleic Acid Aptamers Increase the Anticancer Efficiency and Reduce the Toxicity of Cisplatin-Arabinogalactan Conjugates In Vivo. Nucleic Acid Therapeutics, 2022, 32, 497-506.	2.0	3
2562	Comparative cisplatin reactivity towards human Zn7-metallothionein-2 and MTF-1 zinc fingers: potential implications in anticancer drug resistance. Metallomics, 2022, 14, .	1.0	7
2563	Simultaneous Photoactivation of cGASâ€STING Pathway and Pyroptosis by Platinum(II) Triphenylamine Complexes for Cancer Immunotherapy. Angewandte Chemie - International Edition, 2022, 61, .	7.2	35
2564	Simultaneous Photoactivation of cGASâ€STING Pathway and Pyroptosis by Platinum(II) Triphenylamine Complexes for Cancer Immunotherapy. Angewandte Chemie, 2022, 134, .	1.6	3
2565	Anticancer property and normal cell toxicity profile of pyrrolidineâ€based platinum (II) complexes: Their DNA, BSA interaction, and molecular docking. Applied Organometallic Chemistry, 2022, 36, .	1.7	6
2566	Time-Dependent Studies of Oxaliplatin and Other Nucleolar Stress-Inducing Pt(II) Derivatives. ACS Chemical Biology, 2022, 17, 2262-2271.	1.6	7
2567	Review on recent development of quinoline for anticancer activities. Arabian Journal of Chemistry, 2022, 15, 104168.	2.3	28
2568	Zn(II)-formate Framework of mab topology: Synthesis from tea extract, electronic structure, and DNA-binding. Journal of Molecular Structure, 2022, 1270, 133913.	1.8	11
2569	A split Î²-lactamase sensor for the detection of DNA modification by cisplatin and ruthenium-based chemotherapeutic drugs. Journal of Inorganic Biochemistry, 2022, 236, 111986.	1.5	1
2570	Nitroreductase-induced bioorthogonal ligation for prodrug activation: A traceless strategy for cancer-specific imaging and therapy. Bioorganic Chemistry, 2022, 129, 106167.	2.0	0
2571	Cancer therapies inducing DNA damage. , 2022, , 205-225.		0
2572	Recently Reported Ru-Metal Organic Coordination Complexes and Their Application (A Review). Russian Journal of General Chemistry, 2022, 92, 1546-1561.	0.3	1
2573	Fibroblast-derived conditioned media promotes lung cancer progression. American Journal of the Medical Sciences, 2023, 365, 189-197.	0.4	1
2574	Advanced cisplatin nanoformulations as targeted drug delivery platforms for lung carcinoma treatment: a review. Journal of Materials Science, 2022, 57, 16192-16227.	1.7	9

#	Article	IF	Citations
2575	Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing mice. Nuclear Medicine Communications, 2022, 43, 1121-1127.	0.5	1
2576	Inorganic Complexes and Metal-Based for Biomarkers Sensors. , 2023, , 113-155.		0
2577	Cisplatin-Cross-Linked DNA Origami Nanostructures for Drug Delivery Applications. ACS Applied Nano Materials, 2022, 5, 13267-13275.	2.4	15
2578	Cisplatin-Loaded Tobacco Mosaic Virus for Ovarian Cancer Treatment. Biomacromolecules, 2022, 23, 4379-4387.	2.6	3
2579	Elusive intermediates in cisplatin reaction with target amino acids: Platinum(II)-cysteine complexes assayed by IR ion spectroscopy and DFT calculations. Journal of Inorganic Biochemistry, 2022, 237, 112017.	1.5	2
2580	Cytotoxic sub-nanometer aqueous platinum clusters as potential antitumoral agents. Nanoscale Advances, 0, , .	2.2	0
2581	In vitro studies on the selective cytotoxic effect of luminescent Ru(<scp>ii</scp>)-p-cymene complexes of imidazo-pyridine and imidazo quinoline ligands. Dalton Transactions, 2022, 51, 17263-17276.	1.6	9
2582	Three-Photon AIE Pt(II) Complexes as Cysteine-Targeting Theranostic Agents for Tumor Imaging and Chemotherapy. Analytical Chemistry, 2022, 94, 14769-14777.	3.2	5
2583	Magnesium Isoglycyrrhizinate Reduces the Target-Binding Amount of Cisplatin to Mitochondrial DNA and Renal Injury through SIRT3. International Journal of Molecular Sciences, 2022, 23, 13093.	1.8	0
2584	Structural Determination of Lysine-Linked Cisplatin Complexes via IRMPD Action Spectroscopy: NN_s and NO^{â€“} Binding Modes of Lysine to Platinum Coexist. Journal of Physical Chemistry B, 2022, 126, 9246-9260.	1.2	1
2585	Anticancer activity of Pt-selenolate metallacycles. New Journal of Chemistry, 2022, 46, 23198-23212.	1.4	1
2586	hucMSC-derived exosomes protect ovarian reserve and restore ovarian function in cisplatin treated mice. Journal of Biomedical Research, 2023, 37, 382.	0.7	0
2587	Cervical cancer: a tale from HPV infection to PARP inhibitors. Genes and Diseases, 2023, 10, 1445-1456.	1.5	3
2588	Induction of immunogenic cell death by novel platinum-based anticancer agents. Pharmacological Research, 2023, 187, 106556.	3.1	9
2589	A toxicological evaluation for safety assessment of ruthenium-based diosmetin complex in rats. Regulatory Toxicology and Pharmacology, 2023, 137, 105303.	1.3	1
2590	In Response to Precision Medicine: Current Subcellular Targeting Strategies for Cancer Therapy. Advanced Materials, 2023, 35, .	11.1	21
2591	Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs. International Journal of Molecular Sciences, 2022, 23, 14511.	1.8	6
2592	Synthesis, crystal structure and biological properties of a fluorophore-labelled mixed-ligand copper(II) complex incorporating N-hydroxynaphthalene-1,8-dicarboximide. Acta Crystallographica Section C, Structural Chemistry, 2022, 78, 755-759.	0.2	0

#	Article	IF	Citations
2593	Assessment of toxicity and genotoxic safety profile of novel fisetin ruthenium-p-cymene complex in mice. Toxicological Research, 0, , .	1.1	2
2594	Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Linesâ€"An Isobolographic Analysis. International Journal of Molecular Sciences, 2023, 24, 212.	1.8	3
2595	Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells. Pharmaceutics, 2022, 14, 2780.	2.0	7
2596	Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives. International Journal of Molecular Sciences, 2022, 23, 15410.	1.8	21
2597	Inorganic Drugs as a Tool for Protein Structure Solving and Studies on Conformational Changes. Chemistry - A European Journal, 2023, 29, .	1.7	0
2598	Emerging and established therapies for chemotherapy-induced ototoxicity. Journal of Cancer Survivorship, 2023, 17, 17-26.	1.5	3
2599	Research and Development of Supramolecules as Anticancer Drugs. , 2022, , 55-87.		0
2600	Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4
2601	Two novel Pd thiosemicarbazone complexes as efficient and selective antitumoral drugs. Inorganic Chemistry Frontiers, 2023, 10, 1986-1998.	3.0	4
2602	DNA radiosensitization by terpyridine-platinum: damages induced by the 5 and 10 eV transient anions. Nanoscale, 0, , .	2.8	1
2603	Mathematical Modeling: Cisplatin Binding to Deoxyribonucleic Acid. Mathematics, 2023, 11, 235.	1.1	0
2604	Synthesis, Characterization and Photoactivation Studies on the Novel Pt(IV)-Based [Pt(OCOCH3)3(phterpy)] Complex. International Journal of Molecular Sciences, 2023, 24, 1106.	1.8	3
2605	Cisplatin Binding to Human Serum Transferrin: A Crystallographic Study. Inorganic Chemistry, 2023, 62, 675-678.	1.9	2
2606	Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer. Research, 2023, 6, .	2.8	2
2607	Deciphering plausible role of DNA nanostructures in drug delivery. , 2023, , 215-251.		0
2608	A novel Cu(II)-based DNA-intercalating agent: Structural and biological insights using biophysical and in silico techniques. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023, 293, 122438.	2.0	2
2609	Single molecule force spectroscopy of DNA-ligand complexes in the entropic regime. , 2023, , 135-182.		0
2610	Exploring a new family of designer copper(II) complexes of anthracene-appended polyfunctional organic assembly displaying potential anticancer activity via cytochrome c mediated mitochondrial apoptotic pathway. Journal of Inorganic Biochemistry, 2023, 243, 112182.	1.5	5

#	Article	IF	Citations
2611	Electrochemical detection of Oxaliplatin induced DNA damage in G-quadruplex structures. Analytical Biochemistry, 2023, 671, 115149.	1.1	1
2612	Synthesis, characterization and anticancer properties: A series of highly selective palladium(II) substituted-terpyridine complexes. Journal of Inorganic Biochemistry, 2023, 244, 112219.	1.5	3
2613	Differentiated oxidation modes of guanine between CpG and ^{5m}CpG by a photoactivatable Pt(<scp>iv</scp>) anticancer prodrug. Dalton Transactions, 2023, 52, 2786-2798.	1.6	2
2614	Aquaporin Inhibitors. Advances in Experimental Medicine and Biology, 2023, , 317-330.	0.8	7
2615	A New Fe(III) Complex Derived from Cyclohexane Based Imine Derivative: Studies on H ₂ PO ₄ ^{â^'} Recognition and Antiâ€Cancer Activity Against MCF7 and MDAâ€MBâ€231 Human Breast Cancer Cells. ChemistrySelect, 2023, 8, .	0.7	0
2616	Cisplatin-Conjugated Polyurethane Capsule for Dual Drug Delivery to a Cancer Cell. ACS Applied Materials & Interfaces, 2023, 15, 25193-25200.	4.0	11
2617	Molecular Dynamics and Multi-Spectroscopic of the Interaction Behavior between Bladder Cancer Cells and Calf Thymus DNA with Rebeccamycin: Apoptosis through the Down Regulation of PI3K/AKT Signaling Pathway. Journal of Fluorescence, 2023, 33, 1537-1557.	1.3	40
2618	Ternary Cobalt (II)-Metformin-Glycine/Histidine/Proline Complexes: Multispectroscopic DNA, HSA, and BSA Interaction and Cytotoxicity Studies. Biological Trace Element Research, 2023, 201, 5481-5499.	1.9	1
2619	Hirsutidin Prevents Cisplatin-Evoked Renal Toxicity by Reducing Oxidative Stress/Inflammation and Restoring the Endogenous Enzymatic and Non-Enzymatic Level. Biomedicines, 2023, 11, 804.	1.4	2
2620	Antitumor potential of platinum(II) complexes of selenium donor ligands. Metallomics, 2023, 15, .	1.0	0
2621	MATE1 expression in the cochlea and its potential involvement in cisplatin cellular uptake and ototoxicity. Acta Oto-Laryngologica, 2023, 143, 242-249.	0.3	0
2622	Triphenyltin(IV) Carboxylates with Exceptionally High Cytotoxicity against Different Breast Cancer Cell Lines. Biomolecules, 2023, 13, 595.	1.8	3
2624	Gallic acid and/or cerium oxide nanoparticles synthesized by gamma-irradiation protect cisplatin-induced nephrotoxicity via modulating oxidative stress, inflammation and apoptosis. Archives of Biochemistry and Biophysics, 2023, 740, 109594.	1.4	5
2625	Roles of DNA damage in renal tubular epithelial cells injury. Frontiers in Physiology, 0, 14, .	1.3	5
2627	Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy. Cells, 2023, 12, 1156.	1.8	7
2628	Developing an Anticancer Platinum(II) Compound Based on the Uniqueness of Human Serum Albumin. Journal of Medicinal Chemistry, 2023, 66, 5669-5684.	2.9	14
2629	Strong inhibition of organic cation transporter 2 by flavonoids and attenuation effects on cisplatin-induced cytotoxicity. Chemico-Biological Interactions, 2023, 379, 110504.	1.7	1
2630	Regiumâ^Ï€ Bonds Involving Nucleobases: Theoretical Study and Biological Implications. Inorganic Chemistry, 2023, 62, 6740-6750.	1.9	4

#	Article	IF	Citations
2631	Covalent Modifications of Nucleic Acids and Their Repair. , 2022, , 421-476.		0
2638	Interactions of Mn complexes with DNA: the relevance of therapeutic applications towards cancer treatment. Dalton Transactions, 2023, 52, 10639-10656.	1.6	2
2649	Interaction and Reaction. Lecture Notes in Quantum Chemistry II, 2023, , 165-195.	0.3	0
2673	TGF-Î² in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer. , 2023, 40, .		1
2684	A Fluorescence Resonance Energy Transfer-Based Molecular Probe for Cisplatin Detection. , 2023, , .		0
2687	Modes of Chemically Induced Cell Death. , 2023, , .		0
2691	Response of PRIMPOL-Knockout Human Lung Adenocarcinoma A549 Cells to Genotoxic Stress. Biochemistry (Moscow), 2023, 88, 1933-1943.	0.7	0
2697	Emergence of metal-based anticancer therapeutics: A promising perspective. , 2024, , 411-450.		0